
<html lang="en"     class="pb-page"  data-request-id="1177ef17-06b5-4a01-a0d7-de76d8bc3da4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b02170"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Advances in the Development of Phosphodiesterase-4 Inhibitors" /></meta><meta name="dc.Creator" content="Ting  Peng" /></meta><meta name="dc.Creator" content="Baowen  Qi" /></meta><meta name="dc.Creator" content="Jun  He" /></meta><meta name="dc.Creator" content="Hengming  Ke" /></meta><meta name="dc.Creator" content="Jianyou  Shi" /></meta><meta name="dc.Description" content="Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 in..." /></meta><meta name="Description" content="Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 7, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02170" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02170" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02170" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02170" /></link>
        
    
    

<title>Advances in the Development of Phosphodiesterase-4 Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02170" /></meta><meta property="og:title" content="Advances in the Development of Phosphodiesterase-4 Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0031.jpeg" /></meta><meta property="og:description" content="Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02170"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02170">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02170&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02170&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02170&amp;href=/doi/10.1021/acs.jmedchem.9b02170" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 10594-10617</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01033" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00222" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Advances in the Development of Phosphodiesterase-4 Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ting Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu 610072, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Peng">Ting Peng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Baowen Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baowen Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baowen++Qi">Baowen Qi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Center, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Sichuan 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++He">Jun He</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hengming Ke</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengming Ke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics, and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, United States</div></div><span class="conrtib-corresp"><strong>*</strong>H.K.: email, <a href="/cdn-cgi/l/email-protection#a5cdc0cbc2c8cccbc2facec0e5c8c0c18bd0cbc68bc0c1d0"><span class="__cf_email__" data-cfemail="83ebe6ede4eeeaede4dce8e6c3eee6e7adf6ede0ade6e7f6">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengming++Ke">Hengming Ke</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianyou Shi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianyou Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu 610072, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.S.: phone, 86-18908001802; email, <a href="/cdn-cgi/l/email-protection#93e0fbfaf9faf2fdeafce6f7f6d3a2a1a5bdf0fcfe"><span class="__cf_email__" data-cfemail="ddaeb5b4b7b4bcb3a4b2a8b9b89decefebf3beb2b0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianyou++Shi">Jianyou Shi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1026-0282" title="Orcid link">http://orcid.org/0000-0002-1026-0282</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02170&amp;href=/doi/10.1021%2Facs.jmedchem.9b02170" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 10594–10617</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 December 2019</li><li><span class="item_label"><b>Published</b> online</span>7 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02170" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02170</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10594%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTing%2BPeng%252C%2BBaowen%2BQi%252C%2BJun%2BHe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D19%26contentID%3Dacs.jmedchem.9b02170%26title%3DAdvances%2Bin%2Bthe%2BDevelopment%2Bof%2BPhosphodiesterase-4%2BInhibitors%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10617%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02170"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1978</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02170" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Advances in the Development of Phosphodiesterase-4 Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Baowen&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Hengming&quot;,&quot;last_name&quot;:&quot;Ke&quot;},{&quot;first_name&quot;:&quot;Jianyou&quot;,&quot;last_name&quot;:&quot;Shi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10594-10617&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02170&quot;},&quot;abstract&quot;:&quot;Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02170&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02170" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02170&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02170" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02170&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02170" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02170&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02170&amp;href=/doi/10.1021/acs.jmedchem.9b02170" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02170" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02170" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (12 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02170%26sid%3Dliteratum%253Aachs%26pmid%3D32255344%26genre%3Darticle%26aulast%3DPeng%26date%3D2020%26atitle%3DAdvances%2Bin%2Bthe%2BDevelopment%2Bof%2BPhosphodiesterase-4%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D19%26spage%3D10594%26epage%3D10617%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/jmcmar.2020.63.issue-19/20201008/jmcmar.2020.63.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Cyclic nucleotide phosphodiesterases (PDEs) are a family of enzymes that uniquely hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into 5′-AMP and 5′-GMP. The cAMP and cGMP signaling systems regulate the functions of many physiological processes, such as central nervous, cardiovascular, and immune systems.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Under normal physiological conditions, the intracellular levels of cAMP and cGMP are determined by the rates of cyclic nucleotide production and decomposition and maintained in a dynamic equilibrium between synthesis and hydrolysis. There are two ways to increase intracellular cAMP/cGMP concentrations: (a) increasing cAMP/cGMP synthesis by stimulating adenylyl/guanylyl cyclases through external stimuli such as hormones and neurotransmitters and (b) preventing cAMP/cGMP hydrolysis by inhibiting PDEs. Since many diseases are associated with low intracellular levels of cAMP or cGMP, inhibition of PDEs would be a preferred strategy for drug development. PDEs are involved in the regulation of many physiological and metabolic processes, including inflammation, ion channel signaling, cell differentiation and apoptosis, muscle contraction, lipogenesis, glycogen synthesis, and gluconeogenesis.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> To date, 21 PDE genes have been identified in the human genome. These genes express more than 100 PDE isoforms in human tissues through mRNA splicing, which are grouped into 11 families based on their sequence similarity and biological properties. PDE4, -7, and -8 are cAMP-specific, while PDE5, -6, and -9 specifically hydrolyze cGMP. PDE1, -2, -3, -10, and -11 show dual activity on hydrolysis of both cAMP and cGMP.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Overview of PDE4</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PDE4, the most diverse family of PDEs, is abundantly expressed in most cells<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and prefers to hydrolyze cAMP with the micromolar <i>K</i><sub>m</sub> values. PDE4 molecules are involved in a variety of physiological processes, including brain function, monocyte and macrophage activation, neutrophil infiltration, vascular smooth muscle proliferation, and myocardial contractility (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). PDE4 has been reported to be a target for various inflammatory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis. In addition, PDE4 plays important roles in the development of cardiovascular diseases, autoimmune diseases, and cancers.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> In recent years, involvement of PDE4 in regulation of the central nervous system has received substantial attention.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic presentation of PDE4 and cAMP signaling pathway. The following abbreviations are used: β-AR, β-arrestin; GPCRs, G-protein-coupled receptors; Gs, heterotrimeric guanine nucleotide binding protein; AC, adenylyl cyclase; AKAPs, A-kinase-anchoring proteins; PKA, protein kinase A; EPAC, exchange protein activated by cAMP; CREB, cAMP response element binding protein; C3G, cyanidin-3-glucoside; Rap1, Ras-proximate-1; MEK1/2, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase 1/2; NF-κB, nuclear factor κ-light-chain-enhancer of activated B-cells; MAPK, mitogen-activated protein kinase; mTORC1, mammalian target of rapamycin complex 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PDE4 comprises four subtypes: PDE4A, PDE4B, PDE4C, and PDE4D, which are located on chromosomes 19p13.2, 1p31, 19p13.11, and 5q12, respectively.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Each subtype of PDE4 genes can express 3–11 proteins, resulting in at least 25 different PDE4 isoforms. These PDE4 proteins are located in different cell compartments and regulated by kinases, playing critical roles in cell functions (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). PDE4 molecules exist in long, short, and supershort forms according to their molecular sizes (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The long form of PDE4 has two upstream conserved regions (UCR1 and UCR2) in the N-terminal region, while the short form contains only UCR2 and the supershort form has a truncated UCR2. UCR1 consists of approximate 60 amino acids, while UCR2 has approximate 80 amino acids. All PDE4 molecules have a highly conserved catalytic domain at the C-terminus, which contains 300–350 amino acids.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Domain organization of PDE4. UCR: Upstream conserved region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">X-ray structures of PDE4 molecules have shown that the active site can be divided into three subpockets (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>): a divalent metal pocket that interacts with the phosphate moiety of cAMP; two Q pockets that form hydrogen bonds and hydrophobic interactions with inhibitors; and a solvated pocket (S pocket).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> PDE4 inhibitors occupy this active site with a variety of interactions, including hydrophobic interactions with the conserved phenylalanine and isoleucine, and hydrogen bonds with the invariant glutamine. The highly conserved sequences and structural homology of the catalytic domains of PDE4s make the discovery of PDE4 subtype-selective inhibitors quite challenging.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0023.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Active site of PDE4D2. Dotted lines represent hydrogen bonds. Three inhibitors are shown: compound <b>1</b> (green), compound <b>14</b> (yellow), and compound <b>15</b> (salmon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The UCRs are the unique motifs of the PDE4 family and play an important role in the regulation of PDE4 activity.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The phosphorylation of the UCRs by protein kinase A (PKA) and extracellular signal-regulated kinase (ERK) regulates PDE4 dimerization and catalytic activities. UCR1 contains a conserved PKA phosphorylation site in PDE4 subfamilies. The activity of PDE4 is regulated by long-term transcriptional regulation or short-term posttranslational modifications. In long-term regulation, an increase of cAMP by PDE inhibition conjugates with activation of adenylyl cyclase (AC) by hormone stimulation. Studies have shown that this regulation is highly specific and is a result of increased gene expression. In short-term regulation, increase of cAMP levels activates PKA, which in turn phosphorylates specific serine residues in UCR1 of the long forms of PDE4. As a result, the activity of PDE4 increases rapidly, and the hydrolysis of cAMP causes the cAMP level to return to equilibrium. In addition, PDE4 activity is regulated by several proteins, including arrestin, Src family tyrosine protein kinases, A-kinase anchoring proteins (AKAPs), and receptor for activated C kinase 1 (RACK1).<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  PDE4 as a Therapeutic Target for Treatment of Human Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Members of four subfamilies, PDE4A, PDE4B, PDE4C, and PDE4D are expressed in various tissues and cellular compartments and involved in many physiological processes, including airway immunity, asthma, signaling of CNS, cardiovascular function, inflammatory processes, cell adhesion, and metabolic processes.<a onclick="showRef(event, 'ref7 ref10 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref7 ref10 ref17 ref18 ref19">(7,10,17−19)</a> As the key enzyme hydrolyzing cAMP in immune cells, PDE4 is one of the main targets of anti-inflammatory drugs.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> PDE4 is involved in the regulation of the activation and recruitment of inflammatory cells and the release of excessive or unregulated cytokines in many allergic and autoimmune diseases. For example, lipopolysaccharide (LPS) selectively induces PDE4B2 mRNA expression in human circulating monocytes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> PDE4 inhibitors inhibit LPS-mediated secretion of tumor necrosis factor α (TNF-α) in peripheral monocytes,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> indicating their important roles in anti-inflammation. In addition, PDE4B and PDE4D, but not PDE4A, play important regulatory roles in neutrophil function, such as inhibiting the release of a variety of proinflammatory mediators<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and delaying neutrophil apoptosis.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, PDE4 inhibitors caused airway smooth muscle relaxation, suggesting their potential values for the treatment of airway diseases.</div><div class="NLM_p">At present, four PDE4 inhibitors have been approved for the treatment of human diseases (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>): roflumilast (<b>1</b>) for COPD,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> crisaborole (<b>2</b>) for atopic dermatitis,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> apremilast (<b>3</b>) for psoriatic arthritis,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and ibudilast (<b>4</b>) for the rare child disease Krabbe by USA and for bronchial asthma by Japanese authority.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In addition, the dual selective PDE3/4 inhibitor RPL554 (<b>5</b>) is in phase II clinical trials for the treatment of COPD, and the PDE4 inhibitor BPN14770 (<b>6</b>) is in phase II clinical trials for the treatment of Alzheimer’s disease and fragile X syndrome (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0025.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of PDE4 inhibitors in clinic trials or in market.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. PDE4 Inhibitors in Clinic Trials or in Market</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug, owner</th><th class="colsep0 rowsep0" align="center">condition or disease</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">ClinicalTrials.gov identifiers<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">Roflumilast (<b>1</b>, Daxas, Daliresp), AstraZeneca</td><td class="colsep0 rowsep0" align="left">Severe chronic obstructive pulmonary disease</td><td class="colsep0 rowsep0" align="left">Approved by EU, June 2010, and USA, March 2011</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Asthma</td><td class="colsep0 rowsep0" align="left">Phase I December 2019 to March 2021</td><td class="colsep0 rowsep0" align="left">NCT04108377</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Asthma</td><td class="colsep0 rowsep0" align="left">Phase II, August 2018 to April 2020</td><td class="colsep0 rowsep0" align="left">NCT03532490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bronchiectasis</td><td class="colsep0 rowsep0" align="left">Phase II, July 2019 to December 2020</td><td class="colsep0 rowsep0" align="left">NCT03988816</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lymphoma, B-cell</td><td class="colsep0 rowsep0" align="left">Phase I, May 2018 to December 2020</td><td class="colsep0 rowsep0" align="left">NCT03458546</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bronchiectasis</td><td class="colsep0 rowsep0" align="left">Early Phase I October 1, 2019 to November 2020</td><td class="colsep0 rowsep0" align="left">NCT04090294</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">Crisaborole (<b>2</b>), Pfizer</td><td class="colsep0 rowsep0" align="left">Atopic dermatitis ointment</td><td class="colsep0 rowsep0" align="left">Approved by USA Dec 14, 2016</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Morphea</td><td class="colsep0 rowsep0" align="left">Phase II, September 2018 to December 2019</td><td class="colsep0 rowsep0" align="left">NCT03351114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Seborrheic dermatitis</td><td class="colsep0 rowsep0" align="left">Phase IV September 1, 2018 to September 2020</td><td class="colsep0 rowsep0" align="left">NCT03567980</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Atopic dermatitis eczema</td><td class="colsep0 rowsep0" align="left">Phase IV September 2019 to July 2020</td><td class="colsep0 rowsep0" align="left">NCT04023084</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="11" align="left">Apremilast (<b>3</b>, CC-10004, Otezla), Celgene</td><td class="colsep0 rowsep0" align="left">Psoriatic arthritis</td><td class="colsep0 rowsep0" align="left">Approved by USA, 2014</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Acne conglobata</td><td class="colsep0 rowsep0" align="left">Phase II October 9, 2019 to September 2020</td><td class="colsep0 rowsep0" align="left">NCT04161456</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dermatomyositis, adult type</td><td class="colsep0 rowsep0" align="left">Phase II June 12, 2018 to April 2020</td><td class="colsep0 rowsep0" align="left">NCT03529955</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lichen planus of vulva female genital disease</td><td class="colsep0 rowsep0" align="left">Phase II August 27, 2019 to December 1, 2020</td><td class="colsep0 rowsep0" align="left">NCT03656666</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Behcet syndrome</td><td class="colsep0 rowsep0" align="left">Phase III, December 2014 to March 2021</td><td class="colsep0 rowsep0" align="left">NCT02307513</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Nummular and dermatitis eczema</td><td class="colsep0 rowsep0" align="left">Phase II, July 2017 to March 2020</td><td class="colsep0 rowsep0" align="left">NCT03160248</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Psoriasis, psoriatic nail and vulgaris</td><td class="colsep0 rowsep0" align="left">Phase IV January 2017 to December 2019</td><td class="colsep0 rowsep0" align="left">NCT03022617</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alcohol use disorder</td><td class="colsep0 rowsep0" align="left">Phase II, November 2017 to December 2019</td><td class="colsep0 rowsep0" align="left">NCT03175549</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Recurrent aphthous stomatitis</td><td class="colsep0 rowsep0" align="left">Phase I, October 2018 to December 2019</td><td class="colsep0 rowsep0" align="left">NCT03690544</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dermatomyositis, adult type</td><td class="colsep0 rowsep0" align="left">Phase II, June 2018 to April 2020</td><td class="colsep0 rowsep0" align="left">NCT03529955</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lichen planus of vulva female genital disease</td><td class="colsep0 rowsep0" align="left">Phase II, January 2019 to December 2020</td><td class="colsep0 rowsep0" align="left">NCT03656666</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">Ibudilast (<b>4</b>, MN-166), MediciNova</td><td class="colsep0 rowsep0" align="left">Krabbe disease</td><td class="colsep0 rowsep0" align="left">Approved by USA, June 2016</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">poststroke complications and bronchial asthma</td><td class="colsep0 rowsep0" align="left">Approved by Japan and Korea, 1989</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Methamphetamine dependence</td><td class="colsep0 rowsep0" align="left">Phase II, May 2019 to January 2022</td><td class="colsep0 rowsep0" align="left">NCT03341078</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alcohol use disorder</td><td class="colsep0 rowsep0" align="left">Phase II, July 2018 to June 2020</td><td class="colsep0 rowsep0" align="left">NCT03489850</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alcohol use disorder</td><td class="colsep0 rowsep0" align="left">Phase II, October 2018 to September 2021</td><td class="colsep0 rowsep0" align="left">NCT03594435</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Glioblastoma</td><td class="colsep0 rowsep0" align="left">Phase I/II, December 2018 to December 2020</td><td class="colsep0 rowsep0" align="left">NCT03782415</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RPL554 (<b>5</b>), Verona Pharma</td><td class="colsep0 rowsep0" align="left">COPD</td><td class="colsep0 rowsep0" align="left">Phase II, May 2019 to October 2019</td><td class="colsep0 rowsep0" align="left">NCT03937479</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">BPN14770 (<b>6</b>), Tetra Discovery Partners</td><td class="colsep0 rowsep0" align="left">Alzheimer’s disease</td><td class="colsep0 rowsep0" align="left">Phase II, April 2019 to June 2020</td><td class="colsep0 rowsep0" align="left">NCT03817684</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fragile X syndrome</td><td class="colsep0 rowsep0" align="left">Phase II, June 2018 to December 2019</td><td class="colsep0 rowsep0" align="left">NCT03569631</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data collected from <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> [Last accessed December 1, 2019].</p></div></div></div><div class="NLM_p">In recent years, studies on the medical applications of PDE4 inhibitors have shifted to their uses in treatment of cognitive disorders. PDE4A, -4B, and -4D are expressed in the central nervous system, while PDE4C is mainly expressed in the peripheral nervous system. PDE4A plays an important role in anxiety and emotional memory.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> PDE4B is involved in dopamine and stress-related signaling and may thus potentially relieve cognitive impairment.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> PDE4D is an important regulatory factor in depression, learning, and memory dysfunctions.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> The PDE4D gene is highly expressed in the hippocampus, and PDE4D gene-deficient mice exhibit long-term potentiation that significantly increases learning ability, memory, and nerve regeneration.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> The potential applicability of PDE4 inhibitors in improving learning and memory is well supported experimentally. For example, compound <b>14</b> improves learning and memory by inhibiting PDE4 activity and influencing cAMP-mediated signaling pathways such as the cAMP/PKA/CREB and EPAC/ERK signaling pathways (EPAC, exchange protein directly activated by cAMP).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The intervention and regulation of PDE4 provide new therapeutic strategies for the treatment of neurological diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and cerebral ischemia. PDE4 inhibitors relieve AD through reduction of neuroinflammation and benefit memory consolidation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Although the etiology of PD has not been completely revealed, involvement of PDE4 in regulation of oxidative stress in neurodegeneration of PD is obvious.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a></div><div class="NLM_p">Many PDE4 inhibitors have been developed for the treatment of neurological diseases; for example, HT0712 (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), etazolate (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), compound <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), and MK-0952 (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) were tested in clinical trials. Compound <b>7</b>, also known as IPL-455903, enhanced memory and promoted motor function recovery after cerebral ischemia by stimulating the generation of synapses in the cortex<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and showed the positive results in the phase II clinical trial of age-associated memory impairment (AAMI).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Etazolate (<b>9</b>, EHT-0202), as a PDE4 inhibitor and a GABA-A receptor modulator, increased expression of the α-secretase enzymes and APP alpha secretion.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Compound <b>9</b> was generally tolerated in clinical trials for the treatment of the early Alzheimer’s disease but showed dose-dependent and central nervous system-related adverse events.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Compound <b>6</b>, a PDE4D allosteric modulator, enhanced the long-term potential in hippocampal slices and is currently in phase II clinic trials for treatment of the early Alzheimer’s disease and fragile X syndrome (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> MK-0952 was tested in a phase II clinic trial for its effect on improving cognitive impairment in patients with mild-to-moderate AD.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Compound (<i>S</i>)-Zl-n-91 (<b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) has the IC<sub>50</sub> values of 12 nM for PDE4D and 20 nM for PDE4B and showed potent neuroprotection activities in ICR mice.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> In addition, GEBR PDE4 inhibitors such as GEBR-20b (<b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) facilitated long-term potentiation and improved memory without emetic-like behavior in rodent tests.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45−48)</a> Thus, in-depth studies on the specific functions and regulatory mechanisms of PDE4s and their inhibitors in the central nervous system may result in new platforms for the treatment of neurological diseases.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0026.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PDE4 inhibitors in the nervous system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, regulation of the cellular cAMP level via PDE4 inhibition is directly related to pathological functions of tumors, such as tumor cell migration and proliferation, as well as tumor vascularization and development.<a onclick="showRef(event, 'ref8 ref49'); return false;" href="javascript:void(0);" class="ref ref8 ref49">(8,49)</a> Genetic studies showed that PDE4D is related to the expression of the thiol purine gene set, leading to an investigation of PDE4-based purine drugs for the treatment of various tumors. Moreover, PDE4B was reported to regulate glucocorticoid reactivity of B-cell lymphoma.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> PDE4 has been shown to have the highest cAMP hydrolysis activity in 41 out of 60 tumor cell lines,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> highlighting its potential for the treatment of cancers.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">4.  Subfamily Selective PDE4 Inhibitors and Emesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48843" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48843" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although PDE4 has been identified as a therapeutic target, the clinical development of inhibitors has been hampered by dose-limiting side effects, most notably, nausea and vomiting, which were observed with the first-generation PDE4 inhibitors such as compound <b>14</b> and the second-generation inhibitors such as compound <b>15</b>. The early studies suggested that the emesis results from the inhibition of PDE4D. Knocking out PDE4B, but not PDE4A/PDE4D, significantly inhibited the synthesis of TNF-α in LPS-mediated monocyte and peritoneal macrophages. In mouse allergic asthma models, Th2 cell function was regulated by PDE4B rather than PDE4A/PDE4D.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In addition, a study on lighting reflection of rodents showed that the inhibition of PDE4D but not PDE4B may be the cause of the emesis observed in the study of nonsubfamily selective PDE4 inhibitors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> This is shown by several PDE4B selective inhibitors such as compound <b>38</b> that has potent anti-inflammatory effects and reduced emetic effects.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> However, recent studies implied that inhibition of PDE4D may not be a key factor to cause vomiting.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">Structural superposition between the catalytic domains of PDE4B and PDE4D showed that the active site residues for the binding of PDE4 inhibitors are identical and have the same conformation, including the invariant glutamine and phenylalanine (Q443 and F446 of PDE4B2B, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) that are two basic residues for binding of substrates and inhibitors of PDEs. The only minor difference between the active sites of PDE4B and PDE4D is the conformation of Met431 of PDE4B (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Thus, it will be difficult to design PDE4 subfamily selective inhibitors against only the catalytic domain of PDE4. The crystal structures of PDE4 plus UCR2 domain<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> showed that an UCR2 helix completely covered the active site of PDE4 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The sequence variation in UCR2 among the PDE4 subfamilies may allow the design of PDE4 subfamily selective inhibitors.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0027.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Active site of PDE4. Dotted lines represent hydrogen bonds. Residues are numbered using the PDE4B2B sequence. (A) Surface presentation on binding of compound <b>1</b> (yellow sticks) to PDE4B (green sticks) and PDE4D (white sticks). P1–P3 and CORE denote four potential pharmacophores of PDE4 inhibitors. (B) Coverage of the PDE4 active site by a UCR2 helix (yellow ribbons). (C) Interaction of compound <b>1</b> with the UCR helix.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On basis of the fact that a tyrosine in the UCR2 region of PDE4A/B/C (Tyr274 of PDE4B3) corresponds to a phenylalanine in PDE4D, a PDE4D-selective allosteric modulator was designed and showed good therapeutic efficacy and reduced emesis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> This PDE4 allosteric modulator interacts with both the active site and a helix of UCR2, implying a possibility of development of a PDE4 subfamily selective inhibitor. The crystal structure of PDE4D in complex with inhibitor PMNPQ (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) showed that Phe196 of PDE4D3 from the UCR2 helix, which corresponds to Tyr274 of PDE4B3, plays a key role in ligand binding.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> By utilization of this difference, several PDE4D selective inhibitors have been developed, such as D159687 (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) and compound <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which have a 100-fold selectivity between PDE4D and PDE4B.<a onclick="showRef(event, 'ref55 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref55 ref58 ref59 ref60">(55,58−60)</a> In particular, compound <b>6</b>, the first PDE4D selective inhibitor, entered phase II clinical trials for the treatment of Alzheimer’s disease and fragile X syndrome.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, both PDE4B and PDE4D negative allosteric modulators are shown to play important roles in neurological diseases such as AD.<a onclick="showRef(event, 'ref58 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref58 ref60 ref61">(58,60,61)</a> On the basis of the difference of tyrosine/phenylalanine, the PDE4B allosteric modulators can be designed and showed the potential to reduce neuroinflammation via inhibition of the production of microglia from cerebral amyloid, while the PDE4D allosteric modulator enhances memory consolidation.<a onclick="showRef(event, 'ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61">(58−61)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0028.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PDE4B/4D subfamily selective inhibitors <b>12</b> and <b>13</b> and binding of <b>12</b> to PDE4B (cyan sticks and ribbons, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G45">3G45</a>) and PDE4D (green sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G58">3G58</a>). Tyr274 of PDE4B (a phenylalanine in PDE4D) from UCR helix determines the subfamily selectivity, while the residues in the active sites show great conservation in both sequence and conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The UCR2-catalytic domain interactions block substrate entry into the active site or product release, and therefore the activity of different splice variants of PDE4 can be modulated differently. This study opens a new avenue for the design of small molecule inhibitors specifically targeting PDE4 specific splice variants. Since the PDE4 allosteric modulators interact with both UCR2 and the catalytic domain, they may preferentially inhibit a certain form of PDE4 subfamilies and also have less chance to interact with nontargeted proteins. As a result, they may be less toxic than other PDE4 inhibitors, as shown by BPN14470 that is currently in phase II clinic trials for treatment of Alzheimer’s disease and fragile X syndrome (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">5.  Survey of PDE4 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">5.a.  Catechol Ether-Based PDE4 Inhibitors</h3><div class="NLM_p">Catechol ether simulates the hydrophobic properties of the adenine portion of cAMP and, thus, has been used as a scaffold for many PDE4 inhibitors,<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> such as the first-generation drug rolipram (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and more advanced roflumilast (<b>1</b>) analogs. The crystal structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMY">1XMY</a>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) showed that the catechol ether-containing compounds form a hydrogen bond with the invariant glutamine across the PDE families and also π–π stacking against a conserved phenylalanine (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compound <b>14</b> is sandwiched by the hydrophobic clamp made up of conserved phenylalanine and isoleucine on the two sides (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). These interactions, hydrogen bonding with the invariant glutamine and stacking against the phenylalanine, occurred in almost all the inhibitors-PDEs crystal structures and thus form the basic affinities of the PDE inhibitors.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0029.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of catechol ether-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0030.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray crystal structure of PDE4B-compound <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMY">1XMY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The dialkoxyphenyl attachments of the compounds in this category are often the methoxy and cyclopentyloxy groups, such as in compound <b>14</b> and cilomilast (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The methoxy group oriented into the small Q<sub>1</sub> pocket that is formed by Tyr233, Asn395, Thr407, and Tyr403 of PDE4B. The larger hydrophobic cyclopentyl moiety occupied the Q<sub>2</sub> pocket formed by Phe414, Met411, Met431, and Phe446 of PDE4B.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Compound <b>14</b> has been extensively studied for the treatment of various diseases, including asthma, but shows severe side effects including dizziness, headache, nausea, and vomiting.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> It is often used as a positive control for studies of PDE4 inhibitors. Compound <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), developed by GlaxoSmithKline, is a selective PDE4 inhibitor with an IC<sub>50</sub> of 95 nM. Compound <b>15</b> was tested for the treatment of COPD but caused severe adverse reactions, including nausea, vomiting, headache, abdominal pain, diarrhea, and indigestion.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> In the phase III clinical trial on asthma, the FEV1 values of the patients treated with compound <b>15</b> were <0.03 L, indicating lack of clinical efficacy on the improvement of lung function.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Tetomilast (<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a PDE4 inhibitor with an IC<sub>50</sub> value of 74 nM, suppresses the expression of TNFα and IL-12 in LPS-stimulated human monocytes and the production of interferon γ and IL-10 in CD4 lymphocytes at the transcriptional level.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In a phase II clinical trial of 246 patients with COPD, the 12 week treatment with compound <b>16</b> (50 mg) improved peak FEV1 to 50 mL and forced vital capacity (FVC) to 130 mL. However, this clinical trial was terminated in 2017.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">Compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) is an oral and selective PDE4 inhibitor with IC<sub>50</sub> of 74 nM and was studied for the treatment of autoimmune diseases. Compound <b>3</b> acts on many types of cells and shows a wide range of anti-inflammatory activities such as inhibition on production of TNF-α, IL-12, and IL-23 and responses of natural killer cells and keratinocytes. Clinical data show that compound <b>3</b> significantly improved psoriasis of nails, scalp, and palmar (hands and feet). Compound <b>3</b> was approved by the U.S. FDA in 2014 for the treatment of active psoriatic arthritis and moderate to severe plaque psoriasis by oral administration. Additional clinical trials on the treatment of other diseases are underway (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), including cardiovascular diseases, parapsoriasis, palmoplantar psoriasis, psoriasis of the scalp, and psoriasis vulgaris.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Replacement of the phenyl ring of compound <b>3</b> with a thiophene yields compound <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) that has an IC<sub>50</sub> value of 26 nM.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Expansion of the acetyamide group of compound <b>3</b> led to a series of highly selective PDE4 inhibitors (<b>18</b>, <i>n</i> = 3–9, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) with IC<sub>50</sub> values of 3–8 nM.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Compound <b>19</b> (IC<sub>50</sub> = 40 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and its analogs are benzodiazepinone-derived catechol ether with amine-containing chains.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a></div><div class="NLM_p last">In short, it can be summarized as follows: (1) The two substituents on the catechol ether occupy the hydrophobic Q<sub>1</sub> and Q<sub>2</sub> pockets. (2) The hydrophilic group orients to the solvation region and hence effectively enhances the affinity of the compounds. (3) The interactions with water molecules in metal ion pocket significantly increase the inhibitory capacity of the compounds.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">5.b.  Compound <b>1</b> Analogs</h3><div class="NLM_p">Compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), the first marketed PDE4 inhibitor, was approved for the treatment of severe COPD-associated chronic bronchitis in Europe in 2010 and in the USA in 2011. Clinical studies showed that compound <b>1</b> reduced inflammation and fibrosis in lung, enhanced mucosal clearance, and remodeled the airways. Adverse reactions were mainly diarrhea, weight loss, nausea, atrial fibrillation, and increased mental illness (such as insomnia, anxiety, and depression). In addition, compound <b>1</b> was studied for the treatment of asthma, noncystic fibrosis bronchiectasis, obesity, and lymphoma B-cells (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">Compound <b>1</b> has a remarkable inhibitory affinity toward PDE4B and PDE4D, with IC<sub>50</sub> values of 0.84 nM and 0.68 nM, respectively.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The X-ray crystal structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) showed that the difluoromethoxy group of compound <b>1</b> interacts with the Q<sub>1</sub> pocket and the cyclopropylmethoxy group occupies the Q<sub>2</sub> pocket. The 3,5-dichloropyridyl group extends into the metal binding pocket to form a hydrogen bond with the water molecule.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Replacement of the methyl cyclopropane of compound <b>1</b> with longer-chain aminofuran leads to compound <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Compound <b>20</b> showed IC<sub>50</sub> of 5.4 and 18 nM for PDE4B1 and PDE4D2, respectively.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Compounds <b>21</b>, <b>22</b>, and <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) were designed by modification of the amide linker between the dichloropyridine and catechol ether of roflumilst and showed subnanomolar inhibitory activities against PDE4.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> CHF6001 (<b>23</b>, IC<sub>50</sub> = 26 pM, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) explored the chemical space of the solvent-exposed region of the enzyme and inhibited the release of the proinflammatory cytokine TNF-α from LPS-stimulated PBMCs.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The phase II clinical trial of compound <b>23</b> on 1130 COPD patients was completed in January 2018 and showed no significant emesis at tested doses.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> However, the clinical results of the phase III trial have not been revealed yet.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of compound <b>1</b> analogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Piclamilast (<b>24</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) combines the structural features of compound <b>14</b> and compound <b>1</b> and showed IC<sub>50</sub> values of 41 and 21 pM for PDE4B and PDE4D, respectively. The cyclopentyl ether binds to the Q<sub>2</sub> pocket, while the methoxy group occupies the Q<sub>1</sub> pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XM4">1XM4</a>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b). The 3,5-dichloropyridyl group forms hydrophobic interactions with Met347, Leu393, and Phe414 and extends into the metal pocket to form a hydrogen bond with the water molecule (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The replacement of the central phenyl group of compound <b>24</b> with chromenone yields compound <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) that has an IC<sub>50</sub> of 5 nM against PDE4B.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. X-ray crystal structure of PDE4. (A) Compound <b>1</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>). (B) Compound <b>24</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XM4">1XM4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>26</b> (LEO-29102, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) was designed by modification of dimethyl catechol ether and dichloropyridine of compound <b>1</b>.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> By introduction of a soft spot in the 2′-position, no cases of emesis were observed in the clinical study and may thus work as a soft drug for the treatment of AD. Compound <b>26</b> was tested in a phase II clinical trial for the treatment of eczema, atopic dermatitis and psoriasis, but no recent progress has been reported. The introduction of catechol pyrimidine core, which is a potential bioisostere of adenosine and also mimics the nucleotide part of the cAMP, yielded a series of novel compounds, such as compound <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) that shows an IC<sub>50</sub> of 15 nM against PDE4B.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">In short, we can conclude that (1) the 3,5-dichloropyridine moiety interacts with Mg<sup>2+</sup>-bound water; (2) the Q<sub>1</sub> and Q<sub>2</sub> pockets are filled respectively with the small and large attachments of the catechol ether; and (3) inappropriate modification of the amide linker reduced the affinity of inhibitors, such as in the cases of compounds <b>25</b>, <b>26</b>, and <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic presentation of compound <b>1</b> interaction with PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">5.c.  Quinoline-Based PDE4 Inhibitors</h3><div class="NLM_p">GSK256066 (<b>28</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) has an IC<sub>50</sub> value of 3.2 pM for PDE4 and high selectivity over other PDEs and is an inhaled PDE4 inhibitor for the treatment of asthma.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> A large number of studies showed that compound <b>28</b>, delivered orally or by inhalation, reduced FVC and inhibited allergen-mediated eosinophilia, airway hyperresponsiveness and remodeling, mucin production, and goblet cell hyperplasia in CD rats or other rodent models.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Compound <b>28</b> significantly inhibited early and late allergic responses by 26.2–34.3% but limitedly decreased the FEV1 and weighted FEV1 values by 40.9% and 57.2%, respectively. This compound underwent phase II clinical trials for asthma, COPD, and allergic rhinitis. Clinical trials were completed, but further development of compound <b>28</b> is not evident since the compound no longer appears in the GSK product pipeline.<named-content content-type="anchor" rid="fig14" type="simple"></named-content></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of quinolone analogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. X-ray crystal structure of compound <b>28</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GWT">3GWT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) has a 2-trifluoromethyl-8-methoxyquinoline core and exhibited high PDE4 inhibitory potency (IC<sub>50</sub> = 0.01 nM).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Derivatizing the amide group afforded compound <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), whose xinafoate salt inhibited inflammatory responses by 69% at 0.02 mg kg<sup>–1</sup> day<sup>–1</sup> in rat model, and monkey PK studies of <b>30</b> showed no emesis (AUC = 31 ng·h/mL at 10 mg/kg po).<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> Optimization of both the 4-benzylcarboxamide and 5-α-aminoethyl groups leads to an orally active, highly selective compound with picomolar potency against PDE4. For example, compound <b>31</b> (IC<sub>50</sub> = 60 pM, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) is a very potent PDE4 inhibitor with high selectivity over PDE10 (15 800-fold) and has an IC<sub>50</sub> of 0.6 nM for the inhibition of TNF-α release in a cell-based assay.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> At an oral dose of 10 mg/kg, compound <b>31</b> was found to have <i>C</i><sub>max</sub> = 960 nM and 24% bioavailability in a rat PK study. In an <i>in vivo</i> rat LPS-induced pulmonary inflammation model, compound <b>31</b> was highly efficacious with ED<sub>50</sub> = 0.1 mg/kg following oral administration.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">The binding mode of quinoline inhibitors to PDE4 is summarized as follows (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>): (1) the methoxy and difluoromethyl groups form hydrophobic interactions with the Q<sub>1</sub> and Q<sub>2</sub> pockets of PDE4, respectively; (2) the quinoline ring stacks against the phenylalanine via π–π interactions; (3) R<sub>2</sub> interacts with the S pocket, and thus its size influences the activity.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Interactions of compounds <b>29</b>–<b>31</b> with PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">NVP-ABE-171 (<b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) has the IC<sub>50</sub> values of 602, 34, 1230, and 1.5 nM for four subtypes of PDE4 (A, B, C, D) and was tested for treatment of asthma and chronic obstructive pneumonia.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Compound <b>32</b> inhibited the activation of airway neutrophils with an ED<sub>50</sub> value of 3 mg/kg in BALB/c mice and of 0.2 mg/kg in the Norway rat model. It also inhibited ovalbumin-induced airway eosinophil activation with an ED<sub>50</sub> of 0.1 mg·kg<sup>–1</sup>. However, the relatively poor pharmacokinetic parameters (especially solubility) of compound <b>32</b> hinder its further development. Replacement of the benzoxadiazole of <b>32</b> with fluorobenzene leads to compound <b>33</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), which exhibited 400-fold improvement of water solubility, good pharmacokinetics, and no significant nausea and emesis. YM976 (<b>34</b>,<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) is a pyrimidine derivative and structurally different from the other PDE4 inhibitors such as compound <b>14</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> YM976 inhibited PDE4 with an IC<sub>50</sub> value of 2.2 nM, inhibited cell infiltration into the pleural cavity with an oral ED<sub>30</sub> of 9.1 mg/kg in a rat carrageenan-induced pleurisy model, and produced no emesis at doses of up to 10 mg/kg.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">5.d.  PDE4 Inhibitors with a Scaffold of Fused Bicyclic Rings</h3><div class="NLM_p">Several compounds with a scaffold of the fused bicyclic ring show excellent PDE4 inhibitory activities. Ronomilast (ELB353) (<b>35</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) is a potent oral PDE4 inhibitor with an IC<sub>50</sub> of 3 nM and good pharmacokinetic properties in Lewis rat or ferrets.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In the preclinical and phase I trials, compound <b>35</b> demonstrated efficacy for the treatment of inflammation-related diseases and no severe adverse events in humans. AWD12-281 (<b>36</b>, GSK842470, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) is an inhaled PDE4 inhibitor with an IC<sub>50</sub> of 9.7 nM and an EC<sub>50</sub> of 110 nM for TNF-α release. It was tested in phase II clinical trials for the treatment of COPD, asthma, and allergic rhinitis.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of PDE4 inhibitors with a fused bicyclic ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the combination of dimethoxybenzene, indole, and dihydropyridine, compound <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) was found to be a potent PDE4 inhibitor with IC<sub>50</sub> values of 0.54 and 0.65 nM for PDE4B and PDE4D, respectively.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The docking of <b>37</b> to PDE4B/PDE4D showed that its indole moiety has two possible orientations in PDE4D and forms hydrogen bonds with Glu396 or Glu505, whereas <b>37</b> exhibits a completely different orientation in PDE4B and forms a hydrogen bond with Ser442. The dimethoxy groups of <b>37</b> interact with the metal ions in PDE4B, and the indole moiety forms hydrogen bonds to Gln443.</div><div class="NLM_p">GSK356278 (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), a selective and brain-penetrable PDE4B inhibitor with the pIC<sub>50</sub> value 8.8, showed a therapeutic index superior to both compound <b>14</b> and compound <b>1</b> and had beneficial effects on anxiety and cognition in primates without emesis or other dose-limiting side effects.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> However, compound <b>38</b> was apparently discontinued after phase I safety and tolerability studies in 2012.</div><div class="NLM_p">High throughput screening led to the discovery of pyrazolopyridine-containing compound <b>39</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), a potent and selective PDE4 inhibitor. Compound <b>39</b> inhibits LPS-induced TNF-α production and shows an encouraging PK profile in rat, indicating its suitability for oral administration.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The structure of PDE4B-<b>39</b> showed that the pyrazolo[3,4-<i>b</i>]pyridine moiety forms a hydrogen bond with Gln443, and the <i>N</i>-ethyl substituent occupies the lipophilic pocket, similar to the pattern of compound <b>14</b> binding (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3D3P">3D3P</a>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Exploration of the SAR on the amide fragment of <b>39</b> led to the discovery of compound <b>40</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), which has a few tens of picomolar affinity with PDE4 and subnanomolar inhibition on LPS-induced TNFα production in human peripheral blood mononuclear cells.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0009.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. X-ray crystal structure of <b>39</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3D3P">3D3P</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modification of the pyrazolopyridine scaffold led to preparation of compound <b>41</b> (IC<sub>50</sub> = 26 nM, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Molecular docking of compound <b>41</b> to the crystal structure of PDE4B showed that interactions of the amide, 3-methoxyaryl, and sulfone groups with PDE4B completely coincide with those of compound <b>28</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GWT">3GWT</a>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). A nitrogen in the heterocyclic ring and the amide form hydrogen bonds with Gln443 through a water molecule, in addition to a hydrogen bond between the amide of <b>39</b> and Asn395.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Cyclization of the primary amide at the 5-position of the pyrazolo[1,5-<i>a</i>]pyrimidine yielded compound <b>42</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) and improved the affinity by 200-fold (IC<sub>50</sub> = 0.03 nM). The amide of <b>42</b> contacted Asn395 and displaced a water molecule.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p">We can summarize the above discussion as follows (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). (1) The pyridine core inserts into the hydrophobic clamp and forms a hydrogen bond with Gln443 of PDE4B to increase the binding strength. (2) The amide branch forms a hydrogen bond with Asn321 of PDE4D2 in the active site while interacting with the small hydrophobic pocket (Q<sub>1</sub>). The inhibitory activity could be significantly increased if the amide branch is a lactam. (3) The substituent at the 2- or 3-position of pyridine fills the large hydrophobic pocket (Q<sub>2</sub>). (4) The aryl fragment at the 4-position of pyridine interacts with ion pocket to increase its inhibitory activity.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0010.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Interactions of compounds <b>38</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">5.e.  Pyrimidine-Based PDE4 Inhibitors</h3><div class="NLM_p">Compound <b>43</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) was identified as an orally active PDE4B-selective inhibitor and had IC<sub>50</sub> values of 5.5 nM and 440 nM for PDE4B and PDE4D, respectively.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Its therapeutic index, which was calculated based on its inhibitory effect on LPS inhalation-induced neutrophilia and gastric emptying, was similar to that of compound <b>1</b> in mice. Replacements of the sulfide with a sulfone and of the fluorine with chlorine of <b>43</b> afforded highly selective PDE4B inhibitor <b>44</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), which had an IC<sub>50</sub> of 3 nM for PDE4B and 433-fold selectivity over PDE4D.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Changing the sulfonyl moiety to a lactam and the carboxylic acid to an <i>N</i>-neopentylacetamide afforded compound <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), which has an IC<sub>50</sub> of 7.3 nM against PDE4B and potently inhibited LPS-induced TNF-α production in mouse splenocytes (IC<sub>50</sub> = 0.21 nM) and LPS-induced pulmonary neutrophilia <i>in vivo</i> in mice by 41% at a dose of 1.0 mg/kg (i.t.).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The crystal structure of PDE4B-<b>45</b> showed that its pyrimidine ring forms π–π stacking against Phe446 of PDE4B, while the neopentyl amide moiety occupies a lipophilic Q<sub>1</sub> pocket.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0011.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of pyrimidine-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), with a 2-arylpyrimidine core, showed anti-inflammatory therapeutic potential and a wider safety margin than compound <b>15</b>.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The central pyrimidine ring of <b>46</b> is sandwiched by Phe618 and Ile582 of PDE4B and forms a hydrogen bond with Gln615. The aryl group extends into the metal pocket and forms a hydrogen bond with the water molecule bound to Mg<sup>2+</sup>, while the ethyl and methyl substituents fit the Q<sub>1</sub> pocket. In the mouse model, <b>46</b> showed a strong antidepressant effect in mouse models of forced swim and tail suspension.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p last">Compound <b>47</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) had an IC<sub>50</sub> of 7 nM for PDE4 and an EC<sub>50</sub> of 0.01 mg/kg for TNF-α inhibition in a mouse sepsis model and reduced ear thickness by 40% in a psoriasis model.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Introduction of a pyrido[3,2-<i>d</i>]pyrimidine substituent resulted in compounds such as <b>48</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) with IC<sub>50</sub> = 0.4 nM against PDE4.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">5.f.  Pyridazinone-Based PDE4 Inhibitors</h3><div class="NLM_p">Zardaverine (<b>49</b><a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) interacts with the catalytic site via hydrogen bonds between (1) the catechol oxygen and the side chain of invariant Gln369 of PDE4D2 and (2) the pyridazinone oxygen and the nitrogen atom of His160. The pyridazinone moiety of compound <b>49</b> is surrounded by residues Leu319, Ser320, and Asn321 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOR">1XOR</a>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0013.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of pyridazinone-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0014.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. X-ray crystal structure of PDE4D2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOR">1XOR</a>) in complex with compound <b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tetrahydrophthalazinone derivatives such as compound <b>50</b> (IC<sub>50</sub> = 4 nM, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) can be considered as an analog of compound <b>49</b>, but molecular modeling revealed that the <i>cis</i>-fused cyclohexane ring occupies a different region from that of compound <b>49</b>. Therefore, it was assumed that the steric interactions of these rings with the residues in the binding site of PDE4 play an important role in enzymatic inhibition. On the other hand, substitution of the pyridazinones with pyrazoles/1,2-diazepin-7-ones or N-substitution on compound <b>49</b> led to a series of new derivatives such as <b>51</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) that has pIC<sub>50</sub> of 9.45.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p last">Optimization of the pyridazinone branch resulted in compound <b>52</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The X-ray crystal structure of human PDE4D in complex with <b>52</b> demonstrated that the pyridazinone core sits in the hydrophobic clamp and forms a hydrogen bond with Glu369. The ethyl branch at the 6-position of the benzene ring of <b>52</b> fits in the lipophilic pockets, while the benzoate extends into the outer solvated space. Replacement of the acetyl carbonyl group with a urea link between 3,5-dichloropyridine and pyridazinone led to compounds <b>53</b> and <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), which were shown to be potent, long-acting, and potentially safe inhaled PDE4 inhibitors.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> The combinatorial assembly of functional linkers led to compounds such as <b>55</b>, in which a phenyl ring is connected to the C4 pyridazine atom.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.g.  Methoxy Heteroaromatic-Based PDE4 Inhibitors</h3><div class="NLM_p">Compound <b>4</b> (AV-411 or MN-166, <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), an anti-inflammatory drug approved in Japan and Korea, inhibited human PDE4A-D with IC<sub>50</sub> values of 54, 65, 239, and 166 nM, respectively, as well as weakly inhibiting other PDE families.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Compound <b>4</b> was shown to be a bronchodilator and vasodilator, had neuroprotective effects, and was used for oral treatment of asthma, stroke, and topical treatment of allergic conjunctivitis.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In addition, phase II clinical trials are underway for treatments of progressive multiple sclerosis, neuroinflammation, amyotrophic lateral sclerosis as an adjunct to riluzole, chronic migraine, and alcohol use disorder (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>4</b> was approved as an orphan drug in the U.S. for the treatment of progressive Krabbe disease in 2015 and for the treatment of poststroke complications and bronchial asthma in Japan and Korea in 1989.</div><div class="NLM_p">Installation of a methoxyl substituent and 3,5-dichloropyridine onto the heterocycle of compound <b>4</b> leads to compound <b>56</b> (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) that showed dramatic improvement in PDE4 inhibition (IC<sub>50</sub> of 0.27 nM). The docking of compound <b>56</b> to the PDE4 catalytic domain suggested that the amide linker is largely responsible for the improved activity.<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> The nitrogen at position 1 of the pyrazolopyridine interacted with the invariant glutamine, and the pyridine ring extended into the metal binding pocket to form hydrogen bonds with water.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0015.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of methoxy heteroaromatics PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lotamilast (E6005, RVT-501, <b>57</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) is a selective PDE4 inhibitor with an IC<sub>50</sub> of 2.8 nM and suppresses the production of various cytokines in human lymphocytes and monocytes.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Topical application of 0.03% compound <b>57</b> to the rostral back significantly inhibited the activity of the cutaneous nerves and increased the cAMP concentration in mice with chronic dermatitis.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Lotamilast completed phase II clinical trials sponsored by Dermavant Sciences Inc. for the treatment of atopic dermatitis in July, 2017.</div><div class="NLM_p last">Oglemilast (<b>58</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) is an oral PDE4 inhibitor for asthma and rheumatoid arthritis and exhibited an IC<sub>50</sub> value of 1.4 nM for PDE4 and showed high selectivity over other PDEs. Compound <b>58</b> inhibited LPS-induced TNF-α production (IC<sub>50</sub> = 190 nM) and blocked LPS-induced pulmonary neutrophilia in rats (ID<sub>50</sub> = 1.45 mg/kg) without obvious side effects.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> However, the phase IIb clinical data were discouraging and showed no evidence of clinical effects.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Revamilast (<b>59</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) was launched by Glenmark as a PDE4 inhibitor after the failure of compound <b>58</b> and showed an IC<sub>50</sub> of 2.7 nM for PDE4 and high selectivity over other PDEs. In 2011, Glenmark globally announced the initiation of a phase IIb trial of compound <b>59</b> on chronic inflammatory disorders such as asthma and rheumatoid arthritis. However, the phase IIb data were discouraging and the trial was discontinued.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.h.  Triazine-Based PDE4 Inhibitors</h3><div class="NLM_p">Compound <b>60</b>, a 1,3,5-substituted triazine derivative (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), was identified by screening a compound library and inhibited PDE4A with an IC<sub>50</sub> value of 245 nM. Structure-based design leads to compound <b>61</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KP6">4KP6</a>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), a potent and orally active PDE4 inhibitor with an IC<sub>50</sub> value of 1 nM against PDE4A, -4B, and -4D.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The crystal structure (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) showed that the triazine core was located in the hydrophobic clamp and that the substituents occupied the Q<sub>1</sub> and Q<sub>2</sub> pockets. The triazine ring forms hydrogen bonds directly with Gln443 and indirectly with Asn395, Tyr233, and Asp392 via a water molecule, in addition to π–π stacking interactions with Phe446 and Phe414 of PDE4B.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0016.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of triazine-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0017.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Diagram of the interactions between PDE4B and <b>61</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KP6">4KP6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.i.  Cyclohexanediamide-Based PDE4 Inhibitors</h3><div class="NLM_p">A class of pyridopyrimidinedione derivatives containing cyclohexanediamide, such as compound <b>62</b> (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>), have been reported.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a> Compound <b>62</b> inhibited PDE4B2 with a pIC<sub>50</sub> of 9.9. UK-500,001 (<b>63</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>), developed by Pfizer for inhaled delivery, has IC<sub>50</sub> values of 0.38–1.9 nM for PDE4A, -B, and -D and strongly inhibited TNF-α production (IC<sub>50</sub> = 0.13 nM). However, the phase II clinical data of its use against asthma showed that this compound does not effectively improve allergen-induced FEV1 but shows the typical side effects of PDE4 inhibitors. Therefore, Pfizer ceased further development of compound <b>63</b>. AstraZeneca obtained several patents for 2-phenoxypyridin-3-ylamide derivatives, such as compound <b>64</b> (pIC<sub>50</sub> = 11, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> These compounds contain a cyclohexanediamide motif similar to that of compound <b>63</b> and show pIC<sub>50</sub> values between 10 and 11.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0018.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structures of cyclohexanediamide-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In summary, for the conservation of the binding patterns, PDE4 inhibitors can be divided into four pharmacophores for design: P1–P3 and CORE (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a>). The CORE contributes the basic affinity for all inhibitors and fits to the hydrophobic clamp of the PDE4 active site. Pharmacophores P1–P3 respectively oriented to subpockets of Q<sub>1</sub> and Q<sub>2</sub> and the solvent region.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0019.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Superposition of PDE4 inhibitors, which are colored with green (compound <b>1</b>), yellow (GEBR20b, <b>11</b>), cyan (compound <b>24</b>), salmon (coumarin), orange (compound <b>46</b>), and pink (naph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">6.  Natural Products as PDE4 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Natural products have served as original sources of current drugs and attracted a great deal of attention for their benefits for human health in the past years. While functions of natural products may be achieved via interactions with multiple targets, regulation on the second messenger cAMP has been recognized as an important mechanism.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> As the key regulator of the cAMP signaling pathways in physiological processes, PDE4 probably serves as a cellular receptor for many natural products and traditional herbal medicines to exert their beneficial effects on human health.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Nonselective inhibition of PDEs may be a general pattern for functions of many natural products and traditional herbal medicines. A well-known example of such natural products is theophylline (<b>65</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), which is a nonselective inhibitor of PDEs with IC<sub>50</sub> values of 50–100 μM that is a first generation respiratory drug for the treatment of asthma and COPD.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0020.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of natural products that inhibit PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example is the superfamily of flavonoids that are abundant and key bioactive components of our daily foods and have been thought to exert their nutritional effects via the nonselective inhibition of PDEs.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Many flavonoids with a chromone scaffold (quercetin (<b>66</b>), genistein, luteolin, daidzein, hesperidin, prunetin, diosmetin, biochanin A, apigenin, and myricetin), which are nutrition supplements involved in regulation of various biological processes, are nonselective inhibitors of PDEs with affinity in the tens of micromolar range.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> A recent study showed that the cocktail of antileukemia drug dasatinib and natural product compound <b>66</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) prolongs the lifespan of mice by 36%.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The mechanism for the cocktail to increase lifespan is not clear, but perhaps the PDE4-cAMP signaling pathway plays a critical role since compound <b>66</b> is a well-known PDE4 inhibitor.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p">The catechol ether, a characteristic motif of PDE4 inhibitors, also appears in some of the natural products. For example, mesembrenone (<b>67</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), which is an alkaloid isolated from the South African plant <i>Sceletium tortuosum</i> and has antianxiety and antidepressant effects, is an inhibitor of PDE4 with an IC<sub>50</sub> value of 0.47 μM but not other PDEs.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Compound <b>67</b> is also a selective inhibitor of the serotonin transporter (SERT) with <i>K</i><sub>i</sub> = 27 nM to inhibit reuptake of neurotransmitter serotonin.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p">While most natural products nonselectively inhibit PDEs or even simultaneously target other proteins, some of them showed moderate or high selectivity among PDE families. The most potent component <b>68</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) out of 13 compounds that were isolated from <i>Gaultheria yunnanensis</i> has an IC<sub>50</sub> of 245 nM for PDE4D and moderate selectivity over other PDEs.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Compounds, which were extracted from the Chinese herb “Sang-Bai-Pi” (<i>Morus alba</i> L.) and have been used for the treatment of coughing and inflammatory diseases, also show relatively good selectivity for PDE4 over other PDEs.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Moracin M (<b>69</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) has IC<sub>50</sub> values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Muracin A (<b>70</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), a prenylated flavonoid, shows the highest affinity for PDE4 (IC<sub>50</sub> of 5.4 nM for PDE4D2) and outstanding selectivity over other PDEs.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Thus, PDE4 may be the receptor mediating the functions of the moracin compounds.</div><div class="NLM_p">The natural product selaginpulvilin K (<b>71</b>) is a highly selective inhibitor of PDE4D with an IC<sub>50</sub> of 11 nM (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The cocrystal structure of PDE4D-<b>71</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WQA">5WQA</a>) revealed that <b>71</b> shallowly binds to the active site pocket and forms a hydrogen bond with the side chain of Gln369, while a benzene ring of <b>71</b> contacts Phe372 with π–π stacking (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> These interactions are comparable with those of synthetic PDE4 inhibitors. However, compound <b>71</b> shows more extensive interactions with some PDE4 residues that have rarely been reported in the literature, such as Ser208, Pro356, and Ile376 (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0021.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Diagram of the binding of compound <b>71</b> (yellow sticks) PDE4D (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WQA">5WQA</a>). The dotted line represents hydrogen bond. Compound <b>1</b> is shown as green sticks. The binding residues of PDE4D2 are shown as cyan and white sticks, respectively, for the structures of PDE4D-compound <b>71</b> and PDE4D-compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In short, although natural products may target multiple proteins, PDE4 must be an important receptor for their functions. For their different skeletons and potentially different binding patterns, natural products may be an abundant resource for the development of PDE4 selective inhibitors.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">7.  Dual PDE4 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For the important roles of the cAMP and cGMP signaling in various physiological processes<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> and the existence of multiple PDEs in certain tissues such as seven PDE families in the heart,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> simultaneous inhibition of multiple PDE families may produce synergistic effects of physiological processes. In addition, simultaneous regulation on the cAMP/cGMP signaling pathways and the key proteins in the physiological processes such as cancer development might produce additive or even synergistic effect. On the basis of these considerations, dual selective PDE4 inhibitors that target PDE4 and other PDEs or that conjugate with other functional proteins have been developed in recent decades.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">7.a.  Dual Inhibitors of PDE4 and Other PDEs</h3><div class="NLM_p">Dual inhibition of PDE3/PDE4 and PDE4/PDE7 may synergistically suppress inflammatory diseases such as COPD. However, because of the conservation of the active site of the PDE isozymes, the PDE4 dual inhibitors may also inhibit other PDEs, resulting in unpredictable beneficial or adverse effects.</div><div class="NLM_p">A survey of nonselective PDE inhibitors containing pyrazolopyridine-pyridazinone motifs led to the development of dual PDE3/4 selective inhibitors for the treatment of respiratory diseases. These dual PDE3/4 inhibitors often show both bronchodilatory and anti-inflammatory activities, thus having advantages over the singly selective inhibitors. For example, KCA-1490 (<b>72</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) displayed IC<sub>50</sub> values of 360 and 42 nM against PDE3 and PDE4, respectively.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Compounds <b>73</b> and <b>74</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) are orally active and have well-balanced dual PDE3/4-inhibitory activities. However, most of these agents caused adverse reactions in the gastrointestinal system.<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138,139)</a> In the past, at least five dual PDE3/4 inhibitors, compound <b>49</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), pumafentrine (<b>75</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>), benzafentrine (<b>76</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>), tolafentrine (<b>77</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>), and compound <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), entered clinical trials, but most of them, except compound <b>5</b>, have been discontinued.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0022.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structures of dual PDE inhibitors <b>72</b>–<b>83</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>5</b> is a long-acting dual PDE3/PDE4 inhibitor developed by Verona Pharma as a bronchodilator and anti-inflammatory agent for the treatment of asthma and COPD. Compound <b>5</b> triggers significant bronchiectasis in asthmatics, which is even detectable 7 h after administration, and induces bronchial protection against methacholine. For patients with allergic rhinitis, a single dose of compound <b>5</b> (18 μg/kg) reduced inflammatory cells (eosinophils and neutrophils) 7 and 24 h after the allergen challenge. In the phase II clinical trial, a single dose of nebulized compound <b>5</b> (18 μg/kg) showed a rapid bronchodilator response and a >15% increase in FEV1 in COPD patients and was tolerated without significant side effects. In addition, a phase II clinical trial on compound <b>5</b> for the treatment of cystic fibrosis is in progress.</div><div class="NLM_p">Compound <b>78</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>), which contains a compound <b>49</b> fragment, was claimed as a dual PDE4/PDE7 inhibitor with an IC<sub>50</sub> of 12 nM for PDE4, but its exact number for PDE7 was not reported.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Compound <b>79</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) is a moderate dual inhibitor with IC<sub>50</sub> values of 2.9 μM and 1.4 μM against PDE4 and PDE7.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> In a series of spiroisoxazoline-containing dual inhibitors, compound <b>80</b> (PDE4 IC<sub>50</sub> = 5 nM, PDE7 IC<sub>50</sub> = 55 nM, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) binds to PDE4 through its pyrazolopyridine group in a pattern similar to that of compound <b>28</b>.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Compound <b>81</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) was identified by yeast-based screening and displayed dual PDE4/PDE7 inhibition at the micromolar level: 64–90% inhibition of PDE4 and 98% inhibition of PDE7 at 2 μM concentration of the compound.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> A novel butanehydrazide derivative of purine-2,6-dione (compound <b>82</b>,<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) appeared to be a dual PDE4/7 inhibitor (PDE4 IC<sub>50</sub> = 1.4 μM, PDE7 IC<sub>50</sub> = 3.2 μM).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p last">In addition, a number of pyrazolopyridine derivatives showed inhibitory activities on PDE4/PDE10/JNK (Jun N-terminal kinase) with binding affinity in the micromolar range. For example, compound <b>83</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) showed IC<sub>50</sub> values of 1.2, 7.4, 0.3, and 1.2 μM against PDE4, PDE10, JNK2, and JNK3, respectively. These compounds were considered to be useful for treating neurological diseases such as Parkinson’s disease and neuropathic pain, and some were tested in a chronic constriction injury model in rats.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">7.b.  Dual PDE4 Inhibitors in Conjugation with Other Proteins</h3><div class="NLM_p">Successful examples of the dual PDE4 inhibitors are conjugated with β2 agonists, M3 antagonists, and selective serotonin reuptake inhibitors (SSRIs). These inhibitors are designed by covalently grafting two pharmacophores together with a flexible linker, and each pharmacophore targets its own protein in the anticipation of a synergistic effect.</div><div class="NLM_p">Compound <b>85</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), which combines compound <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) and carmoterol (<b>84</b>,<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), showed activities of both β2 agonist and PDE4 inhibitor with IC<sub>50</sub> values of 8 and 5 nM, respectively.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The combination of the β2 agonist formoterol (<b>86</b>,<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) and the PDE4 inhibitor <b>55</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) yielded compound <b>87</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) that possessed moderate inhibitory activity against PDE4B2 (IC<sub>50</sub> = 278 nM) and excellent relaxant effects on tracheal tissue precontracted by histamine (pEC<sub>50</sub> = 9.3).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> By exploration of the composition and length of the linker, a new series of hybrids that combined formoterol (<b>86</b>) and the PDE4 inhibitor phthalazinone (<b>50</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) were investigated as potent agents for the treatment of asthma and COPD. The most potent one in this class is compound <b>88</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), which exhibited both a β agonist effect (EC<sub>50</sub> = 1.05 nM, pEC<sub>50</sub> = 9.0) and PDE4B2 inhibition (IC<sub>50</sub> = 92 nM).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0024.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structures of dual PDE4 inhibitors <b>84</b>–<b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>89</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), a dual PDE4/SSRI inhibitor, grafted the PDE4 inhibitor compound <b>50</b> to the 2,5-disubstituted tetrahydrofuran of an SSRI inhibitor and inhibited serotonin reuptake with an IC<sub>50</sub> value of 127 nM and PDE4D3 with <i>K</i><sub>i</sub> of 2.0 nM. This combination showed synergistic antidepressant effects.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">The combination of pyrazolopyridine of PDE4 inhibitor <b>39</b> with M3 antagonists yielded a series of compounds with the capacity of dual PDE4 inhibition and M3 antagonism, which have IC<sub>50</sub> values of 0.1–2511 nM for PDE4B and 10 nM to 33 μM for M3 antagonist. The best compound <b>90</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) shows potency for the treatment of respiratory and allergic diseases, such as COPD, asthma, rhinitis, and inflammatory diseases.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Compound <b>91</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>), a carbamate derivative, showed both activities of PDE4 inhibition (IC<sub>50</sub> ≈ 100 nM) and muscarinic M3 receptor antagonism (IC<sub>50</sub> ≈ 100 nM), but its therapeutic effects need further study.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><div class="NLM_p last">In addition, a series of orally bioavailable dual inhibitors of epoxide hydrolase (sEH)/PDE4 were developed for the treatment of inflammatory pain.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Unlike other dual inhibitors that were prepared by simple grafting, compound <b>92</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) was designed by linking the benzyl amide moiety of the sEH inhibitor to a methoxybenzene fragment (compound <b>14</b> simulation) and showed highly potent and dual inhibition of PDE4 and sEH with IC<sub>50</sub> values of 8.1 nM and 2.1 nM, respectively. Compound <b>93</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) is a triple p38α MAPK/JNK3/PDE4 inhibitor with IC<sub>50</sub> values of 500, 700, and 200 nM, respectively, and demonstrated desirable pharmacokinetic properties and low plasma protein binding <i>in vitro</i> and <i>in vivo</i> even at the nanomolar doses.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">8.  Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63447" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63447" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While PDE4 inhibitors have been extensively investigated as therapeutics for treatment of human diseases such as COPD, only a few of them have been approved for practical use, due to side effects. It was thought that the side effects of nausea and emesis are caused by the poor selectivity of the PDE4 inhibitors between subfamilies of PDE4B and PDE4D. However, this argument is not supported by the recent studies of PDE4D inhibitors (see the discussion in <a class="ref internalNav" href="#sec4" aria-label="section 4">section 4</a>).</div><div class="NLM_p">A statistical survey shows that the four approved PDE4 inhibitors for the treatment of human diseases in market have only nanomolar affinity with PDE4, but the compounds that have picomolar affinity never progressed beyond phase II clinical trials. For example, Merck’s compounds <b>29</b> (IC<sub>50</sub> = 10 pM against PDE4B)<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> and <b>31</b> (IC<sub>50</sub> = 60 pM against PDE4B) and compound <b>42</b> (IC<sub>50</sub> of 30 pM for PDE4B)<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> have never been reported to enter clinical trials. The tightest-bound compound <b>28</b> (IC<sub>50</sub> = 3.2 pM against PDE4) was tested in a dozen phase II clinical trials on treatment of various disease but does not seem to advance to further trials. The failure of these very tight binding PDE4 inhibitors might be associated with their side effects. A possible reason to explain the failure might be inhibition of nontargeted cellular proteins, which causes disturbance on normal physiological functions of cAMP signaling. Besides, we believe that the cellular cAMP level needs to be maintained in an equilibrium for cellular functions. Deep inhibition of the PDE4 activity may cause redundant accumulation of cAMP and thus disturb normal physiological processes. This hypothesis of cellular balance of cAMP levels is supported by the case of the first generation PDE4 inhibitor rolipram (compound <b>14)</b> that was shown to have two binding sites with high and low binding affinity states (HARBS/LARBS) against PDE4.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The binding of compound <b>14</b> to the high affinity site showed antidepressant and anti-inflammatory activities but was also correlated with side effects such as vomiting and gastric acid secretion.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a></div><div class="NLM_p last">At present, several dual selective PDE4 inhibitors have been reported to show synergistic effects on human health, implying that simultaneous inhibition on multiple PDEs produces synergistic therapeutic effects. This argument is supported in theory by the facts that both cAMP and cGMP signaling pathways play critical roles in physiological processes and disease development.<a onclick="showRef(event, 'ref152 ref153 ref154 ref155 ref156 ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref152 ref153 ref154 ref155 ref156 ref157 ref158">(152−158)</a> Inhibition of PDE4 and other PDEs may increase levels of cAMP, cGMP, or both in cells and thus boost physiological processes. This assumption of potential synergistic effects from simultaneous inhibition of multiple PDEs is also supported by several experimental observations. First, theophylline (compound <b>65)</b>, the first generation antiasthma drug, nonselectively inhibits most PDEs with a few tens micromolar affinity and presumably functions via inhibition of multiple PDEs. Second, many natural products that are nutritional supplements to benefit human health have been shown to be nonselective PDE inhibitors. For example, resveratrol, a natural phenol that shows several beneficial effects on human diseases, modulates the PDE4/3-cAMP signaling pathway for part of its function.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Another example is the recent report that the cocktail of the antileukemia drug dasatinib and the natural product quercetin prolongs the lifespan of mice by 36%,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> which may be achieved via the regulation of the PDE4-cAMP signaling pathway since compound <b>66</b> is a well-known PDE4 inhibitor.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Thus, simultaneous inhibition of multiple PDE families would be a promising direction for discovery of PDE inhibitors and is worthy of further exploration.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02170" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengming Ke</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics, and Lineberger Comprehensive Cancer
Center, University of North Carolina, Chapel Hill, North Carolina 27599, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4d2528232a2024232a1226280d2028296338232e63282938"><span class="__cf_email__" data-cfemail="ef878a818882868188b0848aaf828a8bc19a818cc18a8b9a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianyou Shi</span> - <span class="hlFld-Affiliation affiliation">Personalized
Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of
Medical Science & Sichuan Provincial People’s Hospital, School of Medicine of University of Electronic Science
and Technology of China, Chengdu 610072, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1026-0282" title="Orcid link">http://orcid.org/0000-0002-1026-0282</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ffce7e6e5e6eee1f6e0faebeacfbebdb9a1ece0e2"><span class="__cf_email__" data-cfemail="f98a91909390989780968c9d9cb9c8cbcfd79a9694">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Peng</span> - <span class="hlFld-Affiliation affiliation">Personalized
Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of
Medical Science & Sichuan Provincial People’s Hospital, School of Medicine of University of Electronic Science
and Technology of China, Chengdu 610072, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baowen Qi</span> - <span class="hlFld-Affiliation affiliation">Center
for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun He</span> - <span class="hlFld-Affiliation affiliation">Cancer
Center, Collaborative Innovation Center for Biotherapy, West China
Hospital, Sichuan University, Sichuan 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.P., B.Q., and J.H. contributed equally to this manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Ting Peng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=BIO-d7e3371-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ting Peng</b> obtained her Bachelor’s degree in Pharmacy at Zhengzhou University, China, in 2016. She is now a graduate student at the University of Electronic Science and Technology of China. Her research interests involve the design and synthesis of small molecules for the treatment of tumor and neurological and inflammatory diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Baowen Qi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=BIO-d7e3376-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Baowen Qi</b> received his Ph.D. from the University of Montreal in Pharmaceutical Science in 2016 and is now a Postdoctoral Fellow at Brigham and Women Hospital, Harvard Medical School. His research focuses on the development and formulation of novel therapeutic agents for the treatment of various diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Jun He</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=BIO-d7e3381-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jun He</b>, a Research Associate, received his Ph.D. in Pharmacy from Sichuan University in 2011 and now works at the State Key Laboratory of Biotherapy of Sichuan University in China. His research focuses on small molecule drug discovery and computer-aided drug design for the treatment of diseases.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Hengming Ke</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=BIO-d7e3386-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hengming Ke</b> received his Ph.D. in Biophysics from Harvard University in 1989 and is now a Professor at the University of North Carolina at Chapel Hill. His research focuses on the crystal structures of medically important proteins and rational drug design for the treatment of diseases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Jianyou Shi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=BIO-d7e3391-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jianyou Shi</b> received his Ph.D. in Medicinal Chemistry from Sichuan University in 2010. After 3 years of postdoctoral training, he joined a group at the University of North Carolina at Chapel Hill in 2016, and he worked in this group for 2 years. He is currently working at the University of Electronic Science and Technology as a professor. His major scientific interests focus on the discovery of small molecules targeting oncogenesis, neurological, and inflammatory diseases.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors are thankful for the financial support from the Sichuan Science and Technology Department Project (Grant 2017JQ0038) and the Sichuan Provincial People’s Hospital Clinical Research and Transformation Fund Key Project (Grant 2016LZ03).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">β-AR</td><td class="NLM_def"><p class="first last">β-arrestin</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">Gs</td><td class="NLM_def"><p class="first last">heterotrimeric guanine nucleotide binding protein</p></td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylyl cyclase</p></td></tr><tr><td class="NLM_term">AKAP</td><td class="NLM_def"><p class="first last">A-kinase-anchoring protein</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">EPAC</td><td class="NLM_def"><p class="first last">exchange protein activated by cAMP</p></td></tr><tr><td class="NLM_term">CREB</td><td class="NLM_def"><p class="first last">cAMP response element binding protein</p></td></tr><tr><td class="NLM_term">C3G</td><td class="NLM_def"><p class="first last">cyanidin-3-glucoside</p></td></tr><tr><td class="NLM_term">Rap1</td><td class="NLM_def"><p class="first last">Ras-proximate-1</p></td></tr><tr><td class="NLM_term">MEK1/2</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">ERK1/2</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase 1/2</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ-light-chain-enhancer of activated B-cells</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">mTORC1</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex 1</p></td></tr><tr><td class="NLM_term">UCR</td><td class="NLM_def"><p class="first last">upstream conserved regions</p></td></tr><tr><td class="NLM_term">RACK1</td><td class="NLM_def"><p class="first last">receptor for activated C kinase 1</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">TNFα</td><td class="NLM_def"><p class="first last">tumor necrosis factor α</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">AAMI</td><td class="NLM_def"><p class="first last">age-associated memory impairment</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">CD4</td><td class="NLM_def"><p class="first last">cluster of differentiation 4</p></td></tr><tr><td class="NLM_term">FEV1</td><td class="NLM_def"><p class="first last">forced expiratory volume</p></td></tr><tr><td class="NLM_term">FVC</td><td class="NLM_def"><p class="first last">forced vital capacity</p></td></tr><tr><td class="NLM_term">FST</td><td class="NLM_def"><p class="first last">forced swim test</p></td></tr><tr><td class="NLM_term">TST</td><td class="NLM_def"><p class="first last">tailsus-pension test</p></td></tr><tr><td class="NLM_term">NAH</td><td class="NLM_def"><p class="first last"><i>N</i>-acylhydrazone</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer cell</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">sEH</td><td class="NLM_def"><p class="first last">epoxide hydrolase</p></td></tr><tr><td class="NLM_term">BALF</td><td class="NLM_def"><p class="first last">bronchoalveolar lavage fluid</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">Jun N-terminal kinase.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 159 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V. C.</span></span> <span> </span><span class="NLM_article-title">Advances in targeting cyclic nucleotide phosphodiesterases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+targeting+cyclic+nucleotide+phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lhhFWnFJaBifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520targeting%2520cyclic%2520nucleotide%2520phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavo, J.</span></span> <span> </span><span class="NLM_article-title">Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.76.060305.150444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev.biochem.76.060305.150444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17376027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVehtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=481-511&author=M.+Contiauthor=J.+Beavo&title=Biochemistry+and+physiology+of+cyclic+nucleotide+phosphodiesterases%3A+essential+components+in+cyclic+nucleotide+signaling&doi=10.1146%2Fannurev.biochem.76.060305.150444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling</span></div><div class="casAuthors">Conti, Marco; Beavo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">481-511</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Although cyclic nucleotide phosphodiesterases (PDEs) were described soon after the discovery of cAMP, their complexity and functions in signaling is only recently beginning to become fully realized.  We now know that ≥100 different PDE proteins degrade cAMP and cGMP in eukaryotes.  A complex PDE gene organization and a large no. of PDE splicing variants serve to fine-tune cyclic nucleotide signals and contribute to specificity in signaling.  Here we review some of the major concepts related to our understanding of PDE function and regulation including: (1) the structure of catalytic and regulatory domains and arrangement in holoenzymes; (2) PDE integration into signaling complexes; (3) the nature and function of neg. and pos. feedback circuits that have been conserved in PDEs from prokaryotes to human; (4) the emerging assocn. of mutant PDE alleles with inherited diseases; and (5) the role of PDEs in generating subcellular signaling compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJviyUqGyR2rVg90H21EOLACvtfcHk0lhhFWnFJaBifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVehtb%252FE&md5=4808b5e4b29337fab57e623d81a5f0f6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.76.060305.150444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.76.060305.150444%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DM.%26aulast%3DBeavo%26aufirst%3DJ.%26atitle%3DBiochemistry%2520and%2520physiology%2520of%2520cyclic%2520nucleotide%2520phosphodiesterases%253A%2520essential%2520components%2520in%2520cyclic%2520nucleotide%2520signaling%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2007%26volume%3D76%26spage%3D481%26epage%3D511%26doi%3D10.1146%2Fannurev.biochem.76.060305.150444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blount, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, J. D.</span></span> <span> </span><span class="NLM_article-title">Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1152/physrev.00030.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1152%2Fphysrev.00030.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21527734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=651-690&author=S.+H.+Francisauthor=M.+A.+Blountauthor=J.+D.+Corbin&title=Mammalian+cyclic+nucleotide+phosphodiesterases%3A+molecular+mechanisms+and+physiological+functions&doi=10.1152%2Fphysrev.00030.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions</span></div><div class="casAuthors">Francis, Sharron H.; Blount, Mitsi A.; Corbin, Jackie D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">651-690</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11 families of enzymes.  PDEs break down cAMP and/or cGMP and are major determinants of cellular cN levels and, consequently, the actions of cN-signaling pathways.  PDEs exhibit a range of catalytic efficiencies for breakdown of cAMP and/or cGMP and are regulated by myriad processes including phosphorylation, cN binding to allosteric GAF domains, changes in expression levels, interaction with regulatory or anchoring proteins, and reversible translocation among subcellular compartments.  Selective PDE inhibitors are currently in clin. use for treatment of erectile dysfunction, pulmonary hypertension, intermittent claudication, and chronic pulmonary obstructive disease; many new inhibitors are being developed for treatment of these and other maladies.  Recently reported x-ray crystallog. structures have defined features that provide for specificity for cAMP or cGMP in PDE catalytic sites or their GAF domains, as well as mechanisms involved in catalysis, oligomerization, autoinhibition, and interactions with inhibitors.  In addn., major advances have been made in understanding the physiol. impact and the biochem. basis for selective localization and/or recruitment of specific PDE isoenzymes to particular subcellular compartments.  The many recent advances in understanding PDE structures, functions, and physiol. actions are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN99wWYsCXRbVg90H21EOLACvtfcHk0lhhFWnFJaBifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7o%253D&md5=4aae757704a6243c9aa2648c32d5c759</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00030.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00030.2010%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DBlount%26aufirst%3DM.%2BA.%26aulast%3DCorbin%26aufirst%3DJ.%2BD.%26atitle%3DMammalian%2520cyclic%2520nucleotide%2520phosphodiesterases%253A%2520molecular%2520mechanisms%2520and%2520physiological%2520functions%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26spage%3D651%26epage%3D690%26doi%3D10.1152%2Fphysrev.00030.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejeda, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0033-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41573-019-0033-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=31388135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFamtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=770-796&author=G.+S.+Baillieauthor=G.+S.+Tejedaauthor=M.+P.+Kelly&title=Therapeutic+targeting+of+3%E2%80%B2%2C5%E2%80%B2-cyclic+nucleotide+phosphodiesterases%3A+inhibition+and+beyond&doi=10.1038%2Fs41573-019-0033-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond</span></div><div class="casAuthors">Baillie, George S.; Tejeda, Gonzalo S.; Kelly, Michy P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">770-796</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterases (PDEs), enzymes that degrade 3',5'-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metab.  Clin. development programs have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts.  However, emerging evidence supports novel strategies to therapeutically target PDE function, including enhancing catalytic activity, normalizing altered compartmentalization and modulating post-translational modifications, as well as the potential use of PDEs as disease biomarkers.  Importantly, a more refined appreciation of the intramol. mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_NtRRCDdas7Vg90H21EOLACvtfcHk0liEuiCxsiReKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFamtLfF&md5=f8a348c9c9e534227d60e4f635d90b25</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0033-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0033-4%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DTejeda%26aufirst%3DG.%2BS.%26aulast%3DKelly%26aufirst%3DM.%2BP.%26atitle%3DTherapeutic%2520targeting%2520of%25203%25E2%2580%25B2%252C5%25E2%2580%25B2-cyclic%2520nucleotide%2520phosphodiesterases%253A%2520inhibition%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D770%26epage%3D796%26doi%3D10.1038%2Fs41573-019-0033-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keravis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugnier, C.</span></span> <span> </span><span class="NLM_article-title">Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01729.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1476-5381.2011.01729.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22014080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1Ohtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1288-1305&author=T.+Keravisauthor=C.+Lugnier&title=Cyclic+nucleotide+phosphodiesterase+%28PDE%29+isozymes+as+targets+of+the+intracellular+signalling+network%3A+benefits+of+PDE+inhibitors+in+various+diseases+and+perspectives+for+future+therapeutic+developments&doi=10.1111%2Fj.1476-5381.2011.01729.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments</span></div><div class="casAuthors">Keravis, Therese; Lugnier, Claire</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1305</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) that specifically inactivate the intracellular messengers cAMP and cGMP in a compartmentalized manner represent an important enzyme class constituted by 11 gene-related families of isoenzymes (PDE1 to PDE11).  Downstream receptors, PDEs play a major role in controlling the signalosome at various levels of phosphorylations and protein/protein interactions.  Due to the multiplicity of isoenzymes, their various intracellular regulations and their different cellular and subcellular distributions, PDEs represent interesting targets in intracellular pathways.  Therefore, the investigation of PDE isoenzyme alterations related to various pathologies and the design of specific PDE inhibitors might lead to the development of new specific therapeutic strategies in numerous pathologies.  This manuscript (i) overviews the different PDEs including their endogenous regulations and their specific inhibitors; (ii) analyses the intracellular implications of PDEs in regulating signalling cascades in pathogenesis, exemplified by two diseases affecting cell cycle and proliferation; and (iii) discusses perspectives for future therapeutic developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvr2jfPTxnY7Vg90H21EOLACvtfcHk0liEuiCxsiReKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1Ohtb8%253D&md5=dbf5913bc6c973d0640258c51b7c481d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01729.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01729.x%26sid%3Dliteratum%253Aachs%26aulast%3DKeravis%26aufirst%3DT.%26aulast%3DLugnier%26aufirst%3DC.%26atitle%3DCyclic%2520nucleotide%2520phosphodiesterase%2520%2528PDE%2529%2520isozymes%2520as%2520targets%2520of%2520the%2520intracellular%2520signalling%2520network%253A%2520benefits%2520of%2520PDE%2520inhibitors%2520in%2520various%2520diseases%2520and%2520perspectives%2520for%2520future%2520therapeutic%2520developments%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D1288%26epage%3D1305%26doi%3D10.1111%2Fj.1476-5381.2011.01729.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskandari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirmosayyeb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordbari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andalib, A.</span></span> <span> </span><span class="NLM_article-title">A short review on structure and role of cyclic-3′,5′-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool</span>. <i>J. Res. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.4103/2279-042X.167043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.4103%2F2279-042X.167043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26645022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFCit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=175-181&author=N.+Eskandariauthor=O.+Mirmosayyebauthor=G.+Bordbariauthor=R.+Bastanauthor=Z.+Yousefiauthor=A.+Andalib&title=A+short+review+on+structure+and+role+of+cyclic-3%E2%80%B2%2C5%E2%80%B2-adenosine+monophosphate-specific+phosphodiesterase+4+as+a+treatment+tool&doi=10.4103%2F2279-042X.167043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool</span></div><div class="casAuthors">Eskandari, Nahid; Mirmosayyeb, Omid; Bordbari, Gazaleh; Bastan, Reza; Yousefi, Zahra; Andalib, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Research in Pharmacy Practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">JRPPAY</span>;
        ISSN:<span class="NLM_cas:issn">2279-042X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metab. of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are expressed in a variety of cell types that can exert various functions based on their cells distribution.  The PDE4 family has been the focus of vast research efforts over recent years because this family is considered as a prime target for therapeutic intervention in a no. of inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis, and it should be used and researched by pharmacists.  This is because the major isoform of PDE that regulates inflammatory cell activity is the cAMP-specific PDE, PDE4.  This review discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells distribution, and pharmacol. properties of PDE4 which can be informative for all pharmacy specialists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCxdfaenP5UrVg90H21EOLACvtfcHk0liEuiCxsiReKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFCit7Y%253D&md5=ab1ac9fb3162e5a24afd2308aae48634</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4103%2F2279-042X.167043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2279-042X.167043%26sid%3Dliteratum%253Aachs%26aulast%3DEskandari%26aufirst%3DN.%26aulast%3DMirmosayyeb%26aufirst%3DO.%26aulast%3DBordbari%26aufirst%3DG.%26aulast%3DBastan%26aufirst%3DR.%26aulast%3DYousefi%26aufirst%3DZ.%26aulast%3DAndalib%26aufirst%3DA.%26atitle%3DA%2520short%2520review%2520on%2520structure%2520and%2520role%2520of%2520cyclic-3%25E2%2580%25B2%252C5%25E2%2580%25B2-adenosine%2520monophosphate-specific%2520phosphodiesterase%25204%2520as%2520a%2520treatment%2520tool%26jtitle%3DJ.%2520Res.%2520Pharm.%2520Pract.%26date%3D2015%26volume%3D4%26spage%3D175%26epage%3D181%26doi%3D10.4103%2F2279-042X.167043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedioune, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandecasteele, G.</span></span> <span> </span><span class="NLM_article-title">Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives</span>. <i>Biol. Aujourd'hui</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1051/jbio/2016019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1051%2Fjbio%2F2016019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27813474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2snjtVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2016&pages=127-138&author=I.+Bediouneauthor=P.+Bobinauthor=S.+Karamauthor=M.+Lindnerauthor=D.+Mikaauthor=P.+Lecheneauthor=J.+Leroyauthor=R.+Fischmeisterauthor=G.+Vandecasteele&title=Cyclic+nucleotide+phosphodiesterases%3A+role+in+the+heart+and+therapeutic+perspectives&doi=10.1051%2Fjbio%2F2016019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives</span></div><div class="casAuthors">Bedioune Ibrahim; Bobin Pierre; Karam Sarah; Lindner Marta; Mika Delphine; Lechene Patrick; Leroy Jerome; Fischmeister Rodolphe; Vandecasteele Gregoire</div><div class="citationInfo"><span class="NLM_cas:title">Biologie aujourd'hui</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">127-138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclic nucleotide phosphodiesterases (PDEs) degrade the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), thereby regulating multiple aspects of cardiac function.  This highly diverse class of enzymes encoded by 21 genes encompasses 11 families that are not only responsible for the termination of cyclic nucleotide signalling, but are also involved in the generation of dynamic microdomains of cAMP and cGMP, controlling specific cell functions in response to various neurohormonal stimuli.  In the myocardium, the PDE3 and PDE4 families predominate, degrading cAMP and thereby regulating cardiac excitation-contraction coupling.  PDE3 inhibitors are positive inotropes and vasodilators in humans, but their use is limited to acute heart failure and intermittent claudication.  PDE5 inhibitors, which are used with success to treat erectile dysfunction and pulmonary hypertension, do not seem efficient in heart failure with preserved ejection fraction.  There is experimental evidence however that these PDE, as well as other PDE families including PDE1, PDE2 and PDE9, may play important roles in cardiac diseases, such as hypertrophy and heart failure (HF).  After a brief presentation of the cyclic nucleotide pathways in cardiac myocytes and the major characteristics of the PDE superfamily, this review will focus on the potential use of PDE inhibitors in HF, and the recent research developments that could lead to a better exploitation of the therapeutic potential of these enzymes in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_ic_eRtYmXJSWdIdmEou5fW6udTcc2eaX9zazUx_pDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snjtVWhsQ%253D%253D&md5=d446eb596152c6a7b8a57f894609a06e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1051%2Fjbio%2F2016019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fjbio%252F2016019%26sid%3Dliteratum%253Aachs%26aulast%3DBedioune%26aufirst%3DI.%26aulast%3DBobin%26aufirst%3DP.%26aulast%3DKaram%26aufirst%3DS.%26aulast%3DLindner%26aufirst%3DM.%26aulast%3DMika%26aufirst%3DD.%26aulast%3DLechene%26aufirst%3DP.%26aulast%3DLeroy%26aufirst%3DJ.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DVandecasteele%26aufirst%3DG.%26atitle%3DCyclic%2520nucleotide%2520phosphodiesterases%253A%2520role%2520in%2520the%2520heart%2520and%2520therapeutic%2520perspectives%26jtitle%3DBiol.%2520Aujourd%2527hui%26date%3D2016%26volume%3D210%26spage%3D127%26epage%3D138%26doi%3D10.1051%2Fjbio%2F2016019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of phosphodiesterase as cancer therapeutics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2018.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29574203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=742-756&author=T.+Pengauthor=J.+Gongauthor=Y.+Jinauthor=Y.+Zhouauthor=R.+Tongauthor=X.+Weiauthor=L.+Baiauthor=J.+Shi&title=Inhibitors+of+phosphodiesterase+as+cancer+therapeutics&doi=10.1016%2Fj.ejmech.2018.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphodiesterase as cancer therapeutics</span></div><div class="casAuthors">Peng, Ting; Gong, Jun; Jin, Yongzhe; Zhou, Yanping; Tong, Rongsheng; Wei, Xin; Bai, Lan; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">742-756</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiol. processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function.  PDEs are composed of 11 different families and each family contains different subtypes.  The distribution, expression, regulation mode and sensitivity to inhibitors of each subtype are different, and they are involved in cancer, inflammation, asthma, depression, erectile dysfunction and other pathol. processes of development.  A large no. of studies have shown that PDEs play an important role in the development of tumors by affecting the intracellular level of cAMP and/or cGMP and PDEs could become diagnostic markers or therapeutic targets.  This review will give a brief overview of the expression and regulation of PDE families in the process of tumorigenesis and their anti-tumor inhibitors, which may guide the design of novel therapeutic drugs targeting PDEs for anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrup-LedN_wNbVg90H21EOLACvtfcHk0li60BMJ2X__9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOmsb4%253D&md5=444c1f6a9a183a97749241eb2f00d6b3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520phosphodiesterase%2520as%2520cancer%2520therapeutics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D742%26epage%3D756%26doi%3D10.1016%2Fj.ejmech.2018.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakkas, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanos, D. P.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3054</span>– <span class="NLM_lpage">3067</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170530093902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F0929867324666170530093902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28554321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3054-3067&author=L.+I.+Sakkasauthor=A.+Mavropoulosauthor=D.+P.+Bogdanos&title=Phosphodiesterase+4+inhibitors+in+immune-mediated+diseases%3A+mode+of+action%2C+clinical+applications%2C+current+and+future+perspectives&doi=10.2174%2F0929867324666170530093902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives</span></div><div class="casAuthors">Sakkas, Lazaros I.; Mavropoulos, Athanasios; Bogdanos, Dimitrios P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3054-3067</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3',5'-monophosphate (cAMP), an intracellular second messenger and regulator of a wide array of genes and proteins.  Increased levels of intracellular cAMP lead to activation of genes but also to inhibition of nuclear factor-kappa B, involved in pro-inflammatory responses.  By increasing cAMP levels, PDE4 inhibitors, such as apremilast, reduced prodn. of pro-inflammatory TNFα, IFNγ, and IL-17 and increased prodn. of anti-inflammatory IL-10 in lipopolysaccharide-stimulated peripheral blood mononuclear cells, and in patients with psoriatic arthritis (PsA).  Among PDE4 inhibitors, apremilast, roflumilast, and crisabolore have been approved for the treatment of psoriasis and PsA, chronic obstructive pulmonary disease, and atopic dermatitis, resp.  In a preliminary study on psoriasis and PsA we showed that at 6 mo apremilast decreased IFNγ+CD3+ Th1 cells and IL- 17+CD3+ Th17 cells and increased regulatory B cells and regulatory T cells.  In this review, we highlight recent findings of PDE4 inhibitors in atopic dermatitis, alopecia areata, uveitis, rheumatoid arthritis, psoriasis and PsA, systemic lupus erythematosus, vasculitis, systemic sclerosis, multiple sclerosis and inflammatory bowel disease.  Given the role of cAMP as second messenger in diverse intracellular pathways, selective PDE4 inhibitors are likely to be therapeutic agents for various immune mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFv8w8tY8frVg90H21EOLACvtfcHk0li60BMJ2X__9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqsr%252FP&md5=d90a39f964094c186a4b4563e30df457</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170530093902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170530093902%26sid%3Dliteratum%253Aachs%26aulast%3DSakkas%26aufirst%3DL.%2BI.%26aulast%3DMavropoulos%26aufirst%3DA.%26aulast%3DBogdanos%26aufirst%3DD.%2BP.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520in%2520immune-mediated%2520diseases%253A%2520mode%2520of%2520action%252C%2520clinical%2520applications%252C%2520current%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3054%26epage%3D3067%26doi%3D10.2174%2F0929867324666170530093902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-T.</span></span> <span> </span><span class="NLM_article-title">The past, present, and future of phosphodiesterase-4 modulation for age-induced memory loss</span>. <i>Advances in neurobiology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-58811-7_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2F978-3-319-58811-7_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28956333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FjtFCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=169-199&author=R.+T.+Hansenauthor=H.-T.+Zhang&title=The+past%2C+present%2C+and+future+of+phosphodiesterase-4+modulation+for+age-induced+memory+loss&doi=10.1007%2F978-3-319-58811-7_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss</span></div><div class="casAuthors">Hansen Rolf T 3rd; Zhang Han-Ting; Zhang Han-Ting; Zhang Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Advances in neurobiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-199</span>
        ISSN:<span class="NLM_cas:issn">2190-5215</span>.
    </div><div class="casAbstract">The purpose of this chapter is to highlight the state of progress for phosphodiesterase-4 (PDE4) modulation as a potential therapeutic for psychiatric illness, and to draw attention to particular hurdles and obstacles that must be overcome in future studies to develop PDE4-mediated therapeutics.  Pathological and non-pathological related memory loss will be the focus of the chapter; however, we will at times also touch upon other psychiatric illnesses like anxiety and depression.  First, we will provide a brief background of PDE4, and the rationale for its extensive study in cognition.  Second, we will explore fundamental differences in individual PDE4 subtypes, and then begin to address differences between pathological and non-pathological aging.  Alterations of cAMP/PDE4 signaling that occur within normal vs. pathological aging, and the potential for PDE4 modulation to combat these alterations within each context will be described.  Finally, we will finish the chapter with obstacles that have hindered the field, and future studies and alternative viewpoints that need to be addressed.  Overall, we hope this chapter will demonstrate the incredible complexity of PDE4 signaling in the brain, and will be useful in forming a strategy to develop future PDE4-mediated therapeutics for psychiatric illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2D_asoAw2RbesJRIHUP1ofW6udTcc2ebkr6yWyU7eArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FjtFCisA%253D%253D&md5=c9eca8fd9d29c81f1775e907c8989b7b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-58811-7_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-58811-7_7%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DH.-T.%26atitle%3DThe%2520past%252C%2520present%252C%2520and%2520future%2520of%2520phosphodiesterase-4%2520modulation%2520for%2520age-induced%2520memory%2520loss%26jtitle%3DAdvances%2520in%2520neurobiology%26date%3D2017%26volume%3D17%26spage%3D169%26epage%3D199%26doi%3D10.1007%2F978-3-319-58811-7_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaeli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, K.</span></span> <span> </span><span class="NLM_article-title">A family of human phosphodiesterases homologous to the dunce learning and memory gene product of drosophila melanogaster are potential targets for antidepressant drugs</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">6558</span>– <span class="NLM_lpage">6571</span>, <span class="refDoi"> DOI: 10.1128/MCB.13.10.6558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1128%2FMCB.13.10.6558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=8413254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2cXisVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1993&pages=6558-6571&author=G.+Bolgerauthor=T.+Michaeliauthor=T.+Martinsauthor=T.+St+Johnauthor=B.+Steinerauthor=L.+Rodgersauthor=M.+Riggsauthor=M.+Wiglerauthor=K.+Ferguson&title=A+family+of+human+phosphodiesterases+homologous+to+the+dunce+learning+and+memory+gene+product+of+drosophila+melanogaster+are+potential+targets+for+antidepressant+drugs&doi=10.1128%2FMCB.13.10.6558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A family of human phosphodiesterases homologs to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs</span></div><div class="casAuthors">Bolger, Graeme; Michaeli, Tamar; Martins, Tim; St. John, Tom; Steiner, Bart; Rodgers, Linda; Riggs, Michael; Wigler, Michael; Ferguson, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6558-71</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors have isolated cDNAs for four human genes (DPDE1 through DPDE4) closely related to the dnc learning and memory locus of Drosophila melanogaster.  The deduced amino acid sequences of the Drosophila and human proteins have considerable homol., extending beyond the putative catalytic region to include two novel, highly conserved, upstream conserved regions (UCR1 and UCR2).  The upstream conserved regions are located in the amino-terminal regions of the proteins and appear to be unique to these genes.  Polymerase chain reaction anal. suggested that these genes encoded the only homologs of dnc in the human genome.  Three of the four genes were expressed in Saccharomyces cerevisiae and shown to encode cAMP-specific phosphodiesterases.  The products of the expressed genes displayed the pattern of sensitivity to inhibitors expected for members of the type IV, cAMP-specific class of phosphodiesterases.  Each of the four genes demonstrated a distinctive pattern of expression in RNA from human cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28TV_dJO357Vg90H21EOLACvtfcHk0li21h_E7FdLgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXisVKhuw%253D%253D&md5=13f0f15fb33cedee41d113788013c744</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.13.10.6558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.13.10.6558%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DMichaeli%26aufirst%3DT.%26aulast%3DMartins%26aufirst%3DT.%26aulast%3DSt%2BJohn%26aufirst%3DT.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DRodgers%26aufirst%3DL.%26aulast%3DRiggs%26aufirst%3DM.%26aulast%3DWigler%26aufirst%3DM.%26aulast%3DFerguson%26aufirst%3DK.%26atitle%3DA%2520family%2520of%2520human%2520phosphodiesterases%2520homologous%2520to%2520the%2520dunce%2520learning%2520and%2520memory%2520gene%2520product%2520of%2520drosophila%2520melanogaster%2520are%2520potential%2520targets%2520for%2520antidepressant%2520drugs%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1993%26volume%3D13%26spage%3D6558%26epage%3D6571%26doi%3D10.1128%2FMCB.13.10.6558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizizad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0li21h_E7FdLgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1825</span>, <span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0liJYnQYLKBObQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehats, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span> <span> </span><span class="NLM_article-title">Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">5493</span>– <span class="NLM_lpage">5496</span>, <span class="refDoi"> DOI: 10.1074/jbc.R200029200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1074%2Fjbc.R200029200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12493749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1aqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=5493-5496&author=M.+Contiauthor=W.+Richterauthor=C.+Mehatsauthor=G.+Liveraauthor=J.-Y.+Parkauthor=C.+Jin&title=Cyclic+AMP-specific+PDE4+phosphodiesterases+as+critical+components+of+cyclic+AMP+signaling&doi=10.1074%2Fjbc.R200029200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling</span></div><div class="casAuthors">Conti, Marco; Richter, Wito; Mehats, Celine; Livera, Gabriel; Park, Jy-Young; Jin, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5493-5496</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review describes the phosphodiesterase 4 (PDE4) family of enzyme and their role in desensitization, feedback regulation, and signal compartmentalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71Pdc9TcAn7Vg90H21EOLACvtfcHk0liJYnQYLKBObQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1aqsr4%253D&md5=88d768d8c99e85e9aa4e4d2c2a28bf03</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R200029200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R200029200%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DM.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DMehats%26aufirst%3DC.%26aulast%3DLivera%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DJ.-Y.%26aulast%3DJin%26aufirst%3DC.%26atitle%3DCyclic%2520AMP-specific%2520PDE4%2520phosphodiesterases%2520as%2520critical%2520components%2520of%2520cyclic%2520AMP%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D5493%26epage%3D5496%26doi%3D10.1074%2Fjbc.R200029200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodge, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouangsathiene, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiloff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langeberg, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span> <span> </span><span class="NLM_article-title">MAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1921</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1093/emboj/20.8.1921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1093%2Femboj%2F20.8.1921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=11296225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt12qtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=1921-1930&author=K.+L.+Dodgeauthor=S.+Khouangsathieneauthor=M.+S.+Kapiloffauthor=R.+Moutonauthor=E.+V.+Hillauthor=M.+D.+Houslayauthor=L.+K.+Langebergauthor=J.+D.+Scott&title=MAKAP+assembles+a+protein+kinase+A%2FPDE4+phosphodiesterase+cAMP+signaling+module&doi=10.1093%2Femboj%2F20.8.1921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module</span></div><div class="casAuthors">Dodge, Kimberly L.; Khouangsathiene, Samone; Kapiloff, Michael S.; Mouton, Robert; Hill, Elaine V.; Houslay, Miles D.; Langeberg, Lorene K.; Scott, John D.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1921-1930</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Spatiotemporal regulation of protein kinase A (PKA) activity involves the manipulation of compartmentalized cAMP pools.  Now we demonstrate that the muscle-selective A-kinase anchoring protein, mAKAP, maintains a cAMP signaling module, including PKA and the rolipram-inhibited cAMP-specific phosphodiesterase (PDE4D3) in heart tissues.  Functional analyses indicate that tonic PDE4D3 activity reduces the activity of the anchored PKA holoenzyme, whereas kinase activation stimulates mAKAP-assocd. phosphodiesterase activity.  Disruption of PKA-mAKAP interaction prevents this enhancement of PDE4D3 activity, suggesting that the proximity of both enzymes in the mAKAP signaling complex forms a neg. feedback loop to restore basal cAMP levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFLD3q3jyYPLVg90H21EOLACvtfcHk0liJYnQYLKBObQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt12qtLY%253D&md5=4864eddded27f8ec57dae34df44bea66</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F20.8.1921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F20.8.1921%26sid%3Dliteratum%253Aachs%26aulast%3DDodge%26aufirst%3DK.%2BL.%26aulast%3DKhouangsathiene%26aufirst%3DS.%26aulast%3DKapiloff%26aufirst%3DM.%2BS.%26aulast%3DMouton%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DLangeberg%26aufirst%3DL.%2BK.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26atitle%3DMAKAP%2520assembles%2520a%2520protein%2520kinase%2520A%252FPDE4%2520phosphodiesterase%2520cAMP%2520signaling%2520module%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D1921%26epage%3D1930%26doi%3D10.1093%2Femboj%2F20.8.1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taskén, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witczak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taskén, K.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">21999</span>– <span class="NLM_lpage">22002</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000911200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1074%2Fjbc.C000911200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=11285255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVant78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=21999-22002&author=K.+A.+Task%C3%A9nauthor=P.+Collasauthor=W.+A.+Kemmnerauthor=O.+Witczakauthor=M.+Contiauthor=K.+Task%C3%A9n&title=Phosphodiesterase+4D+and+protein+kinase+a+type+II+constitute+a+signaling+unit+in+the+centrosomal+area&doi=10.1074%2Fjbc.C000911200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the centrosomal area</span></div><div class="casAuthors">Tasken, Kristin A.; Collas, Philippe; Kemmner, Wolfram A.; Witczak, Oliwia; Conti, Marco; Tasken, Kjetil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">21999-22002</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mediation of cAMP effects by specific pools of protein kinase A (PKA) targeted to distinct subcellular domains raises the question of how inactivation of the cAMP signal is achieved locally and whether similar targeting of phosphodiesterases (PDEs) to sites of cAMP/PKA action could be obsd.  Here, we demonstrate that Sertoli cells of the testis contain an insol. PDE4D3 isoform, which is shown by immunofluorescence to target to centrosomes.  Staining of PDE4D and PKA shows co-localization of PDE4D with PKA-RIIα and RIIβ in the centrosomal region.  Co-pptn. of RII subunits and PDE4D3 from cytoskeletal exts. indicates a phys. assocn. of the two proteins.  Distribution of PDE4D overlaps with that of the centrosomal PKA-anchoring protein, AKAP450, and AKAP450, PDE4D3, and PKA-RIIα co-immunoppt.  Finally, both PDE4D3 and PKA co-ppt. with a sol. fragment of AKAP450 encompassing amino acids 1710 to 2872 when co-expressed in 293T cells.  Thus, a centrosomal complex that includes PDE4D and PKA constitutes a novel signaling unit that may provide accurate spatiotemporal modulation of cAMP signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE1-3CERIugLVg90H21EOLACvtfcHk0lhcRoafE98FOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVant78%253D&md5=1f436e321c98f10975e2aaace3e0b23e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000911200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000911200%26sid%3Dliteratum%253Aachs%26aulast%3DTask%25C3%25A9n%26aufirst%3DK.%2BA.%26aulast%3DCollas%26aufirst%3DP.%26aulast%3DKemmner%26aufirst%3DW.%2BA.%26aulast%3DWitczak%26aufirst%3DO.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DTask%25C3%25A9n%26aufirst%3DK.%26atitle%3DPhosphodiesterase%25204D%2520and%2520protein%2520kinase%2520a%2520type%2520II%2520constitute%2520a%2520signaling%2520unit%2520in%2520the%2520centrosomal%2520area%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D21999%26epage%3D22002%26doi%3D10.1074%2Fjbc.C000911200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span> <span> </span><span class="NLM_article-title">Enhancing cAMP levels as strategy for the treatment of neuropsychiatric disorders</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3527</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160426151306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F1568026616666160426151306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27112214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKks7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3527-3535&author=A.+M.+Garciaauthor=A.+Martinezauthor=C.+Gil&title=Enhancing+cAMP+levels+as+strategy+for+the+treatment+of+neuropsychiatric+disorders&doi=10.2174%2F1568026616666160426151306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders</span></div><div class="casAuthors">Garcia, Ana M.; Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3527-3535</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) have gained attention as potential pharmacol. targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP.  It is well-known the relationship between cAMP signaling and inflammation.  Since neuroinflammation is considered to play an important role in the pathol. of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies.  PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia.  Enhancing the intracellular concn. of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcq3O7Tqq77LVg90H21EOLACvtfcHk0lhcRoafE98FOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKks7fE&md5=7cfb8681f09b981406f77f07ae9cb9e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160426151306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160426151306%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DEnhancing%2520cAMP%2520levels%2520as%2520strategy%2520for%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D3527%26epage%3D3535%26doi%3D10.2174%2F1568026616666160426151306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span> <span> </span><span class="NLM_article-title">PDE4-mediated cAMP signalling</span>. <i>J. Cardiovasc. Dev. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.3390/jcdd5010008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3390%2Fjcdd5010008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=8&author=B.+A.+Fertigauthor=G.+S.+Baillie&title=PDE4-mediated+cAMP+signalling&doi=10.3390%2Fjcdd5010008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4-mediated cAMP signalling</span></div><div class="casAuthors">Fertig, Bracy A.; Baillie, George S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Development and Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8/1-8/14</span>CODEN:
                <span class="NLM_cas:coden">JCDDB4</span>;
        ISSN:<span class="NLM_cas:issn">2308-3425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  CAMP is the archetypal and ubiquitous second messenger utilized for the fine control of many cardiovascular cell signalling systems.  The ability of cAMP to elicit cell surface receptor-specific responses relies on its compartmentalisation by cAMP hydrolyzing enzymes known as phosphodiesterases.  One family of these enzymes, PDE4, is particularly important in the cardiovascular system, where it has been extensively studied and shown to orchestrate complex, localised signalling that underpins many crucial functions of the heart.  In the cardiac myocyte, cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins that drive β-adrenergic enhancement of cardiac function.  The phosphorylation of these substrates, many of which are involved in cardiac excitation-contraction coupling, has been shown to be tightly regulated by highly localised pools of individual PDE4 isoforms.  The spatial and temporal regulation of cardiac signalling is made possible by the formation of macromol. "signalosomes", which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such as an AKAP.  Studies described in the present review highlight the importance of this relationship for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm is coordinated to promote efficient adrenergic enhancement of cardiac function.  The role of PDE4 also extends to the vascular endothelium, where it regulates vascular permeability and barrier function.  In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.  These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.  PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of the compds. which concomitantly attenuate PDE activity in all highly localised "signalosomes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1GQOAKh0NLVg90H21EOLACvtfcHk0liaE3IllAAUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D&md5=55ab00b9daa0cd96454807732bd5f4bc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3390%2Fjcdd5010008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcdd5010008%26sid%3Dliteratum%253Aachs%26aulast%3DFertig%26aufirst%3DB.%2BA.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26atitle%3DPDE4-mediated%2520cAMP%2520signalling%26jtitle%3DJ.%2520Cardiovasc.%2520Dev.%2520Dis.%26date%3D2018%26volume%3D5%26spage%3D8%26doi%3D10.3390%2Fjcdd5010008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, S.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders</span>. <i>Obes. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1111/obr.12385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fobr.12385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26997580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlajsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=429-441&author=C.+Wuauthor=S.+Rajagopalan&title=Phosphodiesterase-4+inhibition+as+a+therapeutic+strategy+for+metabolic+disorders&doi=10.1111%2Fobr.12385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders</span></div><div class="casAuthors">Wu, C.; Rajagopalan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">ORBEBL</span>;
        ISSN:<span class="NLM_cas:issn">1467-7881</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Phosphodiesterase-4 (PDE4) hydrolyzes cyclic adenosine monophosphate (cAMP), a crucial secondary messenger for cellular adaptation to diverse external stimuli.  The activity of PDE4 is tightly controlled by post-translational regulation, structure-based auto-regulation and locus specific 'compartmentalization' of PDE4 with its interactive proteins (signalsomes).  Through these mechanisms, PDE4 regulates cAMP levels and shapes the cAMP signalling, directing signals from the diverse external stimuli to distinct microenvironments exquisitely.  Derangement of the PDE4-cAMP signalling represents a pathophysiol. relevant pathway in metabolic disorders as demonstrated through a crit. role in the processes including inflammation, disordered glucose and lipid metab., hepatic steatosis, abnormal lipolysis, suppressed thermogenic function and deranged neuroendocrine functions.  A limited no. of PDE4 inhibitors are currently undergoing clin. evaluation for treating disorders such as type 2 diabetes and non-alc. steatohepatitis.  The discovery of novel PDE4 allosteric inhibitors and signalsome-based strategies targeting individual PDE4 variants may allow PDE4 isoform selective inhibition, which may offer safer strategies for chronic treatment of metabolic disorders. © 2016 World Obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2lSfJbeCxqrVg90H21EOLACvtfcHk0liaE3IllAAUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlajsro%253D&md5=65c0ed8a5e3986a944965471784e783d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fobr.12385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fobr.12385%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DRajagopalan%26aufirst%3DS.%26atitle%3DPhosphodiesterase-4%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520metabolic%2520disorders%26jtitle%3DObes.%2520Rev.%26date%3D2016%26volume%3D17%26spage%3D429%26epage%3D441%26doi%3D10.1111%2Fobr.12385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohleth, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M. M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1124/mol.56.1.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fmol.56.1.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10385698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK1MXksFOmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=170-174&author=P.+Wangauthor=P.+Wuauthor=K.+M.+Ohlethauthor=R.+W.+Eganauthor=M.+M.+Billah&title=Phosphodiesterase+4B2+is+the+predominant+phosphodiesterase+species+and+undergoes+differential+regulation+of+gene+expression+in+human+monocytes+and+neutrophils&doi=10.1124%2Fmol.56.1.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils</span></div><div class="casAuthors">Wang, Peng; Wu, Ping; Ohleth, Kathleen M.; Egan, Robert W.; Billah, M. Motasim</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-174</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The type 4 phosphodiesterase (PDE4) is the predominant PDE isoenzyme in various leukocytes and plays a key role in the regulation of inflammatory cell activation.  There are four PDE4 subtypes (A, B, C, and D), and within each subtype, there are multiple variants.  Very recently, we found in monocytes that PDE4B gene expression is selectively induced by lipopolysaccharide (LPS) and that the induction is inhibited by interleukin (IL)-10 and IL-4.  In this study, we show that the PDE4B gene is constitutively expressed in neutrophils and that this expression remains unaffected by LPS or IL-10.  PDE4B is the predominant subtype in neutrophils and in unstimulated or LPS-stimulated monocytes, and in these cells, the PDE4B2 variant is the only detectable mol. species of PDE4B.  Therefore, PDE4B2 is the predominant PDE isoform in human neutrophils and monocytes, and its expression is regulated differently by these two cell types.  Furthermore, leukocytes are the most dominant source of PDE4B2, suggesting that PDE4B2 is a relatively specific target for discovering anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgA6N-zJ8JLVg90H21EOLACvtfcHk0liaE3IllAAUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFOmtL8%253D&md5=74202f0ab3597b875560871df18f320b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fmol.56.1.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.56.1.170%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DOhleth%26aufirst%3DK.%2BM.%26aulast%3DEgan%26aufirst%3DR.%2BW.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26atitle%3DPhosphodiesterase%25204B2%2520is%2520the%2520predominant%2520phosphodiesterase%2520species%2520and%2520undergoes%2520differential%2520regulation%2520of%2520gene%2520expression%2520in%2520human%2520monocytes%2520and%2520neutrophils%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D170%26epage%3D174%26doi%3D10.1124%2Fmol.56.1.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+C.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF-%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0liaE3IllAAUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%2BC.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF-%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2004.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pupt.2004.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15649851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1SrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=93-101&author=N.+A.+Jonesauthor=V.+Boswell-Smithauthor=R.+Leverauthor=C.+P.+Page&title=The+effect+of+selective+phosphodiesterase+isoenzyme+inhibition+on+neutrophil+function+in+vitro&doi=10.1016%2Fj.pupt.2004.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro</span></div><div class="casAuthors">Jones, N. A.; Boswell-Smith, V.; Lever, R.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neutrophil-derived proteases such as neutrophil elastase (NE) and matrix metalloproteinase (MMP) are implicated in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD).  In this study, the effects of selective phosphodiesterase (PDE) inhibition on NE and MMP-9 release, as well as Myeloperoxidase (MPO) activity and integrin-mediated neutrophil adhesion to human umbilical vein endothelial cells (HUVECs), were investigated.  Human neutrophils were treated with PDE inhibitors (10-11-10-4 M) in the absence and presence of TNF-α (tumor necrosis factor) (100 U ml-1) for 30 min, prior to fMLP activation.  After 45 min, the cells were removed and NE, MPO and MMP-9 release assessed.  In the adhesion studies, the neutrophils were radio-labeled with 51Cr, stimulated and immediately transferred to cultured HUVEC monolayers for 30 min, prior to assessment of adhesion.  TNF-α (100 U ml-1) acted synergistically with fMLP in stimulating azurophil degranulation with respect to both MPO activity (P<0.01) and NE release (P<0.01).  In contrast, an additive effect was obsd. with TNF-α and fMLP with regard to MMP-9 release and neutrophil adhesion to HUVECs.  The PDE4 inhibitors, roflumilast, roflumilast N-oxide, cilomilast and rolipram significantly suppressed MPO, NE and MMP-9 release in both the presence and absence of TNF-α (P<0.05; n=6-10) and also reduced neutrophil adhesion to HUVECs.  In contrast, milrinone, a PDE3 inhibitor and the non-selective PDE inhibitor, theophylline did not inhibit azurophil degranulation under any of the exptl. conditions.  These data provide further evidence that selective PDE4 isoenzyme inhibitors can inhibit neutrophil degranulation, effects not shared by PDE3 inhibitors or theophylline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRjWtdb7D1bVg90H21EOLACvtfcHk0lgEhiwoKOaifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1SrsQ%253D%253D&md5=b54814cb40a476705cfc9840f834eecd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2004.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2004.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DN.%2BA.%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DLever%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DThe%2520effect%2520of%2520selective%2520phosphodiesterase%2520isoenzyme%2520inhibition%2520on%2520neutrophil%2520function%2520in%2520vitro%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D18%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.pupt.2004.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daguès, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borde, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freslon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, S.</span></span> <span> </span><span class="NLM_article-title">Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1093%2Ftoxsci%2Fkfm161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17569694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKlsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=238-247&author=N.+Dagu%C3%A8sauthor=V.+Pawlowskiauthor=C.+Sobryauthor=G.+Hantonauthor=F.+Bordeauthor=S.+Solerauthor=J.+L.+Freslonauthor=S.+Chevalier&title=Investigation+of+the+molecular+mechanisms+preceding+PDE4+inhibitor-induced+vasculopathy+in+rats%3A+tissue+inhibitor+of+metalloproteinase+1%2C+a+potential+predictive+biomarker&doi=10.1093%2Ftoxsci%2Fkfm161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the Molecular Mechanisms Preceding PDE4 Inhibitor-Induced Vasculopathy in Rats: Tissue Inhibitor of Metalloproteinase 1, a Potential Predictive Biomarker</span></div><div class="casAuthors">Dagues, Nicolas; Pawlowski, Valerie; Sobry, Cecile; Hanton, Gilles; Borde, Francoise; Soler, Sylvain; Freslon, Jean-Louis; Chevalier, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-247</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 inhibitors are a class of drugs that can provide novel therapies for asthma and chronic obstructive pulmonary disease.  Their development is frequently hampered by the induction of vascular toxicity in rat mesenteric tissue during preclin. studies.  Whereas these vascular lesions in rats have been well characterized histol., little is known about their pathogenesis and in turn, sensitive and specific biomarkers for preclin. and clin. monitoring do not exist.  In order to investigate the early mol. mechanisms underlying vascular injury, time-course studies were performed by treating rats for 2-24 h with high doses of the PDE4 inhibitor CI-1044.  Transcriptomics analyses in mesenteric tissue were performed using oligonucleotide microarray and real-time RT-PCR technologies and compared to histopathol. observations.  In addn., protein measurements were performed in serum samples to identify sol. biomarkers of vascular injury.  Our results indicate that mol. alterations preceded the histol. observations of inflammatory and necrotic lesions in mesenteric arteries.  Some gene expression changes suggest that the development of the lesions could follow a primary modulation of the vascular tone in response to the pharmacol. effect of the compd.  Activation of genes coding for pro- and antioxidant enzymes, cytokines, adhesion mols., and tissue inhibitor of metalloproteinase 1 (TIMP-1) indicates that biomech. stimuli may contribute to vascular oxidant stress, inflammation, and tissue remodeling.  TIMP-1 appeared to be an early and sensitive predictive biomarker of the inflammatory and the tissue remodeling components of PDE4 inhibitor-induced vascular injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobr4z5O8AVKbVg90H21EOLACvtfcHk0lgEhiwoKOaifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKlsLvJ&md5=e4450eb1e94698a6ea096f6a6b6be772</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm161%26sid%3Dliteratum%253Aachs%26aulast%3DDagu%25C3%25A8s%26aufirst%3DN.%26aulast%3DPawlowski%26aufirst%3DV.%26aulast%3DSobry%26aufirst%3DC.%26aulast%3DHanton%26aufirst%3DG.%26aulast%3DBorde%26aufirst%3DF.%26aulast%3DSoler%26aufirst%3DS.%26aulast%3DFreslon%26aufirst%3DJ.%2BL.%26aulast%3DChevalier%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520molecular%2520mechanisms%2520preceding%2520PDE4%2520inhibitor-induced%2520vasculopathy%2520in%2520rats%253A%2520tissue%2520inhibitor%2520of%2520metalloproteinase%25201%252C%2520a%2520potential%2520predictive%2520biomarker%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D100%26spage%3D238%26epage%3D247%26doi%3D10.1093%2Ftoxsci%2Fkfm161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puxeddu, E.</span></span> <span> </span><span class="NLM_article-title">Dual bronchodilation and exacerbations of COPD</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2386</span>, <span class="refDoi"> DOI: 10.21037/jtd.2016.08.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.21037%2Fjtd.2016.08.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27746982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2383-2386&author=M.+Cazzolaauthor=J.+Oraauthor=E.+Puxeddu&title=Dual+bronchodilation+and+exacerbations+of+COPD&doi=10.21037%2Fjtd.2016.08.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation and exacerbations of COPD</span></div><div class="casAuthors">Cazzola Mario; Ora Josuel; Puxeddu Ermanno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2383-2386</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-6mjBZyHPbq2q3xNe7a7QfW6udTcc2eYIPd3fSGLZWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtVajsA%253D%253D&md5=0435716edd2b2f4323671c0dad9d6e8f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2016.08.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2016.08.92%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DPuxeddu%26aufirst%3DE.%26atitle%3DDual%2520bronchodilation%2520and%2520exacerbations%2520of%2520COPD%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2016%26volume%3D8%26spage%3D2383%26epage%3D2386%26doi%3D10.21037%2Fjtd.2016.08.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzel, P.</span></span> <span> </span><span class="NLM_article-title">Crisaborole 2% ointment (eucrisa) for atopic dermatitis</span>. <i>Skin Ther. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30970204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjvFKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4-6&author=T.+E.+Wooauthor=P.+Kuzel&title=Crisaborole+2%25+ointment+%28eucrisa%29+for+atopic+dermatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis</span></div><div class="casAuthors">Woo Taylor Evart; Kuzel Paul</div><div class="citationInfo"><span class="NLM_cas:title">Skin therapy letter</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">4-6</span>
        ISSN:<span class="NLM_cas:issn">1201-5989</span>.
    </div><div class="casAbstract">Atopic dermatitis is a common cutaneous disease with significant morbidity affecting children and adults.  The mainstay of atopic dermatitis therapy has typically included emollients, topical corticosteroids, and topical calcineurin inhibitors.  Among the newer advances recently introduced is crisaborole (Eucrisa®), a phosphodiesterase type-4 inhibitor (PDE-4) for the treatment of mild moderate atopic dermatitis.  Evidence from phase 3 trials demonstrates crisaborole as an efficacious topical agent with a favorable safety profile and limited systemic exposure.  While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfD9bI0ZsheM-crCu0nI_sfW6udTcc2ebO1Z3F6C9_nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjvFKjsw%253D%253D&md5=21997509bd7fbabc5e68ab0f707d2324</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DT.%2BE.%26aulast%3DKuzel%26aufirst%3DP.%26atitle%3DCrisaborole%25202%2525%2520ointment%2520%2528eucrisa%2529%2520for%2520atopic%2520dermatitis%26jtitle%3DSkin%2520Ther.%2520Lett.%26date%3D2019%26volume%3D24%26spage%3D4%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerdel, F.</span></span> <span> </span><span class="NLM_article-title">Apremilast and psoriasis in the real world: a retrospective case series</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaad.2019.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=31604095" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=L.+Dozierauthor=G.+Bartosauthor=F.+Kerdel&title=Apremilast+and+psoriasis+in+the+real+world%3A+a+retrospective+case+series&doi=10.1016%2Fj.jaad.2019.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DDozier%26aufirst%3DL.%26aulast%3DBartos%26aufirst%3DG.%26aulast%3DKerdel%26aufirst%3DF.%26atitle%3DApremilast%2520and%2520psoriasis%2520in%2520the%2520real%2520world%253A%2520a%2520retrospective%2520case%2520series%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2019%26doi%3D10.1016%2Fj.jaad.2019.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rolan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span> <span> </span><span class="NLM_article-title">Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2904</span>, <span class="refDoi"> DOI: 10.1517/14656560903426189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1517%2F14656560903426189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=19929708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyjur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=2897-2904&author=P.+Rolanauthor=M.+Hutchinsonauthor=K.+Johnson&title=Ibudilast%3A+a+review+of+its+pharmacology%2C+efficacy+and+safety+in+respiratory+and+neurological+disease&doi=10.1517%2F14656560903426189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease</span></div><div class="casAuthors">Rolan, P.; Hutchinson, Mr; Johnson, Kw</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2897-2904</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma.  More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in the CNS via glial cell attenuation.  This CNS-directed anti-inflammatory activity is of potential use in the treatment of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by decreasing opioid tolerance, withdrawal and reinforcement.  Its suitable pharmacokinetics and generally good tolerability make it a promising potential treatment for these conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9-2fWYWu4bVg90H21EOLACvtfcHk0lj711xZ-FWy9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyjur%252FF&md5=321ef42e8f433e908780f8c19f7f1579</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F14656560903426189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903426189%26sid%3Dliteratum%253Aachs%26aulast%3DRolan%26aufirst%3DP.%26aulast%3DHutchinson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DK.%26atitle%3DIbudilast%253A%2520a%2520review%2520of%2520its%2520pharmacology%252C%2520efficacy%2520and%2520safety%2520in%2520respiratory%2520and%2520neurological%2520disease%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D2897%26epage%3D2904%26doi%3D10.1517%2F14656560903426189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. T.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2941</span>– <span class="NLM_lpage">2954</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3480-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2Fs00213-014-3480-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24563185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFClu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2941-2954&author=R.+T.+Hansenauthor=M.+Contiauthor=H.+T.+Zhang&title=Mice+deficient+in+phosphodiesterase-4A+display+anxiogenic-like+behavior&doi=10.1007%2Fs00213-014-3480-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior</span></div><div class="casAuthors">Hansen, Rolf T., III; Conti, Marco; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2941-2954</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Phosphodiesterases (PDEs) are a super family of enzymes responsible for the halting of intracellular cyclic nucleotide signaling and may represent novel therapeutic targets for treatment of cognitive disorders.  PDE4 is of considerable interest to cognitive research because it is highly expressed in the brain, particularly in the cognition-related brain regions.  Recently, the functional role of PDE4B and PDE4D, two of the four PDE4 subtypes (PDE4A, B, C, and D), in behavior has begun to be identified; however, the role of PDE4A in the regulation of behavior is still unknown.  Objectives: The purpose of this study was to characterize the functional role of PDE4A in behavior.  Methods: The role of PDE4A in behavior was evaluated through a battery of behavioral tests using PDE4A knockout (KO) mice; urine corticosterone levels were also measured.  Results: PDE4A KO mice exhibited improved memory in the step-through-passive-avoidance test.  They also displayed anxiogenic-like behavior in elevated-plus maze, holeboard, light-dark transition, and novelty suppressed feeding tests.  Consistent with the anxiety profile, PDE4A KO mice had elevated corticosterone levels compared with wild-type controls post-stress.  Interestingly, PDE4A KO mice displayed no change in object recognition, Morris water maze, forced swim, tail suspension, and duration of anesthesia induced by co-administration of xylazine and ketamine (suggesting that PDE4A KO may not be emetic).  Conclusions: These results suggest that PDE4A may be important in the regulation of emotional memory and anxiety-like behavior, but not emesis.  PDE4A could possibly represent a novel therapeutic target in the future for anxiety or disorders affecting memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNwi0Mlhwbw7Vg90H21EOLACvtfcHk0lj711xZ-FWy9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFClu7s%253D&md5=89bdb7a8ef607a567b47b131414a00ce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3480-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3480-y%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%2BT.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DMice%2520deficient%2520in%2520phosphodiesterase-4A%2520display%2520anxiogenic-like%2520behavior%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2941%26epage%3D2954%26doi%3D10.1007%2Fs00213-014-3480-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malloy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huston, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porteous, D.</span></span> <span> </span><span class="NLM_article-title">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.1126/science.1112915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1126%2Fscience.1112915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16293762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WgtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=1187-1191&author=J.+Millarauthor=B.+Pickardauthor=S.+Mackieauthor=R.+Jamesauthor=S.+Christieauthor=S.+Buchananauthor=M.+Malloyauthor=J.+Chubbauthor=E.+Hustonauthor=G.+Baillieauthor=P.+Thomsonauthor=E.+Hillauthor=N.+Brandonauthor=J.+Rainauthor=L.+Camargoauthor=P.+Whitingauthor=M.+Houslayauthor=D.+Blackwoodauthor=W.+Muirauthor=D.+Porteous&title=DISC1+and+PDE4B+are+interacting+genetic+factors+in+schizophrenia+that+regulate+cAMP+signaling&doi=10.1126%2Fscience.1112915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span></div><div class="casAuthors">Millar, J. Kirsty; Pickard, Benjamin S.; Mackie, Shaun; James, Rachel; Christie, Sheila; Buchanan, Sebastienne R.; Malloy, M. Pat; Chubb, Jennifer E.; Huston, Elaine; Baillie, George S.; Thomson, Pippa A.; Hill, Elaine V.; Brandon, Nicholas J.; Rain, Jean-Christophe; Camargo, L. Miguel; Whiting, Paul J.; Houslay, Miles D.; Blackwood, Douglas H. R.; Muir, Walter J.; Porteous, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5751</span>),
    <span class="NLM_cas:pages">1187-1191</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The disrupted in schizophrenia 1 (DISC1) gene is a candidate susceptibility factor for schizophrenia, but its mechanistic role in the disorder is unknown.  Here we report that the gene encoding phosphodiesterase 4B (PDE4B) is disrupted by a balanced translocation in a subject diagnosed with schizophrenia and a relative with chronic psychiatric illness.  The PDEs inactivate adenosine 3',5'-monophosphate (cAMP), a second messenger implicated in learning, memory, and mood.  We show that DISC1 interacts with the UCR2 domain of PDE4B and that elevation of cellular cAMP leads to dissocn. of PDE4B from DISC1 and an increase in PDE4B activity.  We propose a mechanistic model whereby DISC1 sequesters PDE4B in resting cells and releases it in an activated state in response to elevated cAMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaCqxUtIeBILVg90H21EOLACvtfcHk0liMB5Uluw2SHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WgtLbL&md5=8ed8ebbebab56f9d4902ce080ba29e47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.1112915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1112915%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%26aulast%3DPickard%26aufirst%3DB.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMalloy%26aufirst%3DM.%26aulast%3DChubb%26aufirst%3DJ.%26aulast%3DHuston%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DG.%26aulast%3DThomson%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DE.%26aulast%3DBrandon%26aufirst%3DN.%26aulast%3DRain%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DL.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DHouslay%26aufirst%3DM.%26aulast%3DBlackwood%26aufirst%3DD.%26aulast%3DMuir%26aufirst%3DW.%26aulast%3DPorteous%26aufirst%3DD.%26atitle%3DDISC1%2520and%2520PDE4B%2520are%2520interacting%2520genetic%2520factors%2520in%2520schizophrenia%2520that%2520regulate%2520cAMP%2520signaling%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D1187%26epage%3D1191%26doi%3D10.1126%2Fscience.1112915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-Î<sup>2</sup>42-induced memory deficits in mice</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.3233/JAD-122236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3233%2FJAD-122236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=269-280&author=C.+Zhangauthor=Y.+Chengauthor=H.+Wangauthor=C.+Wangauthor=S.+P.+Wilsonauthor=J.+Xuauthor=H.+T.+Zhang&title=RNA+interference-mediated+knockdown+of+long-form+phosphodiesterase-4D+%28PDE4D%29+enzyme+reverses+amyloid-%C3%8E242-induced+memory+deficits+in+mice&doi=10.3233%2FJAD-122236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3233%2FJAD-122236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-122236%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DRNA%2520interference-mediated%2520knockdown%2520of%2520long-form%2520phosphodiesterase-4D%2520%2528PDE4D%2529%2520enzyme%2520reverses%2520amyloid-%25C3%258E242-induced%2520memory%2520deficits%2520in%2520mice%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2013%26volume%3D38%26spage%3D269%26epage%3D280%26doi%3D10.3233%2FJAD-122236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5236-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1523%2FJNEUROSCI.5236-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21209202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=172-183&author=Y.+F.+Liauthor=Y.+F.+Chengauthor=Y.+Huangauthor=M.+Contiauthor=S.+P.+Wilsonauthor=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Phosphodiesterase-4D+knockout+and+RNAi-mediated+knockdown+enhance+memory+and+increase+hippocampal+neurogenesis+via+increased+cAMP+signaling&doi=10.1523%2FJNEUROSCI.5236-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span></div><div class="casAuthors">Li, Yun-Feng; Cheng, Yu-Fang; Huang, Ying; Conti, Marco; Wilson, Steven P.; O'Donnell, James M.; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  These effects were mimicked by repeated treatment with rolipram in wild-type mice.  In addn., similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus down-regulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  The present results suggest that PDE4D, in particular long-form PDE4D, plays a crit. role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKG03_qqdl7Vg90H21EOLACvtfcHk0liMB5Uluw2SHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D&md5=928836c09ff122681fdf11db58885b79</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5236-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5236-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DCheng%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DPhosphodiesterase-4D%2520knockout%2520and%2520RNAi-mediated%2520knockdown%2520enhance%2520memory%2520and%2520increase%2520hippocampal%2520neurogenesis%2520via%2520increased%2520cAMP%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D172%26epage%3D183%26doi%3D10.1523%2FJNEUROSCI.5236-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Works, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, T. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2008.06349.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1460-9568.2008.06349.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18702734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BD1crhvFGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=625-632&author=K.+Ruttenauthor=D.+L.+Misnerauthor=M.+Worksauthor=A.+Bloklandauthor=T.+J.+Novakauthor=L.+Santarelliauthor=T.+L.+Wallace&title=Enhanced+long-term+potentiation+and+impaired+learning+in+phosphodiesterase+4D-knockout+%28PDE4D%29+mice&doi=10.1111%2Fj.1460-9568.2008.06349.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice</span></div><div class="casAuthors">Rutten Kris; Misner Dinah L; Works Melissa; Blokland Arjan; Novak Thomas J; Santarelli Luca; Wallace Tanya L</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevation of intracellular cyclic adenosine monophosphate (cAMP) concentrations and subsequent regulation of downstream target gene expression through phosphorylation of cAMP-responsive element binding protein (CREB) is hypothesized to underlie the mechanism(s) of long-term memory (LTM) formation.  The phosphodiesterase 4 (PDE4) enzyme family is believed to play a key role in LTM by regulating cAMP levels.  Thus far, four PDE4 isoforms have been identified (PDE4A, B, C and D); however, the requisite involvement of each of these isoforms in mediating LTM has yet to be elucidated.  In the present study, genetic knockout mice were used to investigate the involvement of the PDE4D isoform in both in vitro and in vivo models of learning and memory.  Hippocampal synaptic transmission measured electrophysiologically in CA1 slice preparations was similar between wild-type and PDE4D (-/-) mice yet, relative to wild-type controls, knockout mice displayed enhanced early long-term potentiation (LTP) following multiple induction protocols.  Interestingly, the PDE4D (-/-) animals exhibited significant behavioral deficits in associative learning using a conditioned fear paradigm as compared with control littermates.  The impairment in fear conditioning observed in the PDE4D (-/-) mice could not be attributed to differences in acquisition of the task, alterations in locomotor activity or effects on shock sensitivity.  Overall, the in vitro and in vivo alterations in synaptic plasticity observed in the PDE4D (-/-) mice may be explained by adaptive responses occurring throughout development, and suggest that the PDE4D isoform may be an important mediator of LTM formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3AIQ_0tQh5Htlzo9xastyfW6udTcc2eYIk24-OR00Kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhvFGrsA%253D%253D&md5=aaf2f2867d552e119c80dad9d3d577b3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2008.06349.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2008.06349.x%26sid%3Dliteratum%253Aachs%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DWorks%26aufirst%3DM.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DWallace%26aufirst%3DT.%2BL.%26atitle%3DEnhanced%2520long-term%2520potentiation%2520and%2520impaired%2520learning%2520in%2520phosphodiesterase%25204D-knockout%2520%2528PDE4D%2529%2520mice%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D625%26epage%3D632%26doi%3D10.1111%2Fj.1460-9568.2008.06349.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitolo, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1624</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.1172/JCI22831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1172%2FJCI22831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15578094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1624-1634&author=B.+Gongauthor=O.+V.+Vitoloauthor=F.+Trincheseauthor=S.+Liuauthor=M.+Shelanskiauthor=O.+Arancio&title=Persistent+improvement+in+synaptic+and+cognitive+functions+in+an+Alzheimer+mouse+model+after+rolipram+treatment&doi=10.1172%2FJCI22831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment</span></div><div class="casAuthors">Gong, Bing; Vitolo, Ottavio V.; Trinchese, Fabrizio; Liu, Shumin; Shelanski, Michael; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1624-1634</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Evidence suggests that Alzheimer disease (AD) begins as a disorder of synaptic function, caused in part by increased levels of amyloid β-peptide 1-42 (Aβ42).  Both synaptic and cognitive deficits are reproduced in mice double transgenic for amyloid precursor protein (AA substitution K670N,M671L) and presenilin-1 (AA substitution M146V).  Here the authors demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice.  Most importantly, this beneficial effect can be extended beyond the duration of the administration.  One course of long-term systemic treatment with rolipram improves LTP and basal synaptic transmission as well as working, ref., and associative memory deficits for at least 2 mo after the end of the treatment.  This protective effect is possibly due to stabilization of synaptic circuitry via alterations in gene expression by activation of the cAMP-dependent protein kinase (PKA)/cAMP regulatory element-binding protein (CREB) signaling pathway that make the synapses more resistant to the insult inflicted by Aβ.  Thus, agents that enhance the cAMP/PKA/CREB pathway have potential for the treatment of AD and other diseases assocd. with elevated Aβ42 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI79h3DC1rU7Vg90H21EOLACvtfcHk0lhPd0stWP6aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhur3I&md5=72e43d10754678b58a452160fe7142e2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1172%2FJCI22831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI22831%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DB.%26aulast%3DVitolo%26aufirst%3DO.%2BV.%26aulast%3DTrinchese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShelanski%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DPersistent%2520improvement%2520in%2520synaptic%2520and%2520cognitive%2520functions%2520in%2520an%2520Alzheimer%2520mouse%2520model%2520after%2520rolipram%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1624%26epage%3D1634%26doi%3D10.1172%2FJCI22831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer’s disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1007/s13311-014-0309-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2Fs13311-014-0309-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25371167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=49-56&author=M.+E.+Gurneyauthor=E.+C.+D%E2%80%99Amatoauthor=A.+B.+Burgin&title=Phosphodiesterase-4+%28PDE4%29+molecular+pharmacology+and+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs13311-014-0309-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease</span></div><div class="casAuthors">Gurney, Mark E.; D'Amato, Emily C.; Burgin, Alex B.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-56</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Between 20% and 25% of patients diagnosed with Alzheimer's disease (AD) do not have amyloid burden as assessed by positron emission tomog. imaging.  Thus, there is a need for nonamyloid-directed therapies for AD, esp. for those patients with non-amyloid AD.  The family of phosphodiesterase-4 (PDE4) enzymes are underexploited therapeutic targets for central nervous system indications.  While the PDE4A, B, and D subtypes are expressed in brain, the strict amino acid sequence conservation of the active site across the four subtypes of PDE4 has made it difficult to discover subtype inhibitors.  The recent elucidation of the structure of the PDE4 N- and C-terminal regulatory domains now makes it possible to design subtype-selective, neg. allosteric modulators (PDE4-NAMs).  These act through closing the N-terminal UCR2 or C-terminal CR3 regulatory domains, and thereby inhibit the enzyme by blocking access of cyclic adenosine monophosphate (cAMP) to the active site.  PDE4B-NAMs have the potential to reduce neuroinflammation by dampening microglia cytokine prodn. triggered by brain amyloid, while PDE4D-NAMs have potent cognitive benefit by augmenting signaling through the cAMP/protein kinase A/cAMP response element-binding protein (CREB) pathway for memory consolidation.  The importance of PDE4D for human cognition is underscored by the recent discovery of PDE4D mutations in acrodysostosis (ACRDY2: MIM 600129), an ultra rare disorder assocd. with intellectual disability.  Thus, the family of PDE4 enzymes provides rich opportunities for the development of mechanistically novel drugs to treat neuroinflammation or the cognitive deficits in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqtOZ-WeMZbVg90H21EOLACvtfcHk0lhPd0stWP6aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqt7%252FI&md5=495386b35844b7f0270712d43c0e9d5d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs13311-014-0309-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-014-0309-7%26sid%3Dliteratum%253Aachs%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DE.%2BC.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26atitle%3DPhosphodiesterase-4%2520%2528PDE4%2529%2520molecular%2520pharmacology%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurotherapeutics%26date%3D2015%26volume%3D12%26spage%3D49%26epage%3D56%26doi%3D10.1007%2Fs13311-014-0309-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pneurobio.2016.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27769868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKmsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=1-19&author=T.+F.+Jiangauthor=Q.+Sunauthor=S.+D.+Chen&title=Oxidative+stress%3A+a+major+pathogenesis+and+potential+therapeutic+target+of+antioxidative+agents+in+Parkinson%E2%80%99s+disease+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2016.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease</span></div><div class="casAuthors">Jiang, Tianfang; Sun, Qian; Chen, Shengdi</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oxidative stress reflects an imbalance between the overprodn. and incorporation of free radicals and the dynamic ability of a biosystem to detoxify reactive intermediates.  Free radicals produced by oxidative stress are one of the common features in several exptl. models of diseases.  Free radicals affect both the structure and function of neural cells, and contribute to a wide range of neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.  Although the precise mechanisms that result in the degeneration of neurons and the relevant pathol. changes remain unclear, the crucial role of oxidative stress in the pathogenesis of neurodegenerative diseases is assocd. with several proteins (such as α-synucleinx, DJ-1, Amyloid β and tau protein) and some signaling pathways (such as extracellular regulated protein kinases, phosphoinositide 3-kinase/Protein Kinase B pathway and extracellular signal-regulated kinases 1/2) that are tightly assocd. with the neural damage.  In this review, we present evidence, gathered over the last decade, concerning a variety of pathogenic proteins, their important signaling pathways and pathogenic mechanisms assocd. with oxidative stress in Parkinson's disease and Alzheimer's disease.  Proper control and regulation of these proteins' functions and the related signaling pathways may be a promising therapeutic approach to the patients.  We also emphasizes antioxidative options, including some new neuroprotective agents that eliminate excess reactive oxygen species efficiently and have a certain therapeutic effect; however, controversy surrounds some of them in terms of the dose and length of therapy.  These agents require further investigation by clin. application in patients suffering Parkinson's disease and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRkTEjvuHFrVg90H21EOLACvtfcHk0lhPd0stWP6aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKmsLnI&md5=df30edd6b191d56792811edaa8a7c4c9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%2BF.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%2BD.%26atitle%3DOxidative%2520stress%253A%2520a%2520major%2520pathogenesis%2520and%2520potential%2520therapeutic%2520target%2520of%2520antioxidative%2520agents%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.pneurobio.2016.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesselet, M. F.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial dysfunction and oxidative stress in Parkinson’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pneurobio.2013.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23643800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVOhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2013&pages=17-32&author=S.+R.+Subramaniamauthor=M.+F.+Chesselet&title=Mitochondrial+dysfunction+and+oxidative+stress+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial dysfunction and oxidative stress in Parkinson's disease</span></div><div class="casAuthors">Subramaniam, Sudhakar Raja; Chesselet, Marie-Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">106-107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a movement disorder that is characterized by the progressive degeneration of dopaminergic neurons in substantia nigra pars compacta resulting in dopamine deficiency in the striatum.  Although majority of the PD cases are sporadic several genetic mutations have also been linked to the disease thus providing new opportunities to study the pathol. of the illness.  Studies in humans and various animal models of PD reveal that mitochondrial dysfunction might be a defect that occurs early in PD pathogenesis and appears to be a widespread feature in both sporadic and monogenic forms of PD.  The general mitochondrial abnormalities linked with the disease include mitochondrial electron transport chain impairment, alterations in mitochondrial morphol. and dynamics, mitochondrial DNA mutations and anomaly in calcium homeostasis.  Mitochondria are vital organelles with multiple functions and their dysfunction can lead to a decline in energy prodn., generation of reactive oxygen species and induction of stress-induced apoptosis.  In this review, we give an outline of mitochondrial functions that are affected in the pathogenesis of sporadic and familial PD, and hence provide insights that might be valuable for focused future research to exploit possible mitochondrial targets for neuroprotective interventions in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIZRfC0Ioj7Vg90H21EOLACvtfcHk0lj8Aw2Hu3qa9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVOhu7s%253D&md5=fba0adc1e483cfba5df548562083e006</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DS.%2BR.%26aulast%3DChesselet%26aufirst%3DM.%2BF.%26atitle%3DMitochondrial%2520dysfunction%2520and%2520oxidative%2520stress%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2013%26volume%3D106%26spage%3D17%26epage%3D32%26doi%3D10.1016%2Fj.pneurobio.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VandenBerg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourtchouladze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. A.</span></span> <span> </span><span class="NLM_article-title">Novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia</span>. <i>Neurorehab. Neural. Re.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1177/1545968307305521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1177%2F1545968307305521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17823313" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=486-496&author=E.+MacDonaldauthor=H.+Van+der+Leeauthor=D.+Pocockauthor=C.+Coleauthor=N.+Thomasauthor=P.+M.+VandenBergauthor=R.+Bourtchouladzeauthor=J.+A.+Kleim&title=Novel+phosphodiesterase+type+4+inhibitor%2C+HT-0712%2C+enhances+rehabilitation-dependent+motor+recovery+and+cortical+reorganization+after+focal+cortical+ischemia&doi=10.1177%2F1545968307305521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F1545968307305521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1545968307305521%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DE.%26aulast%3DVan%2Bder%2BLee%26aufirst%3DH.%26aulast%3DPocock%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DVandenBerg%26aufirst%3DP.%2BM.%26aulast%3DBourtchouladze%26aufirst%3DR.%26aulast%3DKleim%26aufirst%3DJ.%2BA.%26atitle%3DNovel%2520phosphodiesterase%2520type%25204%2520inhibitor%252C%2520HT-0712%252C%2520enhances%2520rehabilitation-dependent%2520motor%2520recovery%2520and%2520cortical%2520reorganization%2520after%2520focal%2520cortical%2520ischemia%26jtitle%3DNeurorehab.%2520Neural.%2520Re.%26date%3D2007%26volume%3D21%26spage%3D486%26epage%3D496%26doi%3D10.1177%2F1545968307305521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>Clinical
trials for HT-0712. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02013310?term=HT-0712&amp;rank=2" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02013310?term=HT-0712&rank=2</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+HT-0712.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02013310%3Fterm%3DHT-0712%26rank%3D2+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sol, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ousset, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemarie, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span> <span> </span><span class="NLM_article-title">EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.2174/156720511795256053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F156720511795256053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21222604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=203-212&author=B.+Vellasauthor=O.+Solauthor=P.+J.+Snyderauthor=P.+J.+Oussetauthor=R.+Haddadauthor=M.+Maurinauthor=J.+C.+Lemarieauthor=L.+Desireauthor=M.+P.+Pandoauthor=M.+P.+Pando&title=EHT0202+in+Alzheimer%E2%80%99s+disease%3A+a+3-month%2C+randomized%2C+placebo-controlled%2C+double-blind+study&doi=10.2174%2F156720511795256053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study</span></div><div class="casAuthors">Vellas, B.; Sol, O.; Snyder, P. J.; Ousset, P.-J.; Haddad, R.; Maurin, M.; Lemarie, J.-C.; Desire, L.; Pando, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: EHT0202 (etazolate hydrochloride) is a new compd. exhibiting both potential diseasemodifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.  Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in 159 randomized patients suffering from mild to moderate Alzheimer's Disease.  EHT0202 (40 or 80mg bid) or placebo was administered as adjunctive therapy to one acetylcholinesterase inhibitor over a 3-mo period.  This study was designed to assess the clin. safety and tolerability of EHT0202 as a primary objective, with secondary endpoints (cognitive function, daily living activities, behavior, caregiver burden and global functioning) included to explore clin. efficacy of EHT0202 vs. placebo.  Results: EHT0202 was shown to be safe and generally well tolerated.  Dose-dependent nos. of early withdrawal and central nervous system related adverse events were obsd.  As expected, since the study was not powered and not designed to show drug efficacy, and except for ratings on the ADCS-ADL scale, no significant differences were seen between treatment groups.  Conclusions: These first encouraging safety results do support further development of EHT0202 in order to assess its clin. efficacy and to confirm its tolerability in a larger cohort of Alzheimer patients and for a longer period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGT7btT8TzVrVg90H21EOLACvtfcHk0lj8Aw2Hu3qa9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOisLk%253D&md5=b48e7cc084616eb4d81bd4d7c25763de</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F156720511795256053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720511795256053%26sid%3Dliteratum%253Aachs%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSol%26aufirst%3DO.%26aulast%3DSnyder%26aufirst%3DP.%2BJ.%26aulast%3DOusset%26aufirst%3DP.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%26aulast%3DMaurin%26aufirst%3DM.%26aulast%3DLemarie%26aufirst%3DJ.%2BC.%26aulast%3DDesire%26aufirst%3DL.%26aulast%3DPando%26aufirst%3DM.%2BP.%26aulast%3DPando%26aufirst%3DM.%2BP.%26atitle%3DEHT0202%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%25203-month%252C%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%2520study%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2011%26volume%3D8%26spage%3D203%26epage%3D212%26doi%3D10.2174%2F156720511795256053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>Clinical
trials for etazolate. <a href="https://www.clinicaltrials.gov/ct2/show/NCT00880412?term=Etazolate&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT00880412?term=Etazolate&rank=1</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+etazolate.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00880412%3Fterm%3DEtazolate%26rank%3D1+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Clinical
trials for BPN14770. <a href="https://www.clinicaltrials.gov/ct2/show/NCT03817684?term=BPN14770&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03817684?term=BPN14770&rank=1</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+BPN14770.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03817684%3Fterm%3DBPN14770%26rank%3D1+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span>Clinical
trials for MK0952. <a href="https://clinicaltrials.gov/ct2/show/NCT00362024?term=MK-0952" class="extLink">https://clinicaltrials.gov/ct2/show/NCT00362024?term=MK-0952</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+MK0952.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00362024%3Fterm%3DMK-0952+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macnaughtan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prestegard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7673</span>– <span class="NLM_lpage">7688</span>, <span class="refDoi"> DOI: 10.1021/jm701635j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701635j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7673-7688&author=S.+Zhengauthor=G.+Kaurauthor=H.+Wangauthor=M.+Liauthor=M.+Macnaughtanauthor=X.+Yangauthor=S.+Reidauthor=J.+Prestegardauthor=B.+Wangauthor=H.+Ke&title=Design%2C+synthesis%2C+and+structure-activity+relationship%2C+molecular+modeling%2C+and+NMR+studies+of+a+series+of+phenyl+alkyl+ketones+as+highly+potent+and+selective+phosphodiesterase-4+inhibitors&doi=10.1021%2Fjm701635j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors</span></div><div class="casAuthors">Zheng, Shilong; Kaur, Gurpreet; Wang, Huanchen; Li, Minyong; Macnaughtan, Megan; Yang, Xiaochuan; Reid, Suazette; Prestegard, James; Wang, Binghe; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7673-7688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 catalyzes the hydrolysis of cAMP and is a target for the development of anti-inflammatory agents.  We have designed and synthesized a series of Ph alkyl ketones as PDE4 inhibitors.  Among them, 13 compds. were identified as having submicromolar IC50 values.  The most potent compds. have IC50 values of in the mid- to low-nanomolar range.  Compd. I (R = i-Pr, X = O)also showed preference for PDE4 with selectivity of >2000-fold over PDE7, PDE9, PDE2, and PDE5.  Docking of I, II (R = i-Pr, X = CH2), and III (R = n-Pr, X = O) into the binding pocket of the PDE4 catalytic domain revealed a similar binding profile to PDE4 with rolipram except that the fluorine atoms of the difluoromethyl groups of I, II, and III are within a reasonable range for hydrogen bond formation with the amide hydrogen of Thr 333 and the long alkyl chain bears addnl. van der Waals interactions with His 160, Asp 318, and Tyr 159.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkyBtbusd487Vg90H21EOLACvtfcHk0lifX9zyByBjSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7vN&md5=cc9e4b0a1e090e8bead52686da67d047</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm701635j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701635j%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMacnaughtan%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DS.%26aulast%3DPrestegard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%252C%2520molecular%2520modeling%252C%2520and%2520NMR%2520studies%2520of%2520a%2520series%2520of%2520phenyl%2520alkyl%2520ketones%2520as%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase-4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7673%26epage%3D7688%26doi%3D10.1021%2Fjm701635j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a PDE4-specific pocket for the design of selective inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4518</span>– <span class="NLM_lpage">4525</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kns7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4518-4525&author=X.+Fengauthor=H.+Wangauthor=M.+Yeauthor=X.+T.+Xuauthor=Y.+Xuauthor=W.+Yangauthor=H.+T.+Zhangauthor=G.+Songauthor=H.+Ke&title=Identification+of+a+PDE4-specific+pocket+for+the+design+of+selective+inhibitors&doi=10.1021%2Facs.biochem.8b00336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PDE4-specific pocket for the design of selective inhibitors</span></div><div class="casAuthors">Feng, Xiaoqing; Wang, Huanchen; Ye, Mengchun; Xu, Xue-Tao; Xu, Ying; Yang, Wenzhe; Zhang, Han-Ting; Song, Guoqiang; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4518-4525</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of phosphodiesterases (PDEs) have been widely studied as therapeutics for the treatment of human diseases, but improvement of inhibitor selectivity is still desirable for the enhancement of inhibitor potency.  Here, we report identification of a water-contg. subpocket as a PDE4-specific pocket for inhibitor binding.  We designed against the pocket and synthesized two enantiomers of PDE4 inhibitor Zl-n-91.  The (S)-Zl-n-91 enantiomer showed IC50 values of 12 and 20 nM for the catalytic domains of PDE4D2 and PDE4B2B, resp., selectivity several thousand-fold greater than those of other PDE families, and potent neuroprotection activities.  Crystal structures of the PDE4D2 catalytic domain in complex with each Zl-n-91 enantiomer revealed that (S)-Zl-n-91 but not (R)-Zl-n-91 formed a hydrogen bond with the bound water in the pocket, thus explaining its higher affinity.  The structural superposition between the PDE families revealed that this water-contg. subpocket is unique to PDE4 and thus valuable for the design of PDE4 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmnqUSd5AmI7Vg90H21EOLACvtfcHk0lifX9zyByBjSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kns7jJ&md5=82687a6d72bc36c6545f1fc8a377a44a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00336%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%2BT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520PDE4-specific%2520pocket%2520for%2520the%2520design%2520of%2520selective%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D4518%26epage%3D4525%26doi%3D10.1021%2Facs.biochem.8b00336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenicotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijselaers, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanmierlo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limebeer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argellati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinari, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronzato, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciarelli, R.</span></span> <span> </span><span class="NLM_article-title">GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">2054</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01524.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1476-5381.2011.01524.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21649644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2054-2063&author=O.+Brunoauthor=E.+Fedeleauthor=J.+Prickaertsauthor=L.+A.+Parkerauthor=E.+Canepaauthor=C.+Brulloauthor=A.+Cavalleroauthor=E.+Gardellaauthor=A.+Balbiauthor=C.+Domenicottiauthor=E.+Bollenauthor=H.+J.+Gijselaersauthor=T.+Vanmierloauthor=K.+Erbauthor=C.+L.+Limebeerauthor=F.+Argellatiauthor=U.+M.+Marinariauthor=M.+A.+Pronzatoauthor=R.+Ricciarelli&title=GEBR-7b%2C+a+novel+PDE4D+selective+inhibitor+that+improves+memory+in+rodents+at+non-emetic+doses&doi=10.1111%2Fj.1476-5381.2011.01524.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses</span></div><div class="casAuthors">Bruno, O.; Fedele, E.; Prickaerts, J.; Parker, L. A.; Canepa, E.; Brullo, C.; Cavallero, A.; Gardella, E.; Balbi, A.; Domenicotti, C.; Bollen, E.; Gijselaers, H. J. M.; Vanmierlo, T.; Erb, K.; Limebeer, C. L.; Argellati, F.; Marinari, U. M.; Pronzato, M. A.; Ricciarelli, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2054-2063</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Strategies designed to enhance cerebral cAMP have been proposed as symptomatic treatments to counteract cognitive deficits.  However, pharmacol. therapies aimed at reducing PDE4, the main class of cAMP catabolizing enzymes in the brain, produce severe emetic side effects.  We have recently synthesized a 3-cyclopentyloxy-4-methoxybenzaldehyde deriv., structurally related to rolipram, and endowed with selective PDE4D inhibitory activity.  The aim of the present study was to investigate the effect of the new drug, namely GEBR-7b, on memory performance, nausea, hippocampal cAMP and amyloid-β (Aβ) levels.  Exptl. Approach: To measure memory performance, we performed object recognition tests on rats and mice treated with GEBR-7b or rolipram.  The emetic potential of the drug, again compared with rolipram, was evaluated in rats using the taste reactivity test and in mice using the xylazine/ketamine anesthesia test.  Extracellular hippocampal cAMP was evaluated by intracerebral microdialysis in freely moving rats.  Levels of sol. Aβ peptides were measured in hippocampal tissues and cultured N2a cells by ELISA.  Key Results: GEBR-7b increased hippocampal cAMP, did not influence Aβ levels and improved spatial, as well as object memory performance in the object recognition tests.  The effect of GEBR-7b on memory was 3 to 10 times more potent than that of rolipram, and its EDs had no effect on surrogate measures of emesis in rodents.  Conclusion and Implications: Our results demonstrate that GEBR-7b enhances memory functions at doses that do not cause emesis-like behavior in rodents, thus offering a promising pharmacol. perspective for the treatment of memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpATGYg_M20rVg90H21EOLACvtfcHk0lifX9zyByBjSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLrN&md5=3cb12b993944a55d6052b10bd07c9c09</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01524.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01524.x%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DFedele%26aufirst%3DE.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DL.%2BA.%26aulast%3DCanepa%26aufirst%3DE.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DCavallero%26aufirst%3DA.%26aulast%3DGardella%26aufirst%3DE.%26aulast%3DBalbi%26aufirst%3DA.%26aulast%3DDomenicotti%26aufirst%3DC.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DGijselaers%26aufirst%3DH.%2BJ.%26aulast%3DVanmierlo%26aufirst%3DT.%26aulast%3DErb%26aufirst%3DK.%26aulast%3DLimebeer%26aufirst%3DC.%2BL.%26aulast%3DArgellati%26aufirst%3DF.%26aulast%3DMarinari%26aufirst%3DU.%2BM.%26aulast%3DPronzato%26aufirst%3DM.%2BA.%26aulast%3DRicciarelli%26aufirst%3DR.%26atitle%3DGEBR-7b%252C%2520a%2520novel%2520PDE4D%2520selective%2520inhibitor%2520that%2520improves%2520memory%2520in%2520rodents%2520at%2520non-emetic%2520doses%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D2054%26epage%3D2063%26doi%3D10.1111%2Fj.1476-5381.2011.01524.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romussi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondavalli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanthuyne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, C.</span></span> <span> </span><span class="NLM_article-title">New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6546</span>– <span class="NLM_lpage">6557</span>, <span class="refDoi"> DOI: 10.1021/jm900977c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900977c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6546-6557&author=O.+Brunoauthor=A.+Romussiauthor=A.+Spallarossaauthor=C.+Brulloauthor=S.+Schenoneauthor=F.+Bondavalliauthor=N.+Vanthuyneauthor=C.+Roussel&title=New+selective+phosphodiesterase+4D+inhibitors+differently+acting+on+long%2C+short%2C+and+supershort+isoforms&doi=10.1021%2Fjm900977c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">New Selective Phosphodiesterase 4D Inhibitors Differently Acting on Long, Short, and Supershort Isoforms</span></div><div class="casAuthors">Bruno, Olga; Romussi, Alessia; Spallarossa, Andrea; Brullo, Chiara; Schenone, Silvia; Bondavalli, Francesco; Vanthuyne, Nicolas; Roussel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6546-6557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The lack of selective inhibitors toward the long, short, or supershort phosphodiesterases (PDE4s) prevented researchers from carefully defining the connection between different enzyme isoforms, their brain localization, and their role in neurodegenerative diseases such as Alzheimer's disease (AD).  In the search for new therapeutic agents for treating memory and learning disorders, we synthesized new rolipram related PDE4 inhibitors, which had some selectivity toward the long form PDE4D3.  The first series was synthesized as racemate and then resolved by semipreparative HPLC on chiral supports.  Herein we report the synthetic pathways to obtain rolipram related compds. and their biol. activities and some SAR considerations that provide some insights and hints for the structural requirements for PDE4D subtype selectivity and enzyme inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrp9k6gslEYrVg90H21EOLACvtfcHk0liLRzRokhuPbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtL3M&md5=db19da5da1e6781c62dd6b6415ca68c3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm900977c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900977c%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DRomussi%26aufirst%3DA.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBondavalli%26aufirst%3DF.%26aulast%3DVanthuyne%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DC.%26atitle%3DNew%2520selective%2520phosphodiesterase%25204D%2520inhibitors%2520differently%2520acting%2520on%2520long%252C%2520short%252C%2520and%2520supershort%2520isoforms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6546%26epage%3D6557%26doi%3D10.1021%2Fjm900977c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricciarelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebosio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hagen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrousi, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronzato, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, E.</span></span> <span> </span><span class="NLM_article-title">Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46320</span>, <span class="refDoi"> DOI: 10.1038/srep46320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fsrep46320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28402318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46320&author=R.+Ricciarelliauthor=C.+Brulloauthor=J.+Prickaertsauthor=O.+Arancioauthor=C.+Villaauthor=C.+Rebosioauthor=E.+Calcagnoauthor=M.+Balbiauthor=B.+T.+van+Hagenauthor=E.+K.+Argyrousiauthor=H.+Zhangauthor=M.+A.+Pronzatoauthor=O.+Brunoauthor=E.+Fedele&title=Memory-enhancing+effects+of+GEBR-32a%2C+a+new+PDE4D+inhibitor+holding+promise+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fsrep46320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ricciarelli, Roberta; Brullo, Chiara; Prickaerts, Jos; Arancio, Ottavio; Villa, Carla; Rebosio, Claudia; Calcagno, Elisa; Balbi, Matilde; van Hagen, Britt T. J.; Argyrousi, Elentina K.; Zhang, Hong; Pronzato, Maria Adelaide; Bruno, Olga; Fedele, Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46320</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Memory loss characterizes several neurodegenerative disorders, including Alzheimer's disease (AD).  Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits.  However, PDE4 exists in several isoforms and pan inhibitors cannot be used in humans due to severe emesis.  Here, we present GEBR-32a, a new PDE4D full inhibitor that has been characterized both in vitro and in vivo using biochem., electrophysiol. and behavioral analyses.  GEBR-32a efficiently enhances cAMP in neuronal cultures and hippocampal slices.  In vivo pharmacokinetic anal. shows that GEBR-32a is rapidly distributed within the central nervous system with a very favorable brain/blood ratio.  Specific behavioral tests (object location and Y-maze continuous alternation tasks) demonstrate that this PDE4D inhibitor is able to enhance memory in AD transgenic mice and concomitantly rescues their hippocampal long-term potentiation deficit.  Of great relevance, our preliminary toxicol. anal. indicates that GEBR-32a is not cytotoxic and genotoxic, and does not seem to possess emetic-like side effects.  In conclusion, GEBR-32a could represent a very promising cognitive-enhancing drug with a great potential for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsjtvwg5_Mq7Vg90H21EOLACvtfcHk0liLRzRokhuPbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCrsbg%253D&md5=718b6fe3b59c3c939a18273c90474fbd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep46320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46320%26sid%3Dliteratum%253Aachs%26aulast%3DRicciarelli%26aufirst%3DR.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DVilla%26aufirst%3DC.%26aulast%3DRebosio%26aufirst%3DC.%26aulast%3DCalcagno%26aufirst%3DE.%26aulast%3DBalbi%26aufirst%3DM.%26aulast%3Dvan%2BHagen%26aufirst%3DB.%2BT.%26aulast%3DArgyrousi%26aufirst%3DE.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPronzato%26aufirst%3DM.%2BA.%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DFedele%26aufirst%3DE.%26atitle%3DMemory-enhancing%2520effects%2520of%2520GEBR-32a%252C%2520a%2520new%2520PDE4D%2520inhibitor%2520holding%2520promise%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46320%26doi%3D10.1038%2Fsrep46320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prosdocimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semrau, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucarelli, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisini, E.</span></span> <span> </span><span class="NLM_article-title">Molecular bases of PDE4D inhibition by memory-enhancing GEBR library compounds</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2876-2888&author=T.+Prosdocimiauthor=L.+Mollicaauthor=S.+Doniniauthor=M.+S.+Semrauauthor=A.+P.+Lucarelliauthor=E.+Aiolfiauthor=A.+Cavalliauthor=P.+Storiciauthor=S.+Alfeiauthor=C.+Brulloauthor=O.+Brunoauthor=E.+Parisini&title=Molecular+bases+of+PDE4D+inhibition+by+memory-enhancing+GEBR+library+compounds&doi=10.1021%2Facs.biochem.8b00288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds</span></div><div class="casAuthors">Prosdocimi, Tommaso; Mollica, Luca; Donini, Stefano; Semrau, Marta S.; Lucarelli, Anna Paola; Aiolfi, Egidio; Cavalli, Andrea; Storici, Paola; Alfei, Silvana; Brullo, Chiara; Bruno, Olga; Parisini, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selected members of the large rolipram-related GEBR family of phosphodiesterase-4 (PDE4) inhibitors have been shown to facilitate long term potentiation (LTP) and improve memory functions without causing emetic-like behavior in rodents.  Despite their micromolar-range binding affinities and their promising pharmacol. and toxicol. profiles, little if any structure-activity relationship studies have so far been carried out in order to elucidate the mol. bases of their action.  Here, we report the crystal structure of a no. of GEBR library compds. in complex with the catalytic domain of PDE4D as well as their inhibitory profiles for both the long PDE4D3 isoform and the catalytic domain alone.  Furthermore, we assessed the stability of the obsd. ligand conformations in the context of the intact enzyme using mol. dynamics simulations.  The longer and more flexible ligands appear to be capable of forming contacts with the regulatory portion of the enzyme, thus possibly allowing some degree of selectivity between the different PDE4 isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiQRAP3UFKrVg90H21EOLACvtfcHk0liLRzRokhuPbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFShurg%253D&md5=12feb16d105483c2b0bbec1fe4b0562a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00288%26sid%3Dliteratum%253Aachs%26aulast%3DProsdocimi%26aufirst%3DT.%26aulast%3DMollica%26aufirst%3DL.%26aulast%3DDonini%26aufirst%3DS.%26aulast%3DSemrau%26aufirst%3DM.%2BS.%26aulast%3DLucarelli%26aufirst%3DA.%2BP.%26aulast%3DAiolfi%26aufirst%3DE.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DAlfei%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DParisini%26aufirst%3DE.%26atitle%3DMolecular%2520bases%2520of%2520PDE4D%2520inhibition%2520by%2520memory-enhancing%2520GEBR%2520library%2520compounds%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facs.biochem.8b00288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, R. C. T.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2886</span>– <span class="NLM_lpage">2890</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-737676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1182%2Fblood-2016-09-737676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27756749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1ait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2886-2890&author=J.+D.+Cooneyauthor=R.+C.+T.+Aguiar&title=Phosphodiesterase+4+inhibitors+have+wide-ranging+activity+in+B-cell+malignancies&doi=10.1182%2Fblood-2016-09-737676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies</span></div><div class="casAuthors">Cooney, Jeffrey D.; Aguiar, Ricardo C. T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2886-2890</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibition restores the suppressive effects of 3',5'-cyclic adenosine monophosphate in lymphocytes.  In this concise review, we detail how PDE4 inhibition down-modulates the B-cell receptor (BCR)-related kinases spleen tyrosine kinase and phosphatidylinositol 3-kinase and inhibits vascular endothelial growth factor A secretion by tumor cells, inducing cancer cell apoptosis and blocking angiogenesis in the microenvironment.  We describe the successful clin. repurposing of PDE4 inhibitors in B-cell malignancies, and propose that given their anti-inflammatory/immunomodulatory activity, these agents will suppress BCR signals without the toxicity assocd. with other targeted biol. doublets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvT7KtkpSFOLVg90H21EOLACvtfcHk0lg7PU-R7NOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1ait7k%253D&md5=fff5d8746f062bc1d9bd7214ad15ae6c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-737676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-737676%26sid%3Dliteratum%253Aachs%26aulast%3DCooney%26aufirst%3DJ.%2BD.%26aulast%3DAguiar%26aufirst%3DR.%2BC.%2BT.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520have%2520wide-ranging%2520activity%2520in%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2886%26epage%3D2890%26doi%3D10.1182%2Fblood-2016-09-737676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, R. C.</span></span> <span> </span><span class="NLM_article-title">Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6723</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1158%2F1078-0432.CCR-11-0770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21742807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6723-6732&author=S.+W.+Kimauthor=D.+Raiauthor=R.+C.+Aguiar&title=Gene+set+enrichment+analysis+unveils+the+mechanism+for+the+phosphodiesterase+4B+control+of+glucocorticoid+response+in+B-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-11-0770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma</span></div><div class="casAuthors">Kim, Sang-Woo; Rai, Deepak; Aguiar, Ricardo C. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6723-6732</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance to glucocorticoid (GC) is a significant problem in the clin. management of lymphoid malignancies.  Addressing this issue via a mechanistic understanding of relevant signaling pathways is more likely to yield pos. outcomes.  Exptl. Design: We used gene set enrichment anal. (GSEA), multiple genetic models of gain and loss of function in B-cell lymphoma cell lines, in vitro and in vivo, and primary patient samples to characterize a novel relationship between the cAMP/phosphodiesterase 4B (cAMP/PDE4B), AKT/mTOR activities, and GC responses.  RESULTS: Starting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.  We used genetically modified cell lines to show that PDE4B modulates cAMP inhibitory activities toward the AKT/mTOR pathway and defines GC resistance in DLBCL.  In agreement with these data, pharmacol. inhibition of PDE4 in a xenograft model of human lymphoma unleashed cAMP effects, inhibited AKT, and restored GC sensitivity.  Finally, we used primary DLBCL samples to confirm the clin. relevance and biomarker potential of AKT/mTOR regulation by PDE4B.  CONCLUSIONS: Together, these data mechanistically elucidated how cAMP modulates GC responses in lymphocytes, defined AKT as the principal transducer of the growth inhibitory effects of cAMP in B cells, and allowed the formulation of genomics-guided clin. trials that test the ability of PDE4 inhibitors to restore GC sensitivity and improve the outcome of patients with B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobCAx2ENYxlLVg90H21EOLACvtfcHk0lg7PU-R7NOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsr%252FM&md5=377b1f30ca0a6b4b8e27d1605049cec6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0770%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DRai%26aufirst%3DD.%26aulast%3DAguiar%26aufirst%3DR.%2BC.%26atitle%3DGene%2520set%2520enrichment%2520analysis%2520unveils%2520the%2520mechanism%2520for%2520the%2520phosphodiesterase%25204B%2520control%2520of%2520glucocorticoid%2520response%2520in%2520B-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6723%26epage%3D6732%26doi%3D10.1158%2F1078-0432.CCR-11-0770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">Cyclic 3′,5′-nucleotide phosphodiesterases: potential targets for anticancer therapy</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1021/tx000090l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000090l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvF2kurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=944-948&author=D.+Markoauthor=G.+Pahlkeauthor=K.+H.+Merzauthor=G.+Eisenbrand&title=Cyclic+3%E2%80%B2%2C5%E2%80%B2-nucleotide+phosphodiesterases%3A+potential+targets+for+anticancer+therapy&doi=10.1021%2Ftx000090l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic 3',5'-Nucleotide Phosphodiesterases: Potential Targets for Anticancer Therapy</span></div><div class="casAuthors">Marko, Doris; Pahlke, Gudrun; Merz, Karl-Heinz; Eisenbrand, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">944-948</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 11 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCi1hocz577Vg90H21EOLACvtfcHk0lg7PU-R7NOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvF2kurg%253D&md5=bdeb99e3e0e32f17e8767dc90402d3c5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Ftx000090l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000090l%26sid%3Dliteratum%253Aachs%26aulast%3DMarko%26aufirst%3DD.%26aulast%3DPahlke%26aufirst%3DG.%26aulast%3DMerz%26aufirst%3DK.%2BH.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DCyclic%25203%25E2%2580%25B2%252C5%25E2%2580%25B2-nucleotide%2520phosphodiesterases%253A%2520potential%2520targets%2520for%2520anticancer%2520therapy%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2000%26volume%3D13%26spage%3D944%26epage%3D948%26doi%3D10.1021%2Ftx000090l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umetsu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaci.2010.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21047676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFantbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=1252-1259&author=S.+L.+Jinauthor=S.+Goyaauthor=S.+Nakaeauthor=D.+Wangauthor=M.+Brussauthor=C.+Houauthor=D.+Umetsuauthor=M.+Conti&title=Phosphodiesterase+4B+is+essential+for+T%28H%292-cell+function+and+development+of+airway+hyperresponsiveness+in+allergic+asthma&doi=10.1016%2Fj.jaci.2010.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma</span></div><div class="casAuthors">Jin, S.-L. Catherine; Goya, Sho; Nakae, Susumu; Wang, Dan; Bruss, Matthew; Hou, Chiaoyin; Umetsu, Dale; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1259, e1252/1-e1252/12</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">cAMP signaling modulates functions of inflammatory cells involved in the pathogenesis of asthma, and type 4 cAMP-specific phosphodiesterases (PDE4s) are essential components of this pathway.  Induction of the PDE4 isoform PDE4B is necessary for Toll-like receptor signaling in monocytes and macrophages and is assocd. with T cell receptor/CD3 in T cells; however, its exact physiol. function in the development of allergic asthma remains undefined.  We investigated the role of PDE4B in the development of allergen-induced airway hyperresponsiveness (AHR) and TH2-driven inflammatory responses.  Wild-type and PDE4B-/- mice were sensitized and challenged with ovalbumin and AHR measured in response to inhaled methacholine.  Airway inflammation was characterized by analyzing leukocyte infiltration and cytokine accumulation in the airways.  Ovalbumin-stimulated cell proliferation and TH2 cytokine prodn. were detd. in cultured bronchial lymph node cells.  Mice deficient in PDE4B do not develop AHR.  This protective effect was assocd. with a significant decrease in eosinophils recruitment to the lungs and decreased TH2 cytokine levels in the bronchoalveolar lavage fluid.  Defects in T-cell replication, TH2 cytokine prodn., and dendritic cell migration were evident in cells from the airway-draining lymph nodes.  Conversely, accumulation of the TH1 cytokine IFN-γ was not affected in PDE4B-/- mice.  Ablation of the orthologous PDE4 gene PDE4A has no impact on airway inflammation.  By relieving a cAMP-neg. constraint, PDE4B plays an essential role in TH2-cell activation and dendritic cell recruitment during airway inflammation.  These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOE66Z0Hj40rVg90H21EOLACvtfcHk0ljsU25NdPednw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFantbfI&md5=9b18c1968c30c89adf0e296d7b050553</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DGoya%26aufirst%3DS.%26aulast%3DNakae%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBruss%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DUmetsu%26aufirst%3DD.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DPhosphodiesterase%25204B%2520is%2520essential%2520for%2520T%2528H%25292-cell%2520function%2520and%2520development%2520of%2520airway%2520hyperresponsiveness%2520in%2520allergic%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D126%26spage%3D1252%26epage%3D1259%26doi%3D10.1016%2Fj.jaci.2010.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberté, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span> <span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12370283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD38XnslSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.+L.+Jinauthor=N.+Lachanceauthor=D.+Macdonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.+C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+alpha%282%29-adrenoceptor-mediated+anesthesia%2C+a+behavioral+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis</span></div><div class="casAuthors">Robichaud, Annette; Stamatiou, Panagiota B.; Jin, S.-L. Catherine; Lachance, Nicholas; MacDonald, Dwight; Laliberte, France; Liu, Susana; Huang, Zheng; Conti, Marco; Chan, Chi-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1052</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A combination of pharmacol. and genetic approaches was used to det. the role of type 4 cAMP-specific cyclic nucleotide phosphodiesterase 4 (PDE4) in reversing α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis in non-vomiting species.  Among the family-specific PDE inhibitors, PDE4 inhibitors reduced the duration of xylazine/ketamine-induced anesthesia in mice, with no effect on pentobarbital-induced anesthesia.  The rank order of the PDE4 inhibitors tested was 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline (PMNPQ) > (R)-rolipram > (S)-rolipram >> (R)-N-{4-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl]phenyl}N'-ethylurea (CT-2450).  The specific roles of PDE4B and PDE4D in this model were studied using mice deficient in either subtype.  PDE4D-deficient mice, but not PDE4B-deficient mice, had a shorter sleeping time than their wild-type littermates under xylazine/ketamine-induced anesthesia, but not under that induced with pentobarbital.  Concomitantly, rolipram-sensitive PDE activity in the brain stem was decreased only in PDE4D-deficient mice compared with their wild-type littermates.  While PMNPQ significantly reduced the xylazine/ketamine-induced anesthesia period in wild-type mice and in PDE4B-null mice, it had no effect in PDE4D-deficient mice.  These findings strongly support the hypothesis that inhibition of PDE4D is pivotal to the anesthesia-reversing effect of PMNPQ and is likely responsible for emesis induced by PDE4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt3ZsNUJs5urVg90H21EOLACvtfcHk0ljsU25NdPednw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnslSktrg%253D&md5=ee8f2f031a8ea513164becaaec075a1a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520alpha%25282%2529-adrenoceptor-mediated%2520anesthesia%252C%2520a%2520behavioral%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancalani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Piaz, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1080/14756360601114700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1080%2F14756360601114700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17674813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslygtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=309-318&author=M.+P.+Giovannoniauthor=N.+Cesariauthor=A.+Grazianoauthor=C.+Vergelliauthor=C.+Biancalaniauthor=P.+Biaginiauthor=V.+Dal+Piaz&title=Synthesis+of+pyrrolo%5B2%2C3-d%5Dpyridazinones+as+potent%2C+subtype+selective+PDE4+inhibitors&doi=10.1080%2F14756360601114700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors</span></div><div class="casAuthors">Giovannoni, Maria P.; Cesari, Nicoletta; Graziano, Alessia; Vergelli, Claudia; Biancalani, Claudio; Biagini, Pierfrancesco; Dal Piaz, Vittorio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyridazinones was synthesized and tested for their inhibitory activity on PDE4 subtypes A, B and D and selectivity toward Rolipram high affinity binding site (HARBS).  New agents with interesting profile were reported; in particular compd. 9e (I) showed a good PDE4 subtype selectivity, being 8 times more potent (IC50 = 0.32 μM) for PDE4B (anti-inflammatory) than for PDE4D (IC50 = 2.5 μM), generally considered the subtype responsible for emesis.  Moreover the ratio HARBS/PDE4B was particularly favorable for 9e (147), suggesting that the best arranged groups around the pyrrolopyridazinone core are an iso-Pr at position-1, an ethoxycarbonyl at position-2, together with an Et group at position-6.  For compds. 8 and 15a the ability to inhibit TNFα prodn. in PBMC was evaluated and the results are consistent with their PDE4 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3mNWjKoRjnbVg90H21EOLACvtfcHk0ljsU25NdPednw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslygtL0%253D&md5=531d6ad2f70e1e3a885ca2f6f153709a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1080%2F14756360601114700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360601114700%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannoni%26aufirst%3DM.%2BP.%26aulast%3DCesari%26aufirst%3DN.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DVergelli%26aufirst%3DC.%26aulast%3DBiancalani%26aufirst%3DC.%26aulast%3DBiagini%26aufirst%3DP.%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3DSynthesis%2520of%2520pyrrolo%255B2%252C3-d%255Dpyridazinones%2520as%2520potent%252C%2520subtype%2520selective%2520PDE4%2520inhibitors%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2007%26volume%3D22%26spage%3D309%26epage%3D318%26doi%3D10.1080%2F14756360601114700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0lhoiiakataGQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cedervall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulabaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span> <span> </span><span class="NLM_article-title">Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1414</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1073/pnas.1419906112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1073%2Fpnas.1419906112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25775568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1414-1422&author=P.+Cedervallauthor=A.+Aulabaughauthor=K.+F.+Geogheganauthor=T.+J.+McLellanauthor=J.+Pandit&title=Engineered+stabilization+and+structural+analysis+of+the+autoinhibited+conformation+of+PDE4&doi=10.1073%2Fpnas.1419906112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4</span></div><div class="casAuthors">Cedervall, Peder; Aulabaugh, Ann; Geoghegan, Kieran F.; McLellan, Thomas J.; Pandit, Jayvardhan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">E1414-E1422</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) is an essential contributor to intracellular signaling and an important drug target.  The 4 members of this enzyme family (PDE4A to PDE4D) are functional dimers in which each subunit contains 2 upstream conserved regions (UCR), UCR1 and UCR2, which precede the C-terminal catalytic domain.  Alternative promoters, transcriptional start sites, and mRNA splicing lead to the existence of >25 variants of PDE4, broadly classified as long, short, and supershort forms.  Here, the authors report the x-ray crystal structure of long form PDE4B contg. UCR1, UCR2, and the catalytic domain, crystd. as a dimer in which a disulfide bond crosslinks Cys residues engineered into UCR2 and the catalytic domain.  Biochem. and mass spectrometric analyses showed that the UCR2-catalytic domain interaction occurred in trans, and established that this interaction regulates the catalytic activity of PDE4.  By elucidating the key structural determinants of dimerization, the authors showed that only long forms of PDE4 can be regulated by this mechanism.  The results also provided a structural basis for the long-standing observation of high- and low-affinity binding sites for the prototypic inhibitor, rolipram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmGjCPFHQ7ULVg90H21EOLACvtfcHk0lhoiiakataGQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCgtb8%253D&md5=28d7c9227da31456ef569b2ee4e77a87</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1419906112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1419906112%26sid%3Dliteratum%253Aachs%26aulast%3DCedervall%26aufirst%3DP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DMcLellan%26aufirst%3DT.%2BJ.%26aulast%3DPandit%26aufirst%3DJ.%26atitle%3DEngineered%2520stabilization%2520and%2520structural%2520analysis%2520of%2520the%2520autoinhibited%2520conformation%2520of%2520PDE4%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1414%26epage%3D1422%26doi%3D10.1073%2Fpnas.1419906112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase+4B+inhibitors&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0lhoiiakataGQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%25204B%2520inhibitors%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auerbach, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span> <span> </span><span class="NLM_article-title">Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2299</span>– <span class="NLM_lpage">2309</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0178-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41386-018-0178-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30131563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=2299-2309&author=C.+Zhangauthor=Y.+Xuauthor=A.+Chowdharyauthor=D.+Foxauthor=M.+E.+Gurneyauthor=H.+T.+Zhangauthor=B.+D.+Auerbachauthor=R.+J.+Salviauthor=M.+Yangauthor=G.+Liauthor=J.+M.+O%E2%80%99Donnell&title=Memory+enhancing+effects+of+BPN14770%2C+an+allosteric+inhibitor+of+phosphodiesterase-4D%2C+in+wild-type+and+humanized+mice&doi=10.1038%2Fs41386-018-0178-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice</span></div><div class="casAuthors">Zhang, Chong; Xu, Ying; Chowdhary, Anirudh; Fox, 3rd, David; Gurney, Mark E.; Zhang, Han-Ting; Auerbach, Benjamin D.; Salvi, Richard J.; Yang, Mingxin; Li, Gaowen; O'Donnell, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2299-2309</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Inhibitors of phosphodiesterase-4 (PDE4) have beneficial effects on memory in preclin. and clin. studies.  Development of these drugs has stalled due to dose-limiting side effects of nausea and emesis.  While use of subtype-selective inhibitors (i.e., for PDE4A, B, or D) could overcome this issue, conservation of the catalytic region, to which classical inhibitors bind, limits this approach.  The present study examd. the effects of BPN14770, an allosteric inhibitor of PDE4D, which binds to a primate-specific, N-terminal region.  In mice engineered to express PDE4D with this primate-specific sequence, BPN14770 was 100-fold more potent for improving memory than in wild-type mice; meanwhile, it exhibited low potency in a mouse surrogate model for emesis.  BPN14770 also antagonized the amnesic effects of scopolamine, increased cAMP signaling in brain, and increased BDNF and markers of neuronal plasticity assocd. with memory.  These data establish a relationship between PDE4D target engagement and effects on memory for BPN14770 and suggest clin. potential for PDE4D-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOsEgzBAlG_LVg90H21EOLACvtfcHk0lj76Qlq6mUJKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLrI&md5=de5eee6e4aa249e64cd971b0c69e4fda</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0178-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0178-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChowdhary%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DAuerbach%26aufirst%3DB.%2BD.%26aulast%3DSalvi%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DMemory%2520enhancing%2520effects%2520of%2520BPN14770%252C%2520an%2520allosteric%2520inhibitor%2520of%2520phosphodiesterase-4D%252C%2520in%2520wild-type%2520and%2520humanized%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D2299%26epage%3D2309%26doi%3D10.1038%2Fs41386-018-0178-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sindac, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groppi, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellekoop, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. F.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4884</span>– <span class="NLM_lpage">4901</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4884-4901&author=M.+E.+Gurneyauthor=R.+A.+Nugentauthor=X.+Moauthor=J.+A.+Sindacauthor=T.+J.+Hagenauthor=D.+Foxauthor=J.+M.+O%E2%80%99Donnellauthor=C.+Zhangauthor=Y.+Xuauthor=H.+T.+Zhangauthor=V.+E.+Groppiauthor=M.+Bailieauthor=R.+E.+Whiteauthor=D.+L.+Romeroauthor=A.+S.+Vellekoopauthor=J.+R.+Walkerauthor=M.+D.+Surmanauthor=L.+Zhuauthor=R.+F.+Campbell&title=Design+and+synthesis+of+selective+phosphodiesterase+4D+%28PDE4D%29+allosteric+inhibitors+for+the+treatment+of+fragile+X+syndrome+and+other+brain+disorders&doi=10.1021%2Facs.jmedchem.9b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders</span></div><div class="casAuthors">Gurney, Mark E.; Nugent, Richard A.; Mo, Xuesheng; Sindac, Janice A.; Hagen, Timothy J.; Fox, David; O'Donnell, James M.; Zhang, Chong; Xu, Ying; Zhang, Han-Ting; Groppi, Vincent E.; Bailie, Marc; White, Ronald E.; Romero, Donna L.; Vellekoop, A. Samuel; Walker, Joel R.; Surman, Matthew D.; Zhu, Lei; Campbell, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4884-4901</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyridine- and pyrimidine-based allosteric inhibitors are reported that achieve PDE4D subtype selectivity through recognition of a single amino acid difference on a key regulatory domain, known as UCR2, that opens and closes over the catalytic site for cAMP hydrolysis.  The design and optimization of lead compds. was based on iterative anal. of X-ray crystal structures combined with metabolite identification.  Selectivity for the activated, dimeric form of PDE4D provided potent memory enhancing effects in a mouse model of novel object recognition with improved tolerability and reduced vascular toxicity over earlier PDE4 inhibitors that lack subtype selectivity.  The lead compd., 28 (BPN14770), has entered midstage, human phase 2 clin. trials for the treatment of Fragile X Syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRN4fRqnWNLVg90H21EOLACvtfcHk0lj76Qlq6mUJKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSjtrc%253D&md5=fccb8282e360d7d9a3cde1a187fd2411</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00193%26sid%3Dliteratum%253Aachs%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DSindac%26aufirst%3DJ.%2BA.%26aulast%3DHagen%26aufirst%3DT.%2BJ.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DBailie%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DVellekoop%26aufirst%3DA.%2BS.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DSurman%26aufirst%3DM.%2BD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520inhibitors%2520for%2520the%2520treatment%2520of%2520fragile%2520X%2520syndrome%2520and%2520other%2520brain%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4884%26epage%3D4901%26doi%3D10.1021%2Facs.jmedchem.9b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Titus, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixte, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C. M.</span></span> <span> </span><span class="NLM_article-title">A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2017.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.nlm.2017.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29294383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvF2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=38-49&author=D.+J.+Titusauthor=N.+M.+Wilsonauthor=O.+Alcazarauthor=D.+A.+Calixteauthor=W.+D.+Dietrichauthor=M.+E.+Gurneyauthor=C.+M.+Atkins&title=A+negative+allosteric+modulator+of+PDE4D+enhances+learning+after+traumatic+brain+injury&doi=10.1016%2Fj.nlm.2017.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury</span></div><div class="casAuthors">Titus, David J.; Wilson, Nicole M.; Alcazar, Oscar; Calixte, Dale A.; Dietrich, W. Dalton; Gurney, Mark E.; Atkins, Coleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-49</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Traumatic brain injury (TBI) significantly decreases cAMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments.  Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation.  Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, neg. allosteric modulator, D159687.  In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI.  To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury.  After 3 mo of recovery, animals were treated with D159687 (0.3 mg/kg, i.p.) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task.  Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals.  Assessment of hippocampal slices at 3 mo post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation.  These results demonstrate that a neg. allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcDR6Nl6uhrVg90H21EOLACvtfcHk0lj76Qlq6mUJKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvF2gug%253D%253D&md5=50d47684152b5ad9756eaf46a6adcfc9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2017.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2017.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DTitus%26aufirst%3DD.%2BJ.%26aulast%3DWilson%26aufirst%3DN.%2BM.%26aulast%3DAlcazar%26aufirst%3DO.%26aulast%3DCalixte%26aufirst%3DD.%2BA.%26aulast%3DDietrich%26aufirst%3DW.%2BD.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DAtkins%26aufirst%3DC.%2BM.%26atitle%3DA%2520negative%2520allosteric%2520modulator%2520of%2520PDE4D%2520enhances%2520learning%2520after%2520traumatic%2520brain%2520injury%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2018%26volume%3D148%26spage%3D38%26epage%3D49%26doi%3D10.1016%2Fj.nlm.2017.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutcheson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span> <span> </span><span class="NLM_article-title">Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e102449</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0102449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1371%2Fjournal.pone.0102449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25050979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ektLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=J.+S.+Sutcliffeauthor=V.+Beaumontauthor=J.+M.+Watsonauthor=C.+S.+Chewauthor=M.+Beconiauthor=D.+M.+Hutchesonauthor=C.+Dominguezauthor=I.+Munoz-Sanjuan&title=Efficacy+of+selective+PDE4D+negative+allosteric+modulators+in+the+object+retrieval+task+in+female+cynomolgus+monkeys+%28Macaca+fascicularis%29&doi=10.1371%2Fjournal.pone.0102449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female Cynomolgus monkeys (Macaca fascicularis)</span></div><div class="casAuthors">Sutcliffe, Jane S.; Beaumont, Vahri; Watson, James M.; Chew, Chang Sing; Beconi, Maria; Hutcheson, Daniel M.; Dominguez, Celia; Munoz-Sanjuan, Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e102449/1-e102449/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cyclic adenosine monophosphate (cAMP) signalling plays an important role in synaptic plasticity and information processing in the hippocampal and basal ganglia systems.  The augmentation of cAMP signalling through the selective inhibition of phosphodiesterases represents a viable strategy to treat disorders assocd. with dysfunction of these circuits.  The phosphodiesterase (PDE) type 4 inhibitor rolipram has shown significant pro-cognitive effects in neurol. disease models, both in rodents and primates.  However, competitive non-isoform selective PDE4 inhibitors have a low therapeutic index which has stalled their clin. development.  Here, we demonstrate the pro-cognitive effects of selective neg. allosteric modulators (NAMs) of PDE4D, D159687 and D159797 in female Cynomolgous macaques, in the object retrieval detour task.  The efficacy displayed by these NAMs in a primate cognitive task which engages the corticostriatal circuitry, together with their suitable pharmacokinetic properties and safety profiles, suggests that clin. development of these allosteric modulators should be considered for the treatment of a variety of brain disorders assocd. with cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSLz0hvkjOiLVg90H21EOLACvtfcHk0lj0M592a8m-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ektLfF&md5=2fecde53f0ce0f0ef801331c226670cd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0102449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0102449%26sid%3Dliteratum%253Aachs%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DChew%26aufirst%3DC.%2BS.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DHutcheson%26aufirst%3DD.%2BM.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DEfficacy%2520of%2520selective%2520PDE4D%2520negative%2520allosteric%2520modulators%2520in%2520the%2520object%2520retrieval%2520task%2520in%2520female%2520cynomolgus%2520monkeys%2520%2528Macaca%2520fascicularis%2529%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0102449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.2174/156802607779941242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F156802607779941242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17305581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2gs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=391-403&author=H.+Keauthor=H.+Wang&title=Crystal+structures+of+phosphodiesterases+and+implications+on+substrate+specificity+and+inhibitor+selectivity&doi=10.2174%2F156802607779941242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity</span></div><div class="casAuthors">Ke, Hengming; Wang, Huanchen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Crystal structures of seven phosphodiesterase families (PDE1-5, 7, 9) show a conserved core catalytic domain that contains about 300 amino acids and fourteen α-helixes.  The catalytic domains of the PDE families 1-4, 7, and 9 have a uniform conformation.  However, the H-loop at the active site of PDE5 shows four different conformations upon binding of inhibitors, probably implying a special mechanism for recognition of substrates and inhibitors by PDE5.  The active site of all PDE families contains two divalent metal ions: zinc and probably magnesium.  The PDE4-AMP and PDE5-GMP structures reveal the conserved interactions of the phosphate groups of the products AMP and GMP, and thus suggest a universal mechanism of nucleophilic attack for all PDE families.  The substrate specificity has not been well understood.  This review will comment on the early proposal, "glutamine switch", on basis of the recent biochem. and structural information.  The PDE-inhibitor structures have identified a common subpocket for non-selective binding of all inhibitors and potential elements for recognition of family-selective inhibitors.  The kinetic anal. on the mutations of PDE7 to PDE4 suggests that the multiple elements must work together to define inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-rZuXgSTCLVg90H21EOLACvtfcHk0lj0M592a8m-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2gs7w%253D&md5=9241f7c476ea2a19faf8167f0c732a75</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.2174%2F156802607779941242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607779941242%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCrystal%2520structures%2520of%2520phosphodiesterases%2520and%2520implications%2520on%2520substrate%2520specificity%2520and%2520inhibitor%2520selectivity%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D391%26epage%3D403%26doi%3D10.2174%2F156802607779941242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0lj0M592a8m-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+Phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0lj0M592a8m-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520Phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fbjp.2008.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18660832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=288-290&author=M.+A.+Giembycz&title=Can+the+anti-inflammatory+potential+of+PDE4+inhibitors+be+realized%3A+guarded+optimism+or+wishful+thinking%3F&doi=10.1038%2Fbjp.2008.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span></div><div class="casAuthors">Giembycz, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">288-290</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.  Despite initial optimism, none have yet reached the market.  In most cases, the development of PDE4 inhibitors of various structural classes, including cilomilast, filaminast, lirimilast, piclamilast, tofimilast, AWD-12-281 (aka GSK 842470), CDP840, CI-1018, D-4418, IC485, L-826,141, SCH 351391 and V11294A has been discontinued due to lack of efficacy.  A primary problem is the low therapeutic ratio of these compds., which severely limits the dose that can be given.  Indeed, for many of these compds. it is likely that the max. tolerated dose is either sub-therapeutic or at the very bottom of the efficacy dose-response curve.  Therefore, the challenge is to overcome this limitation.  It is, therefore, encouraging that many new(er)' PDE4 inhibitors in development are reported to have an improved therapeutic window including tetomilast, oglemilast, apremilast, ONO 6126, IPL-512602 and IPL-455903 (aka HT-0712), although the basis for their superior tolerability has not been disclosed.  In addn., other approaches are possible that may allow the anti-inflammatory activity of PDE inhibitors to be realized.  Accordingly, this Commentary endorses the view of Spina (2008), published in the current issue of the British Journal of Pharmacol., that the therapeutic utility of PDE4 inhibitors to suppress inflammation still remains a viable concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0IqM4s41YrVg90H21EOLACvtfcHk0ljoLP13mdAn5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP&md5=b7209db766a51ebbdf0bf9752635540a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.297%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DCan%2520the%2520anti-inflammatory%2520potential%2520of%2520PDE4%2520inhibitors%2520be%2520realized%253A%2520guarded%2520optimism%2520or%2520wishful%2520thinking%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26spage%3D288%26epage%3D290%26doi%3D10.1038%2Fbjp.2008.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazume, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, T.</span></span> <span> </span><span class="NLM_article-title">Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1002/ibd.20524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1002%2Fibd.20524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18618633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BD1cnns1Wktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1483-1490&author=H.+Ichikawaauthor=S.+Okamotoauthor=N.+Kamadaauthor=H.+Nagamotoauthor=M.+T.+Kitazumeauthor=T.+Kobayashiauthor=H.+Chinenauthor=T.+Hisamatsuauthor=T.+Hibi&title=Tetomilast+suppressed+production+of+proinflammatory+cytokines+from+human+monocytes+and+ameliorated+chronic+colitis+in+IL-10-deficient+mice&doi=10.1002%2Fibd.20524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice</span></div><div class="casAuthors">Ichikawa Hitoshi; Okamoto Susumu; Kamada Nobuhiko; Nagamoto Hisashi; Kitazume Mina T; Kobayashi Taku; Chinen Hiroshi; Hisamatsu Tadakazu; Hibi Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1483-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tetomilast (OPC-6535) was originally developed as a compound inhibiting superoxide production in neutrophils.  Although its mechanism of action is not completely understood, phosphodiesterase type 4 inhibitory function has been postulated.  The therapeutic effect of PDE4 inhibitors has been reported for chronic inflammatory disorders such as chronic obstructive pulmonary diseases.  In this study we aimed to examine whether tetomilast could be a novel drug for inflammatory bowel diseases by further clarifying its antiinflammatory effects.  METHODS:  Cytokines from human peripheral blood mononuclear cells were measured by enzyme-linked immunosorbent assay (ELISA) and Cytokine Beads Array.  The transcripts were quantified by reverse-transcriptase polymerase chain reaction (RT-PCR).  Phosphorylation of transcription factors was examined by phosflow.  To examine its in vivo effect, a once-daily oral dose of tetomilast was tested in murine IL-10(-/-) chronic colitis.  RESULTS:  Tetomilast suppressed TNF-alpha and IL-12 but not IL-10 production from lipopolysaccharide (LPS)-stimulated human monocytes.  It suppressed TNF-alpha, IFN-gamma, and IL-10 from CD4 lymphocytes.  Tetomilast suppressed cytokine production at the transcriptional level but did not alter phosphorylation of p65, ERK, p38, and STAT3.  HT-89, a protein kinase A inhibitor, did not abolish the effect of tetomilast, suggesting that it was independent from the classical cAMP/PKA pathway.  IL-10 was not essential to the inhibitory effect of tetomilast on TNF-alpha and IL-12.  Tetomilast ameliorated IL-10(-/-) chronic colitis with reduced clinical symptoms, serum amyloid A, and histological scores with decreased TNF-alpha mRNA expression.  CONCLUSIONS:  Tetomilast exerts its antiinflammatory effects on human monocytes and CD4 cells.  Combined with in vivo data these findings support the feasibility of tetomilast as a novel drug for inflammatory bowel diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsCHx1oES4ssvLc4ARHEmzfW6udTcc2eaulbQ89rtAobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnns1Wktg%253D%253D&md5=6e13c5c75817122087c91c267c46fff4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fibd.20524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.20524%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DS.%26aulast%3DKamada%26aufirst%3DN.%26aulast%3DNagamoto%26aufirst%3DH.%26aulast%3DKitazume%26aufirst%3DM.%2BT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DChinen%26aufirst%3DH.%26aulast%3DHisamatsu%26aufirst%3DT.%26aulast%3DHibi%26aufirst%3DT.%26atitle%3DTetomilast%2520suppressed%2520production%2520of%2520proinflammatory%2520cytokines%2520from%2520human%2520monocytes%2520and%2520ameliorated%2520chronic%2520colitis%2520in%2520IL-10-deficient%2520mice%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2008%26volume%3D14%26spage%3D1483%26epage%3D1490%26doi%3D10.1002%2Fibd.20524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span>Clinical
trials for tetomilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Tetomilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Tetomilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+tetomilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DTetomilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span>Clinical
trials for apremilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Apremilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Apremilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+apremilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DApremilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zeng, G.</span>; <span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">Thiophene Derivatives</span>. Patent <span class="NLM_patent">WO2010130224</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Zhang&author=G.+Zeng&author=Y.+Gao&title=Thiophene+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThiophene%2520Derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggs-Sauthire, J.</span>; <span class="NLM_string-name">Duarte Franco, J.</span>; <span class="NLM_string-name">Allums-Donald, S.</span></span> <span> </span><span class="NLM_article-title">Oligomer-Containing Apremilast Moiety Compounds</span>. Patent <span class="NLM_patent">WO2012083153</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Riggs-Sauthire&author=J.+Duarte+Franco&author=S.+Allums-Donald&title=Oligomer-Containing+Apremilast+Moiety+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiggs-Sauthire%26aufirst%3DJ.%26atitle%3DOligomer-Containing%2520Apremilast%2520Moiety%2520Compounds%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abarghaz, M.</span>; <span class="NLM_string-name">Oumouch, S.</span>; <span class="NLM_string-name">Lagouge, Y.</span></span> <span> </span><span class="NLM_article-title">5-Substituted-1,4-Benzodiazepines as Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2009037302</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Abarghaz&author=S.+Oumouch&author=Y.+Lagouge&title=5-Substituted-1%2C4-Benzodiazepines+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbarghaz%26aufirst%3DM.%26atitle%3D5-Substituted-1%252C4-Benzodiazepines%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, T.</span>; <span class="NLM_string-name">Emi, H.</span></span> <span> </span><span class="NLM_article-title">Ointment with Excellent Formulation Stability</span>. Patent <span class="NLM_patent">WO2012133492</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+Sakaguchi&author=H.+Emi&title=Ointment+with+Excellent+Formulation+Stability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DT.%26atitle%3DOintment%2520with%2520Excellent%2520Formulation%2520Stability%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanormelingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span> <span> </span><span class="NLM_article-title">Novel Roflumilast analogs as soft PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2014.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25149511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWqs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4594-4597&author=S.+Bolandauthor=J.+Alenauthor=A.+Bourinauthor=K.+Castermansauthor=N.+Boumansauthor=L.+Panittiauthor=J.+Vanormelingenauthor=D.+Leysenauthor=O.+Defert&title=Novel+Roflumilast+analogs+as+soft+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Roflumilast analogs as soft PDE4 inhibitors</span></div><div class="casAuthors">Boland, Sandro; Alen, Jo; Bourin, Arnaud; Castermans, Karolien; Boumans, Nicki; Panitti, Laura; Vanormelingen, Jessica; Leysen, Dirk; Defert, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4594-4597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PDE4 inhibitors are of high interest for treatment of a wide range of inflammatory or autoimmune diseases.  Their potential however has not yet been realized due to target-assocd. side effects, resulting in a low therapeutic window.  We herein report the design, synthesis and evaluation of novel PDE4 inhibitors contg. a γ-lactone structure.  Such mols. are designed to undergo metabolic inactivation when entering circulation, thereby limiting systemic exposure and reducing the risk for side effects.  The resulting inhibitors, e.g., I (n = 3, 4), were highly active on both PDE4B1 and PDE4D2 and underwent rapid degrdn. in human plasma by paraoxonase 1.  In contrast, their metabolites displayed markedly reduced permeability and/or on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT--ZtTKTel7Vg90H21EOLACvtfcHk0lgZk7ViI2i3Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWqs7jM&md5=941e29eda1ba0bb3b2da0bbe14383738</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DS.%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DBourin%26aufirst%3DA.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DBoumans%26aufirst%3DN.%26aulast%3DPanitti%26aufirst%3DL.%26aulast%3DVanormelingen%26aufirst%3DJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DDefert%26aufirst%3DO.%26atitle%3DNovel%2520Roflumilast%2520analogs%2520as%2520soft%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4594%26epage%3D4597%26doi%3D10.1016%2Fj.bmcl.2014.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span>; <span class="NLM_string-name">Amari, G.</span>; <span class="NLM_string-name">Armani, E.</span></span> <span> </span><span class="NLM_article-title">Derivatives of 1-Phenyl-2-Pyridinyl Alkyl Alcohols as Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2009018909</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Delcanale&author=G.+Amari&author=E.+Armani&title=Derivatives+of+1-Phenyl-2-Pyridinyl+Alkyl+Alcohols+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDelcanale%26aufirst%3DM.%26atitle%3DDerivatives%2520of%25201-Phenyl-2-Pyridinyl%2520Alkyl%2520Alcohols%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0li5JUxTSrBEiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span>Clinical
trials for CHF6001. <a href="https://www.clinicaltrials.gov/ct2/results?term=CHF6001&amp;draw=1&amp;rank=8#rowId7" class="extLink">https://www.clinicaltrials.gov/ct2/results?term=CHF6001&draw=1&rank=8#rowId7</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+CHF6001.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DCHF6001%26draw%3D1%26rank%3D8%23rowId7+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span>; <span class="NLM_string-name">Beauregard, C.</span>; <span class="NLM_string-name">Gamache, D. A.</span>; <span class="NLM_string-name">Hellberg, M. R.</span>; <span class="NLM_string-name">Noble, S. A.</span>; <span class="NLM_string-name">Shiau, A. K.</span>; <span class="NLM_string-name">Thomas, D. J.</span>; <span class="NLM_string-name">Yanni, J. M.</span></span> <span> </span><span class="NLM_article-title">Heteroarylalkoxysubstituted Quinolone Inhibitors of PDE4</span>. Patent <span class="NLM_patent">WO2011093924</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+P.+Govek&author=C.+Beauregard&author=D.+A.+Gamache&author=M.+R.+Hellberg&author=S.+A.+Noble&author=A.+K.+Shiau&author=D.+J.+Thomas&author=J.+M.+Yanni&title=Heteroarylalkoxysubstituted+Quinolone+Inhibitors+of+PDE4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26atitle%3DHeteroarylalkoxysubstituted%2520Quinolone%2520Inhibitors%2520of%2520PDE4%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-2-(3,5-dichloro-4-pyridyl)acetyl-2,3-dimethoxyphenoxy}-N-propylac etamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&author=J.+Feldingauthor=M.+D.+Sorensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+Sohoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-2-%283%2C5-dichloro-4-pyridyl%29acetyl-2%2C3-dimethoxyphenoxy%7D-N-propylac+etamide+%28LEO+29102%29%2C+a+soft-drug+inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis</span></div><div class="casAuthors">Felding, Jakob; Soerensen, Morten D.; Poulsen, Tina D.; Larsen, Jens; Andersson, Christina; Refer, Pia; Engell, Karen; Ladefoged, Lotte G.; Thormann, Thorsten; Vinggaard, Anne Marie; Hegardt, Pontus; Soehoel, Anders; Nielsen, Simon Feldbaek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5893-5903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades.  However, only roflumilast has received FDA approval.  One key challenge has been the low therapeutic window obsd. in the clinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects.  Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatol. diseases.  We used a fast follower approach, starting from piclamilast.  In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates.  This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin.  Compd. 20 has reached phase 2 and demonstrated clin. relevant efficacy in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hRC8lktjRrVg90H21EOLACvtfcHk0li5JUxTSrBEiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF&md5=9d236da8f314edec69f5b442e1a41141</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DSohoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-2-%25283%252C5-dichloro-4-pyridyl%2529acetyl-2%252C3-dimethoxyphenoxy%257D-N-propylac%2520etamide%2520%2528LEO%252029102%2529%252C%2520a%2520soft-drug%2520inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushothaman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulsi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2017.12.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29353721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=673-690&author=B.+Purushothamanauthor=P.+Arumugamauthor=G.+Kulsiauthor=J.+M.+Song&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+catecholopyrimidine+based+PDE4+inhibitor+for+the+treatment+of+atopic+dermatitis&doi=10.1016%2Fj.ejmech.2017.12.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis</span></div><div class="casAuthors">Purushothaman, Baskaran; Arumugam, Parthasarathy; Kulsi, Goutam; Song, Joon Myong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">673-690</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this study, a series of novel catechol/morpholino based compds. bearing pyrimidine I (R1 = N,N-di-Et, cyclopropyl, 4-fluorophenyl, 4-pyridinyl, etc.; R2 = morpholino, 3,4-dimethoxyphenyl, [4-(2-hydroxyethyl)piperazin-1-yl]; R3 = SMe, CF3, SO2Me) as the core have been synthesized and screened for the PDE4 inhibitory properties.  The PDE4 selectivity of the active compds. over other PDEs has been investigated.  Compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) bearing pyrimidine core functionalized with catechol, pyridine and trifluoromethyl groups can effectively inhibit the PDE4B with IC50 value in nanomolar range (IC50 = 15±0.4nM).  Compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) exhibited seven fold higher selectivity towards PDE4B over PDE4D.  Mol. Docking study confirmed its stronger affinity towards catalytic domain of PDE4B.  In-vivo anal. confirmed that compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) effectively alleviated the symptoms of atopic dermatitis in DNCB-treated Balb/c mice by suppressing the synthesis of inflammatory mediators such as TNF-α, and Ig-E.  Taken together, this study suggested that compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) could be an effective PDE4 inhibitor for the potential treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5bazHg2F67rVg90H21EOLACvtfcHk0lhPFEsUrP72Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsLk%253D&md5=a722f1878d9e863c2b3d513aa1c335b4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.069%26sid%3Dliteratum%253Aachs%26aulast%3DPurushothaman%26aufirst%3DB.%26aulast%3DArumugam%26aufirst%3DP.%26aulast%3DKulsi%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520catecholopyrimidine%2520based%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D673%26epage%3D690%26doi%3D10.1016%2Fj.ejmech.2017.12.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tralau-Stewart, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nials, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoigne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, A. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, R. G.</span></span> <span> </span><span class="NLM_article-title">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.173690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.110.173690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21205923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=145-154&author=C.+J.+Tralau-Stewartauthor=R.+A.+Williamsonauthor=A.+T.+Nialsauthor=M.+Gascoigneauthor=J.+Dawsonauthor=G.+J.+Hartauthor=A.+D.+R.+Angellauthor=Y.+E.+Solankeauthor=F.+S.+Lucasauthor=J.+Wisemanauthor=P.+Wardauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=GSK256066%2C+an+exceptionally+high-affinity+and+selective+inhibitor+of+phosphodiesterase+4+suitable+for+administration+by+inhalation%3A+in+vitro%2C+kinetic%2C+and+in+vivo+characterization&doi=10.1124%2Fjpet.110.173690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span></div><div class="casAuthors">Tralau-Stewart, Cathy J.; Williamson, Richard A.; Nials, Anthony T.; Gascoigne, Michele; Dawson, John; Hart, Graham J.; Angell, Anthony D. R.; Solanke, Yemisi E.; Lucas, Fiona S.; Wiseman, Joanne; Ward, Peter; Ranshaw, Lisa E.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oral phosphodiesterase 4 (PDE4) inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases.  However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea.  Delivering the inhibitor by the inhaled route may improve therapeutic index, and the authors describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy] phenylamino}-3-quinolinecarboxamide (GSK256066), an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration.  GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC50 3.2 pM; steady-state IC50 <0.5 pM), which is more potent than any previously documented compd., for example, roflumilast (IC50 390 pM), tofimilast (IC50 1.6 nM), and cilomilast (IC50 74 nM).  Consistent with this, GSK256066 inhibited tumor necrosis factor α prodn. by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with 0.01 nM IC50 (compared with IC50 values of 5, 22, and 389 nM for roflumilast, tofimilast, and cilomilast, resp.) and by LPS-stimulated whole blood with 126 pM IC50.  GSK256066 was highly selective for PDE4 (>380,000-fold vs. PDE1, PDE2, PDE3, PDE5, and PDE6 and >2500-fold against PDE7), inhibited PDE4 isoforms A-D with equal affinity, and had a substantial high-affinity rolipram binding site ratio (>17).  When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED50 values of 1.1 μg/kg (aq. suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aq. suspension of the corticosteroid fluticasone propionate (ED50 9.3 μg/kg).  Thus, GSK256066 was demonstrated to have exceptional potency in vitro and in vivo and is being clin. investigated as a treatment for chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRV6i1BfsW87Vg90H21EOLACvtfcHk0lhPFEsUrP72Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D&md5=1a4747eadf3541433b9abc043782a0ca</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173690%26sid%3Dliteratum%253Aachs%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DGascoigne%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DG.%2BJ.%26aulast%3DAngell%26aufirst%3DA.%2BD.%2BR.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DWiseman%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DGSK256066%252C%2520an%2520exceptionally%2520high-affinity%2520and%2520selective%2520inhibitor%2520of%2520phosphodiesterase%25204%2520suitable%2520for%2520administration%2520by%2520inhalation%253A%2520in%2520vitro%252C%2520kinetic%252C%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D145%26epage%3D154%26doi%3D10.1124%2Fjpet.110.173690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petavy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, B. J.</span></span> <span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonaldauthor=A.+L.+Lazaarauthor=B.+J.+O%E2%80%99Connor&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2ea7mDCvSeN_Jbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henriksson, K.</span>; <span class="NLM_string-name">Lisius, A.</span>; <span class="NLM_string-name">Sjo, P.</span>; <span class="NLM_string-name">Storm, P.</span></span> <span> </span><span class="NLM_article-title">Novel 5,6-Dihydropyrazolo[3,4-E][L,4]Diazepin-4 (IH)-One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease</span>. Patent <span class="NLM_patent">WO2007040435</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Henriksson&author=A.+Lisius&author=P.+Sjo&author=P.+Storm&title=Novel+5%2C6-Dihydropyrazolo%5B3%2C4-E%5D%5BL%2C4%5DDiazepin-4+%28IH%29-One+Derivatives+for+the+Treatment+of+Asthma+and+Chronic+Obstructive+Pulmonary+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenriksson%26aufirst%3DK.%26atitle%3DNovel%25205%252C6-Dihydropyrazolo%255B3%252C4-E%255D%255BL%252C4%255DDiazepin-4%2520%2528IH%2529-One%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Asthma%2520and%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V. P.</span>; <span class="NLM_string-name">Balachandran, A.-N. I. I. S.</span>; <span class="NLM_string-name">Gupta, N.</span>; <span class="NLM_string-name">Kukreja, G.</span>; <span class="NLM_string-name">Khera, M. K.</span>; <span class="NLM_string-name">Baregama, L. K.</span>; <span class="NLM_string-name">Mandadapu, R.</span>; <span class="NLM_string-name">Ray, A.</span>; <span class="NLM_string-name">Dastidar, S. G.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2005051931</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=V.+P.+Palle&author=A.-N.+I.+I.+S.+Balachandran&author=N.+Gupta&author=G.+Kukreja&author=M.+K.+Khera&author=L.+K.+Baregama&author=R.+Mandadapu&author=A.+Ray&author=S.+G.+Dastidar&title=Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPalle%26aufirst%3DV.%2BP.%26atitle%3DPhosphodiesterase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ting, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">House, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celly, C. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of oral and inhaled PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5528</span>– <span class="NLM_lpage">5532</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24018187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5528-5532&author=P.+C.+Tingauthor=J.+F.+Leeauthor=R.+Kuangauthor=J.+Caoauthor=D.+Guauthor=Y.+Huangauthor=Z.+Liuauthor=R.+G.+Aslanianauthor=K.-I.+Fengauthor=D.+Preluskyauthor=J.+Lamcaauthor=A.+Houseauthor=J.+E.+Phillipsauthor=P.+Wangauthor=P.+Wuauthor=D.+Lundellauthor=R.+W.+Chapmanauthor=C.+S.+Celly&title=Discovery+of+oral+and+inhaled+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral and inhaled PDE4 inhibitors</span></div><div class="casAuthors">Ting, Pauline C.; Lee, Joe F.; Kuang, Rongze; Cao, Jianhua; Gu, Danlin; Huang, Ying; Liu, Zhidan; Aslanian, Robert G.; Feng, Kung-I.; Prelusky, Daniel; Lamca, James; House, Aileen; Phillips, Jonathan E.; Wang, Peng; Wu, Ping; Lundell, Daniel; Chapman, Richard W.; Celly, Chander S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5528-5532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compd. 16) and inhaled (compd. 34) PDE4 inhibitors.  Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWC60jYiR9G7Vg90H21EOLACvtfcHk0lixMFPBvtNNZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ&md5=5b76d198abe24df922d239e48d8813be</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26aulast%3DFeng%26aufirst%3DK.-I.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DLamca%26aufirst%3DJ.%26aulast%3DHouse%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26atitle%3DDiscovery%2520of%2520oral%2520and%2520inhaled%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5528%26epage%3D5532%26doi%3D10.1016%2Fj.bmcl.2013.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shue, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blythin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerdt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celly, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of oxazole-based PDE4 inhibitors with picomolar potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.01.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22401864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFGisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2594-2597&author=R.+Kuangauthor=H.-J.+Shueauthor=L.+Xiaoauthor=D.+J.+Blythinauthor=N.-Y.+Shihauthor=X.+Chenauthor=D.+Guauthor=J.+Schwerdtauthor=L.+Linauthor=P.+C.+Tingauthor=J.+Caoauthor=R.+Aslanianauthor=J.+J.+Piwinskiauthor=D.+Preluskyauthor=P.+Wuauthor=J.+Zhangauthor=X.+Zhangauthor=C.+S.+Cellyauthor=M.+Billahauthor=P.+Wang&title=Discovery+of+oxazole-based+PDE4+inhibitors+with+picomolar+potency&doi=10.1016%2Fj.bmcl.2012.01.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oxazole-based PDE4 inhibitors with picomolar potency</span></div><div class="casAuthors">Kuang, Rongze; Shue, Ho-Jane; Xiao, Li; Blythin, David J.; Shih, Neng-Yang; Chen, Xiao; Gu, Danlin; Schwerdt, John; Lin, Ling; Ting, Pauline C.; Cao, Jianhua; Aslanian, Robert; Piwinski, John J.; Prelusky, Daniel; Wu, Ping; Zhang, Ji; Zhang, Xiang; Celly, Chander S.; Billah, Motasim; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2594-2597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of oxazole-based PDE4 inhibitors has led to the discovery of a series of quinolyl oxazoles, with 4-benzylcarboxamide and 5-α-aminoethyl groups which exhibit picomolar potency against PDE4.  Selectivity profiles and in vivo biol. activity are also reported.  Compd. 2n (I) was the most potent inhibitor with highest relative selectivity for PDE4/PDE10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBuiSTho0GLVg90H21EOLACvtfcHk0lhm9fOHHrJ6pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFGisrk%253D&md5=b4a00096ad528a400b7661eb6cc4fe98</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.115%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DShue%26aufirst%3DH.-J.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DBlythin%26aufirst%3DD.%2BJ.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DSchwerdt%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DAslanian%26aufirst%3DR.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520oxazole-based%2520PDE4%2520inhibitors%2520with%2520picomolar%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2594%26epage%3D2597%26doi%3D10.1016%2Fj.bmcl.2012.01.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid, an improved PDE4 inhibitor for the Treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6747</span>– <span class="NLM_lpage">6752</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6747-6752&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=A.+Trifilieff&title=Discovery+and+optimization+of+4-%288-%283-Fluorophenyl%29-1%2C7-naphthyridin-6-yl%29transcyclohexanecarboxylic+acid%2C+an+improved+PDE4+inhibitor+for+the+Treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Facs.jmedchem.5b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6747-6752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the optimization of a series of PDE4 inhibitors, with special focus on soly. and pharmacokinetics, to clin. compd. 2, 4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid.  Although compd. 2 produces emesis in humans when given as a single dose, its exemplary pharmacokinetic properties enabled a novel dosing regime comprising multiple escalating doses and the resultant achievement of high plasma drug levels without assocd. nausea or emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmzZuZpBNSLVg90H21EOLACvtfcHk0lhm9fOHHrJ6pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI&md5=ddc41343095c67022590f0dc12c41bb2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00902%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25204-%25288-%25283-Fluorophenyl%2529-1%252C7-naphthyridin-6-yl%2529transcyclohexanecarboxylic%2520acid%252C%2520an%2520improved%2520PDE4%2520inhibitor%2520for%2520the%2520Treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6747%26epage%3D6752%26doi%3D10.1021%2Facs.jmedchem.5b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7472</span>– <span class="NLM_lpage">7479</span>, <span class="refDoi"> DOI: 10.1021/jm300459a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-driven+optimization+of+phosphodiesterase-4+inhibitors+leading+to+a+clinical+candidate&doi=10.1021%2Fjm300459a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0lgORUREcX3elw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-driven%2520optimization%2520of%2520phosphodiesterase-4%2520inhibitors%2520leading%2520to%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7472%26epage%3D7479%26doi%3D10.1021%2Fjm300459a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido 2,3-d pyrimidin-2(1H)-one), with little emetogenic activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10991987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=255-260&author=M.+Aokiauthor=M.+Kobayashiauthor=J.+Ishikawaauthor=Y.+Saitaauthor=Y.+Teraiauthor=K.+Takayamaauthor=K.+Miyataauthor=T.+Yamada&title=A+novel+phosphodiesterase+type+4+inhibitor%2C+YM976+%284-%283-chlorophenyl%29-1%2C7-diethylpyrido+2%2C3-d+pyrimidin-2%281H%29-one%29%2C+with+little+emetogenic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-o ne), with little emetogenic activity</span></div><div class="casAuthors">Aoki, Motonori; Kobayashi, Miki; Ishikawa, Jun; Saita, Yuji; Terai, Yoshiya; Takayama, Kazuhisa; Miyata, Keiji; Yamada, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We synthesized a novel phosphodiesterase type 4 (PDE4) inhibitor, YM976, that is structurally different from the other PDE4 inhibitors like rolipram.  In the present study, the pharmacol. profile of YM976 was investigated.  YM976 exhibited a strong and competitive inhibition against PDE4 purified from human peripheral leukocytes with an IC50 of 2.2 nM.  IC50 values of rolipram and RP73401 were 820 and 0.43 nM, resp.  Test compds. had no effects on the other PDE isoenzymes, PDE1, -2, -3, and -5.  YM976 potentiated prostaglandin E2-induced cAMP accumulation in a human mononuclear cell line, U937, and inhibited tumor necrosis factor-α prodn. from human peripheral blood mononuclear cells stimulated by lipopolysaccharide.  Anti-inflammatory activities of PDE4 inhibitors were compared in rat carrageenan-induced pleurisy models.  YM976, rolipram, and RP73401 inhibited the cell infiltration into the pleural cavity with oral ED30 values of 9.1, 10, and 7.4 mg/kg, resp.  YM976 produced no emesis up to 10 mg/kg, whereas rolipram and RP73401 induced emesis at oral doses of 3 mg/kg.  To evidence the dissocn. of anti-inflammatory activity from emesis, the anti-inflammatory effect of YM976 was examd. in ferrets.  YM976 dose dependently reduced carrageenan-induced leukocyte infiltration at the doses of 1, 3, and 10 mg/kg, p.o.  On the other hand, rolipram failed to show obvious inhibition at doses that do not induce emesis.  In conclusion, YM976 is a novel and orally active PDE4 inhibitor and possesses a good sepn. of emetogenicity from anti-inflammatory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptPaeDyZVsA7Vg90H21EOLACvtfcHk0lgORUREcX3elw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygu7g%253D&md5=d9d5c4ec41d8f93a20152346831ac554</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DJ.%26aulast%3DSaita%26aufirst%3DY.%26aulast%3DTerai%26aufirst%3DY.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520phosphodiesterase%2520type%25204%2520inhibitor%252C%2520YM976%2520%25284-%25283-chlorophenyl%2529-1%252C7-diethylpyrido%25202%252C3-d%2520pyrimidin-2%25281H%2529-one%2529%252C%2520with%2520little%2520emetogenic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D255%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuss, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoefgen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundfeldt, C.</span></span> <span> </span><span class="NLM_article-title">ELB353, a new selective PDE4-inhibitor with a high safety margin and anti-inflammatory effects in rat and ferret lungs</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">S135</span>– <span class="NLM_lpage">S136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=S135-S136&author=H.+Kussauthor=J.+Hoppmannauthor=U.+Egerlandauthor=N.+Hoefgenauthor=T.+Kronbachauthor=C.+Rundfeldt&title=ELB353%2C+a+new+selective+PDE4-inhibitor+with+a+high+safety+margin+and+anti-inflammatory+effects+in+rat+and+ferret+lungs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuss%26aufirst%3DH.%26aulast%3DHoppmann%26aufirst%3DJ.%26aulast%3DEgerland%26aufirst%3DU.%26aulast%3DHoefgen%26aufirst%3DN.%26aulast%3DKronbach%26aufirst%3DT.%26aulast%3DRundfeldt%26aufirst%3DC.%26atitle%3DELB353%252C%2520a%2520new%2520selective%2520PDE4-inhibitor%2520with%2520a%2520high%2520safety%2520margin%2520and%2520anti-inflammatory%2520effects%2520in%2520rat%2520and%2520ferret%2520lungs%26jtitle%3DInflammation%2520Res.%26date%3D2005%26volume%3D54%26spage%3DS135%26epage%3DS136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundfeldt, C.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.059097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.103.059097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=14610230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlSqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=555-563&author=R.+Draheimauthor=U.+Egerlandauthor=C.+Rundfeldt&title=Anti-inflammatory+potential+of+the+selective+phosphodiesterase+4+inhibitor+N-%283%2C5-dichloro-pyrid-4-yl%29-%5B1-%284-fluorobenzyl%29-5-hydroxy-indole-3-yl%5D-glyoxylic+acid+amide+%28AWD+12-281%29%2C+in+human+cell+preparations&doi=10.1124%2Fjpet.103.059097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations</span></div><div class="casAuthors">Draheim, Regina; Egerland, Ute; Rundfeldt, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">555-563</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AWD 12-281 is a potent (IC50 = 9.7 nM) and highly selective inhibitor of the phosphodiesterase 4 (PDE4) isoenzyme with low affinity to the high-affinity rolipram-binding site.  The compd. was optimized for topical treatment of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.  The aim of the present study was to assess the effect of AWD 12-281 in human inflammatory cells.  Peripheral blood mononuclear cells (PBMCs), dild. whole blood, and human nasal polyp cells derived from surgically resected nasal polyps from patients with polyposis comprise sources of target tissue cells that can be used to predict anti-inflammatory effects in patients.  AWD 12-281 was capable of suppressing the prodn. of cytokines in stimulated PBMCs: interleukin-2 (IL-2, phytohemagglutinin stimulation), IL-5 (Con A stimulation), IL-5 and IL-4 (anti-CD3/anti-CD28 co-stimulation), and lipopolysaccharide-stimulated release of tumor necrosis factor α (TNFα).  The corresponding values for half-max. inhibition, EC50, for AWD 12-281 were within a narrow range (46-121 nM).  Comparing the effect of AWD 12-281 with roflumilast, cilomilast (SB 207499), rolipram (RPR-73401), and 1-(3-nitrophenyl)-3-(4-pyridylmethyl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (RS-25344-000), it could be shown that the PDE4 inhibitory activity was closely correlated with inhibitory potential as measured by the above-described assays.  AWD 12-281 was also shown to suppress TNFα release in dispersed nasal polyps (EC50 = 111 nM) and in dild. whole blood (EC50 = 934 nM).  The reduced activity in human blood may be related to high plasma protein binding.  Currently, phase II clin. studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2wROcGWIzO7Vg90H21EOLACvtfcHk0lgORUREcX3elw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlSqtbk%253D&md5=7f3a582d8f5bfe7312ff20d1d3734aef</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.059097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.059097%26sid%3Dliteratum%253Aachs%26aulast%3DDraheim%26aufirst%3DR.%26aulast%3DEgerland%26aufirst%3DU.%26aulast%3DRundfeldt%26aufirst%3DC.%26atitle%3DAnti-inflammatory%2520potential%2520of%2520the%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520N-%25283%252C5-dichloro-pyrid-4-yl%2529-%255B1-%25284-fluorobenzyl%2529-5-hydroxy-indole-3-yl%255D-glyoxylic%2520acid%2520amide%2520%2528AWD%252012-281%2529%252C%2520in%2520human%2520cell%2520preparations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D555%26epage%3D563%26doi%3D10.1124%2Fjpet.103.059097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poondra, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nallamelli, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meda, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muttabathula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voleti, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsa, K. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23294698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1104-1109&author=R.+R.+Poondraauthor=R.+V.+Nallamelliauthor=C.+L.+Medaauthor=B.+N.+Srinivasauthor=A.+Groverauthor=J.+Muttabathulaauthor=S.+R.+Voletiauthor=B.+Sridharauthor=M.+Palauthor=K.+V.+Parsa&title=Discovery+of+novel+1%2C4-dihydropyridine-based+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2012.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors</span></div><div class="casAuthors">Poondra, Rajamohan R.; Nallamelli, Ratnam V.; Meda, Chandana Lakshmi Teja; Srinivas, B. N. V.; Grover, Anushka; Muttabathula, Jyotsna; Voleti, Sreedhara R.; Sridhar, Balasubramanian; Pal, Manojit; Parsa, Kishore V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1104-1109</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Substituted 1,4-dihydropyridines were discovered as a novel and potent series of phosphodiesterase 4 (PDE4) inhibitors.  Structure-activity relationships within this series have been carried out and studies revealed that the dihydropyridine core, with indole moiety and 3,4-dimethoxybenzyl group, is a potent analog for PDE4 inhibition.  These novel series of compds. were prepd. via a 3-component reaction in a single pot.  In vitro biol. activity, modeling studies and crystallog. data are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvy7A1FZqiobVg90H21EOLACvtfcHk0lhnpjG37hcC0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFCgsA%253D%253D&md5=939181e95fa7e399ce491ee3f54a2f91</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DPoondra%26aufirst%3DR.%2BR.%26aulast%3DNallamelli%26aufirst%3DR.%2BV.%26aulast%3DMeda%26aufirst%3DC.%2BL.%26aulast%3DSrinivas%26aufirst%3DB.%2BN.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DMuttabathula%26aufirst%3DJ.%26aulast%3DVoleti%26aufirst%3DS.%2BR.%26aulast%3DSridhar%26aufirst%3DB.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DParsa%26aufirst%3DK.%2BV.%26atitle%3DDiscovery%2520of%2520novel%25201%252C4-dihydropyridine-based%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1104%26epage%3D1109%26doi%3D10.1016%2Fj.bmcl.2012.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poffe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicentini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P. B.</span></span> <span> </span><span class="NLM_article-title">GSK356278, a potent, selective, brain-penetrant Phosphodiesterase 4 Inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.214155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.114.214155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24784567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGkurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=153-163&author=A.+R.+Rutterauthor=A.+Poffeauthor=P.+Cavalliniauthor=T.+G.+Davisauthor=J.+Schneckauthor=M.+Negriauthor=E.+Vicentiniauthor=D.+Montanariauthor=R.+Arbanauthor=F.+A.+Grayauthor=C.+H.+Daviesauthor=P.+B.+Wren&title=GSK356278%2C+a+potent%2C+selective%2C+brain-penetrant+Phosphodiesterase+4+Inhibitor+that+demonstrates+anxiolytic+and+cognition-enhancing+effects+without+inducing+side+effects+in+preclinical+species&doi=10.1124%2Fjpet.114.214155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species</span></div><div class="casAuthors">Rutter, A. Richard; Poffe, Alessandro; Cavallini, Palmina; Davis, T. Gregg; Schneck, Jessica; Negri, Michele; Vicentini, Elena; Montanari, Dino; Arban, Roberto; Gray, Frank A.; Davies, Ceri H.; Wren, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-163, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Small mol. phosphodiesterase (PDE) 4 inhibitors have long been known to show therapeutic benefit in various preclin. models of psychiatric and neurol. diseases because of their ability to elevate cAMP in various cell types of the central nervous system.  Despite the registration of the first PDE4 inhibitor, roflumilast, for the treatment of chronic obstructive pulmonary disease, the therapeutic potential of PDE4 inhibitors in neurol. diseases has never been fulfilled in the clinic due to severe dose-limiting side effects such as nausea and vomiting.  In this study, we describe the detailed pharmacol. characterization of GSK356278 [5-(5-((2,4-dimethylthiazol-5-yl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine], a potent, selective, and brain-penetrant PDE4 inhibitor that shows a superior therapeutic index to both rolipram and roflumilast in various preclin. species and has potential for further development in the clinic for the treatment of psychiatric and neurol. diseases.  GSK356278 inhibited PDE4B enzyme activity with a pIC50 of 8.8 and bound to the high-affinity rolipram binding site with a pIC50 of 8.6.  In preclin. models, the therapeutic index as defined in a rodent lung inflammation model vs. rat pica feeding was >150 compared with 0.5 and 6.4 for rolipram and roflumilast, resp.  In a model of anxiety in common marmosets, the therapeutic index for GSK356278 was >10 vs. <1 for rolipram.  We also demonstrate that GSK356278 enhances performance in a model of executive function in cynomolgus macaques with no adverse effects, a therapeutic profile that supports further evaluation of GSK356278 in a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo53EDHLd83CrVg90H21EOLACvtfcHk0lhnpjG37hcC0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGkurbF&md5=82d72053beda7d67b1d1085470634bf1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.214155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.214155%26sid%3Dliteratum%253Aachs%26aulast%3DRutter%26aufirst%3DA.%2BR.%26aulast%3DPoffe%26aufirst%3DA.%26aulast%3DCavallini%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DT.%2BG.%26aulast%3DSchneck%26aufirst%3DJ.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DVicentini%26aufirst%3DE.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DWren%26aufirst%3DP.%2BB.%26atitle%3DGSK356278%252C%2520a%2520potent%252C%2520selective%252C%2520brain-penetrant%2520Phosphodiesterase%25204%2520Inhibitor%2520that%2520demonstrates%2520anxiolytic%2520and%2520cognition-enhancing%2520effects%2520without%2520inducing%2520side%2520effects%2520in%2520preclinical%2520species%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D153%26epage%3D163%26doi%3D10.1124%2Fjpet.114.214155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, T. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4237</span>– <span class="NLM_lpage">4241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2008.05.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18539455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4237-4241&author=J.+N.+Hamblinauthor=T.+D.+R.+Angellauthor=S.+P.+Ballantineauthor=C.+M.+Cookauthor=A.+W.+J.+Cooperauthor=J.+Dawsonauthor=C.+J.+Delvesauthor=P.+S.+Jonesauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=C.+J.+Mitchellauthor=M.+Y.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span></div><div class="casAuthors">Hamblin, J. Nicole; Angell, Tony D. R.; Ballantine, Stuart P.; Cook, Caroline M.; Cooper, Anthony W. J.; Dawson, John; Delves, Christopher J.; Jones, Paul S.; Lindvall, Mika; Lucas, Fiona S.; Mitchell, Charlotte J.; Neu, Margarete Y.; Ranshaw, Lisa E.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4237-4241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Optimization of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4).  Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogs bound to the PDE4 active site.  Pyrazolopyridine 20a (I) was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-α prodn. from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj75z9PAk27Vg90H21EOLACvtfcHk0lhnpjG37hcC0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D&md5=3b425c80dc0258bab9f2c68297260903</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DAngell%26aufirst%3DT.%2BD.%2BR.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DNeu%26aufirst%3DM.%2BY.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4237%26epage%3D4241%26doi%3D10.1016%2Fj.bmcl.2008.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2010.07.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20732811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5803-5806&author=C.+J.+Mitchellauthor=S.+P.+Ballantineauthor=D.+M.+Coeauthor=C.+M.+Cookauthor=C.+J.+Delvesauthor=M.+D.+Dowleauthor=C.+D.+Edlinauthor=J.+N.+Hamblinauthor=S.+Holmanauthor=M.+R.+Johnsonauthor=P.+S.+Jonesauthor=S.+E.+Keelingauthor=M.+Kranzauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=M.+Neuauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=N.+A.+Trivediauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+potent+PDE4B+inhibitors%3A+5-heterocycle+SAR&doi=10.1016%2Fj.bmcl.2010.07.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR</span></div><div class="casAuthors">Mitchell, Charlotte J.; Ballantine, Stuart P.; Coe, Diane M.; Cook, Caroline M.; Delves, Christopher J.; Dowle, Mike D.; Edlin, Chris D.; Hamblin, J. Nicole; Holman, Stuart; Johnson, Martin R.; Jones, Paul S.; Keeling, Sue E.; Kranz, Michael; Lindvall, Mika; Lucas, Fiona S.; Neu, Margarete; Solanke, Yemisi E.; Somers, Don O.; Trivedi, Naimisha A.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5803-5806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective phosphodiesterase 4B inhibitors, [Hamblin, J. N.; Angell, T.; Ballentine, S., et al. Bioorg. Med. Chem. Lett. 2008, 18, 4237] the SAR of the 5-position was investigated further.  A range of substituted heterocycles showed good potencies against PDE4.  Optimization using X-ray crystallog. and computational modeling led to the discovery of 16, with sub-nM inhibition of LPS-induced TNF-α prodn. from isolated human peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWR2Q-5iCeCrVg90H21EOLACvtfcHk0ljUJPAaCybxQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7%252FN&md5=89c5cd9bc4e3ec6b0be820192a5967be</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.136%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DDowle%26aufirst%3DM.%2BD.%26aulast%3DEdlin%26aufirst%3DC.%2BD.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DTrivedi%26aufirst%3DN.%2BA.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520potent%2520PDE4B%2520inhibitors%253A%25205-heterocycle%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5803%26epage%3D5806%26doi%3D10.1016%2Fj.bmcl.2010.07.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grepin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo 1,5-a pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le%0ARouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Grepinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo+1%2C5-a+pyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0ljUJPAaCybxQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGrepin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%25201%252C5-a%2520pyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1254/jphs.13103FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1254%2Fjphs.13103FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24152964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVygsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=219-226&author=O.+Suzukiauthor=K.+Mizukamiauthor=M.+Etoriauthor=Y.+Sogawaauthor=N.+Takagiauthor=H.+Tsuchidaauthor=K.+Morimotoauthor=T.+Gotoauthor=T.+Yoshinoauthor=T.+Mikkaichiauthor=K.+Hiraharaauthor=S.+Nakamuraauthor=H.+Maeda&title=Evaluation+of+the+therapeutic+index+of+a+novel+phosphodiesterase+4B-selective+inhibitor+over+phosphodiesterase+4D+in+mice&doi=10.1254%2Fjphs.13103FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice</span></div><div class="casAuthors">Suzuki, Osamu; Mizukami, Kiyoshi; Etori, Maki; Sogawa, Yoshitaka; Takagi, Nana; Tsuchida, Hiroshi; Morimoto, Kiyoshi; Goto, Taiji; Yoshino, Toshiharu; Mikkaichi, Tsuyoshi; Hirahara, Kazuki; Nakamura, Satoshi; Maeda, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-226</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of pulmonary inflammatory diseases, but their clin. use was dose-limited by mainly gastric adverse effects.  Recent studies suggested PDE4B-selective inhibitors over PDE4D are supposed to display a wider therapeutic index than subtype non-selective PDE4 inhibitors such as roflumilast.  Compd. A was identified as an orally active PDE4B-selective inhibitor over PDE4D both in humans (80-fold selective) and mice (29-fold selective).  In this study, the therapeutic effects of compd. A and roflumilast were evaluated on lipopolysaccaride (LPS) injection-induced plasma TNF-α elevation and on LPS inhalation-induced pulmonary neutrophilia in mice.  The inhibitory effect on gastric emptying in mice was evaluated as a gastric adverse effect.  The therapeutic index for TNF-α prodn. (TITNF = ID50 in gastric emptying / ID50 in LPS injection-induced plasma TNF-α elevation) of compd. A was larger than roflumilast (9.0 and 0.2, resp.), whereas the therapeutic index for pulmonary neutrophilia (TINeu = ID50 in gastric emptying / ID50 in LPS inhalation-induced pulmonary neutrophilia) of compd. A was comparable to roflumilast (1.0 and 0.5, resp.).  In conclusion, the TINeu of compd. A was not superior compared to that of roflumilast in spite of its high selectivity for PDE4B over PDE4D in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIz67biC5W6rVg90H21EOLACvtfcHk0lhwuiVFHcbyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVygsL7K&md5=4a17a3fa9360fc4c99fc3cec80384ab8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1254%2Fjphs.13103FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.13103FP%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DTsuchida%26aufirst%3DH.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DH.%26atitle%3DEvaluation%2520of%2520the%2520therapeutic%2520index%2520of%2520a%2520novel%2520phosphodiesterase%25204B-selective%2520inhibitor%2520over%2520phosphodiesterase%25204D%2520in%2520mice%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D123%26spage%3D219%26epage%3D226%26doi%3D10.1254%2Fjphs.13103FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano 3,2-d pyrimidine derivatives as highly selective PDE4B inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.12.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24412069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=893-899&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Murataauthor=M.+Tomiiauthor=T.+Yamazakiauthor=K.-i.+Yoshidaauthor=T.+Yoshinoauthor=O.+Suzukiauthor=Y.+Sogawaauthor=K.+Mizukamiauthor=N.+Takagiauthor=T.+Yoshitomiauthor=M.+Etoriauthor=H.+Tsuchidaauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=H.+Takahashiauthor=S.+Sasaki&title=Identification+of+the+5%2C5-dioxo-7%2C8-dihydro-6H-thiopyrano+3%2C2-d+pyrimidine+derivatives+as+highly+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2013.12.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Murata, Takeshi; Tomii, Masato; Yamazaki, Takanori; Yoshida, Ken-ichi; Yoshino, Toshiharu; Suzuki, Osamu; Sogawa, Yoshitaka; Mizukami, Kiyoshi; Takagi, Nana; Yoshitomi, Tomomi; Etori, Maki; Tsuchida, Hiroshi; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Takahashi, Hisashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">893-899</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A PDE4B subtype selective inhibitor is expected to have a wider therapeutic window than non-selective PDE4 inhibitors.  In this Letter, two series of 7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivs. and 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivs. were evaluated for their PDE4B subtype selectivity using human PDE4B2 and PDE4D2 full length enzymes.  To improve their PDE4B selectivity over PDE4D, we optimized the substituents on the pyrimidine ring and the side chain Ph ring, resulting in several derivs. with more than 100-fold selectivity for PDE4B.  Consequently, we identified 2-(3-chloro-4-methoxy-phenyl)-5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine deriv. 54 (I) as a highly selective PDE4B inhibitor, which had potent hPDE4B inhibitory activity with an IC50 value of 3.0 nM and 433-fold PDE4B selectivity over PDE4D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUe43J-5CbirVg90H21EOLACvtfcHk0lhwuiVFHcbyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVenuw%253D%253D&md5=bb81ebe02a372089dca1eaf0db738b95</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.076%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DMurata%26aufirst%3DT.%26aulast%3DTomii%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.-i.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DYoshitomi%26aufirst%3DT.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTsuchida%26aufirst%3DH.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520the%25205%252C5-dioxo-7%252C8-dihydro-6H-thiopyrano%25203%252C2-d%2520pyrimidine%2520derivatives%2520as%2520highly%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D893%26epage%3D899%26doi%3D10.1016%2Fj.bmcl.2013.12.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmc.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24094436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7025-7037&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Synthesis+and+biological+evaluation+of+5-carbamoyl-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmc.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Yoshino, Toshiharu; Mizukami, Kiyoshi; Hirahara, Kazuki; Suzuki, Osamu; Sogawa, Yoshitaka; Takahashi, Tomoko; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Hasegawa, Masashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7025-7037</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-Carbamoyl-2-phenylpyrimidine deriv. has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM).  Modification of the carboxylic acid moiety of the deriv. gave N-neopentylacetamide deriv., which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, i.p.).  Furthermore, based on the x-ray crystallog. of N-neopentylacetamide deriv. bound to the human PDE4B catalytic domain, the authors designed 7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one deriv. I, which has a fused bicyclic lactam scaffold.  Compd. I exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) prodn. in mouse splenocytes (IC50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo66taMP2rurVg90H21EOLACvtfcHk0lhwuiVFHcbyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN&md5=53de746f90ef183a3c89b36895c3fe2b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25205-carbamoyl-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7025%26epage%3D7037%26doi%3D10.1016%2Fj.bmc.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of triazines as selective PDE4B versus PDE4D inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4031</span>– <span class="NLM_lpage">4034</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2014.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24998378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4031-4034&author=T.+J.+Hagenauthor=X.+Moauthor=A.+B.+Burginauthor=D.+Foxauthor=Z.+Zhangauthor=M.+E.+Gurney&title=Discovery+of+triazines+as+selective+PDE4B+versus+PDE4D+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazines as selective PDE4B versus PDE4D inhibitors</span></div><div class="casAuthors">Hagen, Timothy J.; Mo, Xuesheng; Burgin, Alex B.; Fox, David, III; Zhang, Zheng; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4031-4034</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we report a series of triazine derivs. that are potent inhibitors of PDE4B.  We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B vs. PDE4D.  A high resoln. co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive 'closed' conformation.  The results show that the compds. interact with both catalytic domain and CR3 residues.  This provides the first structure-based approach to engineer PDE4B-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx57-V-gPw7Vg90H21EOLACvtfcHk0ljT9Lli5xPGyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtbbF&md5=17be02bb4e2fe4a89b8a07c311d4d140</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DHagen%26aufirst%3DT.%2BJ.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520triazines%2520as%2520selective%2520PDE4B%2520versus%2520PDE4D%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4031%26epage%3D4034%26doi%3D10.1016%2Fj.bmcl.2014.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, V. A. S. S.</span>; <span class="NLM_string-name">Tadiparthi, R.</span>; <span class="NLM_string-name">Sharma, G. V. R.</span>; <span class="NLM_string-name">Sappanimuthu, T.</span>; <span class="NLM_string-name">Bhakiaraj, D. P.</span>; <span class="NLM_string-name">Kachhadia, V.</span>; <span class="NLM_string-name">Narasimhan, K.</span>; <span class="NLM_string-name">Thara, S. N.</span>; <span class="NLM_string-name">Rajagopal, S.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Parameswaran, V.</span>; <span class="NLM_string-name">Janarthanam, V.</span>; <span class="NLM_string-name">Narayanam, M.</span>; <span class="NLM_string-name">Gadde, S.</span>; <span class="NLM_string-name">Ramachandran, U.</span>; <span class="NLM_string-name">Balasubramanian, G.</span>; <span class="NLM_string-name">Surendran, N.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Vishwakarma, L. S.</span>; <span class="NLM_string-name">Saxena, S.</span>; <span class="NLM_string-name">Reddy, G. O.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocycles</span>. Patent <span class="NLM_patent">WO2009095773</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+A.+S.+S.+Srinivas&author=R.+Tadiparthi&author=G.+V.+R.+Sharma&author=T.+Sappanimuthu&author=D.+P.+Bhakiaraj&author=V.+Kachhadia&author=K.+Narasimhan&author=S.+N.+Thara&author=S.+Rajagopal&author=S.+Narayanan&author=V.+Parameswaran&author=V.+Janarthanam&author=M.+Narayanam&author=S.+Gadde&author=U.+Ramachandran&author=G.+Balasubramanian&author=N.+Surendran&author=S.+Narayanan&author=L.+S.+Vishwakarma&author=S.+Saxena&author=G.+O.+Reddy&title=Novel+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivas%26aufirst%3DV.%2BA.%2BS.%2BS.%26atitle%3DNovel%2520Heterocycles%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S. C. A.</span>; <span class="NLM_string-name">Dolusic, E.</span>; <span class="NLM_string-name">Gao, L.-j.</span>; <span class="NLM_string-name">Herdewijn, P. A. M. M.</span>; <span class="NLM_string-name">Pfleiderer, W. E.</span></span> <span> </span><span class="NLM_article-title">Pyrido(3,2-d)Pyrimidines and Pharmaceutical Compositions Useful for Medical Treatment</span>. Patent <span class="NLM_patent">US20090264415</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+C.+A.+De+Jonghe&author=E.+Dolusic&author=L.-j.+Gao&author=P.+A.+M.+M.+Herdewijn&author=W.+E.+Pfleiderer&title=Pyrido%283%2C2-d%29Pyrimidines+and+Pharmaceutical+Compositions+Useful+for+Medical+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJonghe%26aufirst%3DS.%2BC.%2BA.%26atitle%3DPyrido%25283%252C2-d%2529Pyrimidines%2520and%2520Pharmaceutical%2520Compositions%2520Useful%2520for%2520Medical%2520Treatment%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menge, W. M. P. B.</span>; <span class="NLM_string-name">Sterk, G. J.</span>; <span class="NLM_string-name">Hatzelmann, A.</span>; <span class="NLM_string-name">Barsig, J.</span>; <span class="NLM_string-name">Marx, D.</span>; <span class="NLM_string-name">Kley, H.</span>; <span class="NLM_string-name">Christiaans, J. A. M.</span>; <span class="NLM_string-name">Kley, H. P.</span></span> <span> </span><span class="NLM_article-title">New 2-(Piperidin-4-yl)-4,5-Dihydro-2H-Pyridazin-3-one Derivatives Useful for Treatment of e.g. Airway Disorders, Rheumatoid Arthritis, Osteoarthritis, Multiple Sclerosis and Graft Versus Host Reaction</span>. Patent <span class="NLM_patent">WO2005075456</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=W.+M.+P.+B.+Menge&author=G.+J.+Sterk&author=A.+Hatzelmann&author=J.+Barsig&author=D.+Marx&author=H.+Kley&author=J.+A.+M.+Christiaans&author=H.+P.+Kley&title=New+2-%28Piperidin-4-yl%29-4%2C5-Dihydro-2H-Pyridazin-3-one+Derivatives+Useful+for+Treatment+of+e.g.+Airway+Disorders%2C+Rheumatoid+Arthritis%2C+Osteoarthritis%2C+Multiple+Sclerosis+and+Graft+Versus+Host+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenge%26aufirst%3DW.%2BM.%2BP.%2BB.%26atitle%3DNew%25202-%2528Piperidin-4-yl%2529-4%252C5-Dihydro-2H-Pyridazin-3-one%2520Derivatives%2520Useful%2520for%2520Treatment%2520of%2520e.g.%2520Airway%2520Disorders%252C%2520Rheumatoid%2520Arthritis%252C%2520Osteoarthritis%252C%2520Multiple%2520Sclerosis%2520and%2520Graft%2520Versus%2520Host%2520Reaction%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavalda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl Pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Graciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavaldaauthor=B.+Hernandezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pagesauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andresauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+Pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0ljT9Lli5xPGyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavalda%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndres%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520Pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gracia Ferrer, J.</span>; <span class="NLM_string-name">Buil Albero, M. A.</span>; <span class="NLM_string-name">Moreno Mollo, I. M.</span>; <span class="NLM_string-name">Pages Santacana, L. M.</span>; <span class="NLM_string-name">Roberts, R. S.</span>; <span class="NLM_string-name">Sevilla Gome, S.</span>; <span class="NLM_string-name">Taltavull Moll, J.</span></span> <span> </span><span class="NLM_article-title">(3-Oxo)Pyridazin-4-ylurea Derivatives as PDE4 Inhibitors</span>. Patent <span class="NLM_patent">WO2010069504</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Gracia+Ferrer&author=M.+A.+Buil+Albero&author=I.+M.+Moreno+Mollo&author=L.+M.+Pages+Santacana&author=R.+S.+Roberts&author=S.+Sevilla+Gome&author=J.+Taltavull+Moll&title=%283-Oxo%29Pyridazin-4-ylurea+Derivatives+as+PDE4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGracia%2BFerrer%26aufirst%3DJ.%26atitle%3D%25283-Oxo%2529Pyridazin-4-ylurea%2520Derivatives%2520as%2520PDE4%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinsley, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, G. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of substituted pyridazinone-1-acetylhydrazones as novel phosphodiesterase 4 inhibitors</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/ardp.201500363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1002%2Fardp.201500363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26686665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCqs77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2016&pages=104-111&author=H.+M.+Abdel-Rahmanauthor=M.+Abdel-Azizauthor=H.+N.+Tinsleyauthor=B.+D.+Garyauthor=J.+C.+Canzoneriauthor=G.+A.+Piazza&title=Design+and+synthesis+of+substituted+pyridazinone-1-acetylhydrazones+as+novel+phosphodiesterase+4+inhibitors&doi=10.1002%2Fardp.201500363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors</span></div><div class="casAuthors">Abdel-Rahman, Hamdy M.; Abdel-Aziz, Mohamed; Tinsley, Heather N.; Gary, Bernard D.; Canzoneri, Joshua C.; Piazza, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-111</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of novel pyridazin-6-one/acetylhydrazone hybrids I [R1 = H, Me; R2 = 4-MeOC6H4, 2,3-(MeO)2C6H3, 3,4,5-(MeO)3C6H2, 5-F-2-HOC6H3; R3 = 4-FC6H4, 4-MeOC6H4] was rationally designed to inhibit phosphodiesterase 4 (PDE4B).  The prepd. compds. were evaluated for their in vitro ability to inhibit the PDE4B enzyme; several of these compds. showed moderate activity compared to the ref. drug, rolipram.  Compds. I (R1 = H; R2 = R3 = 4-MeOC6H4) and I [R1 = Me; R2 = 5-F-2-HOC6H3, 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] emerged as the most potent inhibitors in this series.  Compd. I [R1 = Me; R2 = 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] showed an IC50 value of 13 μM against PDE4B.  Docking of the compds. I (R1 = H; R2 = R3 = 4-MeOC6H4) and I [R1 = Me; R2 = 5-F-2-HOC6H3, 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] into the active site of PDE4B illustrated their possible binding mode and provided insights for further optimization of this drug scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmswEg2IDFarVg90H21EOLACvtfcHk0lhHHQAxMG5xxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCqs77J&md5=b4ed77a5fa2116a5e0c5b82fadc594f8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fardp.201500363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201500363%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DH.%2BM.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26aulast%3DTinsley%26aufirst%3DH.%2BN.%26aulast%3DGary%26aufirst%3DB.%2BD.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520substituted%2520pyridazinone-1-acetylhydrazones%2520as%2520novel%2520phosphodiesterase%25204%2520inhibitors%26jtitle%3DArch.%2520Pharm.%26date%3D2016%26volume%3D349%26spage%3D104%26epage%3D111%26doi%3D10.1002%2Fardp.201500363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, L. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcphee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darroch, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, S. J.</span></span> <span> </span><span class="NLM_article-title">The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>538</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejphar.2006.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16674936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVynsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2006&pages=39-42&author=L.+C.+D.+Gibsonauthor=S.+F.+Hastingsauthor=I.+Mcpheeauthor=R.+A.+Claytonauthor=C.+E.+Darrochauthor=A.+Mackenzieauthor=F.+L.+Mackenzieauthor=M.+Nagasawaauthor=P.+A.+Stevensauthor=S.+J.+Mackenzie&title=The+inhibitory+profile+of+Ibudilast+against+the+human+phosphodiesterase+enzyme+family&doi=10.1016%2Fj.ejphar.2006.02.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family</span></div><div class="casAuthors">Gibson, Lucien C. D.; Hastings, Stuart F.; McPhee, Ian; Clayton, Robert A.; Darroch, Claire E.; Mackenzie, Alison; MacKenzie, Fiona L.; Nagasawa, Michiaki; Stevens, Patricia A.; MacKenzie, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">39-42</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ibudilast is widely used in Japan to treat ischemic stroke and bronchial asthma.  Its mode of action is through the inhibition of cyclic nucleotide phosphodiesterases (PDEs).  Growing evidence suggests this compd. has utility in a range of neurol. conditions linked to its ability to elevate cellular cyclic nucleotide concns., however limited data exists on Ibudilast's action on individual PDE families.  We therefore used an extensive panel of human PDE enzymes to define the PDE inhibitory profile of this compd.  Ibudilast preferentially inhibits PDE3A, PDE4, PDE10 and PDE11 with lesser inhibition of a no. of other families.  The significance of these findings is discussed in relation to Ibudilast's obsd. effects on certain disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJ3nKv79XRbVg90H21EOLACvtfcHk0lhHHQAxMG5xxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVynsr8%253D&md5=d1e0e22fb1bdc6807d3aa9f249d7aa16</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DL.%2BC.%2BD.%26aulast%3DHastings%26aufirst%3DS.%2BF.%26aulast%3DMcphee%26aufirst%3DI.%26aulast%3DClayton%26aufirst%3DR.%2BA.%26aulast%3DDarroch%26aufirst%3DC.%2BE.%26aulast%3DMackenzie%26aufirst%3DA.%26aulast%3DMackenzie%26aufirst%3DF.%2BL.%26aulast%3DNagasawa%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DP.%2BA.%26aulast%3DMackenzie%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520inhibitory%2520profile%2520of%2520Ibudilast%2520against%2520the%2520human%2520phosphodiesterase%2520enzyme%2520family%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D538%26spage%3D39%26epage%3D42%26doi%3D10.1016%2Fj.ejphar.2006.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. C.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 and its inhibitors in inflammatory diseases</span>. <i>Biomed. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.4103/2319-4170.106152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.4103%2F2319-4170.106152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=197-210&author=S.+L.+Jinauthor=S.+L.+Dingauthor=S.+C.+Lin&title=Phosphodiesterase+4+and+its+inhibitors+in+inflammatory+diseases&doi=10.4103%2F2319-4170.106152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.4103%2F2319-4170.106152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2319-4170.106152%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DDing%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.%2BC.%26atitle%3DPhosphodiesterase%25204%2520and%2520its%2520inhibitors%2520in%2520inflammatory%2520diseases%26jtitle%3DBiomed.%2520J.%26date%3D2012%26volume%3D35%26spage%3D197%26epage%3D210%26doi%3D10.4103%2F2319-4170.106152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yageta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo 1,5-a pyridines with anti-inflammatory activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5311</span>– <span class="NLM_lpage">5316</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.07.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23988356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlKqsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5311-5316&author=A.+Kojimaauthor=S.+Takitaauthor=T.+Sumiyaauthor=K.+Ochiaiauthor=K.+Iwaseauthor=T.+Kishiauthor=A.+Ohinataauthor=Y.+Yagetaauthor=T.+Yasueauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+6%3A+design%2C+synthesis%2C+and+structure-activity+relationships+of+PDE4-inhibitory+pyrazolo+1%2C5-a+pyridines+with+anti-inflammatory+activity&doi=10.1016%2Fj.bmcl.2013.07.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity</span></div><div class="casAuthors">Kojima, Akihiko; Takita, Satoshi; Sumiya, Tatsunobu; Ochiai, Koji; Iwase, Kazuhiko; Kishi, Tetsuya; Ohinata, Akira; Yageta, Yuichi; Yasue, Tokutaro; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5311-5316</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors previously identified KCA-1490 [(-)-6-(7-methoxy-2-trifluoromethyl-pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone], a dual PDE3/4 inhibitor.  In the present study, the authors found highly potent selective PDE4 inhibitors, e.g. I [R = 4-pyridinylmethyl, (2,6-dichloropyridin-4-ylmethyl)carbonyl, 2,6-dichloropyridin-4-ylaminocarbonyl, etc.] derived from the structure of KCA-1490.  Among them, N-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carboxamide I [R = 2,6-dichloropyridin-4-ylaminocarbonyl] had good anti-inflammatory effects in an animal model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcAMD7IN10hrVg90H21EOLACvtfcHk0li8g-zXb0z0iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlKqsr7F&md5=878f5842483e65b15fd2e4355b0bbe10</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.069%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DSumiya%26aufirst%3DT.%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DOhinata%26aufirst%3DA.%26aulast%3DYageta%26aufirst%3DY.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25206%253A%2520design%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%2520of%2520PDE4-inhibitory%2520pyrazolo%25201%252C5-a%2520pyridines%2520with%2520anti-inflammatory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5311%26epage%3D5316%26doi%3D10.1016%2Fj.bmcl.2013.07.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span>; <span class="NLM_string-name">Sumiya, T.</span>; <span class="NLM_string-name">Takita, S.</span>; <span class="NLM_string-name">Kojima, A.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Biaryl Derivative, and PDE4 Inhibitor Comprising Same as Active Ingredient</span>. Patent <span class="NLM_patent">WO2010035745</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Kohno&author=T.+Sumiya&author=S.+Takita&author=A.+Kojima&title=Heterocyclic+Biaryl+Derivative%2C+and+PDE4+Inhibitor+Comprising+Same+as+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DHeterocyclic%2520Biaryl%2520Derivative%252C%2520and%2520PDE4%2520Inhibitor%2520Comprising%2520Same%2520as%2520Active%2520Ingredient%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hishinuma, I.</span></span> <span> </span><span class="NLM_article-title">Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.205542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.113.205542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23674603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=105-112&author=N.+Ishiiauthor=M.+Shiratoauthor=H.+Wakitaauthor=K.+Miyazakiauthor=Y.+Takaseauthor=O.+Asanoauthor=K.+Kusanoauthor=E.+Yamamotoauthor=C.+Inoueauthor=I.+Hishinuma&title=Antipruritic+effect+of+the+topical+phosphodiesterase+4+inhibitor+E6005+ameliorates+skin+lesions+in+a+mouse+atopic+dermatitis+model&doi=10.1124%2Fjpet.113.205542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model</span></div><div class="casAuthors">Ishii, Naoto; Shirato, Manabu; Wakita, Hisashi; Miyazaki, Kazuki; Takase, Yasutaka; Asano, Osamu; Kusano, Kazutomi; Yamamoto, Eiichi; Inoue, Chiharu; Hishinuma, Ieharu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 inhibition is a well-known anti-inflammatory mechanism, but the development of PDE4 inhibitors has been hampered by side effects such as nausea and emesis.  Local delivery of a PDE4 inhibitor to the site of inflammation may overcome these issues.  The purpose of this study was to assess the therapeutic potential of E6005 (Me 4-[({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}amino)carbonyl]benzoate), a novel PDE4 inhibitor developed as a topical agent for atopic dermatitis (AD).  E6005 potently and selectively inhibited human PDE4 activity with an IC50 of 2.8 nM and suppressed the prodn. of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM.  In mice models, the topical application of E6005 produced an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion mols.  On the basis of these obsd. effects, topical E6005 ameliorated the appearance of atopic dermatitis-like skin lesions in two types of AD models, hapten- and mite-elicited models, exhibiting inhibitory effects comparable to that of tacrolimus.  The use of 14C-labeled E6005 showed rapid clearance from the blood and low distribution to the brain, contributing to the low emetic potential of this compd.  These results suggest that E6005 may be a promising novel therapeutic agent with antipruritic activity for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLEhu4MKf8TrVg90H21EOLACvtfcHk0li8g-zXb0z0iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajtrvN&md5=cc100191e813b648080f868823a7fc3a</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.205542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.205542%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DShirato%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DH.%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DO.%26aulast%3DKusano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DE.%26aulast%3DInoue%26aufirst%3DC.%26aulast%3DHishinuma%26aufirst%3DI.%26atitle%3DAntipruritic%2520effect%2520of%2520the%2520topical%2520phosphodiesterase%25204%2520inhibitor%2520E6005%2520ameliorates%2520skin%2520lesions%2520in%2520a%2520mouse%2520atopic%2520dermatitis%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D105%26epage%3D112%26doi%3D10.1124%2Fjpet.113.205542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuraishi, Y.</span></span> <span> </span><span class="NLM_article-title">Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1111/exd.12377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fexd.12377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24645735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=359-361&author=T.+Andohauthor=T.+Yoshidaauthor=Y.+Kuraishi&title=Topical+E6005%2C+a+novel+phosphodiesterase+4+inhibitor%2C+attenuates+spontaneous+itch-related+responses+in+mice+with+chronic+atopy-like+dermatitis&doi=10.1111%2Fexd.12377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis</span></div><div class="casAuthors">Andoh, Tsugunobu; Yoshida, Tetsuro; Kuraishi, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-361</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Atopic dermatitis is a chronic inflammatory cutaneous disease with difficult-to-treat pruritus.  Although phosphodiesterase (PDE) 4 inhibitors have an anti-inflammatory effect on inflammatory skin diseases, such as atopic dermatitis, their acute antipruritic activities remain unclear.  Therefore, in this study, we examd. whether E6005, a novel PDE4 inhibitor, has antipruritic activity in dermatitis, using a mouse model of atopic dermatitis (NC/Nga mice).  A single topical application of E6005 inhibited spontaneous hind-paw scratching, an itch-assocd. response and spontaneous activity of the cutaneous nerve in mice with chronic dermatitis.  The cutaneous concn. of cAMP was significantly decreased in mice with chronic dermatitis, and this decrease was reversed by topical E6005 application.  These results suggest that E6005 increases the cutaneous concn. of cAMP to relieve dermatitis-assocd. itching.  Thus, E6005 may be a useful therapy for pruritic dermatitis such as atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH3-W6ItaX-rVg90H21EOLACvtfcHk0li8g-zXb0z0iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlSktrc%253D&md5=813d6286294025e0f5ee081268bff00b</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fexd.12377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12377%26sid%3Dliteratum%253Aachs%26aulast%3DAndoh%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKuraishi%26aufirst%3DY.%26atitle%3DTopical%2520E6005%252C%2520a%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%2520attenuates%2520spontaneous%2520itch-related%2520responses%2520in%2520mice%2520with%2520chronic%2520atopy-like%2520dermatitis%26jtitle%3DExp.%2520Dermatol.%26date%3D2014%26volume%3D23%26spage%3D359%26epage%3D361%26doi%3D10.1111%2Fexd.12377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span>Clinical
trials for oglemilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Oglemilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Oglemilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+oglemilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DOglemilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span> <span> </span><span class="NLM_article-title">Discovery of triazines as potent, selective and orally active PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4308</span>– <span class="NLM_lpage">4314</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.05.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23806553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSht73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4308-4314&author=R.+Gewaldauthor=C.+Grunwaldauthor=U.+Egerland&title=Discovery+of+triazines+as+potent%2C+selective+and+orally+active+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.05.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazines as potent, selective and orally active PDE4 inhibitors</span></div><div class="casAuthors">Gewald, Rainer; Grunwald, Christian; Egerland, Ute</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4308-4314</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivs. as novel PDE4 inhibitors.  The SAR development and optimization process with the emphasis on ligand efficiency and physicochem. properties led to the discovery of compd. 44 as a potent, selective and orally active PDE4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNEQIHJ0PfFrVg90H21EOLACvtfcHk0lhh8P64CrL1sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSht73M&md5=1bfc86c4cbf79c7fa893b5a556f175ad</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.099%26sid%3Dliteratum%253Aachs%26aulast%3DGewald%26aufirst%3DR.%26aulast%3DGrunwald%26aufirst%3DC.%26aulast%3DEgerland%26aufirst%3DU.%26atitle%3DDiscovery%2520of%2520triazines%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4308%26epage%3D4314%26doi%3D10.1016%2Fj.bmcl.2013.05.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R. V.</span>; <span class="NLM_string-name">Humphries, T.</span>; <span class="NLM_string-name">Hunt, S. F.</span>; <span class="NLM_string-name">Sanganee, H. J.</span></span> <span> </span><span class="NLM_article-title">Chemical Compounds 635: Pyrudopyrimidinediones as PDE4 Inhibitors</span>. Patent <span class="NLM_patent">WO2008084236</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+V.+Bonnert&author=T.+Humphries&author=S.+F.+Hunt&author=H.+J.+Sanganee&title=Chemical+Compounds+635%3A+Pyrudopyrimidinediones+as+PDE4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26atitle%3DChemical%2520Compounds%2520635%253A%2520Pyrudopyrimidinediones%2520as%2520PDE4%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartopp, P.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Sanganee, H. J.</span></span> <span> </span><span class="NLM_article-title">Combination Comprising 6-fluoro-N-((1S,4S)-4-(6-fluoro-2,4-dioxo-1-(4’-(piperazin-1-ylmethyl)biphenyl-3-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)cyclohexyl) imidazo[1,2-a]pyridine-2-carboxamide or A Salt</span>. Patent <span class="NLM_patent">WO2010004319</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=P.+Hartopp&author=T.+Johnson&author=H.+J.+Sanganee&title=Combination+Comprising+6-fluoro-N-%28%281S%2C4S%29-4-%286-fluoro-2%2C4-dioxo-1-%284%E2%80%99-%28piperazin-1-ylmethyl%29biphenyl-3-yl%29-1%2C2-dihydropyrido%5B2%2C3-d%5Dpyrimidin-3%284H%29-yl%29cyclohexyl%29+imidazo%5B1%2C2-a%5Dpyridine-2-carboxamide+or+A+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartopp%26aufirst%3DP.%26atitle%3DCombination%2520Comprising%25206-fluoro-N-%2528%25281S%252C4S%2529-4-%25286-fluoro-2%252C4-dioxo-1-%25284%25E2%2580%2599-%2528piperazin-1-ylmethyl%2529biphenyl-3-yl%2529-1%252C2-dihydropyrido%255B2%252C3-d%255Dpyrimidin-3%25284H%2529-yl%2529cyclohexyl%2529%2520imidazo%255B1%252C2-a%255Dpyridine-2-carboxamide%2520or%2520A%2520Salt%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span>; <span class="NLM_string-name">Cox, R. J.</span>; <span class="NLM_string-name">De Savi, C.</span>; <span class="NLM_string-name">Meghani, P.</span>; <span class="NLM_string-name">Sanganee, H. J.</span>; <span class="NLM_string-name">Warner, D. J.</span></span> <span> </span><span class="NLM_article-title">Phenoxypyridinylamide Derivatives and their Use in the Treatment of PDE4 Mediated Disease States</span>. Patent <span class="NLM_patent">WO2009144494</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Andrews&author=R.+J.+Cox&author=C.+De+Savi&author=P.+Meghani&author=H.+J.+Sanganee&author=D.+J.+Warner&title=Phenoxypyridinylamide+Derivatives+and+their+Use+in+the+Treatment+of+PDE4+Mediated+Disease+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26atitle%3DPhenoxypyridinylamide%2520Derivatives%2520and%2520their%2520Use%2520in%2520the%2520Treatment%2520of%2520PDE4%2520Mediated%2520Disease%2520States%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, G.</span></span> <span> </span><span class="NLM_article-title">Natural products as modulators of the cyclic-AMP pathway: evaluation and synthesis of lead compounds</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6372</span>– <span class="NLM_lpage">6390</span>, <span class="refDoi"> DOI: 10.1039/C8OB01388H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1039%2FC8OB01388H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30140804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyjsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=6372-6390&author=S.+Senguptaauthor=G.+Mehta&title=Natural+products+as+modulators+of+the+cyclic-AMP+pathway%3A+evaluation+and+synthesis+of+lead+compounds&doi=10.1039%2FC8OB01388H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products as modulators of the cyclic-AMP pathway: evaluation and synthesis of lead compounds</span></div><div class="casAuthors">Sengupta, Saumitra; Mehta, Goverdhan</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6372-6390</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that the normal cellular response in mammalian cells is critically regulated by the cyclic-AMP (cAMP) pathway through the appropriate balance of adenylyl cyclase (AC) and phosphodiesterase-4 (PDE4) activities.  Dysfunctions in the cAMP pathway have major implications in various diseases like CNS disorders, inflammation and cardiac syndromes and, hence, the modulation of cAMP signalling through appropriate intervention of AC/PDE4 activities has emerged as a promising new drug discovery strategy of current interest.  In this context, synthetic small mols. have had limited success so far and therefore parallel efforts on natural product leads have been actively pursued.  The early promise of using the diterpene forskolin and its semi-synthetic analogs as AC activators has given way to new leads in the last decade from novel natural products like the marine sesterterpenoids alotaketals and ansellones and the 9,9'-diarylfluorenone cored selaginpulvilins, etc. and their synthesis has drawn much attention.  This review captures these contemporary developments, particularly total synthesis campaigns and structure-guided analog design in the context of AC and PDE-4 modulating attributes and the scope for future possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpru9p4_Eg1J7Vg90H21EOLACvtfcHk0lhh8P64CrL1sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyjsbzP&md5=73bec60647d7da0cbde7c598beac5d69</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1039%2FC8OB01388H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8OB01388H%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DG.%26atitle%3DNatural%2520products%2520as%2520modulators%2520of%2520the%2520cyclic-AMP%2520pathway%253A%2520evaluation%2520and%2520synthesis%2520of%2520lead%2520compounds%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2018%26volume%3D16%26spage%3D6372%26epage%3D6390%26doi%3D10.1039%2FC8OB01388H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, G.</span></span> <span> </span><span class="NLM_article-title">Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">642</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=7664866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2MXmslSnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1995&pages=637-642&author=K.+F.+Rabeauthor=H.+Magnussenauthor=G.+Dent&title=Theophylline+and+selective+PDE+inhibitors+as+bronchodilators+and+smooth+muscle+relaxants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Theophylline and selective phosphodiesterase inhibitors as bronchodilators and smooth muscle relaxants</span></div><div class="casAuthors">Rabe, K. F.; Magnussen, H.; Dent, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">637-42</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with 43 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Zf_Zg8qXYrVg90H21EOLACvtfcHk0lhh8P64CrL1sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmslSnsbc%253D&md5=399fa9044f1583a60ba104c84bf52cc2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DDent%26aufirst%3DG.%26atitle%3DTheophylline%2520and%2520selective%2520PDE%2520inhibitors%2520as%2520bronchodilators%2520and%2520smooth%2520muscle%2520relaxants%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1995%26volume%3D8%26spage%3D637%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boswell-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Are phosphodiesterase 4 inhibitors just more theophylline?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1243</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2006.02.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaci.2006.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16750981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVaqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2006&pages=1237-1243&author=V.+Boswell-Smithauthor=M.+Cazzolaauthor=C.+P.+Page&title=Are+phosphodiesterase+4+inhibitors+just+more+theophylline%3F&doi=10.1016%2Fj.jaci.2006.02.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Are phosphodiesterase 4 inhibitors just more theophylline?</span></div><div class="casAuthors">Boswell-Smith, Victoria; Cazzola, Mario; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1243</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Theophylline has been relegated to a second- or even third-line therapy in the treatment of asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids and β2-agonists, although recent findings have suggested that theophylline possesses anti-inflammatory and immunomodulatory effects in addn. to its well-recognized effects as a bronchodilator.  In part, theophylline has fallen out of favor because of its adverse side-effect profile, and this has led to the search for more effective and safer drugs based on the knowledge that theophylline is orally active and that it is a nonselective phosphodiesterase (PDE) inhibitor.  This has led to the development of selective PDE4 inhibitors, originally designed for depression, for the treatment of both COPD and asthma.  Such drugs have shown clin. efficacy in the treatment of respiratory disease while having a considerably safer side-effect profile in comparison with theophylline, particularly because there are no reported drug interactions with PDE4 inhibitors, a feature that complicates the use of theophylline.  In addn., it is also becoming increasingly apparent that theophylline is not working solely through PDE inhibition, as formerly assumed, and that this drug has other relevant pharmacol. activities that are likely to contribute to its efficacy, such as adenosine receptor antagonism and induction of histone deacetylase.  Thus, the introduction of PDE4 inhibitors represents an entirely new class of drugs for the treatment of respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjribRm-vNzrVg90H21EOLACvtfcHk0ligrcl-UKV3Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVaqt7g%253D&md5=517737e2ad1d9e932c3eaf225e489da2</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2006.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2006.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DAre%2520phosphodiesterase%25204%2520inhibitors%2520just%2520more%2520theophylline%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2006%26volume%3D117%26spage%3D1237%26epage%3D1243%26doi%3D10.1016%2Fj.jaci.2006.02.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of flavonoids as anti-inflammatory agents: a review</span>. <i>Inflammation Allergy: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.2174/187152809788681029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F187152809788681029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=19601883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=229-235&author=P.+Ratheeauthor=H.+Chaudharyauthor=S.+Ratheeauthor=D.+Ratheeauthor=V.+Kumarauthor=K.+Kohli&title=Mechanism+of+action+of+flavonoids+as+anti-inflammatory+agents%3A+a+review&doi=10.2174%2F187152809788681029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of flavonoids as anti-inflammatory agents: a review</span></div><div class="casAuthors">Rathee, Permender; Chaudhary, Hema; Rathee, Sushila; Rathee, Dharmender; Kumar, Vikash; Kohli, Kanchan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation & Allergy: Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-235</span>CODEN:
                <span class="NLM_cas:coden">IADTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1871-5281</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Flavonoids are polyphenolic compds. that occur ubiquitously in plants having a variety of biol. effects both in vitro and in vivo.  They have been found to have antimicrobial, antiviral, anti-ulcerogenic, cytotoxic, antineoplastic, mutagenic, antioxidant, antihepatotoxic, antihypertensive, hypolipidemic, antiplatelet and anti-inflammatory activities.  Flavonoids also have biochem. effects, which inhibit a no. of enzymes such as aldose reductase, xanthine oxidase, phosphodiesterase, Ca+2-ATPase, lipoxygenase, cycloxygenase, etc.  They also have a regulatory role on different hormones like estrogens, androgens and thyroid hormone.  They have been found to have anti-inflammatory activity in both proliferative and exudative phases of inflammation.  Several mechanisms of action have been proposed to explain anti-inflammatory action of flavonoids.  The aim of the present review is to give an overview of the mechanism of action of potential anti-inflammatory flavonoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7p7VbR65-TrVg90H21EOLACvtfcHk0ligrcl-UKV3Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCju7k%253D&md5=507ef0309658f72713da2ae47c03e7ba</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2174%2F187152809788681029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152809788681029%26sid%3Dliteratum%253Aachs%26aulast%3DRathee%26aufirst%3DP.%26aulast%3DChaudhary%26aufirst%3DH.%26aulast%3DRathee%26aufirst%3DS.%26aulast%3DRathee%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKohli%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520action%2520of%2520flavonoids%2520as%2520anti-inflammatory%2520agents%253A%2520a%2520review%26jtitle%3DInflammation%2520Allergy%253A%2520Drug%2520Targets%26date%3D2009%26volume%3D8%26spage%3D229%26epage%3D235%26doi%3D10.2174%2F187152809788681029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bcp.2004.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15476679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot12ntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2087-2094&author=W.+C.+Koauthor=C.+M.+Shihauthor=Y.+H.+Laiauthor=J.+H.+Chenauthor=H.+L.+Huang&title=Inhibitory+effects+of+flavonoids+on+phosphodiesterase+isozymes+from+guinea+pig+and+their+structure-activity+relationships&doi=10.1016%2Fj.bcp.2004.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships</span></div><div class="casAuthors">Ko, Wun-Chang; Shih, Chwen-Ming; Lai, Ya-Hsin; Chen, Jun-Hao; Huang, Hui-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2087-2094</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of flavonoids with regard to their inhibitory effects on phosphodiesterase (PDE) isoenzymes are little known.  The activities of PDE1-5 were measured by a two-step procedure using cAMP with [3H]-cAMP or cGMP with [3H]-cGMP as substrates.  In the present results, PDE1, 5, 2, and 4 isoenzymes were partially purified from guinea pig lungs in that order, and PDE3 was from the heart.  The IC50 values of PDE1-5 were greater than those reported previously for the ref. drugs, vinpocetin, EHNA, milrinone, Ro 20-1724, and zaprinast, by 5-, 5-, 7-, 5-, and 3-fold, resp.  As shown in Table 2, luteolin revealed non-selective inhibition of PDE1-5 with IC50 values in a range of 10-20 μM, as did genistein except with a low potency on PDE5.  Daidzein, an inactive analog of genistein in tyrosine kinase inhibition, showed selective inhibition of PDE3 with an IC50 value of around 30 μM, as did eriodictyol with an IC50 value of around 50 μM.  Hesperetin and prunetin exhibited more-selective inhibition of PDE4 with IC50 values of around 30 and 60 μM, resp.  Luteolin-7-glucoside exhibited dual inhibition of PDE2/PDE4 with an IC50 value of around 40 μM.  Diosmetin more-selectively inhibited PDE2 (IC50 of 4.8 μM) than PDE1, PDE4, or PDE5.  However, biochanin A more-selectively inhibited PDE4 (IC50 of 8.5 μM) than PDE1 or PDE2.  Apigenin inhibited PDE1-3 with IC50 values of around 10-25 μM.  Myricetin inhibited PDE1-4 with IC50 values of around 10-40 μM.  The same was true for quercetin, but we rather consider that it more-selectively inhibited PDE3 and PDE4 (IC50 <10 μM).  In conclusion, it is possible to synthesize useful drugs through elucidating the structure-activity relationships of flavonoids with respect to inhibition of PDE isoenzymes at concns. used in this in vitro study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyjKoy2FKJ7Vg90H21EOLACvtfcHk0ligrcl-UKV3Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot12ntL0%253D&md5=fc0c7a9e7b73a3ef4cbc9d0a0079a96f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BC.%26aulast%3DShih%26aufirst%3DC.%2BM.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26atitle%3DInhibitory%2520effects%2520of%2520flavonoids%2520on%2520phosphodiesterase%2520isozymes%2520from%2520guinea%2520pig%2520and%2520their%2520structure-activity%2520relationships%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2087%26epage%3D2094%26doi%3D10.1016%2Fj.bcp.2004.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirtskhalava, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigand, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weivoda, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogrodnik, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachfeld, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onken, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verzosa, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhi, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrasseur, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garovic, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedernhofer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchkonia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, J. L.</span></span> <span> </span><span class="NLM_article-title">Senolytics improve physical function and increase lifespan in old age</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0092-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41591-018-0092-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29988130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1246-1256&author=M.+Xuauthor=T.+Pirtskhalavaauthor=J.+N.+Farrauthor=B.+M.+Weigandauthor=A.+K.+Palmerauthor=M.+M.+Weivodaauthor=C.+L.+Inmanauthor=M.+B.+Ogrodnikauthor=C.+M.+Hachfeldauthor=D.+G.+Fraserauthor=J.+L.+Onkenauthor=K.+O.+Johnsonauthor=G.+C.+Verzosaauthor=L.+G.+P.+Langhiauthor=M.+Weiglauthor=N.+Giorgadzeauthor=N.+K.+LeBrasseurauthor=J.+D.+Millerauthor=D.+Jurkauthor=R.+J.+Singhauthor=D.+B.+Allisonauthor=K.+Ejimaauthor=G.+B.+Hubbardauthor=Y.+Ikenoauthor=H.+Cubroauthor=V.+D.+Garovicauthor=X.+Houauthor=S.+J.+Werohaauthor=P.+D.+Robbinsauthor=L.+J.+Niedernhoferauthor=S.+Khoslaauthor=T.+Tchkoniaauthor=J.+L.+Kirkland&title=Senolytics+improve+physical+function+and+increase+lifespan+in+old+age&doi=10.1038%2Fs41591-018-0092-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Senolytics improve physical function and increase lifespan in old age</span></div><div class="casAuthors">Xu, Ming; Pirtskhalava, Tamar; Farr, Joshua N.; Weigand, Bettina M.; Palmer, Allyson K.; Weivoda, Megan M.; Inman, Christina L.; Ogrodnik, Mikolaj B.; Hachfeld, Christine M.; Fraser, Daniel G.; Onken, Jennifer L.; Johnson, Kurt O.; Verzosa, Grace C.; Langhi, Larissa G. P.; Weigl, Moritz; Giorgadze, Nino; LeBrasseur, Nathan K.; Miller, Jordan D.; Jurk, Diana; Singh, Ravinder J.; Allison, David B.; Ejima, Keisuke; Hubbard, Gene B.; Ikeno, Yuji; Cubro, Hajrunisa; Garovic, Vesna D.; Hou, Xiaonan; Weroha, S. John; Robbins, Paul D.; Niedernhofer, Laura J.; Khosla, Sundeep; Tchkonia, Tamara; Kirkland, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1246-1256</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Phys. function declines in old age, portending disability, increased health expenditures, and mortality.  Cellular senescence, leading to tissue dysfunction, may contribute to these consequences of aging, but whether senescence can directly drive age-related pathol. and be therapeutically targeted is still unclear.  Here we demonstrate that transplanting relatively small nos. of senescent cells into young mice is sufficient to cause persistent phys. dysfunction, as well as to spread cellular senescence to host tissues.  Transplanting even fewer senescent cells had the same effect in older recipients and was accompanied by reduced survival, indicating the potency of senescent cells in shortening health- and lifespan.  The senolytic cocktail, dasatinib plus quercetin, which causes selective elimination of senescent cells, decreased the no. of naturally occurring senescent cells and their secretion of frailty-related proinflammatory cytokines in explants of human adipose tissue.  Moreover, intermittent oral administration of senolytics to both senescent cell-transplanted young mice and naturally aged mice alleviated phys. dysfunction and increased post-treatment survival by 36% while reducing mortality hazard to 65%.  Our study provides proof-of-concept evidence that senescent cells can cause phys. dysfunction and decreased survival even in young mice, while senolytics can enhance remaining health- and lifespan in old mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdvfVKJxYgrVg90H21EOLACvtfcHk0ljKcmpTlViwtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjs7nE&md5=9f9a509553254b5f6a839d6927801ff3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0092-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0092-9%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPirtskhalava%26aufirst%3DT.%26aulast%3DFarr%26aufirst%3DJ.%2BN.%26aulast%3DWeigand%26aufirst%3DB.%2BM.%26aulast%3DPalmer%26aufirst%3DA.%2BK.%26aulast%3DWeivoda%26aufirst%3DM.%2BM.%26aulast%3DInman%26aufirst%3DC.%2BL.%26aulast%3DOgrodnik%26aufirst%3DM.%2BB.%26aulast%3DHachfeld%26aufirst%3DC.%2BM.%26aulast%3DFraser%26aufirst%3DD.%2BG.%26aulast%3DOnken%26aufirst%3DJ.%2BL.%26aulast%3DJohnson%26aufirst%3DK.%2BO.%26aulast%3DVerzosa%26aufirst%3DG.%2BC.%26aulast%3DLanghi%26aufirst%3DL.%2BG.%2BP.%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DGiorgadze%26aufirst%3DN.%26aulast%3DLeBrasseur%26aufirst%3DN.%2BK.%26aulast%3DMiller%26aufirst%3DJ.%2BD.%26aulast%3DJurk%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DAllison%26aufirst%3DD.%2BB.%26aulast%3DEjima%26aufirst%3DK.%26aulast%3DHubbard%26aufirst%3DG.%2BB.%26aulast%3DIkeno%26aufirst%3DY.%26aulast%3DCubro%26aufirst%3DH.%26aulast%3DGarovic%26aufirst%3DV.%2BD.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DKhosla%26aufirst%3DS.%26aulast%3DTchkonia%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DJ.%2BL.%26atitle%3DSenolytics%2520improve%2520physical%2520function%2520and%2520increase%2520lifespan%2520in%2520old%2520age%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1246%26epage%3D1256%26doi%3D10.1038%2Fs41591-018-0092-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A.</span>; <span class="NLM_string-name">Gericke, N.</span>; <span class="NLM_string-name">Viljoen, A.</span></span> <span> </span><span class="NLM_article-title">Use of Pharmaceutical Compositions Containing Mesembrenone</span>. Patent <span class="NLM_patent">WO2010106494</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Harvey&author=N.+Gericke&author=A.+Viljoen&title=Use+of+Pharmaceutical+Compositions+Containing+Mesembrenone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%26atitle%3DUse%2520of%2520Pharmaceutical%2520Compositions%2520Containing%2520Mesembrenone%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljoen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, N. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of the south African medicinal and functional food plant <i>Sceletium tortuosum</i> and its principal alkaloids</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.jep.2011.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jep.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21798331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOksbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=1124-1129&author=A.+L.+Harveyauthor=L.+C.+Youngauthor=A.+M.+Viljoenauthor=N.+P.+Gericke&title=Pharmacological+actions+of+the+south+African+medicinal+and+functional+food+plant+Sceletium+tortuosum+and+its+principal+alkaloids&doi=10.1016%2Fj.jep.2011.07.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids</span></div><div class="casAuthors">Harvey, Alan L.; Young, Louise C.; Viljoen, Alvaro M.; Gericke, Nigel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The South African plant Sceletium tortuosum has been known for centuries for a variety of traditional uses, and, more recently, as a possible source of anti-anxiety or anti-depressant effects.  A standardised ext. Zembrin was used to test for pharmacol. activities that might be relevant to the ethnopharmacol. uses, and three of the main alkaloids were also tested.  A standardised ethanolic ext. was prepd. from dried plant material, along with the purified alkaloids mesembrine, mesembrenone and mesembrenol.  These were tested on a panel of receptors, enzymes and other drug targets, and for cytotoxic effects on mammalian cells.  The ext. was a potent blocker in 5-HT transporter binding assays (IC50 4.3 μg/mL) and had powerful inhibitory effects on phosphodiesterase 4 (PDE4) (IC50 8.5 μg/mL), but not other phosphodiesterases.  There were no cytotoxic effects.  Mesembrine was the most active alkaloid against the 5-HT transporter (Ki 1.4 nM), while mesembrenone was active against the 5-HT transporter and PDE4 (IC50's < 1 μM).  The activity of the Sceletium tortuosum ext. on the 5-HT transporter and PDE4 may explain the clin. effects of prepns. made from this plant.  The activities relate to the presence of alkaloids, particularly mesembrine and mesembrenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc9_BiKIeVCLVg90H21EOLACvtfcHk0ljKcmpTlViwtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOksbnL&md5=142b80eafa58077de45622f21e3518bc</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%2BL.%26aulast%3DYoung%26aufirst%3DL.%2BC.%26aulast%3DViljoen%26aufirst%3DA.%2BM.%26aulast%3DGericke%26aufirst%3DN.%2BP.%26atitle%3DPharmacological%2520actions%2520of%2520the%2520south%2520African%2520medicinal%2520and%2520functional%2520food%2520plant%2520Sceletium%2520tortuosum%2520and%2520its%2520principal%2520alkaloids%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2011%26volume%3D137%26spage%3D1124%26epage%3D1129%26doi%3D10.1016%2Fj.jep.2011.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and modelling studies of natural ingredients from <i>Gaultheria yunnanensis</i> (FRANCH.) against phosphodiesterase-4</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2015.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26978121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFeqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=134-140&author=Y.+H.+Caiauthor=Y.+Guoauthor=Z.+Liauthor=D.+Wuauthor=X.+Liauthor=H.+Zhangauthor=J.+Yangauthor=H.+Luauthor=Z.+Sunauthor=H.-B.+Luoauthor=S.+Yinauthor=Y.+Wu&title=Discovery+and+modelling+studies+of+natural+ingredients+from+Gaultheria+yunnanensis+%28FRANCH.%29+against+phosphodiesterase-4&doi=10.1016%2Fj.ejmech.2015.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4</span></div><div class="casAuthors">Cai, Ying-Hong; Guo, Yanqiong; Li, Zhe; Wu, Deyang; Li, Xiruo; Zhang, Heng; Yang, Junjie; Lu, Heng; Sun, Zhaowei; Luo, Hai-Bin; Yin, Sheng; Wu, Yinuo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-140</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) is an anti-inflammatory target for treatment of asthma and chronic obstructive pulmonary disease (COPD).  Here, the authors report the isolation and characterization of 13 compds. by bioassay-guided fractionation of the Et acetate extn. of Gaultheria yunnanensis (FRANCH.), one of which pentacyclic triterpene I has never been reported.  Four of them inhibit PDE4 with the IC50 values < 20 μM and I is the most potent ingredient with an IC50 of 245 nM and moderate selectivity over other PDE families.  Mol. dynamics simulations suggest that I forms a hydrogen bond with Asn362, in addn. to the hydrogen bond with Gln369 and π-π interactions with Phe372, which are commonly obsd. in the binding of most PDE4 inhibitors.  The calcd. binding free energies for the interactions of PDE4-I and PDE4-II are -19.4 and -18.8 kcal/mol, in consistence with the bioassay that I and II have IC50 of 245 nM and 542 nM, resp.  The modeling results of these active compds. may aid the rational design of novel PDE4 inhibitors as anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLBW4itpbzLVg90H21EOLACvtfcHk0lhnkBcfrWXwhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFeqs7w%253D&md5=8d77d41002edb04508e44e12504a7624</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DY.%2BH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DH.-B.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520modelling%2520studies%2520of%2520natural%2520ingredients%2520from%2520Gaultheria%2520yunnanensis%2520%2528FRANCH.%2529%2520against%2520phosphodiesterase-4%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D114%26spage%3D134%26epage%3D140%26doi%3D10.1016%2Fj.ejmech.2015.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span> <span> </span><span class="NLM_article-title">Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3261</span>– <span class="NLM_lpage">3264</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22483586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1ahurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3261-3264&author=S.+K.+Chenauthor=P.+Zhaoauthor=Y.+X.+Shaoauthor=Z.+Liauthor=C.+Zhangauthor=P.+Liuauthor=X.+Heauthor=H.-B.+Luoauthor=X.+Hu&title=Moracin+M+from+Morus+alba+L.+is+a+natural+phosphodiesterase-4+inhibitor&doi=10.1016%2Fj.bmcl.2012.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor</span></div><div class="casAuthors">Chen, Shang-Ke; Zhao, Peng; Shao, Yong-Xian; Li, Zhe; Zhang, Cuixian; Liu, Peiqing; He, Xixin; Luo, Hai-Bin; Hu, Xiaopeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3261-3264</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) has been identified to be a promising target for treatment of asthma.  Moracin M extd. from Chinese herbal drug 'Sang-Bai-Pi' (Morus alba L.) was studied for the inhibitory affinity towards PDE4.  It inhibited PDE4D2, PDE4B2, PDE5A1, and PDE9A2 with the IC50 values of 2.9, 4.5, >40, and >100 μM, resp.  Our mol. docking and 8 ns mol. dynamics (MD) simulations demonstrated that moracin M forms three hydrogen bonds with Gln369, Asn321, and Asp318 in the active site and stacks against Phe372.  In addn., comparative kinetics anal. of its analog moracin C was carried out to qual. validate their inhibitory potency as predicted by the binding free energy calcns. after MD simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhLEN0Zrmc7Vg90H21EOLACvtfcHk0lhnkBcfrWXwhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1ahurc%253D&md5=af16683e16f894e760cf27724eea0360</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BK.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DShao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.-B.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DMoracin%2520M%2520from%2520Morus%2520alba%2520L.%2520is%2520a%2520natural%2520phosphodiesterase-4%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3261%26epage%3D3264%26doi%3D10.1016%2Fj.bmcl.2012.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span> <span> </span><span class="NLM_article-title">Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2017.12.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29291443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=758-766&author=Y.+Q.+Guoauthor=G.+H.+Tangauthor=L.+L.+Louauthor=W.+Liauthor=B.+Zhangauthor=B.+Liuauthor=S.+Yin&title=Prenylated+flavonoids+as+potent+phosphodiesterase-4+inhibitors+from+Morus+alba%3A+Isolation%2C+modification%2C+and+structure-activity+relationship+study&doi=10.1016%2Fj.ejmech.2017.12.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study</span></div><div class="casAuthors">Guo, Yan-Qiong; Tang, Gui-Hua; Lou, Lan-Lan; Li, Wei; Zhang, Bei; Liu, Bo; Yin, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">758-766</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A bioassay-guided phytochem. study of a traditional Chinese medicine, M. alba root bark, led to the isolation of 18 prenylflavonoids (1-18), of which (±)-cyclomorusin (1/2), a pair of enantiomers, and 14-methoxy-dihydromorusin (3) are new compds.  Subsequent structural modification of the selected components by methylation, esterification, hydrogenation, and oxidative cyclization led to 14 more derivs. (19-32).  The small library was screened for its inhibition against phosphodiesterase-4 (PDE4), which is a drug target for the treatment of asthma and chronic obstructive pulmonary disease (COPD).  Among them, 9 compds. (1-5, 8, 10, 16, and 17) exhibited remarkable activities with IC50 values ranging from 0.0054 to 0.40 μM, being more active than the pos. control, rolipram (IC50 = 0.62 μM).  (+)-Cyclomorusin (1), the most active natural PDE4 inhibitor reported so far, also showed a high selectivity across other PDE members with a selective fold of >55.  The SAR study revealed that the presence of prenyl groups at C-3 and/or C-8, 2H-pyran ring D, and phenolic OH groups were important for the activity, which was further supported by the recognition mechanism study of the inhibitors with PDE4 by using mol. modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGUEMMg82erVg90H21EOLACvtfcHk0lhnkBcfrWXwhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWgtA%253D%253D&md5=af2011096b1eb003cc73e9607e5f82e5</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.057%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BQ.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DLou%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DS.%26atitle%3DPrenylated%2520flavonoids%2520as%2520potent%2520phosphodiesterase-4%2520inhibitors%2520from%2520Morus%2520alba%253A%2520Isolation%252C%2520modification%252C%2520and%2520structure-activity%2520relationship%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D758%26epage%3D766%26doi%3D10.1016%2Fj.ejmech.2017.12.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span> <span> </span><span class="NLM_article-title">The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from <i>Selaginella pulvinata</i></span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bcp.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28159622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFeitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=51-59&author=Y.+Huangauthor=X.+Liuauthor=D.+Wuauthor=G.+Tangauthor=Z.+Laiauthor=X.+Zhengauthor=S.+Yinauthor=H.-B.+Luo&title=The+discovery%2C+complex+crystal+structure%2C+and+recognition+mechanism+of+a+novel+natural+PDE4+inhibitor+from+Selaginella+pulvinata&doi=10.1016%2Fj.bcp.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata</span></div><div class="casAuthors">Huang, Yiyou; Liu, Xin; Wu, Deyan; Tang, Guihua; Lai, Zengwei; Zheng, Xuehua; Yin, Sheng; Luo, Hai-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) is an important drug target for treatment of inflammation-related diseases.  Till now, natural PDE4 inhibitors are rare and their co-crystal structures with PDE4 are hardly available.  In the present study, selaginpulvilins K (I) and L, two novel fluorene derivs., were isolated from a traditional Chinese medicine Selaginella pulvinata and exhibited remarkable inhibition against phosphodiesterase-4D (PDE4D) at IC50 11 nM and 90 nM, resp.  Compd. I also showed a good selectivity across PDE families with the selective fold ranging from 30 to 909.  To understand the recognition mechanism of selaginpulvilins towards PDE4, the crystal structure of PDE4D bound with I was successfully detd. by the X-ray diffraction method and presented an unusual binding mode in which the stretched skeleton of the inhibitor bound shallowly to the active site but had interactions with multi sub-pockets, such as Q, HC, M, and S, esp. strong interaction with the metal region.  Assisted with mol. modeling, the structure-activity relationship and the selectivity of selaginpulvilins were also well explored, which would facilitate the future rational inhibitor design or structural optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmSGuWv9caMLVg90H21EOLACvtfcHk0lg_3W0trwCsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFeitL4%253D&md5=799a1437e87de5926a1dba69e91faf71</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DH.-B.%26atitle%3DThe%2520discovery%252C%2520complex%2520crystal%2520structure%252C%2520and%2520recognition%2520mechanism%2520of%2520a%2520novel%2520natural%2520PDE4%2520inhibitor%2520from%2520Selaginella%2520pulvinata%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D130%26spage%3D51%26epage%3D59%26doi%3D10.1016%2Fj.bcp.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Nanodomain regulation of cardiac cyclic nucleotide signaling by phosphodiesterases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010716-104756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev-pharmtox-010716-104756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27732797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=455-479&author=K.+Kokkonenauthor=D.+A.+Kass&title=Nanodomain+regulation+of+cardiac+cyclic+nucleotide+signaling+by+phosphodiesterases&doi=10.1146%2Fannurev-pharmtox-010716-104756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases</span></div><div class="casAuthors">Kokkonen, Kristen; Kass, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-479</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3',5'-monophosphate (cAMP or cGMP).  These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides.  Seven PDE family members are physiol. relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP.  New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors.  In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHS7lTakIRrVg90H21EOLACvtfcHk0lg_3W0trwCsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN&md5=0bbfd7fecacc24ec40b76e7406495313</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104756%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonen%26aufirst%3DK.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DNanodomain%2520regulation%2520of%2520cardiac%2520cyclic%2520nucleotide%2520signaling%2520by%2520phosphodiesterases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D455%26epage%3D479%26doi%3D10.1146%2Fannurev-pharmtox-010716-104756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting beta(2)-adrenoceptor agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.210997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.113.210997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24513870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=85-93&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=Z.-H.+Cuiauthor=M.+Kimauthor=L.+Patelauthor=W.+R.+Bakerauthor=G.+B.+Phillipsauthor=C.+D.+Wrightauthor=M.+Salmon&title=The+in+vitro+pharmacology+of+GS-5759%2C+a+novel+bifunctional+phosphodiesterase+4+inhibitor+and+long+acting+beta%282%29-adrenoceptor+agonist&doi=10.1124%2Fjpet.113.210997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Cui, Zhi-Hua; Kim, Musong; Patel, Leena; Baker, William R.; Phillips, Gary B.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhaled long-acting β2-adrenoceptor agonists (LABA) that act as bronchodilators and the oral anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast are both approved therapies for chronic obstructive pulmonary disease (COPD).  Here we describe the activity of a novel, inhaled, bifunctional, small mol. (R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GS-5759), which has specific β2 agonist and PDE4 inhibitory activity.  GS-5759 demonstrated potent and full agonist activity at β2 adrenoceptors (EC50 = 8 ± 4 nM) and is a potent inhibitor of the PDE4 enzyme (IC50 = 5 ± 3 nM).  In cell assays, GS-5759 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) prodn. in human peripheral mononuclear cells (PBMC) with an IC50 = 0.3 nM [confidence interval (CI) 0.1-0.6] and in human neutrophils formyl-methionyl-leucyl-phenylalanine (fMLP)-induced super oxide anion prodn. with an IC50 = 3 nM (CI 0.8-8).  The addn. of the β2 antagonist ICI 118551 shifted the IC50 in these cell assays to 4 and 38 nM, resp., demonstrating the contribution of both β2 agonist and PDE4 inhibitory activity to GS-5759.  GS-5759 was also a potent inhibitor of profibrotic and proinflammatory mediator release from human lung fibroblasts.  GS-5759 relaxed guinea pig airway smooth muscle strips precontracted with carbachol in a concn.-dependent manner with an EC50 = 0.5 μM (CI 0.2-2) and had slow dissocn. kinetics with an Off T1/2 > 720 min at an EC80 concn. of 3 μM.  GS-5759 is a novel bifunctional mol. with both potent β2 agonist and PDE4 inhibitor activity that could provide inhaled bronchodilator and anti-inflammatory therapy for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_BKbLa3cVLVg90H21EOLACvtfcHk0lg_3W0trwCsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D&md5=b0017107ab4935141406708f98a8eec3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210997%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DCui%26aufirst%3DZ.-H.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26aulast%3DPhillips%26aufirst%3DG.%2BB.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520in%2520vitro%2520pharmacology%2520of%2520GS-5759%252C%2520a%2520novel%2520bifunctional%2520phosphodiesterase%25204%2520inhibitor%2520and%2520long%2520acting%2520beta%25282%2529-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D85%26epage%3D93%26doi%3D10.1124%2Fjpet.113.210997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. S.</span></span> <span> </span><span class="NLM_article-title">Dual beta(2)-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22297114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1523-1526&author=W.+J.+Shanauthor=L.+Huangauthor=Q.+Zhouauthor=H.+L.+Jiangauthor=Z.+H.+Luoauthor=K.+F.+Laiauthor=X.+S.+Li&title=Dual+beta%282%29-adrenoceptor+agonists-PDE4+inhibitors+for+the+treatment+of+asthma+and+COPD&doi=10.1016%2Fj.bmcl.2012.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD</span></div><div class="casAuthors">Shan, Wen-Jun; Huang, Ling; Zhou, Qi; Jiang, Huai-Lei; Luo, Zong-Hua; Lai, Ke-fang; Li, Xing-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1523-1526</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized a novel class of dual pharmacol. bronchodilators targeting both β2-adrenoceptor and PDE4 by applying a multivalent approach.  The most potent dual pharmacol. mol., compd. 29, possessed good inhibitory activity on PDE4B2 (IC50 = 0.278 μM, which was more potent than phthalazinone, IC50 = 0.520 μM) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC50 = 9.3).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxvQC2OsmiBbVg90H21EOLACvtfcHk0lh9aD3g9DFmhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCks7c%253D&md5=bb62adf5681621c26bf29aa8dce93e21</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DW.%2BJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DLuo%26aufirst%3DZ.%2BH.%26aulast%3DLai%26aufirst%3DK.%2BF.%26aulast%3DLi%26aufirst%3DX.%2BS.%26atitle%3DDual%2520beta%25282%2529-adrenoceptor%2520agonists-PDE4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1523%26epage%3D1526%26doi%3D10.1016%2Fj.bmcl.2012.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of dual pharmacology beta(2)-adrenoceptor agonists and PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24300734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWrsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=249-253&author=L.+Huangauthor=W.+Shanauthor=Q.+Zhouauthor=J.+Xieauthor=K.+Laiauthor=X.+Li&title=Design%2C+synthesis+and+evaluation+of+dual+pharmacology+beta%282%29-adrenoceptor+agonists+and+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors</span></div><div class="casAuthors">Huang, Ling; Shan, Wenjun; Zhou, Qi; Xie, Jiaxing; Lai, Kefang; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-253</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of formoterol-phthalazinone hybrids were synthesized and evaluated as dual pharmacol. β2-adrenoceptor agonists and PDE4 inhibitors.  Most of the hybrids displayed high β2-adrenoceptor agonist and moderate PDE4 inhibitory activities.  The most potent compd., I, exhibited agonist (EC50 = 1.05 nM, pEC50 = 9.0) and potent PDE4B2 inhibitory activities (IC50 = 0.092 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcYmhg2Ao4NbVg90H21EOLACvtfcHk0lh9aD3g9DFmhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWrsbnL&md5=f57566d3c422ba339f0dd7d4113c5e92</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520dual%2520pharmacology%2520beta%25282%2529-adrenoceptor%2520agonists%2520and%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D249%26epage%3D253%26doi%3D10.1016%2Fj.bmcl.2013.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cashman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of phosphodiesterase-4 and serotonin reuptake</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1021/jm8010993</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010993" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ars7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1530-1539&author=J.+R.+Cashmanauthor=T.+Voelkerauthor=H.+T.+Zhangauthor=J.+M.+O%E2%80%99Donnell&title=Dual+inhibitors+of+phosphodiesterase-4+and+serotonin+reuptake&doi=10.1021%2Fjm8010993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Phosphodiesterase-4 and Serotonin Reuptake</span></div><div class="casAuthors">Cashman, John R.; Voelker, Troy; Zhang, Han-Ting; O'Donnell, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1530-1539</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of multitarget compds. was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4 inhibitor.  The new dual PDE4 inhibitor/SSRI showed antidepressant-like activity in the forced swim test in mice.  The SSRIs 2-{5-[3-(5-fluoro-2-methoxyphenyl)ethyl]tetrahydrofuran-2-yl}ethylamine and 2-{5-[3-(5-fluoro-2-methoxyphenyl)propyl]tetrahydrofuran-2-yl}ethylamine were both individually linked to the PDE4 inhibitor 4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, via a five-carbon chain.  The dual PDE4 inhibitor/SSRI 2-{5-[3-(5-fluoro-2-methoxyphenylethyltetrahydrofuran-2-yl}ethylamino)pentyl]-4,5,8,8a-tetrahydro-2H-phthalazin-1-one (I) showed potent and selective serotonin reuptake inhibition (IC50 value of 127 nM).  The dual PDE4 inhibitor/SSRI I also inhibited PDE4D3 with a Ki value of 2.0 nM.  The dual PDE4 inhibitor/SSRI was significantly more effective than the individual SSRI alone or fluoxetine in the forced swim test at std. doses.  On a molar basis, the antidepressant-like effect of the dual PDE4 inhibitor/SSRI I showed a 129-fold increase in in vivo efficacy compared to fluoxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqll1QZUolKq7Vg90H21EOLACvtfcHk0lh9aD3g9DFmhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ars7w%253D&md5=2a0fcfa45c51500a029f231f7df4e48e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm8010993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010993%26sid%3Dliteratum%253Aachs%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DVoelker%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520inhibitors%2520of%2520phosphodiesterase-4%2520and%2520serotonin%2520reuptake%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1530%26epage%3D1539%26doi%3D10.1021%2Fjm8010993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J.F.</span>; <span class="NLM_string-name">Wan, Z.</span>; <span class="NLM_string-name">Yan, H.</span></span> <span> </span><span class="NLM_article-title">Dual Pharmacophores-PDE4-Muscarinic Antagonistics</span>. Patent <span class="NLM_patent">WO2009100170</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.F.+Callahan&author=Z.+Wan&author=H.+Yan&title=Dual+Pharmacophores-PDE4-Muscarinic+Antagonistics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DJ.F.%26atitle%3DDual%2520Pharmacophores-PDE4-Muscarinic%2520Antagonistics%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elisabetta, A.</span>; <span class="NLM_string-name">Gabriele, A.</span>; <span class="NLM_string-name">Carmelida, C.</span>; <span class="NLM_string-name">Baker-Glenn, C.</span></span> <span> </span><span class="NLM_article-title">Carbamate Derivatives which are both Phosphodiesterase 4 (PDE4) Enzyme Inhibitors and Muscarinic M3 Receptor Antagonists</span>. Patent <span class="NLM_patent">WO2015185650</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Elisabetta&author=A.+Gabriele&author=C.+Carmelida&author=C.+Baker-Glenn&title=Carbamate+Derivatives+which+are+both+Phosphodiesterase+4+%28PDE4%29+Enzyme+Inhibitors+and+Muscarinic+M3+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DElisabetta%26aufirst%3DA.%26atitle%3DCarbamate%2520Derivatives%2520which%2520are%2520both%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Enzyme%2520Inhibitors%2520and%2520Muscarinic%2520M3%2520Receptor%2520Antagonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blocher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopireddy, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnych, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Orally available soluble epoxide hydrolase/phosphodiesterase 4 dual inhibitor treats inflammatory pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3541</span>– <span class="NLM_lpage">3550</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01804</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01804" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3541-3550&author=R.+Blocherauthor=K.+M.+Wagnerauthor=R.+R.+Gopireddyauthor=T.+R.+Harrisauthor=H.+Wuauthor=B.+Barnychauthor=S.+H.+Hwangauthor=Y.+K.+Xiangauthor=E.+Proschakauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Orally+available+soluble+epoxide+hydrolase%2Fphosphodiesterase+4+dual+inhibitor+treats+inflammatory+pain&doi=10.1021%2Facs.jmedchem.7b01804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain</span></div><div class="casAuthors">Blocher, Rene; Wagner, Karen M.; Gopireddy, Raghavender R.; Harris, Todd R.; Wu, Hao; Barnych, Bogdan; Hwang, Sung Hee; Xiang, Yang K.; Proschak, Ewgenij; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3541-3550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by previously discovered enhanced analgesic efficacy between sol. epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors.  The best of these displayed good efficacy in in vitro assays.  Further pharmacokinetic studies of a subset of four selected compds. led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA).  In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h.  Addnl., MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorY4r0p-vHgbVg90H21EOLACvtfcHk0lhK17RUR-W-7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCnsb4%253D&md5=3a1321852da65c85999de6e5bf993a9b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01804%26sid%3Dliteratum%253Aachs%26aulast%3DBlocher%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DGopireddy%26aufirst%3DR.%2BR.%26aulast%3DHarris%26aufirst%3DT.%2BR.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DBarnych%26aufirst%3DB.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DXiang%26aufirst%3DY.%2BK.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOrally%2520available%2520soluble%2520epoxide%2520hydrolase%252Fphosphodiesterase%25204%2520dual%2520inhibitor%2520treats%2520inflammatory%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3541%26epage%3D3550%26doi%3D10.1021%2Facs.jmedchem.7b01804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, Y.</span>; <span class="NLM_string-name">Ochiai, K.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Kojima, A.</span></span> <span> </span><span class="NLM_article-title">2-Alkyl-6-(pyrazolopyridin-4-yl)pyridazinone Derivative and PDE Inhibitor Using them as Active Ingredient</span>. Patent <span class="NLM_patent">JP2010013354</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Kono&author=K.+Ochiai&author=T.+Takita&author=A.+Kojima&title=2-Alkyl-6-%28pyrazolopyridin-4-yl%29pyridazinone+Derivative+and+PDE+Inhibitor+Using+them+as+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DY.%26atitle%3D2-Alkyl-6-%2528pyrazolopyridin-4-yl%2529pyridazinone%2520Derivative%2520and%2520PDE%2520Inhibitor%2520Using%2520them%2520as%2520Active%2520Ingredient%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiraku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allcock, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 3: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmc.2012.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22336247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1644-1658&author=K.+Ochiaiauthor=S.+Takitaauthor=T.+Eirakuauthor=A.+Kojimaauthor=K.+Iwaseauthor=T.+Kishiauthor=K.+Fukuchiauthor=T.+Yasueauthor=D.+R.+Adamsauthor=R.+W.+Allcockauthor=Z.+Jiangauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+3%3A+design%2C+synthesis+and+structure-activity+relationships+of+dual+PDE3%2F4-inhibitory+fused+bicyclic+heteroaromatic-dihydropyridazinones+with+anti-inflammatory+and+bronchodilatory+activity&doi=10.1016%2Fj.bmc.2012.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity</span></div><div class="casAuthors">Ochiai, Koji; Takita, Satoshi; Eiraku, Tomohiko; Kojima, Akihiko; Iwase, Kazuhiko; Kishi, Tetsuya; Fukuchi, Kazunori; Yasue, Tokutaro; Adams, David R.; Allcock, Robert W.; Jiang, Zhong; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1644-1658</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity.  A survey of potential bicyclic heteroarom. replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin-5-yl analogs as dual PDE3/4-inhibitory compds. that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx4LlKRHG4R7Vg90H21EOLACvtfcHk0lhK17RUR-W-7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12gsrc%253D&md5=d4ef993ba2bd87efd2b87f76cf98d8c9</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DEiraku%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DFukuchi%26aufirst%3DK.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DAllcock%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25203%253A%2520design%252C%2520synthesis%2520and%2520structure-activity%2520relationships%2520of%2520dual%2520PDE3%252F4-inhibitory%2520fused%2520bicyclic%2520heteroaromatic-dihydropyridazinones%2520with%2520anti-inflammatory%2520and%2520bronchodilatory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1644%26epage%3D1658%26doi%3D10.1016%2Fj.bmc.2012.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiraku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yageta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5838</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.07.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22884989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5833-5838&author=K.+Ochiaiauthor=S.+Takitaauthor=A.+Kojimaauthor=T.+Eirakuauthor=N.+Andoauthor=K.+Iwaseauthor=T.+Kishiauthor=A.+Ohinataauthor=Y.+Yagetaauthor=T.+Yasueauthor=D.+R.+Adamsauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+4%3A+design%2C+synthesis+and+structure-activity+relationships+of+dual+PDE3%2F4-inhibitory+fused+bicyclic+heteroaromatic-4%2C4-dimethylpyrazolones&doi=10.1016%2Fj.bmcl.2012.07.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Part 4: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones</span></div><div class="casAuthors">Ochiai, Koji; Takita, Satoshi; Kojima, Akihiko; Eiraku, Tomohiko; Ando, Naoki; Iwase, Kazuhiko; Kishi, Tetsuya; Ohinata, Akira; Yageta, Yuichi; Yasue, Tokutaro; Adams, David R.; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5838</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity.  Here we show that a 4,4-dimethylpyrazolone subunit serves as an effective surrogate for the 5-methyl-4,5-dihydropyridazin-3(2H)-one ring of KCA-1490 while lacking a stereogenic center.  The 2- and 7-substituents in the pyrazolo[1,5-a]pyridine subunit markedly influence the PDE-inhibitory profile and can be adjusted to afford either potent PDE4-selective inhibitors or dual PDE3/4 inhibitors.  A survey of bicyclic heteroarom. replacements for the pyrazolo[1,5-a]pyridine allowed further refinement of the inhibitory profile and identified 3-(8-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)-4,4-dimethyl-1H-pyrazol-5(4H)-one as an orally active, achiral KCA-1490 analog with well-balanced dual PDE3/4-inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KLCxyhkIvbVg90H21EOLACvtfcHk0lhAXdYCrG_Ksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzL&md5=956a10c4d4f8f192f2bbf3282947b9ac</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.088%26sid%3Dliteratum%253Aachs%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DEiraku%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DN.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DOhinata%26aufirst%3DA.%26aulast%3DYageta%26aufirst%3DY.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25204%253A%2520design%252C%2520synthesis%2520and%2520structure-activity%2520relationships%2520of%2520dual%2520PDE3%252F4-inhibitory%2520fused%2520bicyclic%2520heteroaromatic-4%252C4-dimethylpyrazolones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5833%26epage%3D5838%26doi%3D10.1016%2Fj.bmcl.2012.07.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbott-Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fbcpt.12209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24517491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=365-376&author=K.+H.+Abbott-Bannerauthor=C.+P.+Page&title=Dual+PDE3%2F4+and+PDE4+inhibitors%3A+novel+treatments+for+COPD+and+other+inflammatory+airway+diseases&doi=10.1111%2Fbcpt.12209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases</span></div><div class="casAuthors">Abbott-Banner, Katharine H.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential therapeutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bronchodilator/anti-inflammatory (PDE3/4) effects.  Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled.  Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization.  The majority of the compds. that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes.  Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with subtype specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy vs. inhibition of either PDE3 or PDE4 alone, given the potential pos. interactions with regard to anti-inflammatory and bronchodilator effects that have been obsd. pre-clin. with dual inhibition of PDE3 and PDE4 compared with inhibition of either isoenzyme alone.  This MiniReview will summarize recent clin. data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj1ILnRPA11rVg90H21EOLACvtfcHk0lhAXdYCrG_Ksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D&md5=d29edfe27d2514633d532bdd47d938d4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott-Banner%26aufirst%3DK.%2BH.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DDual%2520PDE3%252F4%2520and%2520PDE4%2520inhibitors%253A%2520novel%2520treatments%2520for%2520COPD%2520and%2520other%2520inflammatory%2520airway%2520diseases%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D365%26epage%3D376%26doi%3D10.1111%2Fbcpt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelcman, B.</span>; <span class="NLM_string-name">Krog-Jensen, C.</span>; <span class="NLM_string-name">No, K.</span>; <span class="NLM_string-name">Sanin, A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidinones for Use as Medicaments</span>. Patent <span class="NLM_patent">WO2011114103</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Pelcman&author=C.+Krog-Jensen&author=K.+No&author=A.+Sanin&title=Pyrimidinones+for+Use+as+Medicaments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPelcman%26aufirst%3DB.%26atitle%3DPyrimidinones%2520for%2520Use%2520as%2520Medicaments%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelcman, B.</span>; <span class="NLM_string-name">Yee, J.</span>; <span class="NLM_string-name">Gee, K.</span>; <span class="NLM_string-name">Mackenzie, L. F.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Han, K.</span></span> <span> </span><span class="NLM_article-title">Isochromenones Useful in the Treatment of Inflammation</span>. Patent <span class="NLM_patent">WO2010076564</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=B.+Pelcman&author=J.+Yee&author=K.+Gee&author=L.+F.+Mackenzie&author=Y.+Zhou&author=K.+Han&title=Isochromenones+Useful+in+the+Treatment+of+Inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPelcman%26aufirst%3DB.%26atitle%3DIsochromenones%2520Useful%2520in%2520the%2520Treatment%2520of%2520Inflammation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span>; <span class="NLM_string-name">Gupta, N.</span>; <span class="NLM_string-name">Chandrakant, K. G.</span>; <span class="NLM_string-name">Jain, T.</span>; <span class="NLM_string-name">Voleti, S. R.</span>; <span class="NLM_string-name">Ray, A.</span>; <span class="NLM_string-name">Dastidar, S. G.</span>; <span class="NLM_string-name">Vijaykrishnan, L.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2010046791</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Rudra&author=N.+Gupta&author=K.+G.+Chandrakant&author=T.+Jain&author=S.+R.+Voleti&author=A.+Ray&author=S.+G.+Dastidar&author=L.+Vijaykrishnan&title=Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRudra%26aufirst%3DS.%26atitle%3DPhosphodiesterase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C. S.</span>; <span class="NLM_string-name">Ivey, F. D.</span>; <span class="NLM_string-name">Wyman Petri, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclic AMP Phosphodiesterases</span>. Patent <span class="NLM_patent">US20100227853</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+S.+Hoffman&author=F.+D.+Ivey&author=A.+Wyman+Petri&title=Inhibitors+of+Cyclic+AMP+Phosphodiesterases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520Cyclic%2520AMP%2520Phosphodiesterases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chlon-Rzepa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swierczek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pociecha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawalska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2018.01.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29407965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=381-394&author=G.+Chlon-Rzepaauthor=A.+Jankowskaauthor=M.+Slusarczykauthor=A.+Swierczekauthor=K.+Pociechaauthor=E.+Wyskaauthor=A.+Buckiauthor=A.+Gawalskaauthor=M.+Kolaczkowskiauthor=M.+Pawlowski&title=Novel+butanehydrazide+derivatives+of+purine-2%2C6-dione+as+dual+PDE4%2F7+inhibitors+with+potential+anti-inflammatory+activity%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.01.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Chlon-Rzepa, Grazyna; Jankowska, Agnieszka; Slusarczyk, Marietta; Swierczek, Artur; Pociecha, Krzysztof; Wyska, Elzbieta; Bucki, Adam; Gawalska, Alicja; Kolaczkowski, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381-394</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel butanehydrazide derivs. of purine-2,6-dione I [R = H, EtO, PhCH2NH, (furan-2-ylmethyl)amino, etc.; R1 = 2-HOC6H4, 2,4-(HO)2C6H3, 2,3,4-(HO)3C6H2, 2-HO-4-MeOC6H3] designed using a ligand-based approach were synthesized and their in vitro activity against both PDE4B and PDE7A isoenzymes was assessed.  The 7,8-disubstituted purine-2,6-dione derivs. I [R = PhCH2NH, PhCH2CH2NH, (furan-2-ylmethyl)amino, (pyridin-2-ylmethyl)amino; R1 = 2,3,4-(HO)3C6H2] appeared to be the most potent PDE4/7 inhibitors with IC50 values in the range of that of the ref. rolipram and BRL-50481, resp.  Moreover, docking studies explained the importance of N-(2,3,4-trihydroxybenzylidene)butanehydrazide substituent in position 7 of purine-2,6-dione core for dual PDE4/7 inhibitory properties.  The inhibition of both the cAMP-specific PDE isoenzymes resulted in a strong anti-TNF-α effect.  Compds. I [R = PhCH2NH, PhCH2CH2NH, (furan-2-ylmethyl)amino; R1 = 2,3,4-(HO)3C6H2] in the in vivo study in rats with LPS-induced endotoxemia decreased the max. concn. of this proinflammatory cytokine by 53, 84 and 88%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrENI95nbu1DLVg90H21EOLACvtfcHk0lhAXdYCrG_Ksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrtLk%253D&md5=088cb6d842d7dbf0ce5ca44c4623631c</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.068%26sid%3Dliteratum%253Aachs%26aulast%3DChlon-Rzepa%26aufirst%3DG.%26aulast%3DJankowska%26aufirst%3DA.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSwierczek%26aufirst%3DA.%26aulast%3DPociecha%26aufirst%3DK.%26aulast%3DWyska%26aufirst%3DE.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DGawalska%26aufirst%3DA.%26aulast%3DKolaczkowski%26aufirst%3DM.%26aulast%3DPawlowski%26aufirst%3DM.%26atitle%3DNovel%2520butanehydrazide%2520derivatives%2520of%2520purine-2%252C6-dione%2520as%2520dual%2520PDE4%252F7%2520inhibitors%2520with%2520potential%2520anti-inflammatory%2520activity%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D381%26epage%3D394%26doi%3D10.1016%2Fj.ejmech.2018.01.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaeta, F. C. A.</span>; <span class="NLM_string-name">Johnson, K. W.</span>; <span class="NLM_string-name">Gross, M. I.</span>; <span class="NLM_string-name">Ledeboer, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Pyrazolo[1,5-a]pyridine Compounds Having Multi-Target Activity</span>. Patent <span class="NLM_patent">WO2010144416</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=F.+C.+A.+Gaeta&author=K.+W.+Johnson&author=M.+I.+Gross&author=A.+Ledeboer&title=Substituted+Pyrazolo%5B1%2C5-a%5Dpyridine+Compounds+Having+Multi-Target+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaeta%26aufirst%3DF.%2BC.%2BA.%26atitle%3DSubstituted%2520Pyrazolo%255B1%252C5-a%255Dpyridine%2520Compounds%2520Having%2520Multi-Target%2520Activity%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span>; <span class="NLM_string-name">Blythin, D.</span>; <span class="NLM_string-name">Shih, N. Y.</span>; <span class="NLM_string-name">Shue, H. J.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Gu, D.</span>; <span class="NLM_string-name">Huang, Y.</span>; <span class="NLM_string-name">Schwerdt, J. H.</span>; <span class="NLM_string-name">Ting, P. C.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors</span>. Patent <span class="NLM_patent">WO2005116009</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Kuang&author=D.+Blythin&author=N.+Y.+Shih&author=H.+J.+Shue&author=X.+Chen&author=J.+Cao&author=D.+Gu&author=Y.+Huang&author=J.+H.+Schwerdt&author=P.+C.+Ting&title=Substituted+2-quinolyl-oxazoles+useful+as+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DR.%26atitle%3DSubstituted%25202-quinolyl-oxazoles%2520useful%2520as%2520PDE4%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grepin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le+Rouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Grepinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0ljRYRMf6s4Hdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGrepin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=7791113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2MXmsVCgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1995&pages=1396-1402&author=M.+S.+Barnetteauthor=M.+Grousauthor=L.+B.+Cieslinskiauthor=M.+Burmanauthor=S.+B.+Christensenauthor=T.+J.+Torphy&title=Inhibitors+of+phosphodiesterase+IV+%28PDE+IV%29+increase+acid+secretion+in+rabbit+isolated+gastric+glands%3A+correlation+between+function+and+interaction+with+a+high-affinity+rolipram+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site</span></div><div class="casAuthors">Barnette, Mary S.; Grous, Marilyn; Cieslinski, Lenora B.; Burman, Miriam; Christensen, Siegfried B.; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1396-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In this report, we describe the ability of selective inhibitors of phosphodiesterase (PDE) isoenzymes to increase aminopyrine accumulation in rabbit isolated gastric glands.  Aminopyrine accumulation in the presence of histamine was increased by the nonselective PDE inhibitor isobutylmethylxanthine (EC50 = 4.8 μM) and by two selective PDE IV inhibitors, rolipram and Ro 20-1724 (EC50 = 0.013 and 0.07 μM, resp.) but not by selective PDE III inhibitors (siguazodan and SK&F 94120) or by a selective PDE V inhibitor (zaprinast).  These results suggest that PDE IV is an important regulator of acid secretion in response to histamine.  One of the more fascinating properties of PDE IV is the expression of a high-affinity binding site for [3H]-rolipram in addn. to cAMP catalytic activity.  Although agents that inhibit PDE IV catalytic activity also appear to bind to the high-affinity rolipram-binding site, the rank-order potencies of compds. for these two effects are poorly correlated.  Also, certain pharmacol. actions of PDE IV inhibitors appear to be related to an interaction with this binding site.  In this study, we obsd. that the ability of PDE IV inhibitors to enhance acid secretion was not assocd. with their ability to inhibit PDE IV catalytic activity but did show a strong correlation with their ability to compete for [3H]-rolipram binding.  Furthermore, we were able to detect [3H]-rolipram binding sites in gastric glands that had characteristics similar to those of the [3H]-rolipram binding sites in rat brain microsomes and human recombinant PDE IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGYysc0iW3hbVg90H21EOLACvtfcHk0ljRYRMf6s4Hdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsVCgu7o%253D&md5=cc7c72c84e09753b8d46d8df2bb60b36</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DInhibitors%2520of%2520phosphodiesterase%2520IV%2520%2528PDE%2520IV%2529%2520increase%2520acid%2520secretion%2520in%2520rabbit%2520isolated%2520gastric%2520glands%253A%2520correlation%2520between%2520function%2520and%2520interaction%2520with%2520a%2520high-affinity%2520rolipram%2520binding%2520site%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D273%26spage%3D1396%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmiechen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachtel, H.</span></span> <span> </span><span class="NLM_article-title">Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1007/BF02245738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2FBF02245738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=2392503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVGhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1990&pages=17-20&author=R.+Schmiechenauthor=H.+H.+Schneiderauthor=H.+Wachtel&title=Close+correlation+between+behavioural+response+and+binding+in+vivo+for+inhibitors+of+the+rolipram-sensitive+phosphodiesterase&doi=10.1007%2FBF02245738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase</span></div><div class="casAuthors">Schmiechen, Ralph; Schneider, Herbert H.; Wachtel, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-20</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The antidepressant rolipram interacts in vitro with a binding site in brain tissue labeled by [3H]rolipram.  A [3H]rolipram binding assay was employed in vivo to compare the affinity of rolipram-related compds. and ref. phosphodiesterase (PDE) inhibitors with their potency in behavioral measures for potential antidepressant property.  In mice and rats, the potency of a no. of compds. to antagonize reserpine-induced hypothermia (mice) and to induce head twitches (rats) was detd., as well as their potency to displace [3H]rolipram from forebrain binding sites in vivo.  The treatment schedules for the two series of expts. were identical.  Correlations between pharmacol. effects and displacement of [3H]rolipram binding in vivo were obsd. in both species.  Since the ref. PDE inhibitors closely fit into the binding-pharmacol. activity relationship, the PDE inhibitory properties of the substances involved are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvgKEhvFtsrVg90H21EOLACvtfcHk0lhKxmzIAHPXzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVGhtL0%253D&md5=c8596b92dab447707f96919309ea24e4</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2FBF02245738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02245738%26sid%3Dliteratum%253Aachs%26aulast%3DSchmiechen%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DH.%2BH.%26aulast%3DWachtel%26aufirst%3DH.%26atitle%3DClose%2520correlation%2520between%2520behavioural%2520response%2520and%2520binding%2520in%2520vivo%2520for%2520inhibitors%2520of%2520the%2520rolipram-sensitive%2520phosphodiesterase%26jtitle%3DPsychopharmacology%26date%3D1990%26volume%3D102%26spage%3D17%26epage%3D20%26doi%3D10.1007%2FBF02245738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=8863835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=891-899&author=S.+Jacobitzauthor=M.+M.+McLaughlinauthor=G.+P.+Liviauthor=M.+Burmanauthor=T.+J.+Torphy&title=Mapping+the+functional+domains+of+human+recombinant+phosphodiesterase+4A%3A+structural+requirements+for+catalytic+activity+and+rolipram+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding</span></div><div class="casAuthors">Jacobitz, Susanne; McLaughlin, Megan M.; Livi, George P.; Burman, Miriam; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To identify functional domains of the 886-amino acid human recombinant cAMP-specific phosphodiesterase (PDE) subtype A (rhPDE4A), we engineered the expression of seven mutant proteins contg. both NH2- and COOH-terminal truncations.  The level of rhPDE4A protein expression in yeast was monitored by immunoblotting using enzyme-specific antisera.  Biochem. profiles of the mutant proteins were compared with those of the full-length protein or a fully active truncated form of the enzyme (rhPDE4A Met265-886), lacking the first 264 amino acids.  The smallest catalytically active fragment generated was Met332-722, which at 45 kDa is less than half the mass of the full-length enzyme (∼110 kDa) but spans the most highly conserved region of the PDE superfamily.  Two prototypical PDE4 inhibitors, rolipram and RP 73401, inhibited cAMP-hydrolyzing activity of all truncated forms of the enzyme, with IC50 values of 70-2000 nM and 0.2-0.6 nM, resp.  [3H](R)-Rolipram bound to two sites on Met265-886, a high affinity site (Kd1 = 0.7 ± 0.3 nM) and a low affinity site (Kd2 = 34 ± 10 nM).  Interestingly, [3H](R)-rolipram failed to bind to Met332-886 with high affinity, indicating that high affinity binding is not required for inhibition of enzyme activity.  Low affinity rolipram-binding was still present in Met332-886 (Kd = 101 ± 7 nM).  In contrast to [3H](R)-rolipram, [3H]RP 73401 bound to a single class of high affinity sites on Met265-886 (Kd = 0.4 ± 0.1 nM).  Further truncation of the enzyme to Met332-886 had no effect on [3H]RP 73401 binding (Kd = 0.2 ± 0.03 nM).  We conclude that the catalytic center of rhPDE4A lies between amino acids 332 and 722.  Furthermore, amino acids 265-332 may form a high affinity binding site for rolipram that is outside the catalytic domain.  As a more likely alternative, these amino acids may not form a distinct binding site but instead may be required for the recombinant enzyme to assume a conformation that binds rolipram at the catalytic domain with a high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQO9hB-XY4nrVg90H21EOLACvtfcHk0lhKxmzIAHPXzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D&md5=17e514f10560b1472aedbac336b58882</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobitz%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DMapping%2520the%2520functional%2520domains%2520of%2520human%2520recombinant%2520phosphodiesterase%25204A%253A%2520structural%2520requirements%2520for%2520catalytic%2520activity%2520and%2520rolipram%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauda, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, E. C.</span></span> <span> </span><span class="NLM_article-title">Revisiting cAMP signaling in the carotid body</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">406</span>, <span class="refDoi"> DOI: 10.3389/fphys.2014.00406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphys.2014.00406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25389406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2M3nsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=406&author=A.+R.+Nunesauthor=A.+P.+Holmesauthor=S.+V.+Condeauthor=E.+B.+Gaudaauthor=E.+C.+Monteiro&title=Revisiting+cAMP+signaling+in+the+carotid+body&doi=10.3389%2Ffphys.2014.00406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting cAMP signaling in the carotid body</span></div><div class="casAuthors">Nunes Ana R; Conde Silvia V; Monteiro Emilia C; Holmes Andrew P; Gauda Estelle B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">406</span>
        ISSN:<span class="NLM_cas:issn">1664-042X</span>.
    </div><div class="casAbstract">Chronic carotid body (CB) activation is now recognized as being essential in the development of hypertension and promoting insulin resistance; thus, it is imperative to characterize the chemotransduction mechanisms of this organ in order to modulate its activity and improve patient outcomes.  For several years, and although controversial, cyclic adenosine monophosphate (cAMP) was considered an important player in initiating the activation of the CB.  However, its relevance was partially displaced in the 90s by the emerging role of the mitochondria and molecules such as AMP-activated protein kinase and O2-sensitive K(+) channels.  Neurotransmitters/neuromodulators binding to metabotropic receptors are essential to chemotransmission in the CB, and cAMP is central to this process. cAMP also contributes to raise intracellular Ca(2+) levels, and is intimately related to the cellular energetic status (AMP/ATP ratio).  Furthermore, cAMP signaling is a target of multiple current pharmacological agents used in clinical practice.  This review (1) provides an outline on the classical view of the cAMP-signaling pathway in the CB that originally supported its role in the O2/CO2 sensing mechanism, (2) presents recent evidence on CB cAMP neuromodulation and (3) discusses how CB activity is affected by current clinical therapies that modify cAMP-signaling, namely dopaminergic drugs, caffeine (modulation of A2A/A2B receptors) and roflumilast (PDE4 inhibitors). cAMP is key to any process that involves metabotropic receptors and the intracellular pathways involved in CB disease states are likely to involve this classical second messenger.  Research examining the potential modification of cAMP levels and/or interactions with molecules associated with CB hyperactivity is currently in its beginning and this review will open doors for future explorations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK20E-hdrxgDEwO064Z95rfW6udTcc2eb_YfEhggWQ_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3nsVKksQ%253D%253D&md5=9b044d38fa02de39d985d73d152adf92</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2014.00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2014.00406%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DA.%2BR.%26aulast%3DHolmes%26aufirst%3DA.%2BP.%26aulast%3DConde%26aufirst%3DS.%2BV.%26aulast%3DGauda%26aufirst%3DE.%2BB.%26aulast%3DMonteiro%26aufirst%3DE.%2BC.%26atitle%3DRevisiting%2520cAMP%2520signaling%2520in%2520the%2520carotid%2520body%26jtitle%3DFront.%2520Physiol.%26date%3D2014%26volume%3D5%26spage%3D406%26doi%3D10.3389%2Ffphys.2014.00406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prysyazhna, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, P.</span></span> <span> </span><span class="NLM_article-title">Redox regulation of cGMP-dependent protein kinase Ialpha in the cardiovascular system</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26236235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=139&author=O.+Prysyazhnaauthor=P.+Eaton&title=Redox+regulation+of+cGMP-dependent+protein+kinase+Ialpha+in+the+cardiovascular+system&doi=10.3389%2Ffphar.2015.00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Redox regulation of cGMP-dependent protein kinase Iα in the cardiovascular system</span></div><div class="casAuthors">Prysyazhna, Oleksandra; Eaton, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139/1-139/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Elevated levels of oxidants in biol. systems have been historically referred to as "oxidative stress," a choice of words that perhaps conveys an imbalanced view of reactive oxygen species in cells and tissues.  The term stress suggests a harmful role, whereas a contemporary view is that oxidants are also crucial for the maintenance of homeostasis or adaptive signaling that can actually limit injury.  This regulatory role for oxidants is achieved in part by them inducing oxidative post-translational modifications of proteins which may alter their function or interactions.  Such mechanisms allow changes in cell oxidant levels to be coupled to regulated alterations in enzymic function (i.e., signal transduction), which enables "redox signaling." In this review we focus on the role of cGMP-dependent protein kinase (PKG) Iα disulfide dimerization, an oxidative modification that is induced by oxidants that directly activates the enzyme, discussing how this impacts on the cardiovascular system.  Addnl., how this oxidative activation of PKG may coordinate with or differ from classical activation of this kinase by cGMP is also considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG5unr18UpcbVg90H21EOLACvtfcHk0lhKxmzIAHPXzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals77E&md5=fabe432b3ae84c251bd8395323a40f6c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00139%26sid%3Dliteratum%253Aachs%26aulast%3DPrysyazhna%26aufirst%3DO.%26aulast%3DEaton%26aufirst%3DP.%26atitle%3DRedox%2520regulation%2520of%2520cGMP-dependent%2520protein%2520kinase%2520Ialpha%2520in%2520the%2520cardiovascular%2520system%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D139%26doi%3D10.3389%2Ffphar.2015.00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inserte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Dorado, D.</span></span> <span> </span><span class="NLM_article-title">The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1996</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1111/bph.12959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fbph.12959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25297462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslems7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1996-2009&author=J.+Inserteauthor=D.+Garcia-Dorado&title=The+cGMP%2FPKG+pathway+as+a+common+mediator+of+cardioprotection%3A+translatability+and+mechanism&doi=10.1111%2Fbph.12959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism</span></div><div class="casAuthors">Inserte, Javier; Garcia-Dorado, David</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1996-2009</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cardiomyocyte cell death occurring during myocardial reperfusion (reperfusion injury) contributes to final infarct size after transient coronary occlusion.  Different interrelated mechanisms of reperfusion injury have been identified, including alterations in cytosolic Ca2+ handling, sarcoplasmic reticulum-mediated Ca2+ oscillations and hypercontracture, proteolysis secondary to calpain activation and mitochondrial permeability transition.  All these mechanisms occur during the initial minutes of reperfusion and are inhibited by intracellular acidosis.  The cGMP/PKG pathway modulates the rate of recovery of intracellular pH, but has also direct effect on Ca2+ oscillations and mitochondrial permeability transition.  The cGMP/PKG pathway is depressed in cardiomyocytes by ischemia/reperfusion and preserved by ischemic postconditioning, which importantly contributes to postconditioning protection.  The present article reviews the mechanisms and consequences of the effect of ischemic postconditioning on the cGMP/PKG pathway, the different pharmacol. strategies aimed to stimulate it during myocardial reperfusion and the evidence, limitations and promise of translation of these strategies to the clin. practice.  Overall, the preclin. and clin. evidence suggests that modulation of the cGMP/PKG pathway may be a therapeutic target in the context of myocardial infarction.  Linked Articles : This article is part of a themed section on Conditioning the Heart - Pathways to Translation.  To view the other articles in this section visit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_vbPKbLCAJ7Vg90H21EOLACvtfcHk0lgLiJGJWTeu-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslems7o%253D&md5=e4f6edfa8bbeabafbf7f731e70543cee</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1111%2Fbph.12959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12959%26sid%3Dliteratum%253Aachs%26aulast%3DInserte%26aufirst%3DJ.%26aulast%3DGarcia-Dorado%26aufirst%3DD.%26atitle%3DThe%2520cGMP%252FPKG%2520pathway%2520as%2520a%2520common%2520mediator%2520of%2520cardioprotection%253A%2520translatability%2520and%2520mechanism%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1996%26epage%3D2009%26doi%3D10.1111%2Fbph.12959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span> <span> </span><span class="NLM_article-title">Imaging alterations of cardiomyocyte cAMP microdomains in disease</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">172</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26379548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=172&author=A.+Froeseauthor=V.+O.+Nikolaev&title=Imaging+alterations+of+cardiomyocyte+cAMP+microdomains+in+disease&doi=10.3389%2Ffphar.2015.00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging alterations of cardiomyocyte cAMP microdomains in disease</span></div><div class="casAuthors">Froese, Alexander; Nikolaev, Viacheslav O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172/1-172/5</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">3',5'-Cyclic adenosine monophosphate (cAMP) is an important second messenger which regulates heart function by acting in distinct subcellular microdomains.  Recent years have provided deeper mechanistic insights into compartmentalized cAMP signaling and its link to cardiac disease.  In this mini review, we summarize newest developments in this field achieved by cutting-edge biochem. and biophys. techniques.  We further compile the data from different studies into a bigger picture of so far uncovered alterations in cardiomyocyte cAMP microdomains which occur in compensated cardiac hypertrophy and chronic heart failure.  Finally, future research directions and translational perspectives are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYBE_4d12BAbVg90H21EOLACvtfcHk0lgLiJGJWTeu-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wjt7vN&md5=d92490a473560c77209d792615fec6cc</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00172%26sid%3Dliteratum%253Aachs%26aulast%3DFroese%26aufirst%3DA.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26atitle%3DImaging%2520alterations%2520of%2520cardiomyocyte%2520cAMP%2520microdomains%2520in%2520disease%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D172%26doi%3D10.3389%2Ffphar.2015.00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Nanodomain regulation of cardiac cyclic nucleotide signaling by phosphodiesterases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010716-104756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev-pharmtox-010716-104756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27732797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=455-479&author=K.+Kokkonenauthor=D.+A.+Kass&title=Nanodomain+regulation+of+cardiac+cyclic+nucleotide+signaling+by+phosphodiesterases&doi=10.1146%2Fannurev-pharmtox-010716-104756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases</span></div><div class="casAuthors">Kokkonen, Kristen; Kass, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-479</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3',5'-monophosphate (cAMP or cGMP).  These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides.  Seven PDE family members are physiol. relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP.  New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors.  In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHS7lTakIRrVg90H21EOLACvtfcHk0lgLiJGJWTeu-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN&md5=0bbfd7fecacc24ec40b76e7406495313</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104756%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonen%26aufirst%3DK.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DNanodomain%2520regulation%2520of%2520cardiac%2520cyclic%2520nucleotide%2520signaling%2520by%2520phosphodiesterases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D455%26epage%3D479%26doi%3D10.1146%2Fannurev-pharmtox-010716-104756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boularan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, C.</span></span> <span> </span><span class="NLM_article-title">Cardiac cAMP: production, hydrolysis, modulation and detection</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">203</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26483685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC28zjs1Kguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=203&author=C.+Boularanauthor=C.+Gales&title=Cardiac+cAMP%3A+production%2C+hydrolysis%2C+modulation+and+detection&doi=10.3389%2Ffphar.2015.00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac cAMP: production, hydrolysis, modulation and detection</span></div><div class="casAuthors">Boularan Cedric; Gales Celine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Cyclic adenosine 3',5'-monophosphate (cAMP) modulates a broad range of biological processes including the regulation of cardiac myocyte contractile function where it constitutes the main second messenger for β-adrenergic receptors' signaling to fulfill positive chronotropic, inotropic and lusitropic effects.  A growing number of studies pinpoint the role of spatial organization of the cAMP signaling as an essential mechanism to regulate cAMP outcomes in cardiac physiology.  Here, we will briefly discuss the complexity of cAMP synthesis and degradation in the cardiac context, describe the way to detect it and review the main pharmacological arsenal to modulate its availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLm-3l1g5G-9bHMBt0mMIXfW6udTcc2eYxMF1HzQyP3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjs1Kguw%253D%253D&md5=a528a924581daefb03da81c8b10d47b8</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00203%26sid%3Dliteratum%253Aachs%26aulast%3DBoularan%26aufirst%3DC.%26aulast%3DGales%26aufirst%3DC.%26atitle%3DCardiac%2520cAMP%253A%2520production%252C%2520hydrolysis%252C%2520modulation%2520and%2520detection%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D203%26doi%3D10.3389%2Ffphar.2015.00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurumaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki-Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takehara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisada, T.</span></span> <span> </span><span class="NLM_article-title">Roles of cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1346</span>, <span class="refDoi"> DOI: 10.3390/ijms20061346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3390%2Fijms20061346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1346&author=Y.+Kogaauthor=H.+Tsurumakiauthor=H.+Aoki-Saitoauthor=M.+Satoauthor=M.+Yatomiauthor=K.+Takeharaauthor=T.+Hisada&title=Roles+of+cyclic+AMP+response+element+binding+activation+in+the+ERK1%2F2+and+p38+MAPK+signalling+pathway+in+central+nervous+system%2C+cardiovascular+system%2C+osteoclast+differentiation+and+mucin+and+cytokine+production&doi=10.3390%2Fijms20061346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production</span></div><div class="casAuthors">Koga, Yasuhiko; Tsurumaki, Hiroaki; Aoki-Saito, Haruka; Sato, Makiko; Yatomi, Masakiyo; Takehara, Kazutaka; Hisada, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1346</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There are many downstream targets of mitogen-activated protein kinase (MAPK) signalling that are involved in neuronal development, cellular differentiation, cell migration, cancer, cardiovascular dysfunction and inflammation via their functions in promoting apoptosis and cell motility and regulating various cytokines.  It has been reported that cAMP response element-binding protein (CREB) is phosphorylated and activated by cAMP signalling and calcium/calmodulin kinase.  Recent evidence also points to CREB phosphorylation by the MAPK signalling pathway.  However, the specific roles of CREB phosphorylation in MAPK signalling have not yet been reviewed in detail.  Here, we describe the recent advances in the study of this MAPK-CREB signalling axis in human diseases.  Overall, the crosstalk between extracellular signal-related kinase (ERK) 1/2 and p38 MAPK signalling has been shown to regulate various physiol. functions, including central nervous system, cardiac fibrosis, alc. cardiac fibrosis, osteoclast differentiation, mucin prodn. in the airway, vascular smooth muscle cell migration, steroidogenesis and asthmatic inflammation.  In this review, we focus on ERK1/2 and/or p38 MAPK-dependent CREB activation assocd. with various diseases to provide insights for basic and clin. researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Kdas4OAHmrVg90H21EOLACvtfcHk0lipYV8N0zT58g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWgurg%253D&md5=38d299804b0054cbf46ca8db20abcff0</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3390%2Fijms20061346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061346%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DTsurumaki%26aufirst%3DH.%26aulast%3DAoki-Saito%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DYatomi%26aufirst%3DM.%26aulast%3DTakehara%26aufirst%3DK.%26aulast%3DHisada%26aufirst%3DT.%26atitle%3DRoles%2520of%2520cyclic%2520AMP%2520response%2520element%2520binding%2520activation%2520in%2520the%2520ERK1%252F2%2520and%2520p38%2520MAPK%2520signalling%2520pathway%2520in%2520central%2520nervous%2520system%252C%2520cardiovascular%2520system%252C%2520osteoclast%2520differentiation%2520and%2520mucin%2520and%2520cytokine%2520production%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1346%26doi%3D10.3390%2Fijms20061346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span> <span> </span><span class="NLM_article-title">Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.cell.2012.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22304913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=421-433&author=S.+J.+Parkauthor=F.+Ahmadauthor=A.+Philpauthor=K.+Baarauthor=T.+Williamsauthor=H.+Luoauthor=H.+Keauthor=H.+Rehmannauthor=R.+Taussigauthor=A.+L.+Brownauthor=M.+K.+Kimauthor=M.+A.+Beavenauthor=A.+B.+Burginauthor=V.+Manganielloauthor=J.+H.+Chung&title=Resveratrol+ameliorates+aging-related+metabolic+phenotypes+by+inhibiting+cAMP+phosphodiesterases&doi=10.1016%2Fj.cell.2012.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases</span></div><div class="casAuthors">Park, Sung-Jun; Ahmad, Faiyaz; Philp, Andrew; Baar, Keith; Williams, Tishan; Luo, Haibin; Ke, Hengming; Rehmann, Holger; Taussig, Ronald; Brown, Alexandra L.; Kim, Myung K.; Beaven, Michael A.; Burgin, Alex B.; Manganiello, Vincent; Chung, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-433</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Resveratrol, a polyphenol in red wine, has been reported as a calorie restriction mimetic with potential antiaging and antidiabetogenic properties.  It is widely consumed as a nutritional supplement, but its mechanism of action remains a mystery.  Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels.  The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca2+ levels and activates the CamKKβ-AMPK pathway via phospholipase C and the ryanodine receptor Ca2+-release channel.  As a consequence, resveratrol increases NAD+ and the activity of Sirt1.  Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, phys. stamina, and glucose tolerance in mice.  Therefore, administration of PDE4 inhibitors may also protect against and ameliorate the symptoms of metabolic diseases assocd. with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8zHottwfaS7Vg90H21EOLACvtfcHk0lipYV8N0zT58g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFakurc%253D&md5=6e8e92e1140c0c63c0fc92314e0f0c5c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DPhilp%26aufirst%3DA.%26aulast%3DBaar%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DRehmann%26aufirst%3DH.%26aulast%3DTaussig%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DA.%2BL.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DManganiello%26aufirst%3DV.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26atitle%3DResveratrol%2520ameliorates%2520aging-related%2520metabolic%2520phenotypes%2520by%2520inhibiting%2520cAMP%2520phosphodiesterases%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D421%26epage%3D433%26doi%3D10.1016%2Fj.cell.2012.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Bailly</span>. </span><span class="cited-content_cbyCitation_article-title">The traditional and modern uses of Selaginella tamariscina (P.Beauv.) Spring, in medicine and cosmetic: Applications and bioactive ingredients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ethnopharmacology</span><span> <strong>2021,</strong> <em>280 </em>, 114444. <a href="https://doi.org/10.1016/j.jep.2021.114444" title="DOI URL">https://doi.org/10.1016/j.jep.2021.114444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jep.2021.114444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jep.2021.114444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ethnopharmacology%26atitle%3DThe%252Btraditional%252Band%252Bmodern%252Buses%252Bof%252BSelaginella%252Btamariscina%252B%252528P.Beauv.%252529%252BSpring%25252C%252Bin%252Bmedicine%252Band%252Bcosmetic%25253A%252BApplications%252Band%252Bbioactive%252Bingredients%26aulast%3DBailly%26aufirst%3DChristian%26date%3D2021%26volume%3D280%26spage%3D114444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  liu</span>, <span class="hlFld-ContribAuthor ">Wan  Ye</span>, <span class="hlFld-ContribAuthor ">Jiang-Ping  Xu</span>, <span class="hlFld-ContribAuthor ">Hai-Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Fang  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Ya  Wang</span>, <span class="hlFld-ContribAuthor ">Zhong-Zhen  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113700. <a href="https://doi.org/10.1016/j.ejmech.2021.113700" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113700</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113700%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Btrimethoxyphenylbenzo%25255Bd%25255Doxazoles%252Bas%252Bdual%252Btubulin%25252FPDE4%252Binhibitors%252Bcapable%252Bof%252Binducing%252Bapoptosis%252Bat%252BG2%25252FM%252Bphase%252Barrest%252Bin%252Bglioma%252Band%252Blung%252Bcancer%252Bcells%26aulast%3Dliu%26aufirst%3DJie%26date%3D2021%26volume%3D224%26spage%3D113700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuhisa  Kamikaseda</span>, <span class="hlFld-ContribAuthor ">Takehito  Uruno</span>, <span class="hlFld-ContribAuthor ">Kazufumi  Kunimura</span>, <span class="hlFld-ContribAuthor ">Akihito  Harada</span>, <span class="hlFld-ContribAuthor ">Kuniko  Saiki</span>, <span class="hlFld-ContribAuthor ">Kounosuke  Oisaki</span>, <span class="hlFld-ContribAuthor ">Daiji  Sakata</span>, <span class="hlFld-ContribAuthor ">Takeshi  Nakahara</span>, <span class="hlFld-ContribAuthor ">Makiko  Kido-Nakahara</span>, <span class="hlFld-ContribAuthor ">Motomu  Kanai</span>, <span class="hlFld-ContribAuthor ">Seiji  Nakamura</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Ohkawa</span>, <span class="hlFld-ContribAuthor ">Masutaka  Furue</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Fukui</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted inhibition of EPAS1-driven IL-31 production by a small-molecule compound. </span><span class="cited-content_cbyCitation_journal-name">Journal of Allergy and Clinical Immunology</span><span> <strong>2021,</strong> <em>148 </em>
                                    (2)
                                     , 633-638. <a href="https://doi.org/10.1016/j.jaci.2021.03.029" title="DOI URL">https://doi.org/10.1016/j.jaci.2021.03.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaci.2021.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaci.2021.03.029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Allergy%2520and%2520Clinical%2520Immunology%26atitle%3DTargeted%252Binhibition%252Bof%252BEPAS1-driven%252BIL-31%252Bproduction%252Bby%252Ba%252Bsmall-molecule%252Bcompound%26aulast%3DKamikaseda%26aufirst%3DYasuhisa%26date%3D2021%26volume%3D148%26issue%3D2%26spage%3D633%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dean  Paes</span>, <span class="hlFld-ContribAuthor ">Melissa  Schepers</span>, <span class="hlFld-ContribAuthor ">Ben  Rombaut</span>, <span class="hlFld-ContribAuthor ">Daniel  van den Hove</span>, <span class="hlFld-ContribAuthor ">Tim  Vanmierlo</span>, <span class="hlFld-ContribAuthor ">Jos  Prickaerts</span>, . </span><span class="cited-content_cbyCitation_article-title">The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (3)
                                     , 1016-1049. <a href="https://doi.org/10.1124/pharmrev.120.000273" title="DOI URL">https://doi.org/10.1124/pharmrev.120.000273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pharmrev.120.000273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpharmrev.120.000273%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DThe%252BMolecular%252BBiology%252Bof%252BPhosphodiesterase%252B4%252BEnzymes%252Bas%252BPharmacological%252BTargets%25253A%252BAn%252BInterplay%252Bof%252BIsoforms%25252C%252BConformational%252BStates%25252C%252Band%252BInhibitors%26aulast%3DPaes%26aufirst%3DDean%26date%3D2021%26date%3D2021%26volume%3D73%26issue%3D3%26spage%3D1016%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">W.  Zhong</span>, <span class="hlFld-ContribAuthor ">N. A.  Darmani</span>. </span><span class="cited-content_cbyCitation_article-title">The HCN Channel Blocker ZD7288 Induces Emesis in the Least Shrew (Cryptotis parva). </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.647021" title="DOI URL">https://doi.org/10.3389/fphar.2021.647021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.647021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.647021%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DThe%252BHCN%252BChannel%252BBlocker%252BZD7288%252BInduces%252BEmesis%252Bin%252Bthe%252BLeast%252BShrew%252B%252528Cryptotis%252Bparva%252529%26aulast%3DZhong%26aufirst%3DW.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ingrid  Allart-Simon</span>, <span class="hlFld-ContribAuthor ">Aurélie  Moniot</span>, <span class="hlFld-ContribAuthor ">Nicolo  Bisi</span>, <span class="hlFld-ContribAuthor ">Miguel  Ponce-Vargas</span>, <span class="hlFld-ContribAuthor ">Sandra  Audonnet</span>, <span class="hlFld-ContribAuthor ">Marie  Laronze-Cochard</span>, <span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Eric  Hénon</span>, <span class="hlFld-ContribAuthor ">Frédéric  Velard</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 584-592. <a href="https://doi.org/10.1039/D0MD00423E" title="DOI URL">https://doi.org/10.1039/D0MD00423E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00423E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00423E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPyridazinone%252Bderivatives%252Bas%252Bpotential%252Banti-inflammatory%252Bagents%25253A%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bas%252BPDE4%252Binhibitors%26aulast%3DAllart-Simon%26aufirst%3DIngrid%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D584%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veronika  Furlan</span>, <span class="hlFld-ContribAuthor ">Urban  Bren</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 479. <a href="https://doi.org/10.3390/biom11030479" title="DOI URL">https://doi.org/10.3390/biom11030479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11030479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11030479%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DInsight%252Binto%252BInhibitory%252BMechanism%252Bof%252BPDE4D%252Bby%252BDietary%252BPolyphenols%252BUsing%252BMolecular%252BDynamics%252BSimulations%252Band%252BFree%252BEnergy%252BCalculations%26aulast%3DFurlan%26aufirst%3DVeronika%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Gabriella  Matera</span>, <span class="hlFld-ContribAuthor ">Josuel  Ora</span>, <span class="hlFld-ContribAuthor ">Francesco  Cavalli</span>, <span class="hlFld-ContribAuthor ">Paola  Rogliani</span>, <span class="hlFld-ContribAuthor ">Mario  Cazzola</span>. </span><span class="cited-content_cbyCitation_article-title">New Avenues for Phosphodiesterase Inhibitors in Asthma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental Pharmacology</span><span> <strong>2021,</strong> <em>Volume 13 </em>, 291-302. <a href="https://doi.org/10.2147/JEP.S242961" title="DOI URL">https://doi.org/10.2147/JEP.S242961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/JEP.S242961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FJEP.S242961%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520Pharmacology%26atitle%3DNew%252BAvenues%252Bfor%252BPhosphodiesterase%252BInhibitors%252Bin%252BAsthma%26aulast%3DMatera%26aufirst%3DMaria%2BGabriella%26date%3D2021%26date%3D2021%26volume%3DVolume%252013%26spage%3D291%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic presentation of PDE4 and cAMP signaling pathway. The following abbreviations are used: β-AR, β-arrestin; GPCRs, G-protein-coupled receptors; Gs, heterotrimeric guanine nucleotide binding protein; AC, adenylyl cyclase; AKAPs, A-kinase-anchoring proteins; PKA, protein kinase A; EPAC, exchange protein activated by cAMP; CREB, cAMP response element binding protein; C3G, cyanidin-3-glucoside; Rap1, Ras-proximate-1; MEK1/2, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase 1/2; NF-κB, nuclear factor κ-light-chain-enhancer of activated B-cells; MAPK, mitogen-activated protein kinase; mTORC1, mammalian target of rapamycin complex 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Domain organization of PDE4. UCR: Upstream conserved region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0023.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Active site of PDE4D2. Dotted lines represent hydrogen bonds. Three inhibitors are shown: compound <b>1</b> (green), compound <b>14</b> (yellow), and compound <b>15</b> (salmon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0025.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of PDE4 inhibitors in clinic trials or in market.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0026.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PDE4 inhibitors in the nervous system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0027.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Active site of PDE4. Dotted lines represent hydrogen bonds. Residues are numbered using the PDE4B2B sequence. (A) Surface presentation on binding of compound <b>1</b> (yellow sticks) to PDE4B (green sticks) and PDE4D (white sticks). P1–P3 and CORE denote four potential pharmacophores of PDE4 inhibitors. (B) Coverage of the PDE4 active site by a UCR2 helix (yellow ribbons). (C) Interaction of compound <b>1</b> with the UCR helix.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0028.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PDE4B/4D subfamily selective inhibitors <b>12</b> and <b>13</b> and binding of <b>12</b> to PDE4B (cyan sticks and ribbons, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G45">3G45</a>) and PDE4D (green sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G58">3G58</a>). Tyr274 of PDE4B (a phenylalanine in PDE4D) from UCR helix determines the subfamily selectivity, while the residues in the active sites show great conservation in both sequence and conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0029.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of catechol ether-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0030.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray crystal structure of PDE4B-compound <b>14</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMY">1XMY</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of compound <b>1</b> analogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. X-ray crystal structure of PDE4. (A) Compound <b>1</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>). (B) Compound <b>24</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XM4">1XM4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic presentation of compound <b>1</b> interaction with PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of quinolone analogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. X-ray crystal structure of compound <b>28</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GWT">3GWT</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Interactions of compounds <b>29</b>–<b>31</b> with PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of PDE4 inhibitors with a fused bicyclic ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0009.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. X-ray crystal structure of <b>39</b> bound to PDE4B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3D3P">3D3P</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0010.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Interactions of compounds <b>38</b>–<b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0011.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of pyrimidine-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0013.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of pyridazinone-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0014.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. X-ray crystal structure of PDE4D2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOR">1XOR</a>) in complex with compound <b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0015.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of methoxy heteroaromatics PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0016.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of triazine-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0017.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Diagram of the interactions between PDE4B and <b>61</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KP6">4KP6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0018.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structures of cyclohexanediamide-based PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0019.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Superposition of PDE4 inhibitors, which are colored with green (compound <b>1</b>), yellow (GEBR20b, <b>11</b>), cyan (compound <b>24</b>), salmon (coumarin), orange (compound <b>46</b>), and pink (naph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0020.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of natural products that inhibit PDE4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0021.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Diagram of the binding of compound <b>71</b> (yellow sticks) PDE4D (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WQA">5WQA</a>). The dotted line represents hydrogen bond. Compound <b>1</b> is shown as green sticks. The binding residues of PDE4D2 are shown as cyan and white sticks, respectively, for the structures of PDE4D-compound <b>71</b> and PDE4D-compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0022.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structures of dual PDE inhibitors <b>72</b>–<b>83</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/medium/jm9b02170_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0024.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structures of dual PDE4 inhibitors <b>84</b>–<b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.9b02170/20201019/images/large/jm9b02170_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02170&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 159 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V. C.</span></span> <span> </span><span class="NLM_article-title">Advances in targeting cyclic nucleotide phosphodiesterases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+targeting+cyclic+nucleotide+phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lhSZNjtgFXUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520targeting%2520cyclic%2520nucleotide%2520phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavo, J.</span></span> <span> </span><span class="NLM_article-title">Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.76.060305.150444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev.biochem.76.060305.150444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17376027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVehtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=481-511&author=M.+Contiauthor=J.+Beavo&title=Biochemistry+and+physiology+of+cyclic+nucleotide+phosphodiesterases%3A+essential+components+in+cyclic+nucleotide+signaling&doi=10.1146%2Fannurev.biochem.76.060305.150444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling</span></div><div class="casAuthors">Conti, Marco; Beavo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">481-511</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Although cyclic nucleotide phosphodiesterases (PDEs) were described soon after the discovery of cAMP, their complexity and functions in signaling is only recently beginning to become fully realized.  We now know that ≥100 different PDE proteins degrade cAMP and cGMP in eukaryotes.  A complex PDE gene organization and a large no. of PDE splicing variants serve to fine-tune cyclic nucleotide signals and contribute to specificity in signaling.  Here we review some of the major concepts related to our understanding of PDE function and regulation including: (1) the structure of catalytic and regulatory domains and arrangement in holoenzymes; (2) PDE integration into signaling complexes; (3) the nature and function of neg. and pos. feedback circuits that have been conserved in PDEs from prokaryotes to human; (4) the emerging assocn. of mutant PDE alleles with inherited diseases; and (5) the role of PDEs in generating subcellular signaling compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJviyUqGyR2rVg90H21EOLACvtfcHk0lhSZNjtgFXUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVehtb%252FE&md5=4808b5e4b29337fab57e623d81a5f0f6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.76.060305.150444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.76.060305.150444%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DM.%26aulast%3DBeavo%26aufirst%3DJ.%26atitle%3DBiochemistry%2520and%2520physiology%2520of%2520cyclic%2520nucleotide%2520phosphodiesterases%253A%2520essential%2520components%2520in%2520cyclic%2520nucleotide%2520signaling%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2007%26volume%3D76%26spage%3D481%26epage%3D511%26doi%3D10.1146%2Fannurev.biochem.76.060305.150444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blount, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, J. D.</span></span> <span> </span><span class="NLM_article-title">Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1152/physrev.00030.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1152%2Fphysrev.00030.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21527734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=651-690&author=S.+H.+Francisauthor=M.+A.+Blountauthor=J.+D.+Corbin&title=Mammalian+cyclic+nucleotide+phosphodiesterases%3A+molecular+mechanisms+and+physiological+functions&doi=10.1152%2Fphysrev.00030.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions</span></div><div class="casAuthors">Francis, Sharron H.; Blount, Mitsi A.; Corbin, Jackie D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">651-690</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11 families of enzymes.  PDEs break down cAMP and/or cGMP and are major determinants of cellular cN levels and, consequently, the actions of cN-signaling pathways.  PDEs exhibit a range of catalytic efficiencies for breakdown of cAMP and/or cGMP and are regulated by myriad processes including phosphorylation, cN binding to allosteric GAF domains, changes in expression levels, interaction with regulatory or anchoring proteins, and reversible translocation among subcellular compartments.  Selective PDE inhibitors are currently in clin. use for treatment of erectile dysfunction, pulmonary hypertension, intermittent claudication, and chronic pulmonary obstructive disease; many new inhibitors are being developed for treatment of these and other maladies.  Recently reported x-ray crystallog. structures have defined features that provide for specificity for cAMP or cGMP in PDE catalytic sites or their GAF domains, as well as mechanisms involved in catalysis, oligomerization, autoinhibition, and interactions with inhibitors.  In addn., major advances have been made in understanding the physiol. impact and the biochem. basis for selective localization and/or recruitment of specific PDE isoenzymes to particular subcellular compartments.  The many recent advances in understanding PDE structures, functions, and physiol. actions are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN99wWYsCXRbVg90H21EOLACvtfcHk0lhSZNjtgFXUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7o%253D&md5=4aae757704a6243c9aa2648c32d5c759</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00030.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00030.2010%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DBlount%26aufirst%3DM.%2BA.%26aulast%3DCorbin%26aufirst%3DJ.%2BD.%26atitle%3DMammalian%2520cyclic%2520nucleotide%2520phosphodiesterases%253A%2520molecular%2520mechanisms%2520and%2520physiological%2520functions%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26spage%3D651%26epage%3D690%26doi%3D10.1152%2Fphysrev.00030.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejeda, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0033-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41573-019-0033-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=31388135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFamtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=770-796&author=G.+S.+Baillieauthor=G.+S.+Tejedaauthor=M.+P.+Kelly&title=Therapeutic+targeting+of+3%E2%80%B2%2C5%E2%80%B2-cyclic+nucleotide+phosphodiesterases%3A+inhibition+and+beyond&doi=10.1038%2Fs41573-019-0033-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond</span></div><div class="casAuthors">Baillie, George S.; Tejeda, Gonzalo S.; Kelly, Michy P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">770-796</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterases (PDEs), enzymes that degrade 3',5'-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metab.  Clin. development programs have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts.  However, emerging evidence supports novel strategies to therapeutically target PDE function, including enhancing catalytic activity, normalizing altered compartmentalization and modulating post-translational modifications, as well as the potential use of PDEs as disease biomarkers.  Importantly, a more refined appreciation of the intramol. mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_NtRRCDdas7Vg90H21EOLACvtfcHk0lgnJSCE9z6q7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFamtLfF&md5=f8a348c9c9e534227d60e4f635d90b25</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0033-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0033-4%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DTejeda%26aufirst%3DG.%2BS.%26aulast%3DKelly%26aufirst%3DM.%2BP.%26atitle%3DTherapeutic%2520targeting%2520of%25203%25E2%2580%25B2%252C5%25E2%2580%25B2-cyclic%2520nucleotide%2520phosphodiesterases%253A%2520inhibition%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D770%26epage%3D796%26doi%3D10.1038%2Fs41573-019-0033-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keravis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugnier, C.</span></span> <span> </span><span class="NLM_article-title">Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01729.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1476-5381.2011.01729.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22014080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1Ohtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1288-1305&author=T.+Keravisauthor=C.+Lugnier&title=Cyclic+nucleotide+phosphodiesterase+%28PDE%29+isozymes+as+targets+of+the+intracellular+signalling+network%3A+benefits+of+PDE+inhibitors+in+various+diseases+and+perspectives+for+future+therapeutic+developments&doi=10.1111%2Fj.1476-5381.2011.01729.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments</span></div><div class="casAuthors">Keravis, Therese; Lugnier, Claire</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1305</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) that specifically inactivate the intracellular messengers cAMP and cGMP in a compartmentalized manner represent an important enzyme class constituted by 11 gene-related families of isoenzymes (PDE1 to PDE11).  Downstream receptors, PDEs play a major role in controlling the signalosome at various levels of phosphorylations and protein/protein interactions.  Due to the multiplicity of isoenzymes, their various intracellular regulations and their different cellular and subcellular distributions, PDEs represent interesting targets in intracellular pathways.  Therefore, the investigation of PDE isoenzyme alterations related to various pathologies and the design of specific PDE inhibitors might lead to the development of new specific therapeutic strategies in numerous pathologies.  This manuscript (i) overviews the different PDEs including their endogenous regulations and their specific inhibitors; (ii) analyses the intracellular implications of PDEs in regulating signalling cascades in pathogenesis, exemplified by two diseases affecting cell cycle and proliferation; and (iii) discusses perspectives for future therapeutic developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvr2jfPTxnY7Vg90H21EOLACvtfcHk0lgnJSCE9z6q7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1Ohtb8%253D&md5=dbf5913bc6c973d0640258c51b7c481d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01729.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01729.x%26sid%3Dliteratum%253Aachs%26aulast%3DKeravis%26aufirst%3DT.%26aulast%3DLugnier%26aufirst%3DC.%26atitle%3DCyclic%2520nucleotide%2520phosphodiesterase%2520%2528PDE%2529%2520isozymes%2520as%2520targets%2520of%2520the%2520intracellular%2520signalling%2520network%253A%2520benefits%2520of%2520PDE%2520inhibitors%2520in%2520various%2520diseases%2520and%2520perspectives%2520for%2520future%2520therapeutic%2520developments%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D1288%26epage%3D1305%26doi%3D10.1111%2Fj.1476-5381.2011.01729.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskandari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirmosayyeb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordbari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andalib, A.</span></span> <span> </span><span class="NLM_article-title">A short review on structure and role of cyclic-3′,5′-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool</span>. <i>J. Res. Pharm. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.4103/2279-042X.167043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.4103%2F2279-042X.167043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26645022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFCit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=175-181&author=N.+Eskandariauthor=O.+Mirmosayyebauthor=G.+Bordbariauthor=R.+Bastanauthor=Z.+Yousefiauthor=A.+Andalib&title=A+short+review+on+structure+and+role+of+cyclic-3%E2%80%B2%2C5%E2%80%B2-adenosine+monophosphate-specific+phosphodiesterase+4+as+a+treatment+tool&doi=10.4103%2F2279-042X.167043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool</span></div><div class="casAuthors">Eskandari, Nahid; Mirmosayyeb, Omid; Bordbari, Gazaleh; Bastan, Reza; Yousefi, Zahra; Andalib, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Research in Pharmacy Practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">JRPPAY</span>;
        ISSN:<span class="NLM_cas:issn">2279-042X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metab. of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are expressed in a variety of cell types that can exert various functions based on their cells distribution.  The PDE4 family has been the focus of vast research efforts over recent years because this family is considered as a prime target for therapeutic intervention in a no. of inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis, and it should be used and researched by pharmacists.  This is because the major isoform of PDE that regulates inflammatory cell activity is the cAMP-specific PDE, PDE4.  This review discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells distribution, and pharmacol. properties of PDE4 which can be informative for all pharmacy specialists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCxdfaenP5UrVg90H21EOLACvtfcHk0ljRvbREthA0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFCit7Y%253D&md5=ab1ac9fb3162e5a24afd2308aae48634</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4103%2F2279-042X.167043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2279-042X.167043%26sid%3Dliteratum%253Aachs%26aulast%3DEskandari%26aufirst%3DN.%26aulast%3DMirmosayyeb%26aufirst%3DO.%26aulast%3DBordbari%26aufirst%3DG.%26aulast%3DBastan%26aufirst%3DR.%26aulast%3DYousefi%26aufirst%3DZ.%26aulast%3DAndalib%26aufirst%3DA.%26atitle%3DA%2520short%2520review%2520on%2520structure%2520and%2520role%2520of%2520cyclic-3%25E2%2580%25B2%252C5%25E2%2580%25B2-adenosine%2520monophosphate-specific%2520phosphodiesterase%25204%2520as%2520a%2520treatment%2520tool%26jtitle%3DJ.%2520Res.%2520Pharm.%2520Pract.%26date%3D2015%26volume%3D4%26spage%3D175%26epage%3D181%26doi%3D10.4103%2F2279-042X.167043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedioune, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandecasteele, G.</span></span> <span> </span><span class="NLM_article-title">Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives</span>. <i>Biol. Aujourd'hui</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1051/jbio/2016019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1051%2Fjbio%2F2016019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27813474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2snjtVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2016&pages=127-138&author=I.+Bediouneauthor=P.+Bobinauthor=S.+Karamauthor=M.+Lindnerauthor=D.+Mikaauthor=P.+Lecheneauthor=J.+Leroyauthor=R.+Fischmeisterauthor=G.+Vandecasteele&title=Cyclic+nucleotide+phosphodiesterases%3A+role+in+the+heart+and+therapeutic+perspectives&doi=10.1051%2Fjbio%2F2016019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives</span></div><div class="casAuthors">Bedioune Ibrahim; Bobin Pierre; Karam Sarah; Lindner Marta; Mika Delphine; Lechene Patrick; Leroy Jerome; Fischmeister Rodolphe; Vandecasteele Gregoire</div><div class="citationInfo"><span class="NLM_cas:title">Biologie aujourd'hui</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">127-138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclic nucleotide phosphodiesterases (PDEs) degrade the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), thereby regulating multiple aspects of cardiac function.  This highly diverse class of enzymes encoded by 21 genes encompasses 11 families that are not only responsible for the termination of cyclic nucleotide signalling, but are also involved in the generation of dynamic microdomains of cAMP and cGMP, controlling specific cell functions in response to various neurohormonal stimuli.  In the myocardium, the PDE3 and PDE4 families predominate, degrading cAMP and thereby regulating cardiac excitation-contraction coupling.  PDE3 inhibitors are positive inotropes and vasodilators in humans, but their use is limited to acute heart failure and intermittent claudication.  PDE5 inhibitors, which are used with success to treat erectile dysfunction and pulmonary hypertension, do not seem efficient in heart failure with preserved ejection fraction.  There is experimental evidence however that these PDE, as well as other PDE families including PDE1, PDE2 and PDE9, may play important roles in cardiac diseases, such as hypertrophy and heart failure (HF).  After a brief presentation of the cyclic nucleotide pathways in cardiac myocytes and the major characteristics of the PDE superfamily, this review will focus on the potential use of PDE inhibitors in HF, and the recent research developments that could lead to a better exploitation of the therapeutic potential of these enzymes in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_ic_eRtYmXJSWdIdmEou5fW6udTcc2eadwjil9bSUTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snjtVWhsQ%253D%253D&md5=d446eb596152c6a7b8a57f894609a06e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1051%2Fjbio%2F2016019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fjbio%252F2016019%26sid%3Dliteratum%253Aachs%26aulast%3DBedioune%26aufirst%3DI.%26aulast%3DBobin%26aufirst%3DP.%26aulast%3DKaram%26aufirst%3DS.%26aulast%3DLindner%26aufirst%3DM.%26aulast%3DMika%26aufirst%3DD.%26aulast%3DLechene%26aufirst%3DP.%26aulast%3DLeroy%26aufirst%3DJ.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DVandecasteele%26aufirst%3DG.%26atitle%3DCyclic%2520nucleotide%2520phosphodiesterases%253A%2520role%2520in%2520the%2520heart%2520and%2520therapeutic%2520perspectives%26jtitle%3DBiol.%2520Aujourd%2527hui%26date%3D2016%26volume%3D210%26spage%3D127%26epage%3D138%26doi%3D10.1051%2Fjbio%2F2016019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of phosphodiesterase as cancer therapeutics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2018.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29574203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=742-756&author=T.+Pengauthor=J.+Gongauthor=Y.+Jinauthor=Y.+Zhouauthor=R.+Tongauthor=X.+Weiauthor=L.+Baiauthor=J.+Shi&title=Inhibitors+of+phosphodiesterase+as+cancer+therapeutics&doi=10.1016%2Fj.ejmech.2018.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphodiesterase as cancer therapeutics</span></div><div class="casAuthors">Peng, Ting; Gong, Jun; Jin, Yongzhe; Zhou, Yanping; Tong, Rongsheng; Wei, Xin; Bai, Lan; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">742-756</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiol. processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function.  PDEs are composed of 11 different families and each family contains different subtypes.  The distribution, expression, regulation mode and sensitivity to inhibitors of each subtype are different, and they are involved in cancer, inflammation, asthma, depression, erectile dysfunction and other pathol. processes of development.  A large no. of studies have shown that PDEs play an important role in the development of tumors by affecting the intracellular level of cAMP and/or cGMP and PDEs could become diagnostic markers or therapeutic targets.  This review will give a brief overview of the expression and regulation of PDE families in the process of tumorigenesis and their anti-tumor inhibitors, which may guide the design of novel therapeutic drugs targeting PDEs for anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrup-LedN_wNbVg90H21EOLACvtfcHk0ljRvbREthA0PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOmsb4%253D&md5=444c1f6a9a183a97749241eb2f00d6b3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520phosphodiesterase%2520as%2520cancer%2520therapeutics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D742%26epage%3D756%26doi%3D10.1016%2Fj.ejmech.2018.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakkas, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanos, D. P.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3054</span>– <span class="NLM_lpage">3067</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170530093902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F0929867324666170530093902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28554321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3054-3067&author=L.+I.+Sakkasauthor=A.+Mavropoulosauthor=D.+P.+Bogdanos&title=Phosphodiesterase+4+inhibitors+in+immune-mediated+diseases%3A+mode+of+action%2C+clinical+applications%2C+current+and+future+perspectives&doi=10.2174%2F0929867324666170530093902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives</span></div><div class="casAuthors">Sakkas, Lazaros I.; Mavropoulos, Athanasios; Bogdanos, Dimitrios P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3054-3067</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3',5'-monophosphate (cAMP), an intracellular second messenger and regulator of a wide array of genes and proteins.  Increased levels of intracellular cAMP lead to activation of genes but also to inhibition of nuclear factor-kappa B, involved in pro-inflammatory responses.  By increasing cAMP levels, PDE4 inhibitors, such as apremilast, reduced prodn. of pro-inflammatory TNFα, IFNγ, and IL-17 and increased prodn. of anti-inflammatory IL-10 in lipopolysaccharide-stimulated peripheral blood mononuclear cells, and in patients with psoriatic arthritis (PsA).  Among PDE4 inhibitors, apremilast, roflumilast, and crisabolore have been approved for the treatment of psoriasis and PsA, chronic obstructive pulmonary disease, and atopic dermatitis, resp.  In a preliminary study on psoriasis and PsA we showed that at 6 mo apremilast decreased IFNγ+CD3+ Th1 cells and IL- 17+CD3+ Th17 cells and increased regulatory B cells and regulatory T cells.  In this review, we highlight recent findings of PDE4 inhibitors in atopic dermatitis, alopecia areata, uveitis, rheumatoid arthritis, psoriasis and PsA, systemic lupus erythematosus, vasculitis, systemic sclerosis, multiple sclerosis and inflammatory bowel disease.  Given the role of cAMP as second messenger in diverse intracellular pathways, selective PDE4 inhibitors are likely to be therapeutic agents for various immune mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFv8w8tY8frVg90H21EOLACvtfcHk0lgj4PZZLD5IgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqsr%252FP&md5=d90a39f964094c186a4b4563e30df457</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170530093902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170530093902%26sid%3Dliteratum%253Aachs%26aulast%3DSakkas%26aufirst%3DL.%2BI.%26aulast%3DMavropoulos%26aufirst%3DA.%26aulast%3DBogdanos%26aufirst%3DD.%2BP.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520in%2520immune-mediated%2520diseases%253A%2520mode%2520of%2520action%252C%2520clinical%2520applications%252C%2520current%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3054%26epage%3D3067%26doi%3D10.2174%2F0929867324666170530093902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-T.</span></span> <span> </span><span class="NLM_article-title">The past, present, and future of phosphodiesterase-4 modulation for age-induced memory loss</span>. <i>Advances in neurobiology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-58811-7_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2F978-3-319-58811-7_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28956333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FjtFCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=169-199&author=R.+T.+Hansenauthor=H.-T.+Zhang&title=The+past%2C+present%2C+and+future+of+phosphodiesterase-4+modulation+for+age-induced+memory+loss&doi=10.1007%2F978-3-319-58811-7_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss</span></div><div class="casAuthors">Hansen Rolf T 3rd; Zhang Han-Ting; Zhang Han-Ting; Zhang Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Advances in neurobiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-199</span>
        ISSN:<span class="NLM_cas:issn">2190-5215</span>.
    </div><div class="casAbstract">The purpose of this chapter is to highlight the state of progress for phosphodiesterase-4 (PDE4) modulation as a potential therapeutic for psychiatric illness, and to draw attention to particular hurdles and obstacles that must be overcome in future studies to develop PDE4-mediated therapeutics.  Pathological and non-pathological related memory loss will be the focus of the chapter; however, we will at times also touch upon other psychiatric illnesses like anxiety and depression.  First, we will provide a brief background of PDE4, and the rationale for its extensive study in cognition.  Second, we will explore fundamental differences in individual PDE4 subtypes, and then begin to address differences between pathological and non-pathological aging.  Alterations of cAMP/PDE4 signaling that occur within normal vs. pathological aging, and the potential for PDE4 modulation to combat these alterations within each context will be described.  Finally, we will finish the chapter with obstacles that have hindered the field, and future studies and alternative viewpoints that need to be addressed.  Overall, we hope this chapter will demonstrate the incredible complexity of PDE4 signaling in the brain, and will be useful in forming a strategy to develop future PDE4-mediated therapeutics for psychiatric illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2D_asoAw2RbesJRIHUP1ofW6udTcc2eaehgOCFXlTk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FjtFCisA%253D%253D&md5=c9eca8fd9d29c81f1775e907c8989b7b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-58811-7_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-58811-7_7%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DH.-T.%26atitle%3DThe%2520past%252C%2520present%252C%2520and%2520future%2520of%2520phosphodiesterase-4%2520modulation%2520for%2520age-induced%2520memory%2520loss%26jtitle%3DAdvances%2520in%2520neurobiology%26date%3D2017%26volume%3D17%26spage%3D169%26epage%3D199%26doi%3D10.1007%2F978-3-319-58811-7_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaeli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, K.</span></span> <span> </span><span class="NLM_article-title">A family of human phosphodiesterases homologous to the dunce learning and memory gene product of drosophila melanogaster are potential targets for antidepressant drugs</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">6558</span>– <span class="NLM_lpage">6571</span>, <span class="refDoi"> DOI: 10.1128/MCB.13.10.6558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1128%2FMCB.13.10.6558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=8413254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2cXisVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1993&pages=6558-6571&author=G.+Bolgerauthor=T.+Michaeliauthor=T.+Martinsauthor=T.+St+Johnauthor=B.+Steinerauthor=L.+Rodgersauthor=M.+Riggsauthor=M.+Wiglerauthor=K.+Ferguson&title=A+family+of+human+phosphodiesterases+homologous+to+the+dunce+learning+and+memory+gene+product+of+drosophila+melanogaster+are+potential+targets+for+antidepressant+drugs&doi=10.1128%2FMCB.13.10.6558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A family of human phosphodiesterases homologs to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs</span></div><div class="casAuthors">Bolger, Graeme; Michaeli, Tamar; Martins, Tim; St. John, Tom; Steiner, Bart; Rodgers, Linda; Riggs, Michael; Wigler, Michael; Ferguson, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6558-71</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors have isolated cDNAs for four human genes (DPDE1 through DPDE4) closely related to the dnc learning and memory locus of Drosophila melanogaster.  The deduced amino acid sequences of the Drosophila and human proteins have considerable homol., extending beyond the putative catalytic region to include two novel, highly conserved, upstream conserved regions (UCR1 and UCR2).  The upstream conserved regions are located in the amino-terminal regions of the proteins and appear to be unique to these genes.  Polymerase chain reaction anal. suggested that these genes encoded the only homologs of dnc in the human genome.  Three of the four genes were expressed in Saccharomyces cerevisiae and shown to encode cAMP-specific phosphodiesterases.  The products of the expressed genes displayed the pattern of sensitivity to inhibitors expected for members of the type IV, cAMP-specific class of phosphodiesterases.  Each of the four genes demonstrated a distinctive pattern of expression in RNA from human cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28TV_dJO357Vg90H21EOLACvtfcHk0lgj4PZZLD5IgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXisVKhuw%253D%253D&md5=13f0f15fb33cedee41d113788013c744</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.13.10.6558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.13.10.6558%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DMichaeli%26aufirst%3DT.%26aulast%3DMartins%26aufirst%3DT.%26aulast%3DSt%2BJohn%26aufirst%3DT.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DRodgers%26aufirst%3DL.%26aulast%3DRiggs%26aufirst%3DM.%26aulast%3DWigler%26aufirst%3DM.%26aulast%3DFerguson%26aufirst%3DK.%26atitle%3DA%2520family%2520of%2520human%2520phosphodiesterases%2520homologous%2520to%2520the%2520dunce%2520learning%2520and%2520memory%2520gene%2520product%2520of%2520drosophila%2520melanogaster%2520are%2520potential%2520targets%2520for%2520antidepressant%2520drugs%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1993%26volume%3D13%26spage%3D6558%26epage%3D6571%26doi%3D10.1128%2FMCB.13.10.6558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizizad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lh9UcdrwwK-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span> <span> </span><span class="NLM_article-title">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1825</span>, <span class="refDoi"> DOI: 10.1126/science.288.5472.1822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1126%2Fscience.288.5472.1822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10846163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2000&pages=1822-1825&author=R.+X.+Xuauthor=A.+M.+Hassellauthor=D.+Vanderwallauthor=M.+H.+Lambertauthor=W.+D.+Holmesauthor=M.+A.+Lutherauthor=W.+J.+Rocqueauthor=M.+V.+Milburnauthor=Y.+Zhaoauthor=H.+Keauthor=R.+T.+Nolte&title=Atomic+structure+of+PDE4%3A+insights+into+phosphodiesterase+mechanism+and+specificity&doi=10.1126%2Fscience.288.5472.1822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity</span></div><div class="casAuthors">Xu, Robert X.; Hassell, Anne M.; Vanderwall, Dana; Lambert, Millard H.; Holmes, William D.; Luther, Michael A.; Rocque, Warren J.; Milburn, Michael V.; Zhao, Yingdong; Ke, Hengming; Nolte, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">5472</span>),
    <span class="NLM_cas:pages">1822-1825</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclic nucleotides are second messengers that are essential in vision, muscle contraction, neurotransmission, exocytosis, cell growth, and differentiation.  These mols. are degraded by a family of enzymes known as phosphodiesterases, which serve a crit. function by regulating the intracellular concn. of cyclic nucleotides.  We have detd. the three-dimensional structure of the catalytic domain of phosphodiesterase 4B2B to 1.77 angstrom resoln.  The active site has been identified and contains a cluster of two metal atoms.  The structure suggests the mechanism of action and basis for specificity and will provide a framework for structure-assisted drug design for members of the phosphodiesterase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjHOVmP5GzU7Vg90H21EOLACvtfcHk0lh9UcdrwwK-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFCisbY%253D&md5=4f7e42a9f7a6a0763a9dcc064ad903c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.288.5472.1822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.288.5472.1822%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%2BX.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DLuther%26aufirst%3DM.%2BA.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DAtomic%2520structure%2520of%2520PDE4%253A%2520insights%2520into%2520phosphodiesterase%2520mechanism%2520and%2520specificity%26jtitle%3DScience%26date%3D2000%26volume%3D288%26spage%3D1822%26epage%3D1825%26doi%3D10.1126%2Fscience.288.5472.1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehats, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span> <span> </span><span class="NLM_article-title">Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">5493</span>– <span class="NLM_lpage">5496</span>, <span class="refDoi"> DOI: 10.1074/jbc.R200029200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1074%2Fjbc.R200029200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12493749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1aqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=5493-5496&author=M.+Contiauthor=W.+Richterauthor=C.+Mehatsauthor=G.+Liveraauthor=J.-Y.+Parkauthor=C.+Jin&title=Cyclic+AMP-specific+PDE4+phosphodiesterases+as+critical+components+of+cyclic+AMP+signaling&doi=10.1074%2Fjbc.R200029200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling</span></div><div class="casAuthors">Conti, Marco; Richter, Wito; Mehats, Celine; Livera, Gabriel; Park, Jy-Young; Jin, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5493-5496</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review describes the phosphodiesterase 4 (PDE4) family of enzyme and their role in desensitization, feedback regulation, and signal compartmentalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71Pdc9TcAn7Vg90H21EOLACvtfcHk0lgrG73UW9znxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1aqsr4%253D&md5=88d768d8c99e85e9aa4e4d2c2a28bf03</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R200029200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R200029200%26sid%3Dliteratum%253Aachs%26aulast%3DConti%26aufirst%3DM.%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DMehats%26aufirst%3DC.%26aulast%3DLivera%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DJ.-Y.%26aulast%3DJin%26aufirst%3DC.%26atitle%3DCyclic%2520AMP-specific%2520PDE4%2520phosphodiesterases%2520as%2520critical%2520components%2520of%2520cyclic%2520AMP%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D5493%26epage%3D5496%26doi%3D10.1074%2Fjbc.R200029200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodge, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouangsathiene, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiloff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langeberg, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span> <span> </span><span class="NLM_article-title">MAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1921</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1093/emboj/20.8.1921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1093%2Femboj%2F20.8.1921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=11296225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt12qtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=1921-1930&author=K.+L.+Dodgeauthor=S.+Khouangsathieneauthor=M.+S.+Kapiloffauthor=R.+Moutonauthor=E.+V.+Hillauthor=M.+D.+Houslayauthor=L.+K.+Langebergauthor=J.+D.+Scott&title=MAKAP+assembles+a+protein+kinase+A%2FPDE4+phosphodiesterase+cAMP+signaling+module&doi=10.1093%2Femboj%2F20.8.1921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module</span></div><div class="casAuthors">Dodge, Kimberly L.; Khouangsathiene, Samone; Kapiloff, Michael S.; Mouton, Robert; Hill, Elaine V.; Houslay, Miles D.; Langeberg, Lorene K.; Scott, John D.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1921-1930</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Spatiotemporal regulation of protein kinase A (PKA) activity involves the manipulation of compartmentalized cAMP pools.  Now we demonstrate that the muscle-selective A-kinase anchoring protein, mAKAP, maintains a cAMP signaling module, including PKA and the rolipram-inhibited cAMP-specific phosphodiesterase (PDE4D3) in heart tissues.  Functional analyses indicate that tonic PDE4D3 activity reduces the activity of the anchored PKA holoenzyme, whereas kinase activation stimulates mAKAP-assocd. phosphodiesterase activity.  Disruption of PKA-mAKAP interaction prevents this enhancement of PDE4D3 activity, suggesting that the proximity of both enzymes in the mAKAP signaling complex forms a neg. feedback loop to restore basal cAMP levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFLD3q3jyYPLVg90H21EOLACvtfcHk0lhR619sXmz_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt12qtLY%253D&md5=4864eddded27f8ec57dae34df44bea66</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F20.8.1921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F20.8.1921%26sid%3Dliteratum%253Aachs%26aulast%3DDodge%26aufirst%3DK.%2BL.%26aulast%3DKhouangsathiene%26aufirst%3DS.%26aulast%3DKapiloff%26aufirst%3DM.%2BS.%26aulast%3DMouton%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DE.%2BV.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DLangeberg%26aufirst%3DL.%2BK.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26atitle%3DMAKAP%2520assembles%2520a%2520protein%2520kinase%2520A%252FPDE4%2520phosphodiesterase%2520cAMP%2520signaling%2520module%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D1921%26epage%3D1930%26doi%3D10.1093%2Femboj%2F20.8.1921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taskén, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witczak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taskén, K.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">21999</span>– <span class="NLM_lpage">22002</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000911200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1074%2Fjbc.C000911200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=11285255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVant78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=21999-22002&author=K.+A.+Task%C3%A9nauthor=P.+Collasauthor=W.+A.+Kemmnerauthor=O.+Witczakauthor=M.+Contiauthor=K.+Task%C3%A9n&title=Phosphodiesterase+4D+and+protein+kinase+a+type+II+constitute+a+signaling+unit+in+the+centrosomal+area&doi=10.1074%2Fjbc.C000911200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the centrosomal area</span></div><div class="casAuthors">Tasken, Kristin A.; Collas, Philippe; Kemmner, Wolfram A.; Witczak, Oliwia; Conti, Marco; Tasken, Kjetil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">21999-22002</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mediation of cAMP effects by specific pools of protein kinase A (PKA) targeted to distinct subcellular domains raises the question of how inactivation of the cAMP signal is achieved locally and whether similar targeting of phosphodiesterases (PDEs) to sites of cAMP/PKA action could be obsd.  Here, we demonstrate that Sertoli cells of the testis contain an insol. PDE4D3 isoform, which is shown by immunofluorescence to target to centrosomes.  Staining of PDE4D and PKA shows co-localization of PDE4D with PKA-RIIα and RIIβ in the centrosomal region.  Co-pptn. of RII subunits and PDE4D3 from cytoskeletal exts. indicates a phys. assocn. of the two proteins.  Distribution of PDE4D overlaps with that of the centrosomal PKA-anchoring protein, AKAP450, and AKAP450, PDE4D3, and PKA-RIIα co-immunoppt.  Finally, both PDE4D3 and PKA co-ppt. with a sol. fragment of AKAP450 encompassing amino acids 1710 to 2872 when co-expressed in 293T cells.  Thus, a centrosomal complex that includes PDE4D and PKA constitutes a novel signaling unit that may provide accurate spatiotemporal modulation of cAMP signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE1-3CERIugLVg90H21EOLACvtfcHk0lhR619sXmz_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVant78%253D&md5=1f436e321c98f10975e2aaace3e0b23e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000911200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000911200%26sid%3Dliteratum%253Aachs%26aulast%3DTask%25C3%25A9n%26aufirst%3DK.%2BA.%26aulast%3DCollas%26aufirst%3DP.%26aulast%3DKemmner%26aufirst%3DW.%2BA.%26aulast%3DWitczak%26aufirst%3DO.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DTask%25C3%25A9n%26aufirst%3DK.%26atitle%3DPhosphodiesterase%25204D%2520and%2520protein%2520kinase%2520a%2520type%2520II%2520constitute%2520a%2520signaling%2520unit%2520in%2520the%2520centrosomal%2520area%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D21999%26epage%3D22002%26doi%3D10.1074%2Fjbc.C000911200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span> <span> </span><span class="NLM_article-title">Enhancing cAMP levels as strategy for the treatment of neuropsychiatric disorders</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3527</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160426151306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F1568026616666160426151306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27112214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKks7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3527-3535&author=A.+M.+Garciaauthor=A.+Martinezauthor=C.+Gil&title=Enhancing+cAMP+levels+as+strategy+for+the+treatment+of+neuropsychiatric+disorders&doi=10.2174%2F1568026616666160426151306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders</span></div><div class="casAuthors">Garcia, Ana M.; Martinez, Ana; Gil, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3527-3535</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) have gained attention as potential pharmacol. targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP.  It is well-known the relationship between cAMP signaling and inflammation.  Since neuroinflammation is considered to play an important role in the pathol. of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies.  PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia.  Enhancing the intracellular concn. of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcq3O7Tqq77LVg90H21EOLACvtfcHk0lhR619sXmz_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKks7fE&md5=7cfb8681f09b981406f77f07ae9cb9e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160426151306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160426151306%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGil%26aufirst%3DC.%26atitle%3DEnhancing%2520cAMP%2520levels%2520as%2520strategy%2520for%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D3527%26epage%3D3535%26doi%3D10.2174%2F1568026616666160426151306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span> <span> </span><span class="NLM_article-title">PDE4-mediated cAMP signalling</span>. <i>J. Cardiovasc. Dev. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.3390/jcdd5010008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3390%2Fjcdd5010008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=8&author=B.+A.+Fertigauthor=G.+S.+Baillie&title=PDE4-mediated+cAMP+signalling&doi=10.3390%2Fjcdd5010008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4-mediated cAMP signalling</span></div><div class="casAuthors">Fertig, Bracy A.; Baillie, George S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Development and Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8/1-8/14</span>CODEN:
                <span class="NLM_cas:coden">JCDDB4</span>;
        ISSN:<span class="NLM_cas:issn">2308-3425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  CAMP is the archetypal and ubiquitous second messenger utilized for the fine control of many cardiovascular cell signalling systems.  The ability of cAMP to elicit cell surface receptor-specific responses relies on its compartmentalisation by cAMP hydrolyzing enzymes known as phosphodiesterases.  One family of these enzymes, PDE4, is particularly important in the cardiovascular system, where it has been extensively studied and shown to orchestrate complex, localised signalling that underpins many crucial functions of the heart.  In the cardiac myocyte, cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins that drive β-adrenergic enhancement of cardiac function.  The phosphorylation of these substrates, many of which are involved in cardiac excitation-contraction coupling, has been shown to be tightly regulated by highly localised pools of individual PDE4 isoforms.  The spatial and temporal regulation of cardiac signalling is made possible by the formation of macromol. "signalosomes", which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such as an AKAP.  Studies described in the present review highlight the importance of this relationship for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm is coordinated to promote efficient adrenergic enhancement of cardiac function.  The role of PDE4 also extends to the vascular endothelium, where it regulates vascular permeability and barrier function.  In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.  These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.  PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of the compds. which concomitantly attenuate PDE activity in all highly localised "signalosomes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1GQOAKh0NLVg90H21EOLACvtfcHk0lhgoEYgXptTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D&md5=55ab00b9daa0cd96454807732bd5f4bc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3390%2Fjcdd5010008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcdd5010008%26sid%3Dliteratum%253Aachs%26aulast%3DFertig%26aufirst%3DB.%2BA.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26atitle%3DPDE4-mediated%2520cAMP%2520signalling%26jtitle%3DJ.%2520Cardiovasc.%2520Dev.%2520Dis.%26date%3D2018%26volume%3D5%26spage%3D8%26doi%3D10.3390%2Fjcdd5010008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, S.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders</span>. <i>Obes. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1111/obr.12385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fobr.12385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26997580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlajsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=429-441&author=C.+Wuauthor=S.+Rajagopalan&title=Phosphodiesterase-4+inhibition+as+a+therapeutic+strategy+for+metabolic+disorders&doi=10.1111%2Fobr.12385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders</span></div><div class="casAuthors">Wu, C.; Rajagopalan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">ORBEBL</span>;
        ISSN:<span class="NLM_cas:issn">1467-7881</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Phosphodiesterase-4 (PDE4) hydrolyzes cyclic adenosine monophosphate (cAMP), a crucial secondary messenger for cellular adaptation to diverse external stimuli.  The activity of PDE4 is tightly controlled by post-translational regulation, structure-based auto-regulation and locus specific 'compartmentalization' of PDE4 with its interactive proteins (signalsomes).  Through these mechanisms, PDE4 regulates cAMP levels and shapes the cAMP signalling, directing signals from the diverse external stimuli to distinct microenvironments exquisitely.  Derangement of the PDE4-cAMP signalling represents a pathophysiol. relevant pathway in metabolic disorders as demonstrated through a crit. role in the processes including inflammation, disordered glucose and lipid metab., hepatic steatosis, abnormal lipolysis, suppressed thermogenic function and deranged neuroendocrine functions.  A limited no. of PDE4 inhibitors are currently undergoing clin. evaluation for treating disorders such as type 2 diabetes and non-alc. steatohepatitis.  The discovery of novel PDE4 allosteric inhibitors and signalsome-based strategies targeting individual PDE4 variants may allow PDE4 isoform selective inhibition, which may offer safer strategies for chronic treatment of metabolic disorders. © 2016 World Obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2lSfJbeCxqrVg90H21EOLACvtfcHk0lhgoEYgXptTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlajsro%253D&md5=65c0ed8a5e3986a944965471784e783d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fobr.12385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fobr.12385%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DRajagopalan%26aufirst%3DS.%26atitle%3DPhosphodiesterase-4%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520metabolic%2520disorders%26jtitle%3DObes.%2520Rev.%26date%3D2016%26volume%3D17%26spage%3D429%26epage%3D441%26doi%3D10.1111%2Fobr.12385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohleth, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M. M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1124/mol.56.1.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fmol.56.1.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10385698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK1MXksFOmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=170-174&author=P.+Wangauthor=P.+Wuauthor=K.+M.+Ohlethauthor=R.+W.+Eganauthor=M.+M.+Billah&title=Phosphodiesterase+4B2+is+the+predominant+phosphodiesterase+species+and+undergoes+differential+regulation+of+gene+expression+in+human+monocytes+and+neutrophils&doi=10.1124%2Fmol.56.1.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils</span></div><div class="casAuthors">Wang, Peng; Wu, Ping; Ohleth, Kathleen M.; Egan, Robert W.; Billah, M. Motasim</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-174</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The type 4 phosphodiesterase (PDE4) is the predominant PDE isoenzyme in various leukocytes and plays a key role in the regulation of inflammatory cell activation.  There are four PDE4 subtypes (A, B, C, and D), and within each subtype, there are multiple variants.  Very recently, we found in monocytes that PDE4B gene expression is selectively induced by lipopolysaccharide (LPS) and that the induction is inhibited by interleukin (IL)-10 and IL-4.  In this study, we show that the PDE4B gene is constitutively expressed in neutrophils and that this expression remains unaffected by LPS or IL-10.  PDE4B is the predominant subtype in neutrophils and in unstimulated or LPS-stimulated monocytes, and in these cells, the PDE4B2 variant is the only detectable mol. species of PDE4B.  Therefore, PDE4B2 is the predominant PDE isoform in human neutrophils and monocytes, and its expression is regulated differently by these two cell types.  Furthermore, leukocytes are the most dominant source of PDE4B2, suggesting that PDE4B2 is a relatively specific target for discovering anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgA6N-zJ8JLVg90H21EOLACvtfcHk0lhgoEYgXptTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFOmtL8%253D&md5=74202f0ab3597b875560871df18f320b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fmol.56.1.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.56.1.170%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DOhleth%26aufirst%3DK.%2BM.%26aulast%3DEgan%26aufirst%3DR.%2BW.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26atitle%3DPhosphodiesterase%25204B2%2520is%2520the%2520predominant%2520phosphodiesterase%2520species%2520and%2520undergoes%2520differential%2520regulation%2520of%2520gene%2520expression%2520in%2520human%2520monocytes%2520and%2520neutrophils%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D170%26epage%3D174%26doi%3D10.1124%2Fmol.56.1.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+C.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF-%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lhgoEYgXptTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%2BC.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF-%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2004.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pupt.2004.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15649851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1SrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=93-101&author=N.+A.+Jonesauthor=V.+Boswell-Smithauthor=R.+Leverauthor=C.+P.+Page&title=The+effect+of+selective+phosphodiesterase+isoenzyme+inhibition+on+neutrophil+function+in+vitro&doi=10.1016%2Fj.pupt.2004.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro</span></div><div class="casAuthors">Jones, N. A.; Boswell-Smith, V.; Lever, R.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-101</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neutrophil-derived proteases such as neutrophil elastase (NE) and matrix metalloproteinase (MMP) are implicated in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD).  In this study, the effects of selective phosphodiesterase (PDE) inhibition on NE and MMP-9 release, as well as Myeloperoxidase (MPO) activity and integrin-mediated neutrophil adhesion to human umbilical vein endothelial cells (HUVECs), were investigated.  Human neutrophils were treated with PDE inhibitors (10-11-10-4 M) in the absence and presence of TNF-α (tumor necrosis factor) (100 U ml-1) for 30 min, prior to fMLP activation.  After 45 min, the cells were removed and NE, MPO and MMP-9 release assessed.  In the adhesion studies, the neutrophils were radio-labeled with 51Cr, stimulated and immediately transferred to cultured HUVEC monolayers for 30 min, prior to assessment of adhesion.  TNF-α (100 U ml-1) acted synergistically with fMLP in stimulating azurophil degranulation with respect to both MPO activity (P<0.01) and NE release (P<0.01).  In contrast, an additive effect was obsd. with TNF-α and fMLP with regard to MMP-9 release and neutrophil adhesion to HUVECs.  The PDE4 inhibitors, roflumilast, roflumilast N-oxide, cilomilast and rolipram significantly suppressed MPO, NE and MMP-9 release in both the presence and absence of TNF-α (P<0.05; n=6-10) and also reduced neutrophil adhesion to HUVECs.  In contrast, milrinone, a PDE3 inhibitor and the non-selective PDE inhibitor, theophylline did not inhibit azurophil degranulation under any of the exptl. conditions.  These data provide further evidence that selective PDE4 isoenzyme inhibitors can inhibit neutrophil degranulation, effects not shared by PDE3 inhibitors or theophylline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRjWtdb7D1bVg90H21EOLACvtfcHk0lhMS4HN53206A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1SrsQ%253D%253D&md5=b54814cb40a476705cfc9840f834eecd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2004.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2004.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DN.%2BA.%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DLever%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DThe%2520effect%2520of%2520selective%2520phosphodiesterase%2520isoenzyme%2520inhibition%2520on%2520neutrophil%2520function%2520in%2520vitro%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D18%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.pupt.2004.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daguès, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borde, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freslon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, S.</span></span> <span> </span><span class="NLM_article-title">Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1093%2Ftoxsci%2Fkfm161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17569694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKlsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=238-247&author=N.+Dagu%C3%A8sauthor=V.+Pawlowskiauthor=C.+Sobryauthor=G.+Hantonauthor=F.+Bordeauthor=S.+Solerauthor=J.+L.+Freslonauthor=S.+Chevalier&title=Investigation+of+the+molecular+mechanisms+preceding+PDE4+inhibitor-induced+vasculopathy+in+rats%3A+tissue+inhibitor+of+metalloproteinase+1%2C+a+potential+predictive+biomarker&doi=10.1093%2Ftoxsci%2Fkfm161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the Molecular Mechanisms Preceding PDE4 Inhibitor-Induced Vasculopathy in Rats: Tissue Inhibitor of Metalloproteinase 1, a Potential Predictive Biomarker</span></div><div class="casAuthors">Dagues, Nicolas; Pawlowski, Valerie; Sobry, Cecile; Hanton, Gilles; Borde, Francoise; Soler, Sylvain; Freslon, Jean-Louis; Chevalier, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-247</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 inhibitors are a class of drugs that can provide novel therapies for asthma and chronic obstructive pulmonary disease.  Their development is frequently hampered by the induction of vascular toxicity in rat mesenteric tissue during preclin. studies.  Whereas these vascular lesions in rats have been well characterized histol., little is known about their pathogenesis and in turn, sensitive and specific biomarkers for preclin. and clin. monitoring do not exist.  In order to investigate the early mol. mechanisms underlying vascular injury, time-course studies were performed by treating rats for 2-24 h with high doses of the PDE4 inhibitor CI-1044.  Transcriptomics analyses in mesenteric tissue were performed using oligonucleotide microarray and real-time RT-PCR technologies and compared to histopathol. observations.  In addn., protein measurements were performed in serum samples to identify sol. biomarkers of vascular injury.  Our results indicate that mol. alterations preceded the histol. observations of inflammatory and necrotic lesions in mesenteric arteries.  Some gene expression changes suggest that the development of the lesions could follow a primary modulation of the vascular tone in response to the pharmacol. effect of the compd.  Activation of genes coding for pro- and antioxidant enzymes, cytokines, adhesion mols., and tissue inhibitor of metalloproteinase 1 (TIMP-1) indicates that biomech. stimuli may contribute to vascular oxidant stress, inflammation, and tissue remodeling.  TIMP-1 appeared to be an early and sensitive predictive biomarker of the inflammatory and the tissue remodeling components of PDE4 inhibitor-induced vascular injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobr4z5O8AVKbVg90H21EOLACvtfcHk0lhMS4HN53206A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKlsLvJ&md5=e4450eb1e94698a6ea096f6a6b6be772</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm161%26sid%3Dliteratum%253Aachs%26aulast%3DDagu%25C3%25A8s%26aufirst%3DN.%26aulast%3DPawlowski%26aufirst%3DV.%26aulast%3DSobry%26aufirst%3DC.%26aulast%3DHanton%26aufirst%3DG.%26aulast%3DBorde%26aufirst%3DF.%26aulast%3DSoler%26aufirst%3DS.%26aulast%3DFreslon%26aufirst%3DJ.%2BL.%26aulast%3DChevalier%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520molecular%2520mechanisms%2520preceding%2520PDE4%2520inhibitor-induced%2520vasculopathy%2520in%2520rats%253A%2520tissue%2520inhibitor%2520of%2520metalloproteinase%25201%252C%2520a%2520potential%2520predictive%2520biomarker%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D100%26spage%3D238%26epage%3D247%26doi%3D10.1093%2Ftoxsci%2Fkfm161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puxeddu, E.</span></span> <span> </span><span class="NLM_article-title">Dual bronchodilation and exacerbations of COPD</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2386</span>, <span class="refDoi"> DOI: 10.21037/jtd.2016.08.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.21037%2Fjtd.2016.08.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27746982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2srhtVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2383-2386&author=M.+Cazzolaauthor=J.+Oraauthor=E.+Puxeddu&title=Dual+bronchodilation+and+exacerbations+of+COPD&doi=10.21037%2Fjtd.2016.08.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation and exacerbations of COPD</span></div><div class="casAuthors">Cazzola Mario; Ora Josuel; Puxeddu Ermanno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2383-2386</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-6mjBZyHPbq2q3xNe7a7QfW6udTcc2ebVJcKoUByhyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhtVajsA%253D%253D&md5=0435716edd2b2f4323671c0dad9d6e8f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2016.08.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2016.08.92%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DPuxeddu%26aufirst%3DE.%26atitle%3DDual%2520bronchodilation%2520and%2520exacerbations%2520of%2520COPD%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2016%26volume%3D8%26spage%3D2383%26epage%3D2386%26doi%3D10.21037%2Fjtd.2016.08.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzel, P.</span></span> <span> </span><span class="NLM_article-title">Crisaborole 2% ointment (eucrisa) for atopic dermatitis</span>. <i>Skin Ther. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30970204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjvFKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4-6&author=T.+E.+Wooauthor=P.+Kuzel&title=Crisaborole+2%25+ointment+%28eucrisa%29+for+atopic+dermatitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis</span></div><div class="casAuthors">Woo Taylor Evart; Kuzel Paul</div><div class="citationInfo"><span class="NLM_cas:title">Skin therapy letter</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">4-6</span>
        ISSN:<span class="NLM_cas:issn">1201-5989</span>.
    </div><div class="casAbstract">Atopic dermatitis is a common cutaneous disease with significant morbidity affecting children and adults.  The mainstay of atopic dermatitis therapy has typically included emollients, topical corticosteroids, and topical calcineurin inhibitors.  Among the newer advances recently introduced is crisaborole (Eucrisa®), a phosphodiesterase type-4 inhibitor (PDE-4) for the treatment of mild moderate atopic dermatitis.  Evidence from phase 3 trials demonstrates crisaborole as an efficacious topical agent with a favorable safety profile and limited systemic exposure.  While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfD9bI0ZsheM-crCu0nI_sfW6udTcc2eahAVcewCZtTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjvFKjsw%253D%253D&md5=21997509bd7fbabc5e68ab0f707d2324</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DT.%2BE.%26aulast%3DKuzel%26aufirst%3DP.%26atitle%3DCrisaborole%25202%2525%2520ointment%2520%2528eucrisa%2529%2520for%2520atopic%2520dermatitis%26jtitle%3DSkin%2520Ther.%2520Lett.%26date%3D2019%26volume%3D24%26spage%3D4%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerdel, F.</span></span> <span> </span><span class="NLM_article-title">Apremilast and psoriasis in the real world: a retrospective case series</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaad.2019.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=31604095" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=L.+Dozierauthor=G.+Bartosauthor=F.+Kerdel&title=Apremilast+and+psoriasis+in+the+real+world%3A+a+retrospective+case+series&doi=10.1016%2Fj.jaad.2019.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DDozier%26aufirst%3DL.%26aulast%3DBartos%26aufirst%3DG.%26aulast%3DKerdel%26aufirst%3DF.%26atitle%3DApremilast%2520and%2520psoriasis%2520in%2520the%2520real%2520world%253A%2520a%2520retrospective%2520case%2520series%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2019%26doi%3D10.1016%2Fj.jaad.2019.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rolan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span> <span> </span><span class="NLM_article-title">Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2904</span>, <span class="refDoi"> DOI: 10.1517/14656560903426189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1517%2F14656560903426189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=19929708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyjur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=2897-2904&author=P.+Rolanauthor=M.+Hutchinsonauthor=K.+Johnson&title=Ibudilast%3A+a+review+of+its+pharmacology%2C+efficacy+and+safety+in+respiratory+and+neurological+disease&doi=10.1517%2F14656560903426189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease</span></div><div class="casAuthors">Rolan, P.; Hutchinson, Mr; Johnson, Kw</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2897-2904</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma.  More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in the CNS via glial cell attenuation.  This CNS-directed anti-inflammatory activity is of potential use in the treatment of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by decreasing opioid tolerance, withdrawal and reinforcement.  Its suitable pharmacokinetics and generally good tolerability make it a promising potential treatment for these conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9-2fWYWu4bVg90H21EOLACvtfcHk0li-1lt0ExLd5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyjur%252FF&md5=321ef42e8f433e908780f8c19f7f1579</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F14656560903426189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903426189%26sid%3Dliteratum%253Aachs%26aulast%3DRolan%26aufirst%3DP.%26aulast%3DHutchinson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DK.%26atitle%3DIbudilast%253A%2520a%2520review%2520of%2520its%2520pharmacology%252C%2520efficacy%2520and%2520safety%2520in%2520respiratory%2520and%2520neurological%2520disease%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D2897%26epage%3D2904%26doi%3D10.1517%2F14656560903426189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. T.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">2941</span>– <span class="NLM_lpage">2954</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3480-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2Fs00213-014-3480-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24563185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFClu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2941-2954&author=R.+T.+Hansenauthor=M.+Contiauthor=H.+T.+Zhang&title=Mice+deficient+in+phosphodiesterase-4A+display+anxiogenic-like+behavior&doi=10.1007%2Fs00213-014-3480-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior</span></div><div class="casAuthors">Hansen, Rolf T., III; Conti, Marco; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2941-2954</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Phosphodiesterases (PDEs) are a super family of enzymes responsible for the halting of intracellular cyclic nucleotide signaling and may represent novel therapeutic targets for treatment of cognitive disorders.  PDE4 is of considerable interest to cognitive research because it is highly expressed in the brain, particularly in the cognition-related brain regions.  Recently, the functional role of PDE4B and PDE4D, two of the four PDE4 subtypes (PDE4A, B, C, and D), in behavior has begun to be identified; however, the role of PDE4A in the regulation of behavior is still unknown.  Objectives: The purpose of this study was to characterize the functional role of PDE4A in behavior.  Methods: The role of PDE4A in behavior was evaluated through a battery of behavioral tests using PDE4A knockout (KO) mice; urine corticosterone levels were also measured.  Results: PDE4A KO mice exhibited improved memory in the step-through-passive-avoidance test.  They also displayed anxiogenic-like behavior in elevated-plus maze, holeboard, light-dark transition, and novelty suppressed feeding tests.  Consistent with the anxiety profile, PDE4A KO mice had elevated corticosterone levels compared with wild-type controls post-stress.  Interestingly, PDE4A KO mice displayed no change in object recognition, Morris water maze, forced swim, tail suspension, and duration of anesthesia induced by co-administration of xylazine and ketamine (suggesting that PDE4A KO may not be emetic).  Conclusions: These results suggest that PDE4A may be important in the regulation of emotional memory and anxiety-like behavior, but not emesis.  PDE4A could possibly represent a novel therapeutic target in the future for anxiety or disorders affecting memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNwi0Mlhwbw7Vg90H21EOLACvtfcHk0li-1lt0ExLd5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFClu7s%253D&md5=89bdb7a8ef607a567b47b131414a00ce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3480-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3480-y%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DR.%2BT.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DMice%2520deficient%2520in%2520phosphodiesterase-4A%2520display%2520anxiogenic-like%2520behavior%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2941%26epage%3D2954%26doi%3D10.1007%2Fs00213-014-3480-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malloy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huston, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porteous, D.</span></span> <span> </span><span class="NLM_article-title">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.1126/science.1112915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1126%2Fscience.1112915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16293762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WgtLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=1187-1191&author=J.+Millarauthor=B.+Pickardauthor=S.+Mackieauthor=R.+Jamesauthor=S.+Christieauthor=S.+Buchananauthor=M.+Malloyauthor=J.+Chubbauthor=E.+Hustonauthor=G.+Baillieauthor=P.+Thomsonauthor=E.+Hillauthor=N.+Brandonauthor=J.+Rainauthor=L.+Camargoauthor=P.+Whitingauthor=M.+Houslayauthor=D.+Blackwoodauthor=W.+Muirauthor=D.+Porteous&title=DISC1+and+PDE4B+are+interacting+genetic+factors+in+schizophrenia+that+regulate+cAMP+signaling&doi=10.1126%2Fscience.1112915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling</span></div><div class="casAuthors">Millar, J. Kirsty; Pickard, Benjamin S.; Mackie, Shaun; James, Rachel; Christie, Sheila; Buchanan, Sebastienne R.; Malloy, M. Pat; Chubb, Jennifer E.; Huston, Elaine; Baillie, George S.; Thomson, Pippa A.; Hill, Elaine V.; Brandon, Nicholas J.; Rain, Jean-Christophe; Camargo, L. Miguel; Whiting, Paul J.; Houslay, Miles D.; Blackwood, Douglas H. R.; Muir, Walter J.; Porteous, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5751</span>),
    <span class="NLM_cas:pages">1187-1191</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The disrupted in schizophrenia 1 (DISC1) gene is a candidate susceptibility factor for schizophrenia, but its mechanistic role in the disorder is unknown.  Here we report that the gene encoding phosphodiesterase 4B (PDE4B) is disrupted by a balanced translocation in a subject diagnosed with schizophrenia and a relative with chronic psychiatric illness.  The PDEs inactivate adenosine 3',5'-monophosphate (cAMP), a second messenger implicated in learning, memory, and mood.  We show that DISC1 interacts with the UCR2 domain of PDE4B and that elevation of cellular cAMP leads to dissocn. of PDE4B from DISC1 and an increase in PDE4B activity.  We propose a mechanistic model whereby DISC1 sequesters PDE4B in resting cells and releases it in an activated state in response to elevated cAMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaCqxUtIeBILVg90H21EOLACvtfcHk0li-1lt0ExLd5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WgtLbL&md5=8ed8ebbebab56f9d4902ce080ba29e47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.1112915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1112915%26sid%3Dliteratum%253Aachs%26aulast%3DMillar%26aufirst%3DJ.%26aulast%3DPickard%26aufirst%3DB.%26aulast%3DMackie%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DS.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMalloy%26aufirst%3DM.%26aulast%3DChubb%26aufirst%3DJ.%26aulast%3DHuston%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DG.%26aulast%3DThomson%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DE.%26aulast%3DBrandon%26aufirst%3DN.%26aulast%3DRain%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DL.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DHouslay%26aufirst%3DM.%26aulast%3DBlackwood%26aufirst%3DD.%26aulast%3DMuir%26aufirst%3DW.%26aulast%3DPorteous%26aufirst%3DD.%26atitle%3DDISC1%2520and%2520PDE4B%2520are%2520interacting%2520genetic%2520factors%2520in%2520schizophrenia%2520that%2520regulate%2520cAMP%2520signaling%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D1187%26epage%3D1191%26doi%3D10.1126%2Fscience.1112915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-Î<sup>2</sup>42-induced memory deficits in mice</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.3233/JAD-122236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3233%2FJAD-122236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=269-280&author=C.+Zhangauthor=Y.+Chengauthor=H.+Wangauthor=C.+Wangauthor=S.+P.+Wilsonauthor=J.+Xuauthor=H.+T.+Zhang&title=RNA+interference-mediated+knockdown+of+long-form+phosphodiesterase-4D+%28PDE4D%29+enzyme+reverses+amyloid-%C3%8E242-induced+memory+deficits+in+mice&doi=10.3233%2FJAD-122236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3233%2FJAD-122236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-122236%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DRNA%2520interference-mediated%2520knockdown%2520of%2520long-form%2520phosphodiesterase-4D%2520%2528PDE4D%2529%2520enzyme%2520reverses%2520amyloid-%25C3%258E242-induced%2520memory%2520deficits%2520in%2520mice%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2013%26volume%3D38%26spage%3D269%26epage%3D280%26doi%3D10.3233%2FJAD-122236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4D knockout and RNAi-mediated knockdown enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.5236-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1523%2FJNEUROSCI.5236-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21209202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=172-183&author=Y.+F.+Liauthor=Y.+F.+Chengauthor=Y.+Huangauthor=M.+Contiauthor=S.+P.+Wilsonauthor=J.+M.+O%E2%80%99Donnellauthor=H.+T.+Zhang&title=Phosphodiesterase-4D+knockout+and+RNAi-mediated+knockdown+enhance+memory+and+increase+hippocampal+neurogenesis+via+increased+cAMP+signaling&doi=10.1523%2FJNEUROSCI.5236-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling</span></div><div class="casAuthors">Li, Yun-Feng; Cheng, Yu-Fang; Huang, Ying; Conti, Marco; Wilson, Steven P.; O'Donnell, James M.; Zhang, Han-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory.  However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis.  PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants.  Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests.  These effects were mimicked by repeated treatment with rolipram in wild-type mice.  In addn., similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB).  Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus down-regulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB.  Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not.  The present results suggest that PDE4D, in particular long-form PDE4D, plays a crit. role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis.  These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKG03_qqdl7Vg90H21EOLACvtfcHk0liJi-HylF25dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ygsg%253D%253D&md5=928836c09ff122681fdf11db58885b79</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5236-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5236-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DCheng%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26atitle%3DPhosphodiesterase-4D%2520knockout%2520and%2520RNAi-mediated%2520knockdown%2520enhance%2520memory%2520and%2520increase%2520hippocampal%2520neurogenesis%2520via%2520increased%2520cAMP%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D172%26epage%3D183%26doi%3D10.1523%2FJNEUROSCI.5236-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Works, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, T. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2008.06349.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1460-9568.2008.06349.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18702734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BD1crhvFGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=625-632&author=K.+Ruttenauthor=D.+L.+Misnerauthor=M.+Worksauthor=A.+Bloklandauthor=T.+J.+Novakauthor=L.+Santarelliauthor=T.+L.+Wallace&title=Enhanced+long-term+potentiation+and+impaired+learning+in+phosphodiesterase+4D-knockout+%28PDE4D%29+mice&doi=10.1111%2Fj.1460-9568.2008.06349.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice</span></div><div class="casAuthors">Rutten Kris; Misner Dinah L; Works Melissa; Blokland Arjan; Novak Thomas J; Santarelli Luca; Wallace Tanya L</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevation of intracellular cyclic adenosine monophosphate (cAMP) concentrations and subsequent regulation of downstream target gene expression through phosphorylation of cAMP-responsive element binding protein (CREB) is hypothesized to underlie the mechanism(s) of long-term memory (LTM) formation.  The phosphodiesterase 4 (PDE4) enzyme family is believed to play a key role in LTM by regulating cAMP levels.  Thus far, four PDE4 isoforms have been identified (PDE4A, B, C and D); however, the requisite involvement of each of these isoforms in mediating LTM has yet to be elucidated.  In the present study, genetic knockout mice were used to investigate the involvement of the PDE4D isoform in both in vitro and in vivo models of learning and memory.  Hippocampal synaptic transmission measured electrophysiologically in CA1 slice preparations was similar between wild-type and PDE4D (-/-) mice yet, relative to wild-type controls, knockout mice displayed enhanced early long-term potentiation (LTP) following multiple induction protocols.  Interestingly, the PDE4D (-/-) animals exhibited significant behavioral deficits in associative learning using a conditioned fear paradigm as compared with control littermates.  The impairment in fear conditioning observed in the PDE4D (-/-) mice could not be attributed to differences in acquisition of the task, alterations in locomotor activity or effects on shock sensitivity.  Overall, the in vitro and in vivo alterations in synaptic plasticity observed in the PDE4D (-/-) mice may be explained by adaptive responses occurring throughout development, and suggest that the PDE4D isoform may be an important mediator of LTM formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3AIQ_0tQh5Htlzo9xastyfW6udTcc2eYA-jKX1kVy8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crhvFGrsA%253D%253D&md5=aaf2f2867d552e119c80dad9d3d577b3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2008.06349.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2008.06349.x%26sid%3Dliteratum%253Aachs%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DWorks%26aufirst%3DM.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DNovak%26aufirst%3DT.%2BJ.%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DWallace%26aufirst%3DT.%2BL.%26atitle%3DEnhanced%2520long-term%2520potentiation%2520and%2520impaired%2520learning%2520in%2520phosphodiesterase%25204D-knockout%2520%2528PDE4D%2529%2520mice%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D625%26epage%3D632%26doi%3D10.1111%2Fj.1460-9568.2008.06349.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitolo, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinchese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span> <span> </span><span class="NLM_article-title">Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1624</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.1172/JCI22831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1172%2FJCI22831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15578094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1624-1634&author=B.+Gongauthor=O.+V.+Vitoloauthor=F.+Trincheseauthor=S.+Liuauthor=M.+Shelanskiauthor=O.+Arancio&title=Persistent+improvement+in+synaptic+and+cognitive+functions+in+an+Alzheimer+mouse+model+after+rolipram+treatment&doi=10.1172%2FJCI22831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment</span></div><div class="casAuthors">Gong, Bing; Vitolo, Ottavio V.; Trinchese, Fabrizio; Liu, Shumin; Shelanski, Michael; Arancio, Ottavio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1624-1634</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Evidence suggests that Alzheimer disease (AD) begins as a disorder of synaptic function, caused in part by increased levels of amyloid β-peptide 1-42 (Aβ42).  Both synaptic and cognitive deficits are reproduced in mice double transgenic for amyloid precursor protein (AA substitution K670N,M671L) and presenilin-1 (AA substitution M146V).  Here the authors demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice.  Most importantly, this beneficial effect can be extended beyond the duration of the administration.  One course of long-term systemic treatment with rolipram improves LTP and basal synaptic transmission as well as working, ref., and associative memory deficits for at least 2 mo after the end of the treatment.  This protective effect is possibly due to stabilization of synaptic circuitry via alterations in gene expression by activation of the cAMP-dependent protein kinase (PKA)/cAMP regulatory element-binding protein (CREB) signaling pathway that make the synapses more resistant to the insult inflicted by Aβ.  Thus, agents that enhance the cAMP/PKA/CREB pathway have potential for the treatment of AD and other diseases assocd. with elevated Aβ42 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI79h3DC1rU7Vg90H21EOLACvtfcHk0ljqZ0B3oyg7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhur3I&md5=72e43d10754678b58a452160fe7142e2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1172%2FJCI22831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI22831%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DB.%26aulast%3DVitolo%26aufirst%3DO.%2BV.%26aulast%3DTrinchese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShelanski%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26atitle%3DPersistent%2520improvement%2520in%2520synaptic%2520and%2520cognitive%2520functions%2520in%2520an%2520Alzheimer%2520mouse%2520model%2520after%2520rolipram%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1624%26epage%3D1634%26doi%3D10.1172%2FJCI22831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer’s disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1007/s13311-014-0309-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2Fs13311-014-0309-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25371167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=49-56&author=M.+E.+Gurneyauthor=E.+C.+D%E2%80%99Amatoauthor=A.+B.+Burgin&title=Phosphodiesterase-4+%28PDE4%29+molecular+pharmacology+and+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs13311-014-0309-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease</span></div><div class="casAuthors">Gurney, Mark E.; D'Amato, Emily C.; Burgin, Alex B.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-56</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Between 20% and 25% of patients diagnosed with Alzheimer's disease (AD) do not have amyloid burden as assessed by positron emission tomog. imaging.  Thus, there is a need for nonamyloid-directed therapies for AD, esp. for those patients with non-amyloid AD.  The family of phosphodiesterase-4 (PDE4) enzymes are underexploited therapeutic targets for central nervous system indications.  While the PDE4A, B, and D subtypes are expressed in brain, the strict amino acid sequence conservation of the active site across the four subtypes of PDE4 has made it difficult to discover subtype inhibitors.  The recent elucidation of the structure of the PDE4 N- and C-terminal regulatory domains now makes it possible to design subtype-selective, neg. allosteric modulators (PDE4-NAMs).  These act through closing the N-terminal UCR2 or C-terminal CR3 regulatory domains, and thereby inhibit the enzyme by blocking access of cyclic adenosine monophosphate (cAMP) to the active site.  PDE4B-NAMs have the potential to reduce neuroinflammation by dampening microglia cytokine prodn. triggered by brain amyloid, while PDE4D-NAMs have potent cognitive benefit by augmenting signaling through the cAMP/protein kinase A/cAMP response element-binding protein (CREB) pathway for memory consolidation.  The importance of PDE4D for human cognition is underscored by the recent discovery of PDE4D mutations in acrodysostosis (ACRDY2: MIM 600129), an ultra rare disorder assocd. with intellectual disability.  Thus, the family of PDE4 enzymes provides rich opportunities for the development of mechanistically novel drugs to treat neuroinflammation or the cognitive deficits in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqtOZ-WeMZbVg90H21EOLACvtfcHk0ljqZ0B3oyg7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqt7%252FI&md5=495386b35844b7f0270712d43c0e9d5d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs13311-014-0309-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-014-0309-7%26sid%3Dliteratum%253Aachs%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DE.%2BC.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26atitle%3DPhosphodiesterase-4%2520%2528PDE4%2529%2520molecular%2520pharmacology%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurotherapeutics%26date%3D2015%26volume%3D12%26spage%3D49%26epage%3D56%26doi%3D10.1007%2Fs13311-014-0309-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pneurobio.2016.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27769868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKmsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=1-19&author=T.+F.+Jiangauthor=Q.+Sunauthor=S.+D.+Chen&title=Oxidative+stress%3A+a+major+pathogenesis+and+potential+therapeutic+target+of+antioxidative+agents+in+Parkinson%E2%80%99s+disease+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2016.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease</span></div><div class="casAuthors">Jiang, Tianfang; Sun, Qian; Chen, Shengdi</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oxidative stress reflects an imbalance between the overprodn. and incorporation of free radicals and the dynamic ability of a biosystem to detoxify reactive intermediates.  Free radicals produced by oxidative stress are one of the common features in several exptl. models of diseases.  Free radicals affect both the structure and function of neural cells, and contribute to a wide range of neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.  Although the precise mechanisms that result in the degeneration of neurons and the relevant pathol. changes remain unclear, the crucial role of oxidative stress in the pathogenesis of neurodegenerative diseases is assocd. with several proteins (such as α-synucleinx, DJ-1, Amyloid β and tau protein) and some signaling pathways (such as extracellular regulated protein kinases, phosphoinositide 3-kinase/Protein Kinase B pathway and extracellular signal-regulated kinases 1/2) that are tightly assocd. with the neural damage.  In this review, we present evidence, gathered over the last decade, concerning a variety of pathogenic proteins, their important signaling pathways and pathogenic mechanisms assocd. with oxidative stress in Parkinson's disease and Alzheimer's disease.  Proper control and regulation of these proteins' functions and the related signaling pathways may be a promising therapeutic approach to the patients.  We also emphasizes antioxidative options, including some new neuroprotective agents that eliminate excess reactive oxygen species efficiently and have a certain therapeutic effect; however, controversy surrounds some of them in terms of the dose and length of therapy.  These agents require further investigation by clin. application in patients suffering Parkinson's disease and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRkTEjvuHFrVg90H21EOLACvtfcHk0ljqZ0B3oyg7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKmsLnI&md5=df30edd6b191d56792811edaa8a7c4c9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%2BF.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%2BD.%26atitle%3DOxidative%2520stress%253A%2520a%2520major%2520pathogenesis%2520and%2520potential%2520therapeutic%2520target%2520of%2520antioxidative%2520agents%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.pneurobio.2016.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesselet, M. F.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial dysfunction and oxidative stress in Parkinson’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.pneurobio.2013.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23643800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVOhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2013&pages=17-32&author=S.+R.+Subramaniamauthor=M.+F.+Chesselet&title=Mitochondrial+dysfunction+and+oxidative+stress+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial dysfunction and oxidative stress in Parkinson's disease</span></div><div class="casAuthors">Subramaniam, Sudhakar Raja; Chesselet, Marie-Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">106-107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a movement disorder that is characterized by the progressive degeneration of dopaminergic neurons in substantia nigra pars compacta resulting in dopamine deficiency in the striatum.  Although majority of the PD cases are sporadic several genetic mutations have also been linked to the disease thus providing new opportunities to study the pathol. of the illness.  Studies in humans and various animal models of PD reveal that mitochondrial dysfunction might be a defect that occurs early in PD pathogenesis and appears to be a widespread feature in both sporadic and monogenic forms of PD.  The general mitochondrial abnormalities linked with the disease include mitochondrial electron transport chain impairment, alterations in mitochondrial morphol. and dynamics, mitochondrial DNA mutations and anomaly in calcium homeostasis.  Mitochondria are vital organelles with multiple functions and their dysfunction can lead to a decline in energy prodn., generation of reactive oxygen species and induction of stress-induced apoptosis.  In this review, we give an outline of mitochondrial functions that are affected in the pathogenesis of sporadic and familial PD, and hence provide insights that might be valuable for focused future research to exploit possible mitochondrial targets for neuroprotective interventions in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIZRfC0Ioj7Vg90H21EOLACvtfcHk0li0c7GSYkl_5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVOhu7s%253D&md5=fba0adc1e483cfba5df548562083e006</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSubramaniam%26aufirst%3DS.%2BR.%26aulast%3DChesselet%26aufirst%3DM.%2BF.%26atitle%3DMitochondrial%2520dysfunction%2520and%2520oxidative%2520stress%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2013%26volume%3D106%26spage%3D17%26epage%3D32%26doi%3D10.1016%2Fj.pneurobio.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VandenBerg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourtchouladze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. A.</span></span> <span> </span><span class="NLM_article-title">Novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia</span>. <i>Neurorehab. Neural. Re.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1177/1545968307305521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1177%2F1545968307305521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17823313" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=486-496&author=E.+MacDonaldauthor=H.+Van+der+Leeauthor=D.+Pocockauthor=C.+Coleauthor=N.+Thomasauthor=P.+M.+VandenBergauthor=R.+Bourtchouladzeauthor=J.+A.+Kleim&title=Novel+phosphodiesterase+type+4+inhibitor%2C+HT-0712%2C+enhances+rehabilitation-dependent+motor+recovery+and+cortical+reorganization+after+focal+cortical+ischemia&doi=10.1177%2F1545968307305521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F1545968307305521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1545968307305521%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DE.%26aulast%3DVan%2Bder%2BLee%26aufirst%3DH.%26aulast%3DPocock%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DVandenBerg%26aufirst%3DP.%2BM.%26aulast%3DBourtchouladze%26aufirst%3DR.%26aulast%3DKleim%26aufirst%3DJ.%2BA.%26atitle%3DNovel%2520phosphodiesterase%2520type%25204%2520inhibitor%252C%2520HT-0712%252C%2520enhances%2520rehabilitation-dependent%2520motor%2520recovery%2520and%2520cortical%2520reorganization%2520after%2520focal%2520cortical%2520ischemia%26jtitle%3DNeurorehab.%2520Neural.%2520Re.%26date%3D2007%26volume%3D21%26spage%3D486%26epage%3D496%26doi%3D10.1177%2F1545968307305521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>Clinical
trials for HT-0712. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02013310?term=HT-0712&amp;rank=2" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02013310?term=HT-0712&rank=2</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+HT-0712.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02013310%3Fterm%3DHT-0712%26rank%3D2+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sol, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ousset, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemarie, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span> <span> </span><span class="NLM_article-title">EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.2174/156720511795256053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F156720511795256053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21222604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=203-212&author=B.+Vellasauthor=O.+Solauthor=P.+J.+Snyderauthor=P.+J.+Oussetauthor=R.+Haddadauthor=M.+Maurinauthor=J.+C.+Lemarieauthor=L.+Desireauthor=M.+P.+Pandoauthor=M.+P.+Pando&title=EHT0202+in+Alzheimer%E2%80%99s+disease%3A+a+3-month%2C+randomized%2C+placebo-controlled%2C+double-blind+study&doi=10.2174%2F156720511795256053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study</span></div><div class="casAuthors">Vellas, B.; Sol, O.; Snyder, P. J.; Ousset, P.-J.; Haddad, R.; Maurin, M.; Lemarie, J.-C.; Desire, L.; Pando, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: EHT0202 (etazolate hydrochloride) is a new compd. exhibiting both potential diseasemodifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.  Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in 159 randomized patients suffering from mild to moderate Alzheimer's Disease.  EHT0202 (40 or 80mg bid) or placebo was administered as adjunctive therapy to one acetylcholinesterase inhibitor over a 3-mo period.  This study was designed to assess the clin. safety and tolerability of EHT0202 as a primary objective, with secondary endpoints (cognitive function, daily living activities, behavior, caregiver burden and global functioning) included to explore clin. efficacy of EHT0202 vs. placebo.  Results: EHT0202 was shown to be safe and generally well tolerated.  Dose-dependent nos. of early withdrawal and central nervous system related adverse events were obsd.  As expected, since the study was not powered and not designed to show drug efficacy, and except for ratings on the ADCS-ADL scale, no significant differences were seen between treatment groups.  Conclusions: These first encouraging safety results do support further development of EHT0202 in order to assess its clin. efficacy and to confirm its tolerability in a larger cohort of Alzheimer patients and for a longer period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGT7btT8TzVrVg90H21EOLACvtfcHk0li0c7GSYkl_5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOisLk%253D&md5=b48e7cc084616eb4d81bd4d7c25763de</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F156720511795256053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720511795256053%26sid%3Dliteratum%253Aachs%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSol%26aufirst%3DO.%26aulast%3DSnyder%26aufirst%3DP.%2BJ.%26aulast%3DOusset%26aufirst%3DP.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%26aulast%3DMaurin%26aufirst%3DM.%26aulast%3DLemarie%26aufirst%3DJ.%2BC.%26aulast%3DDesire%26aufirst%3DL.%26aulast%3DPando%26aufirst%3DM.%2BP.%26aulast%3DPando%26aufirst%3DM.%2BP.%26atitle%3DEHT0202%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%25203-month%252C%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%2520study%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2011%26volume%3D8%26spage%3D203%26epage%3D212%26doi%3D10.2174%2F156720511795256053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>Clinical
trials for etazolate. <a href="https://www.clinicaltrials.gov/ct2/show/NCT00880412?term=Etazolate&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT00880412?term=Etazolate&rank=1</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+etazolate.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00880412%3Fterm%3DEtazolate%26rank%3D1+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Clinical
trials for BPN14770. <a href="https://www.clinicaltrials.gov/ct2/show/NCT03817684?term=BPN14770&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03817684?term=BPN14770&rank=1</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+BPN14770.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03817684%3Fterm%3DBPN14770%26rank%3D1+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span>Clinical
trials for MK0952. <a href="https://clinicaltrials.gov/ct2/show/NCT00362024?term=MK-0952" class="extLink">https://clinicaltrials.gov/ct2/show/NCT00362024?term=MK-0952</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+MK0952.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00362024%3Fterm%3DMK-0952+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macnaughtan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prestegard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7673</span>– <span class="NLM_lpage">7688</span>, <span class="refDoi"> DOI: 10.1021/jm701635j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701635j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7673-7688&author=S.+Zhengauthor=G.+Kaurauthor=H.+Wangauthor=M.+Liauthor=M.+Macnaughtanauthor=X.+Yangauthor=S.+Reidauthor=J.+Prestegardauthor=B.+Wangauthor=H.+Ke&title=Design%2C+synthesis%2C+and+structure-activity+relationship%2C+molecular+modeling%2C+and+NMR+studies+of+a+series+of+phenyl+alkyl+ketones+as+highly+potent+and+selective+phosphodiesterase-4+inhibitors&doi=10.1021%2Fjm701635j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors</span></div><div class="casAuthors">Zheng, Shilong; Kaur, Gurpreet; Wang, Huanchen; Li, Minyong; Macnaughtan, Megan; Yang, Xiaochuan; Reid, Suazette; Prestegard, James; Wang, Binghe; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7673-7688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 catalyzes the hydrolysis of cAMP and is a target for the development of anti-inflammatory agents.  We have designed and synthesized a series of Ph alkyl ketones as PDE4 inhibitors.  Among them, 13 compds. were identified as having submicromolar IC50 values.  The most potent compds. have IC50 values of in the mid- to low-nanomolar range.  Compd. I (R = i-Pr, X = O)also showed preference for PDE4 with selectivity of >2000-fold over PDE7, PDE9, PDE2, and PDE5.  Docking of I, II (R = i-Pr, X = CH2), and III (R = n-Pr, X = O) into the binding pocket of the PDE4 catalytic domain revealed a similar binding profile to PDE4 with rolipram except that the fluorine atoms of the difluoromethyl groups of I, II, and III are within a reasonable range for hydrogen bond formation with the amide hydrogen of Thr 333 and the long alkyl chain bears addnl. van der Waals interactions with His 160, Asp 318, and Tyr 159.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkyBtbusd487Vg90H21EOLACvtfcHk0ljU08lTj_hsoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7vN&md5=cc9e4b0a1e090e8bead52686da67d047</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm701635j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701635j%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMacnaughtan%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DS.%26aulast%3DPrestegard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%252C%2520molecular%2520modeling%252C%2520and%2520NMR%2520studies%2520of%2520a%2520series%2520of%2520phenyl%2520alkyl%2520ketones%2520as%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase-4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7673%26epage%3D7688%26doi%3D10.1021%2Fjm701635j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a PDE4-specific pocket for the design of selective inhibitors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4518</span>– <span class="NLM_lpage">4525</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kns7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4518-4525&author=X.+Fengauthor=H.+Wangauthor=M.+Yeauthor=X.+T.+Xuauthor=Y.+Xuauthor=W.+Yangauthor=H.+T.+Zhangauthor=G.+Songauthor=H.+Ke&title=Identification+of+a+PDE4-specific+pocket+for+the+design+of+selective+inhibitors&doi=10.1021%2Facs.biochem.8b00336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a PDE4-specific pocket for the design of selective inhibitors</span></div><div class="casAuthors">Feng, Xiaoqing; Wang, Huanchen; Ye, Mengchun; Xu, Xue-Tao; Xu, Ying; Yang, Wenzhe; Zhang, Han-Ting; Song, Guoqiang; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4518-4525</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of phosphodiesterases (PDEs) have been widely studied as therapeutics for the treatment of human diseases, but improvement of inhibitor selectivity is still desirable for the enhancement of inhibitor potency.  Here, we report identification of a water-contg. subpocket as a PDE4-specific pocket for inhibitor binding.  We designed against the pocket and synthesized two enantiomers of PDE4 inhibitor Zl-n-91.  The (S)-Zl-n-91 enantiomer showed IC50 values of 12 and 20 nM for the catalytic domains of PDE4D2 and PDE4B2B, resp., selectivity several thousand-fold greater than those of other PDE families, and potent neuroprotection activities.  Crystal structures of the PDE4D2 catalytic domain in complex with each Zl-n-91 enantiomer revealed that (S)-Zl-n-91 but not (R)-Zl-n-91 formed a hydrogen bond with the bound water in the pocket, thus explaining its higher affinity.  The structural superposition between the PDE families revealed that this water-contg. subpocket is unique to PDE4 and thus valuable for the design of PDE4 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmnqUSd5AmI7Vg90H21EOLACvtfcHk0ljU08lTj_hsoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kns7jJ&md5=82687a6d72bc36c6545f1fc8a377a44a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00336%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DX.%2BT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520PDE4-specific%2520pocket%2520for%2520the%2520design%2520of%2520selective%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D4518%26epage%3D4525%26doi%3D10.1021%2Facs.biochem.8b00336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenicotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijselaers, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanmierlo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limebeer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argellati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinari, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronzato, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciarelli, R.</span></span> <span> </span><span class="NLM_article-title">GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">2054</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01524.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1476-5381.2011.01524.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21649644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2054-2063&author=O.+Brunoauthor=E.+Fedeleauthor=J.+Prickaertsauthor=L.+A.+Parkerauthor=E.+Canepaauthor=C.+Brulloauthor=A.+Cavalleroauthor=E.+Gardellaauthor=A.+Balbiauthor=C.+Domenicottiauthor=E.+Bollenauthor=H.+J.+Gijselaersauthor=T.+Vanmierloauthor=K.+Erbauthor=C.+L.+Limebeerauthor=F.+Argellatiauthor=U.+M.+Marinariauthor=M.+A.+Pronzatoauthor=R.+Ricciarelli&title=GEBR-7b%2C+a+novel+PDE4D+selective+inhibitor+that+improves+memory+in+rodents+at+non-emetic+doses&doi=10.1111%2Fj.1476-5381.2011.01524.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses</span></div><div class="casAuthors">Bruno, O.; Fedele, E.; Prickaerts, J.; Parker, L. A.; Canepa, E.; Brullo, C.; Cavallero, A.; Gardella, E.; Balbi, A.; Domenicotti, C.; Bollen, E.; Gijselaers, H. J. M.; Vanmierlo, T.; Erb, K.; Limebeer, C. L.; Argellati, F.; Marinari, U. M.; Pronzato, M. A.; Ricciarelli, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2054-2063</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Strategies designed to enhance cerebral cAMP have been proposed as symptomatic treatments to counteract cognitive deficits.  However, pharmacol. therapies aimed at reducing PDE4, the main class of cAMP catabolizing enzymes in the brain, produce severe emetic side effects.  We have recently synthesized a 3-cyclopentyloxy-4-methoxybenzaldehyde deriv., structurally related to rolipram, and endowed with selective PDE4D inhibitory activity.  The aim of the present study was to investigate the effect of the new drug, namely GEBR-7b, on memory performance, nausea, hippocampal cAMP and amyloid-β (Aβ) levels.  Exptl. Approach: To measure memory performance, we performed object recognition tests on rats and mice treated with GEBR-7b or rolipram.  The emetic potential of the drug, again compared with rolipram, was evaluated in rats using the taste reactivity test and in mice using the xylazine/ketamine anesthesia test.  Extracellular hippocampal cAMP was evaluated by intracerebral microdialysis in freely moving rats.  Levels of sol. Aβ peptides were measured in hippocampal tissues and cultured N2a cells by ELISA.  Key Results: GEBR-7b increased hippocampal cAMP, did not influence Aβ levels and improved spatial, as well as object memory performance in the object recognition tests.  The effect of GEBR-7b on memory was 3 to 10 times more potent than that of rolipram, and its EDs had no effect on surrogate measures of emesis in rodents.  Conclusion and Implications: Our results demonstrate that GEBR-7b enhances memory functions at doses that do not cause emesis-like behavior in rodents, thus offering a promising pharmacol. perspective for the treatment of memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpATGYg_M20rVg90H21EOLACvtfcHk0ljU08lTj_hsoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsLrN&md5=3cb12b993944a55d6052b10bd07c9c09</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01524.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01524.x%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DFedele%26aufirst%3DE.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DL.%2BA.%26aulast%3DCanepa%26aufirst%3DE.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DCavallero%26aufirst%3DA.%26aulast%3DGardella%26aufirst%3DE.%26aulast%3DBalbi%26aufirst%3DA.%26aulast%3DDomenicotti%26aufirst%3DC.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DGijselaers%26aufirst%3DH.%2BJ.%26aulast%3DVanmierlo%26aufirst%3DT.%26aulast%3DErb%26aufirst%3DK.%26aulast%3DLimebeer%26aufirst%3DC.%2BL.%26aulast%3DArgellati%26aufirst%3DF.%26aulast%3DMarinari%26aufirst%3DU.%2BM.%26aulast%3DPronzato%26aufirst%3DM.%2BA.%26aulast%3DRicciarelli%26aufirst%3DR.%26atitle%3DGEBR-7b%252C%2520a%2520novel%2520PDE4D%2520selective%2520inhibitor%2520that%2520improves%2520memory%2520in%2520rodents%2520at%2520non-emetic%2520doses%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D2054%26epage%3D2063%26doi%3D10.1111%2Fj.1476-5381.2011.01524.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romussi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondavalli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanthuyne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, C.</span></span> <span> </span><span class="NLM_article-title">New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6546</span>– <span class="NLM_lpage">6557</span>, <span class="refDoi"> DOI: 10.1021/jm900977c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900977c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6546-6557&author=O.+Brunoauthor=A.+Romussiauthor=A.+Spallarossaauthor=C.+Brulloauthor=S.+Schenoneauthor=F.+Bondavalliauthor=N.+Vanthuyneauthor=C.+Roussel&title=New+selective+phosphodiesterase+4D+inhibitors+differently+acting+on+long%2C+short%2C+and+supershort+isoforms&doi=10.1021%2Fjm900977c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">New Selective Phosphodiesterase 4D Inhibitors Differently Acting on Long, Short, and Supershort Isoforms</span></div><div class="casAuthors">Bruno, Olga; Romussi, Alessia; Spallarossa, Andrea; Brullo, Chiara; Schenone, Silvia; Bondavalli, Francesco; Vanthuyne, Nicolas; Roussel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6546-6557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The lack of selective inhibitors toward the long, short, or supershort phosphodiesterases (PDE4s) prevented researchers from carefully defining the connection between different enzyme isoforms, their brain localization, and their role in neurodegenerative diseases such as Alzheimer's disease (AD).  In the search for new therapeutic agents for treating memory and learning disorders, we synthesized new rolipram related PDE4 inhibitors, which had some selectivity toward the long form PDE4D3.  The first series was synthesized as racemate and then resolved by semipreparative HPLC on chiral supports.  Herein we report the synthetic pathways to obtain rolipram related compds. and their biol. activities and some SAR considerations that provide some insights and hints for the structural requirements for PDE4D subtype selectivity and enzyme inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrp9k6gslEYrVg90H21EOLACvtfcHk0liwrWBKV1z2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtL3M&md5=db19da5da1e6781c62dd6b6415ca68c3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm900977c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900977c%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DRomussi%26aufirst%3DA.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBondavalli%26aufirst%3DF.%26aulast%3DVanthuyne%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DC.%26atitle%3DNew%2520selective%2520phosphodiesterase%25204D%2520inhibitors%2520differently%2520acting%2520on%2520long%252C%2520short%252C%2520and%2520supershort%2520isoforms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6546%26epage%3D6557%26doi%3D10.1021%2Fjm900977c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricciarelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prickaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebosio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hagen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrousi, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronzato, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, E.</span></span> <span> </span><span class="NLM_article-title">Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46320</span>, <span class="refDoi"> DOI: 10.1038/srep46320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fsrep46320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28402318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46320&author=R.+Ricciarelliauthor=C.+Brulloauthor=J.+Prickaertsauthor=O.+Arancioauthor=C.+Villaauthor=C.+Rebosioauthor=E.+Calcagnoauthor=M.+Balbiauthor=B.+T.+van+Hagenauthor=E.+K.+Argyrousiauthor=H.+Zhangauthor=M.+A.+Pronzatoauthor=O.+Brunoauthor=E.+Fedele&title=Memory-enhancing+effects+of+GEBR-32a%2C+a+new+PDE4D+inhibitor+holding+promise+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fsrep46320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ricciarelli, Roberta; Brullo, Chiara; Prickaerts, Jos; Arancio, Ottavio; Villa, Carla; Rebosio, Claudia; Calcagno, Elisa; Balbi, Matilde; van Hagen, Britt T. J.; Argyrousi, Elentina K.; Zhang, Hong; Pronzato, Maria Adelaide; Bruno, Olga; Fedele, Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46320</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Memory loss characterizes several neurodegenerative disorders, including Alzheimer's disease (AD).  Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits.  However, PDE4 exists in several isoforms and pan inhibitors cannot be used in humans due to severe emesis.  Here, we present GEBR-32a, a new PDE4D full inhibitor that has been characterized both in vitro and in vivo using biochem., electrophysiol. and behavioral analyses.  GEBR-32a efficiently enhances cAMP in neuronal cultures and hippocampal slices.  In vivo pharmacokinetic anal. shows that GEBR-32a is rapidly distributed within the central nervous system with a very favorable brain/blood ratio.  Specific behavioral tests (object location and Y-maze continuous alternation tasks) demonstrate that this PDE4D inhibitor is able to enhance memory in AD transgenic mice and concomitantly rescues their hippocampal long-term potentiation deficit.  Of great relevance, our preliminary toxicol. anal. indicates that GEBR-32a is not cytotoxic and genotoxic, and does not seem to possess emetic-like side effects.  In conclusion, GEBR-32a could represent a very promising cognitive-enhancing drug with a great potential for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsjtvwg5_Mq7Vg90H21EOLACvtfcHk0liwrWBKV1z2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCrsbg%253D&md5=718b6fe3b59c3c939a18273c90474fbd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep46320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46320%26sid%3Dliteratum%253Aachs%26aulast%3DRicciarelli%26aufirst%3DR.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DVilla%26aufirst%3DC.%26aulast%3DRebosio%26aufirst%3DC.%26aulast%3DCalcagno%26aufirst%3DE.%26aulast%3DBalbi%26aufirst%3DM.%26aulast%3Dvan%2BHagen%26aufirst%3DB.%2BT.%26aulast%3DArgyrousi%26aufirst%3DE.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPronzato%26aufirst%3DM.%2BA.%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DFedele%26aufirst%3DE.%26atitle%3DMemory-enhancing%2520effects%2520of%2520GEBR-32a%252C%2520a%2520new%2520PDE4D%2520inhibitor%2520holding%2520promise%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46320%26doi%3D10.1038%2Fsrep46320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prosdocimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semrau, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucarelli, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisini, E.</span></span> <span> </span><span class="NLM_article-title">Molecular bases of PDE4D inhibition by memory-enhancing GEBR library compounds</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2876-2888&author=T.+Prosdocimiauthor=L.+Mollicaauthor=S.+Doniniauthor=M.+S.+Semrauauthor=A.+P.+Lucarelliauthor=E.+Aiolfiauthor=A.+Cavalliauthor=P.+Storiciauthor=S.+Alfeiauthor=C.+Brulloauthor=O.+Brunoauthor=E.+Parisini&title=Molecular+bases+of+PDE4D+inhibition+by+memory-enhancing+GEBR+library+compounds&doi=10.1021%2Facs.biochem.8b00288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds</span></div><div class="casAuthors">Prosdocimi, Tommaso; Mollica, Luca; Donini, Stefano; Semrau, Marta S.; Lucarelli, Anna Paola; Aiolfi, Egidio; Cavalli, Andrea; Storici, Paola; Alfei, Silvana; Brullo, Chiara; Bruno, Olga; Parisini, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selected members of the large rolipram-related GEBR family of phosphodiesterase-4 (PDE4) inhibitors have been shown to facilitate long term potentiation (LTP) and improve memory functions without causing emetic-like behavior in rodents.  Despite their micromolar-range binding affinities and their promising pharmacol. and toxicol. profiles, little if any structure-activity relationship studies have so far been carried out in order to elucidate the mol. bases of their action.  Here, we report the crystal structure of a no. of GEBR library compds. in complex with the catalytic domain of PDE4D as well as their inhibitory profiles for both the long PDE4D3 isoform and the catalytic domain alone.  Furthermore, we assessed the stability of the obsd. ligand conformations in the context of the intact enzyme using mol. dynamics simulations.  The longer and more flexible ligands appear to be capable of forming contacts with the regulatory portion of the enzyme, thus possibly allowing some degree of selectivity between the different PDE4 isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiQRAP3UFKrVg90H21EOLACvtfcHk0liwrWBKV1z2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFShurg%253D&md5=12feb16d105483c2b0bbec1fe4b0562a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00288%26sid%3Dliteratum%253Aachs%26aulast%3DProsdocimi%26aufirst%3DT.%26aulast%3DMollica%26aufirst%3DL.%26aulast%3DDonini%26aufirst%3DS.%26aulast%3DSemrau%26aufirst%3DM.%2BS.%26aulast%3DLucarelli%26aufirst%3DA.%2BP.%26aulast%3DAiolfi%26aufirst%3DE.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DAlfei%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DO.%26aulast%3DParisini%26aufirst%3DE.%26atitle%3DMolecular%2520bases%2520of%2520PDE4D%2520inhibition%2520by%2520memory-enhancing%2520GEBR%2520library%2520compounds%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facs.biochem.8b00288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, R. C. T.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2886</span>– <span class="NLM_lpage">2890</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-737676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1182%2Fblood-2016-09-737676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27756749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1ait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2886-2890&author=J.+D.+Cooneyauthor=R.+C.+T.+Aguiar&title=Phosphodiesterase+4+inhibitors+have+wide-ranging+activity+in+B-cell+malignancies&doi=10.1182%2Fblood-2016-09-737676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies</span></div><div class="casAuthors">Cooney, Jeffrey D.; Aguiar, Ricardo C. T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2886-2890</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibition restores the suppressive effects of 3',5'-cyclic adenosine monophosphate in lymphocytes.  In this concise review, we detail how PDE4 inhibition down-modulates the B-cell receptor (BCR)-related kinases spleen tyrosine kinase and phosphatidylinositol 3-kinase and inhibits vascular endothelial growth factor A secretion by tumor cells, inducing cancer cell apoptosis and blocking angiogenesis in the microenvironment.  We describe the successful clin. repurposing of PDE4 inhibitors in B-cell malignancies, and propose that given their anti-inflammatory/immunomodulatory activity, these agents will suppress BCR signals without the toxicity assocd. with other targeted biol. doublets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvT7KtkpSFOLVg90H21EOLACvtfcHk0lhi-tcjlBLHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1ait7k%253D&md5=fff5d8746f062bc1d9bd7214ad15ae6c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-737676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-737676%26sid%3Dliteratum%253Aachs%26aulast%3DCooney%26aufirst%3DJ.%2BD.%26aulast%3DAguiar%26aufirst%3DR.%2BC.%2BT.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520have%2520wide-ranging%2520activity%2520in%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2886%26epage%3D2890%26doi%3D10.1182%2Fblood-2016-09-737676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, R. C.</span></span> <span> </span><span class="NLM_article-title">Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6723</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1158%2F1078-0432.CCR-11-0770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21742807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6723-6732&author=S.+W.+Kimauthor=D.+Raiauthor=R.+C.+Aguiar&title=Gene+set+enrichment+analysis+unveils+the+mechanism+for+the+phosphodiesterase+4B+control+of+glucocorticoid+response+in+B-cell+lymphoma&doi=10.1158%2F1078-0432.CCR-11-0770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma</span></div><div class="casAuthors">Kim, Sang-Woo; Rai, Deepak; Aguiar, Ricardo C. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6723-6732</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance to glucocorticoid (GC) is a significant problem in the clin. management of lymphoid malignancies.  Addressing this issue via a mechanistic understanding of relevant signaling pathways is more likely to yield pos. outcomes.  Exptl. Design: We used gene set enrichment anal. (GSEA), multiple genetic models of gain and loss of function in B-cell lymphoma cell lines, in vitro and in vivo, and primary patient samples to characterize a novel relationship between the cAMP/phosphodiesterase 4B (cAMP/PDE4B), AKT/mTOR activities, and GC responses.  RESULTS: Starting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.  We used genetically modified cell lines to show that PDE4B modulates cAMP inhibitory activities toward the AKT/mTOR pathway and defines GC resistance in DLBCL.  In agreement with these data, pharmacol. inhibition of PDE4 in a xenograft model of human lymphoma unleashed cAMP effects, inhibited AKT, and restored GC sensitivity.  Finally, we used primary DLBCL samples to confirm the clin. relevance and biomarker potential of AKT/mTOR regulation by PDE4B.  CONCLUSIONS: Together, these data mechanistically elucidated how cAMP modulates GC responses in lymphocytes, defined AKT as the principal transducer of the growth inhibitory effects of cAMP in B cells, and allowed the formulation of genomics-guided clin. trials that test the ability of PDE4 inhibitors to restore GC sensitivity and improve the outcome of patients with B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobCAx2ENYxlLVg90H21EOLACvtfcHk0lhi-tcjlBLHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsr%252FM&md5=377b1f30ca0a6b4b8e27d1605049cec6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0770%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DRai%26aufirst%3DD.%26aulast%3DAguiar%26aufirst%3DR.%2BC.%26atitle%3DGene%2520set%2520enrichment%2520analysis%2520unveils%2520the%2520mechanism%2520for%2520the%2520phosphodiesterase%25204B%2520control%2520of%2520glucocorticoid%2520response%2520in%2520B-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6723%26epage%3D6732%26doi%3D10.1158%2F1078-0432.CCR-11-0770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahlke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">Cyclic 3′,5′-nucleotide phosphodiesterases: potential targets for anticancer therapy</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1021/tx000090l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000090l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvF2kurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=944-948&author=D.+Markoauthor=G.+Pahlkeauthor=K.+H.+Merzauthor=G.+Eisenbrand&title=Cyclic+3%E2%80%B2%2C5%E2%80%B2-nucleotide+phosphodiesterases%3A+potential+targets+for+anticancer+therapy&doi=10.1021%2Ftx000090l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic 3',5'-Nucleotide Phosphodiesterases: Potential Targets for Anticancer Therapy</span></div><div class="casAuthors">Marko, Doris; Pahlke, Gudrun; Merz, Karl-Heinz; Eisenbrand, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">944-948</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 11 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCi1hocz577Vg90H21EOLACvtfcHk0lhi-tcjlBLHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvF2kurg%253D&md5=bdeb99e3e0e32f17e8767dc90402d3c5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Ftx000090l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000090l%26sid%3Dliteratum%253Aachs%26aulast%3DMarko%26aufirst%3DD.%26aulast%3DPahlke%26aufirst%3DG.%26aulast%3DMerz%26aufirst%3DK.%2BH.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DCyclic%25203%25E2%2580%25B2%252C5%25E2%2580%25B2-nucleotide%2520phosphodiesterases%253A%2520potential%2520targets%2520for%2520anticancer%2520therapy%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2000%26volume%3D13%26spage%3D944%26epage%3D948%26doi%3D10.1021%2Ftx000090l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umetsu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaci.2010.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21047676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFantbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=1252-1259&author=S.+L.+Jinauthor=S.+Goyaauthor=S.+Nakaeauthor=D.+Wangauthor=M.+Brussauthor=C.+Houauthor=D.+Umetsuauthor=M.+Conti&title=Phosphodiesterase+4B+is+essential+for+T%28H%292-cell+function+and+development+of+airway+hyperresponsiveness+in+allergic+asthma&doi=10.1016%2Fj.jaci.2010.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma</span></div><div class="casAuthors">Jin, S.-L. Catherine; Goya, Sho; Nakae, Susumu; Wang, Dan; Bruss, Matthew; Hou, Chiaoyin; Umetsu, Dale; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1259, e1252/1-e1252/12</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">cAMP signaling modulates functions of inflammatory cells involved in the pathogenesis of asthma, and type 4 cAMP-specific phosphodiesterases (PDE4s) are essential components of this pathway.  Induction of the PDE4 isoform PDE4B is necessary for Toll-like receptor signaling in monocytes and macrophages and is assocd. with T cell receptor/CD3 in T cells; however, its exact physiol. function in the development of allergic asthma remains undefined.  We investigated the role of PDE4B in the development of allergen-induced airway hyperresponsiveness (AHR) and TH2-driven inflammatory responses.  Wild-type and PDE4B-/- mice were sensitized and challenged with ovalbumin and AHR measured in response to inhaled methacholine.  Airway inflammation was characterized by analyzing leukocyte infiltration and cytokine accumulation in the airways.  Ovalbumin-stimulated cell proliferation and TH2 cytokine prodn. were detd. in cultured bronchial lymph node cells.  Mice deficient in PDE4B do not develop AHR.  This protective effect was assocd. with a significant decrease in eosinophils recruitment to the lungs and decreased TH2 cytokine levels in the bronchoalveolar lavage fluid.  Defects in T-cell replication, TH2 cytokine prodn., and dendritic cell migration were evident in cells from the airway-draining lymph nodes.  Conversely, accumulation of the TH1 cytokine IFN-γ was not affected in PDE4B-/- mice.  Ablation of the orthologous PDE4 gene PDE4A has no impact on airway inflammation.  By relieving a cAMP-neg. constraint, PDE4B plays an essential role in TH2-cell activation and dendritic cell recruitment during airway inflammation.  These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOE66Z0Hj40rVg90H21EOLACvtfcHk0lhi-tcjlBLHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFantbfI&md5=9b18c1968c30c89adf0e296d7b050553</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DGoya%26aufirst%3DS.%26aulast%3DNakae%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBruss%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DUmetsu%26aufirst%3DD.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DPhosphodiesterase%25204B%2520is%2520essential%2520for%2520T%2528H%25292-cell%2520function%2520and%2520development%2520of%2520airway%2520hyperresponsiveness%2520in%2520allergic%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D126%26spage%3D1252%26epage%3D1259%26doi%3D10.1016%2Fj.jaci.2010.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberté, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span> <span> </span><span class="NLM_article-title">Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1172/JCI0215506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1172%2FJCI0215506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=12370283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD38XnslSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=1045-1052&author=A.+Robichaudauthor=P.+B.+Stamatiouauthor=S.+L.+Jinauthor=N.+Lachanceauthor=D.+Macdonaldauthor=F.+Lalibert%C3%A9author=S.+Liuauthor=Z.+Huangauthor=M.+Contiauthor=C.+C.+Chan&title=Deletion+of+phosphodiesterase+4D+in+mice+shortens+alpha%282%29-adrenoceptor-mediated+anesthesia%2C+a+behavioral+correlate+of+emesis&doi=10.1172%2FJCI0215506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis</span></div><div class="casAuthors">Robichaud, Annette; Stamatiou, Panagiota B.; Jin, S.-L. Catherine; Lachance, Nicholas; MacDonald, Dwight; Laliberte, France; Liu, Susana; Huang, Zheng; Conti, Marco; Chan, Chi-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1052</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A combination of pharmacol. and genetic approaches was used to det. the role of type 4 cAMP-specific cyclic nucleotide phosphodiesterase 4 (PDE4) in reversing α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis in non-vomiting species.  Among the family-specific PDE inhibitors, PDE4 inhibitors reduced the duration of xylazine/ketamine-induced anesthesia in mice, with no effect on pentobarbital-induced anesthesia.  The rank order of the PDE4 inhibitors tested was 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline (PMNPQ) > (R)-rolipram > (S)-rolipram >> (R)-N-{4-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl]phenyl}N'-ethylurea (CT-2450).  The specific roles of PDE4B and PDE4D in this model were studied using mice deficient in either subtype.  PDE4D-deficient mice, but not PDE4B-deficient mice, had a shorter sleeping time than their wild-type littermates under xylazine/ketamine-induced anesthesia, but not under that induced with pentobarbital.  Concomitantly, rolipram-sensitive PDE activity in the brain stem was decreased only in PDE4D-deficient mice compared with their wild-type littermates.  While PMNPQ significantly reduced the xylazine/ketamine-induced anesthesia period in wild-type mice and in PDE4B-null mice, it had no effect in PDE4D-deficient mice.  These findings strongly support the hypothesis that inhibition of PDE4D is pivotal to the anesthesia-reversing effect of PMNPQ and is likely responsible for emesis induced by PDE4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt3ZsNUJs5urVg90H21EOLACvtfcHk0lhGc3wkEmJSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnslSktrg%253D&md5=ee8f2f031a8ea513164becaaec075a1a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1172%2FJCI0215506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215506%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DLalibert%25C3%25A9%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DDeletion%2520of%2520phosphodiesterase%25204D%2520in%2520mice%2520shortens%2520alpha%25282%2529-adrenoceptor-mediated%2520anesthesia%252C%2520a%2520behavioral%2520correlate%2520of%2520emesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D110%26spage%3D1045%26epage%3D1052%26doi%3D10.1172%2FJCI0215506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancalani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Piaz, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1080/14756360601114700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1080%2F14756360601114700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17674813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslygtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=309-318&author=M.+P.+Giovannoniauthor=N.+Cesariauthor=A.+Grazianoauthor=C.+Vergelliauthor=C.+Biancalaniauthor=P.+Biaginiauthor=V.+Dal+Piaz&title=Synthesis+of+pyrrolo%5B2%2C3-d%5Dpyridazinones+as+potent%2C+subtype+selective+PDE4+inhibitors&doi=10.1080%2F14756360601114700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors</span></div><div class="casAuthors">Giovannoni, Maria P.; Cesari, Nicoletta; Graziano, Alessia; Vergelli, Claudia; Biancalani, Claudio; Biagini, Pierfrancesco; Dal Piaz, Vittorio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyridazinones was synthesized and tested for their inhibitory activity on PDE4 subtypes A, B and D and selectivity toward Rolipram high affinity binding site (HARBS).  New agents with interesting profile were reported; in particular compd. 9e (I) showed a good PDE4 subtype selectivity, being 8 times more potent (IC50 = 0.32 μM) for PDE4B (anti-inflammatory) than for PDE4D (IC50 = 2.5 μM), generally considered the subtype responsible for emesis.  Moreover the ratio HARBS/PDE4B was particularly favorable for 9e (147), suggesting that the best arranged groups around the pyrrolopyridazinone core are an iso-Pr at position-1, an ethoxycarbonyl at position-2, together with an Et group at position-6.  For compds. 8 and 15a the ability to inhibit TNFα prodn. in PBMC was evaluated and the results are consistent with their PDE4 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3mNWjKoRjnbVg90H21EOLACvtfcHk0lhGc3wkEmJSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslygtL0%253D&md5=531d6ad2f70e1e3a885ca2f6f153709a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1080%2F14756360601114700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360601114700%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannoni%26aufirst%3DM.%2BP.%26aulast%3DCesari%26aufirst%3DN.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DVergelli%26aufirst%3DC.%26aulast%3DBiancalani%26aufirst%3DC.%26aulast%3DBiagini%26aufirst%3DP.%26aulast%3DDal%2BPiaz%26aufirst%3DV.%26atitle%3DSynthesis%2520of%2520pyrrolo%255B2%252C3-d%255Dpyridazinones%2520as%2520potent%252C%2520subtype%2520selective%2520PDE4%2520inhibitors%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2007%26volume%3D22%26spage%3D309%26epage%3D318%26doi%3D10.1080%2F14756360601114700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-72&author=A.+B.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0lhGc3wkEmJSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D72%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cedervall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulabaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandit, J.</span></span> <span> </span><span class="NLM_article-title">Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1414</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1073/pnas.1419906112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1073%2Fpnas.1419906112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25775568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1414-1422&author=P.+Cedervallauthor=A.+Aulabaughauthor=K.+F.+Geogheganauthor=T.+J.+McLellanauthor=J.+Pandit&title=Engineered+stabilization+and+structural+analysis+of+the+autoinhibited+conformation+of+PDE4&doi=10.1073%2Fpnas.1419906112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4</span></div><div class="casAuthors">Cedervall, Peder; Aulabaugh, Ann; Geoghegan, Kieran F.; McLellan, Thomas J.; Pandit, Jayvardhan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">E1414-E1422</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) is an essential contributor to intracellular signaling and an important drug target.  The 4 members of this enzyme family (PDE4A to PDE4D) are functional dimers in which each subunit contains 2 upstream conserved regions (UCR), UCR1 and UCR2, which precede the C-terminal catalytic domain.  Alternative promoters, transcriptional start sites, and mRNA splicing lead to the existence of >25 variants of PDE4, broadly classified as long, short, and supershort forms.  Here, the authors report the x-ray crystal structure of long form PDE4B contg. UCR1, UCR2, and the catalytic domain, crystd. as a dimer in which a disulfide bond crosslinks Cys residues engineered into UCR2 and the catalytic domain.  Biochem. and mass spectrometric analyses showed that the UCR2-catalytic domain interaction occurred in trans, and established that this interaction regulates the catalytic activity of PDE4.  By elucidating the key structural determinants of dimerization, the authors showed that only long forms of PDE4 can be regulated by this mechanism.  The results also provided a structural basis for the long-standing observation of high- and low-affinity binding sites for the prototypic inhibitor, rolipram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmGjCPFHQ7ULVg90H21EOLACvtfcHk0liGAV_9zLNMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCgtb8%253D&md5=28d7c9227da31456ef569b2ee4e77a87</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1419906112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1419906112%26sid%3Dliteratum%253Aachs%26aulast%3DCedervall%26aufirst%3DP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DMcLellan%26aufirst%3DT.%2BJ.%26aulast%3DPandit%26aufirst%3DJ.%26atitle%3DEngineered%2520stabilization%2520and%2520structural%2520analysis%2520of%2520the%2520autoinhibited%2520conformation%2520of%2520PDE4%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1414%26epage%3D1422%26doi%3D10.1073%2Fpnas.1419906112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.cellsig.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24361374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=657-663&author=D.+Foxauthor=A.+B.+Burginauthor=M.+E.+Gurney&title=Structural+basis+for+the+design+of+selective+phosphodiesterase+4B+inhibitors&doi=10.1016%2Fj.cellsig.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of selective phosphodiesterase 4B inhibitors</span></div><div class="casAuthors">Fox, David, III; Burgin, Alex B.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phosphodiesterase-4B (PDE4B) regulates the pro-inflammatory Toll Receptor -Tumor Necrosis Factor α (TNFα) pathway in monocytes, macrophages and microglial cells.  As such, it is an important, although under-exploited mol. target for anti-inflammatory drugs.  This is due in part to the difficulty of developing selective PDE4B inhibitors as the amino acid sequence of the PDE4 active site is identical in all PDE4 subtypes (PDE4A-D).  We show that highly selective PDE4B inhibitors can be designed by exploiting sequence differences outside the active site.  Specifically, PDE4B selectivity can be achieved by capture of a C-terminal regulatory helix, now termed CR3 (Control Region 3), across the active site in a conformation that closes access by cAMP.  PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 vs. Gln594 in PDE4D).  The reciprocal mutations in PDE4B and PDE4D cause a 70-80 fold shift in selectivity.  Our structural studies show that CR3 is flexible and can adopt multiple orientations and multiple registries in the closed conformation.  The new co-crystal structure with bound ligand provides a guide map for the design of PDE4B selective anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKu3hgg1Kl7Vg90H21EOLACvtfcHk0liGAV_9zLNMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOmtbs%253D&md5=ab8e72afbfeadffeae27950206402bd9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DD.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DStructural%2520basis%2520for%2520the%2520design%2520of%2520selective%2520phosphodiesterase%25204B%2520inhibitors%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D657%26epage%3D663%26doi%3D10.1016%2Fj.cellsig.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auerbach, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span> <span> </span><span class="NLM_article-title">Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2299</span>– <span class="NLM_lpage">2309</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0178-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41386-018-0178-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30131563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=2299-2309&author=C.+Zhangauthor=Y.+Xuauthor=A.+Chowdharyauthor=D.+Foxauthor=M.+E.+Gurneyauthor=H.+T.+Zhangauthor=B.+D.+Auerbachauthor=R.+J.+Salviauthor=M.+Yangauthor=G.+Liauthor=J.+M.+O%E2%80%99Donnell&title=Memory+enhancing+effects+of+BPN14770%2C+an+allosteric+inhibitor+of+phosphodiesterase-4D%2C+in+wild-type+and+humanized+mice&doi=10.1038%2Fs41386-018-0178-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice</span></div><div class="casAuthors">Zhang, Chong; Xu, Ying; Chowdhary, Anirudh; Fox, 3rd, David; Gurney, Mark E.; Zhang, Han-Ting; Auerbach, Benjamin D.; Salvi, Richard J.; Yang, Mingxin; Li, Gaowen; O'Donnell, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2299-2309</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Inhibitors of phosphodiesterase-4 (PDE4) have beneficial effects on memory in preclin. and clin. studies.  Development of these drugs has stalled due to dose-limiting side effects of nausea and emesis.  While use of subtype-selective inhibitors (i.e., for PDE4A, B, or D) could overcome this issue, conservation of the catalytic region, to which classical inhibitors bind, limits this approach.  The present study examd. the effects of BPN14770, an allosteric inhibitor of PDE4D, which binds to a primate-specific, N-terminal region.  In mice engineered to express PDE4D with this primate-specific sequence, BPN14770 was 100-fold more potent for improving memory than in wild-type mice; meanwhile, it exhibited low potency in a mouse surrogate model for emesis.  BPN14770 also antagonized the amnesic effects of scopolamine, increased cAMP signaling in brain, and increased BDNF and markers of neuronal plasticity assocd. with memory.  These data establish a relationship between PDE4D target engagement and effects on memory for BPN14770 and suggest clin. potential for PDE4D-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOsEgzBAlG_LVg90H21EOLACvtfcHk0liGAV_9zLNMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLrI&md5=de5eee6e4aa249e64cd971b0c69e4fda</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0178-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0178-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChowdhary%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DAuerbach%26aufirst%3DB.%2BD.%26aulast%3DSalvi%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DMemory%2520enhancing%2520effects%2520of%2520BPN14770%252C%2520an%2520allosteric%2520inhibitor%2520of%2520phosphodiesterase-4D%252C%2520in%2520wild-type%2520and%2520humanized%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D2299%26epage%3D2309%26doi%3D10.1038%2Fs41386-018-0178-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sindac, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groppi, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellekoop, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. F.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4884</span>– <span class="NLM_lpage">4901</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4884-4901&author=M.+E.+Gurneyauthor=R.+A.+Nugentauthor=X.+Moauthor=J.+A.+Sindacauthor=T.+J.+Hagenauthor=D.+Foxauthor=J.+M.+O%E2%80%99Donnellauthor=C.+Zhangauthor=Y.+Xuauthor=H.+T.+Zhangauthor=V.+E.+Groppiauthor=M.+Bailieauthor=R.+E.+Whiteauthor=D.+L.+Romeroauthor=A.+S.+Vellekoopauthor=J.+R.+Walkerauthor=M.+D.+Surmanauthor=L.+Zhuauthor=R.+F.+Campbell&title=Design+and+synthesis+of+selective+phosphodiesterase+4D+%28PDE4D%29+allosteric+inhibitors+for+the+treatment+of+fragile+X+syndrome+and+other+brain+disorders&doi=10.1021%2Facs.jmedchem.9b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders</span></div><div class="casAuthors">Gurney, Mark E.; Nugent, Richard A.; Mo, Xuesheng; Sindac, Janice A.; Hagen, Timothy J.; Fox, David; O'Donnell, James M.; Zhang, Chong; Xu, Ying; Zhang, Han-Ting; Groppi, Vincent E.; Bailie, Marc; White, Ronald E.; Romero, Donna L.; Vellekoop, A. Samuel; Walker, Joel R.; Surman, Matthew D.; Zhu, Lei; Campbell, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4884-4901</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyridine- and pyrimidine-based allosteric inhibitors are reported that achieve PDE4D subtype selectivity through recognition of a single amino acid difference on a key regulatory domain, known as UCR2, that opens and closes over the catalytic site for cAMP hydrolysis.  The design and optimization of lead compds. was based on iterative anal. of X-ray crystal structures combined with metabolite identification.  Selectivity for the activated, dimeric form of PDE4D provided potent memory enhancing effects in a mouse model of novel object recognition with improved tolerability and reduced vascular toxicity over earlier PDE4 inhibitors that lack subtype selectivity.  The lead compd., 28 (BPN14770), has entered midstage, human phase 2 clin. trials for the treatment of Fragile X Syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRN4fRqnWNLVg90H21EOLACvtfcHk0lib4kaxFApChg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSjtrc%253D&md5=fccb8282e360d7d9a3cde1a187fd2411</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00193%26sid%3Dliteratum%253Aachs%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DSindac%26aufirst%3DJ.%2BA.%26aulast%3DHagen%26aufirst%3DT.%2BJ.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DGroppi%26aufirst%3DV.%2BE.%26aulast%3DBailie%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DR.%2BE.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DVellekoop%26aufirst%3DA.%2BS.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DSurman%26aufirst%3DM.%2BD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%2BF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520inhibitors%2520for%2520the%2520treatment%2520of%2520fragile%2520X%2520syndrome%2520and%2520other%2520brain%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4884%26epage%3D4901%26doi%3D10.1021%2Facs.jmedchem.9b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Titus, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixte, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C. M.</span></span> <span> </span><span class="NLM_article-title">A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2017.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.nlm.2017.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29294383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvF2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=38-49&author=D.+J.+Titusauthor=N.+M.+Wilsonauthor=O.+Alcazarauthor=D.+A.+Calixteauthor=W.+D.+Dietrichauthor=M.+E.+Gurneyauthor=C.+M.+Atkins&title=A+negative+allosteric+modulator+of+PDE4D+enhances+learning+after+traumatic+brain+injury&doi=10.1016%2Fj.nlm.2017.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury</span></div><div class="casAuthors">Titus, David J.; Wilson, Nicole M.; Alcazar, Oscar; Calixte, Dale A.; Dietrich, W. Dalton; Gurney, Mark E.; Atkins, Coleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-49</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Traumatic brain injury (TBI) significantly decreases cAMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments.  Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation.  Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, neg. allosteric modulator, D159687.  In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI.  To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury.  After 3 mo of recovery, animals were treated with D159687 (0.3 mg/kg, i.p.) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task.  Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals.  Assessment of hippocampal slices at 3 mo post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation.  These results demonstrate that a neg. allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcDR6Nl6uhrVg90H21EOLACvtfcHk0lib4kaxFApChg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvF2gug%253D%253D&md5=50d47684152b5ad9756eaf46a6adcfc9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2017.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2017.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DTitus%26aufirst%3DD.%2BJ.%26aulast%3DWilson%26aufirst%3DN.%2BM.%26aulast%3DAlcazar%26aufirst%3DO.%26aulast%3DCalixte%26aufirst%3DD.%2BA.%26aulast%3DDietrich%26aufirst%3DW.%2BD.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DAtkins%26aufirst%3DC.%2BM.%26atitle%3DA%2520negative%2520allosteric%2520modulator%2520of%2520PDE4D%2520enhances%2520learning%2520after%2520traumatic%2520brain%2520injury%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2018%26volume%3D148%26spage%3D38%26epage%3D49%26doi%3D10.1016%2Fj.nlm.2017.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutcheson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span> <span> </span><span class="NLM_article-title">Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e102449</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0102449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1371%2Fjournal.pone.0102449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25050979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ektLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=J.+S.+Sutcliffeauthor=V.+Beaumontauthor=J.+M.+Watsonauthor=C.+S.+Chewauthor=M.+Beconiauthor=D.+M.+Hutchesonauthor=C.+Dominguezauthor=I.+Munoz-Sanjuan&title=Efficacy+of+selective+PDE4D+negative+allosteric+modulators+in+the+object+retrieval+task+in+female+cynomolgus+monkeys+%28Macaca+fascicularis%29&doi=10.1371%2Fjournal.pone.0102449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female Cynomolgus monkeys (Macaca fascicularis)</span></div><div class="casAuthors">Sutcliffe, Jane S.; Beaumont, Vahri; Watson, James M.; Chew, Chang Sing; Beconi, Maria; Hutcheson, Daniel M.; Dominguez, Celia; Munoz-Sanjuan, Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e102449/1-e102449/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cyclic adenosine monophosphate (cAMP) signalling plays an important role in synaptic plasticity and information processing in the hippocampal and basal ganglia systems.  The augmentation of cAMP signalling through the selective inhibition of phosphodiesterases represents a viable strategy to treat disorders assocd. with dysfunction of these circuits.  The phosphodiesterase (PDE) type 4 inhibitor rolipram has shown significant pro-cognitive effects in neurol. disease models, both in rodents and primates.  However, competitive non-isoform selective PDE4 inhibitors have a low therapeutic index which has stalled their clin. development.  Here, we demonstrate the pro-cognitive effects of selective neg. allosteric modulators (NAMs) of PDE4D, D159687 and D159797 in female Cynomolgous macaques, in the object retrieval detour task.  The efficacy displayed by these NAMs in a primate cognitive task which engages the corticostriatal circuitry, together with their suitable pharmacokinetic properties and safety profiles, suggests that clin. development of these allosteric modulators should be considered for the treatment of a variety of brain disorders assocd. with cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSLz0hvkjOiLVg90H21EOLACvtfcHk0lib4kaxFApChg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ektLfF&md5=2fecde53f0ce0f0ef801331c226670cd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0102449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0102449%26sid%3Dliteratum%253Aachs%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DChew%26aufirst%3DC.%2BS.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DHutcheson%26aufirst%3DD.%2BM.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26atitle%3DEfficacy%2520of%2520selective%2520PDE4D%2520negative%2520allosteric%2520modulators%2520in%2520the%2520object%2520retrieval%2520task%2520in%2520female%2520cynomolgus%2520monkeys%2520%2528Macaca%2520fascicularis%2529%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0102449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.2174/156802607779941242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F156802607779941242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17305581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2gs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=391-403&author=H.+Keauthor=H.+Wang&title=Crystal+structures+of+phosphodiesterases+and+implications+on+substrate+specificity+and+inhibitor+selectivity&doi=10.2174%2F156802607779941242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity</span></div><div class="casAuthors">Ke, Hengming; Wang, Huanchen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Crystal structures of seven phosphodiesterase families (PDE1-5, 7, 9) show a conserved core catalytic domain that contains about 300 amino acids and fourteen α-helixes.  The catalytic domains of the PDE families 1-4, 7, and 9 have a uniform conformation.  However, the H-loop at the active site of PDE5 shows four different conformations upon binding of inhibitors, probably implying a special mechanism for recognition of substrates and inhibitors by PDE5.  The active site of all PDE families contains two divalent metal ions: zinc and probably magnesium.  The PDE4-AMP and PDE5-GMP structures reveal the conserved interactions of the phosphate groups of the products AMP and GMP, and thus suggest a universal mechanism of nucleophilic attack for all PDE families.  The substrate specificity has not been well understood.  This review will comment on the early proposal, "glutamine switch", on basis of the recent biochem. and structural information.  The PDE-inhibitor structures have identified a common subpocket for non-selective binding of all inhibitors and potential elements for recognition of family-selective inhibitors.  The kinetic anal. on the mutations of PDE7 to PDE4 suggests that the multiple elements must work together to define inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-rZuXgSTCLVg90H21EOLACvtfcHk0ljVzR9QdOnpvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2gs7w%253D&md5=9241f7c476ea2a19faf8167f0c732a75</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.2174%2F156802607779941242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607779941242%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCrystal%2520structures%2520of%2520phosphodiesterases%2520and%2520implications%2520on%2520substrate%2520specificity%2520and%2520inhibitor%2520selectivity%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D391%26epage%3D403%26doi%3D10.2174%2F156802607779941242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span> <span> </span><span class="NLM_article-title">The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.05.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jmb.2007.05.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=17582435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=302-307&author=H.+Wangauthor=H.+Robinsonauthor=H.+Ke&title=The+molecular+basis+for+different+recognition+of+substrates+by+phosphodiesterase+families+4+and+10&doi=10.1016%2Fj.jmb.2007.05.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10</span></div><div class="casAuthors">Wang, Huanchen; Robinson, Howard; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-307</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are key enzymes that control the cellular concns. of the second messengers cAMP and cGMP.  The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle.  To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been detd. at 1.56 Å resoln.  The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP.  This finding provides exptl. evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely to be the mechanism for substrate recognition by PDEs.  A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addn. to different contact patterns of cAMP in these two structures.  These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr8WN9h4LiP7Vg90H21EOLACvtfcHk0ljVzR9QdOnpvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWktro%253D&md5=2f7f20be9aba1cae9a4d90e349581583</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.05.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DThe%2520molecular%2520basis%2520for%2520different%2520recognition%2520of%2520substrates%2520by%2520phosphodiesterase%2520families%25204%2520and%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D371%26spage%3D302%26epage%3D307%26doi%3D10.1016%2Fj.jmb.2007.05.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+Phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0ljVzR9QdOnpvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520Phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fbjp.2008.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18660832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=288-290&author=M.+A.+Giembycz&title=Can+the+anti-inflammatory+potential+of+PDE4+inhibitors+be+realized%3A+guarded+optimism+or+wishful+thinking%3F&doi=10.1038%2Fbjp.2008.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span></div><div class="casAuthors">Giembycz, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">288-290</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.  Despite initial optimism, none have yet reached the market.  In most cases, the development of PDE4 inhibitors of various structural classes, including cilomilast, filaminast, lirimilast, piclamilast, tofimilast, AWD-12-281 (aka GSK 842470), CDP840, CI-1018, D-4418, IC485, L-826,141, SCH 351391 and V11294A has been discontinued due to lack of efficacy.  A primary problem is the low therapeutic ratio of these compds., which severely limits the dose that can be given.  Indeed, for many of these compds. it is likely that the max. tolerated dose is either sub-therapeutic or at the very bottom of the efficacy dose-response curve.  Therefore, the challenge is to overcome this limitation.  It is, therefore, encouraging that many new(er)' PDE4 inhibitors in development are reported to have an improved therapeutic window including tetomilast, oglemilast, apremilast, ONO 6126, IPL-512602 and IPL-455903 (aka HT-0712), although the basis for their superior tolerability has not been disclosed.  In addn., other approaches are possible that may allow the anti-inflammatory activity of PDE inhibitors to be realized.  Accordingly, this Commentary endorses the view of Spina (2008), published in the current issue of the British Journal of Pharmacol., that the therapeutic utility of PDE4 inhibitors to suppress inflammation still remains a viable concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0IqM4s41YrVg90H21EOLACvtfcHk0lhk6m_Ykqm5HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP&md5=b7209db766a51ebbdf0bf9752635540a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.297%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DCan%2520the%2520anti-inflammatory%2520potential%2520of%2520PDE4%2520inhibitors%2520be%2520realized%253A%2520guarded%2520optimism%2520or%2520wishful%2520thinking%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26spage%3D288%26epage%3D290%26doi%3D10.1038%2Fbjp.2008.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazume, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, T.</span></span> <span> </span><span class="NLM_article-title">Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1002/ibd.20524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1002%2Fibd.20524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18618633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BD1cnns1Wktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1483-1490&author=H.+Ichikawaauthor=S.+Okamotoauthor=N.+Kamadaauthor=H.+Nagamotoauthor=M.+T.+Kitazumeauthor=T.+Kobayashiauthor=H.+Chinenauthor=T.+Hisamatsuauthor=T.+Hibi&title=Tetomilast+suppressed+production+of+proinflammatory+cytokines+from+human+monocytes+and+ameliorated+chronic+colitis+in+IL-10-deficient+mice&doi=10.1002%2Fibd.20524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice</span></div><div class="casAuthors">Ichikawa Hitoshi; Okamoto Susumu; Kamada Nobuhiko; Nagamoto Hisashi; Kitazume Mina T; Kobayashi Taku; Chinen Hiroshi; Hisamatsu Tadakazu; Hibi Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1483-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tetomilast (OPC-6535) was originally developed as a compound inhibiting superoxide production in neutrophils.  Although its mechanism of action is not completely understood, phosphodiesterase type 4 inhibitory function has been postulated.  The therapeutic effect of PDE4 inhibitors has been reported for chronic inflammatory disorders such as chronic obstructive pulmonary diseases.  In this study we aimed to examine whether tetomilast could be a novel drug for inflammatory bowel diseases by further clarifying its antiinflammatory effects.  METHODS:  Cytokines from human peripheral blood mononuclear cells were measured by enzyme-linked immunosorbent assay (ELISA) and Cytokine Beads Array.  The transcripts were quantified by reverse-transcriptase polymerase chain reaction (RT-PCR).  Phosphorylation of transcription factors was examined by phosflow.  To examine its in vivo effect, a once-daily oral dose of tetomilast was tested in murine IL-10(-/-) chronic colitis.  RESULTS:  Tetomilast suppressed TNF-alpha and IL-12 but not IL-10 production from lipopolysaccharide (LPS)-stimulated human monocytes.  It suppressed TNF-alpha, IFN-gamma, and IL-10 from CD4 lymphocytes.  Tetomilast suppressed cytokine production at the transcriptional level but did not alter phosphorylation of p65, ERK, p38, and STAT3.  HT-89, a protein kinase A inhibitor, did not abolish the effect of tetomilast, suggesting that it was independent from the classical cAMP/PKA pathway.  IL-10 was not essential to the inhibitory effect of tetomilast on TNF-alpha and IL-12.  Tetomilast ameliorated IL-10(-/-) chronic colitis with reduced clinical symptoms, serum amyloid A, and histological scores with decreased TNF-alpha mRNA expression.  CONCLUSIONS:  Tetomilast exerts its antiinflammatory effects on human monocytes and CD4 cells.  Combined with in vivo data these findings support the feasibility of tetomilast as a novel drug for inflammatory bowel diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsCHx1oES4ssvLc4ARHEmzfW6udTcc2eYs62XP0coI6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnns1Wktg%253D%253D&md5=6e13c5c75817122087c91c267c46fff4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fibd.20524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.20524%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DS.%26aulast%3DKamada%26aufirst%3DN.%26aulast%3DNagamoto%26aufirst%3DH.%26aulast%3DKitazume%26aufirst%3DM.%2BT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DChinen%26aufirst%3DH.%26aulast%3DHisamatsu%26aufirst%3DT.%26aulast%3DHibi%26aufirst%3DT.%26atitle%3DTetomilast%2520suppressed%2520production%2520of%2520proinflammatory%2520cytokines%2520from%2520human%2520monocytes%2520and%2520ameliorated%2520chronic%2520colitis%2520in%2520IL-10-deficient%2520mice%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2008%26volume%3D14%26spage%3D1483%26epage%3D1490%26doi%3D10.1002%2Fibd.20524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span>Clinical
trials for tetomilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Tetomilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Tetomilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+tetomilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DTetomilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span>Clinical
trials for apremilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Apremilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Apremilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+apremilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DApremilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Zeng, G.</span>; <span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">Thiophene Derivatives</span>. Patent <span class="NLM_patent">WO2010130224</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Zhang&author=G.+Zeng&author=Y.+Gao&title=Thiophene+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThiophene%2520Derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggs-Sauthire, J.</span>; <span class="NLM_string-name">Duarte Franco, J.</span>; <span class="NLM_string-name">Allums-Donald, S.</span></span> <span> </span><span class="NLM_article-title">Oligomer-Containing Apremilast Moiety Compounds</span>. Patent <span class="NLM_patent">WO2012083153</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Riggs-Sauthire&author=J.+Duarte+Franco&author=S.+Allums-Donald&title=Oligomer-Containing+Apremilast+Moiety+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiggs-Sauthire%26aufirst%3DJ.%26atitle%3DOligomer-Containing%2520Apremilast%2520Moiety%2520Compounds%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abarghaz, M.</span>; <span class="NLM_string-name">Oumouch, S.</span>; <span class="NLM_string-name">Lagouge, Y.</span></span> <span> </span><span class="NLM_article-title">5-Substituted-1,4-Benzodiazepines as Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2009037302</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Abarghaz&author=S.+Oumouch&author=Y.+Lagouge&title=5-Substituted-1%2C4-Benzodiazepines+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbarghaz%26aufirst%3DM.%26atitle%3D5-Substituted-1%252C4-Benzodiazepines%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, T.</span>; <span class="NLM_string-name">Emi, H.</span></span> <span> </span><span class="NLM_article-title">Ointment with Excellent Formulation Stability</span>. Patent <span class="NLM_patent">WO2012133492</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+Sakaguchi&author=H.+Emi&title=Ointment+with+Excellent+Formulation+Stability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DT.%26atitle%3DOintment%2520with%2520Excellent%2520Formulation%2520Stability%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanormelingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span> <span> </span><span class="NLM_article-title">Novel Roflumilast analogs as soft PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2014.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25149511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWqs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4594-4597&author=S.+Bolandauthor=J.+Alenauthor=A.+Bourinauthor=K.+Castermansauthor=N.+Boumansauthor=L.+Panittiauthor=J.+Vanormelingenauthor=D.+Leysenauthor=O.+Defert&title=Novel+Roflumilast+analogs+as+soft+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Roflumilast analogs as soft PDE4 inhibitors</span></div><div class="casAuthors">Boland, Sandro; Alen, Jo; Bourin, Arnaud; Castermans, Karolien; Boumans, Nicki; Panitti, Laura; Vanormelingen, Jessica; Leysen, Dirk; Defert, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4594-4597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PDE4 inhibitors are of high interest for treatment of a wide range of inflammatory or autoimmune diseases.  Their potential however has not yet been realized due to target-assocd. side effects, resulting in a low therapeutic window.  We herein report the design, synthesis and evaluation of novel PDE4 inhibitors contg. a γ-lactone structure.  Such mols. are designed to undergo metabolic inactivation when entering circulation, thereby limiting systemic exposure and reducing the risk for side effects.  The resulting inhibitors, e.g., I (n = 3, 4), were highly active on both PDE4B1 and PDE4D2 and underwent rapid degrdn. in human plasma by paraoxonase 1.  In contrast, their metabolites displayed markedly reduced permeability and/or on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT--ZtTKTel7Vg90H21EOLACvtfcHk0lhKf437qMdY6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWqs7jM&md5=941e29eda1ba0bb3b2da0bbe14383738</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DS.%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DBourin%26aufirst%3DA.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DBoumans%26aufirst%3DN.%26aulast%3DPanitti%26aufirst%3DL.%26aulast%3DVanormelingen%26aufirst%3DJ.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DDefert%26aufirst%3DO.%26atitle%3DNovel%2520Roflumilast%2520analogs%2520as%2520soft%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4594%26epage%3D4597%26doi%3D10.1016%2Fj.bmcl.2014.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span>; <span class="NLM_string-name">Amari, G.</span>; <span class="NLM_string-name">Armani, E.</span></span> <span> </span><span class="NLM_article-title">Derivatives of 1-Phenyl-2-Pyridinyl Alkyl Alcohols as Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2009018909</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Delcanale&author=G.+Amari&author=E.+Armani&title=Derivatives+of+1-Phenyl-2-Pyridinyl+Alkyl+Alcohols+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDelcanale%26aufirst%3DM.%26atitle%3DDerivatives%2520of%25201-Phenyl-2-Pyridinyl%2520Alkyl%2520Alcohols%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0lhKf437qMdY6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span>Clinical
trials for CHF6001. <a href="https://www.clinicaltrials.gov/ct2/results?term=CHF6001&amp;draw=1&amp;rank=8#rowId7" class="extLink">https://www.clinicaltrials.gov/ct2/results?term=CHF6001&draw=1&rank=8#rowId7</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+CHF6001.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DCHF6001%26draw%3D1%26rank%3D8%23rowId7+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span>; <span class="NLM_string-name">Beauregard, C.</span>; <span class="NLM_string-name">Gamache, D. A.</span>; <span class="NLM_string-name">Hellberg, M. R.</span>; <span class="NLM_string-name">Noble, S. A.</span>; <span class="NLM_string-name">Shiau, A. K.</span>; <span class="NLM_string-name">Thomas, D. J.</span>; <span class="NLM_string-name">Yanni, J. M.</span></span> <span> </span><span class="NLM_article-title">Heteroarylalkoxysubstituted Quinolone Inhibitors of PDE4</span>. Patent <span class="NLM_patent">WO2011093924</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+P.+Govek&author=C.+Beauregard&author=D.+A.+Gamache&author=M.+R.+Hellberg&author=S.+A.+Noble&author=A.+K.+Shiau&author=D.+J.+Thomas&author=J.+M.+Yanni&title=Heteroarylalkoxysubstituted+Quinolone+Inhibitors+of+PDE4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26atitle%3DHeteroarylalkoxysubstituted%2520Quinolone%2520Inhibitors%2520of%2520PDE4%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-2-(3,5-dichloro-4-pyridyl)acetyl-2,3-dimethoxyphenoxy}-N-propylac etamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&author=J.+Feldingauthor=M.+D.+Sorensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+Sohoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-2-%283%2C5-dichloro-4-pyridyl%29acetyl-2%2C3-dimethoxyphenoxy%7D-N-propylac+etamide+%28LEO+29102%29%2C+a+soft-drug+inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis</span></div><div class="casAuthors">Felding, Jakob; Soerensen, Morten D.; Poulsen, Tina D.; Larsen, Jens; Andersson, Christina; Refer, Pia; Engell, Karen; Ladefoged, Lotte G.; Thormann, Thorsten; Vinggaard, Anne Marie; Hegardt, Pontus; Soehoel, Anders; Nielsen, Simon Feldbaek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5893-5903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades.  However, only roflumilast has received FDA approval.  One key challenge has been the low therapeutic window obsd. in the clinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects.  Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatol. diseases.  We used a fast follower approach, starting from piclamilast.  In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates.  This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin.  Compd. 20 has reached phase 2 and demonstrated clin. relevant efficacy in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hRC8lktjRrVg90H21EOLACvtfcHk0ljKd416ZmoU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF&md5=9d236da8f314edec69f5b442e1a41141</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DSohoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-2-%25283%252C5-dichloro-4-pyridyl%2529acetyl-2%252C3-dimethoxyphenoxy%257D-N-propylac%2520etamide%2520%2528LEO%252029102%2529%252C%2520a%2520soft-drug%2520inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushothaman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulsi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2017.12.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29353721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=673-690&author=B.+Purushothamanauthor=P.+Arumugamauthor=G.+Kulsiauthor=J.+M.+Song&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+catecholopyrimidine+based+PDE4+inhibitor+for+the+treatment+of+atopic+dermatitis&doi=10.1016%2Fj.ejmech.2017.12.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis</span></div><div class="casAuthors">Purushothaman, Baskaran; Arumugam, Parthasarathy; Kulsi, Goutam; Song, Joon Myong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">673-690</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this study, a series of novel catechol/morpholino based compds. bearing pyrimidine I (R1 = N,N-di-Et, cyclopropyl, 4-fluorophenyl, 4-pyridinyl, etc.; R2 = morpholino, 3,4-dimethoxyphenyl, [4-(2-hydroxyethyl)piperazin-1-yl]; R3 = SMe, CF3, SO2Me) as the core have been synthesized and screened for the PDE4 inhibitory properties.  The PDE4 selectivity of the active compds. over other PDEs has been investigated.  Compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) bearing pyrimidine core functionalized with catechol, pyridine and trifluoromethyl groups can effectively inhibit the PDE4B with IC50 value in nanomolar range (IC50 = 15±0.4nM).  Compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) exhibited seven fold higher selectivity towards PDE4B over PDE4D.  Mol. Docking study confirmed its stronger affinity towards catalytic domain of PDE4B.  In-vivo anal. confirmed that compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) effectively alleviated the symptoms of atopic dermatitis in DNCB-treated Balb/c mice by suppressing the synthesis of inflammatory mediators such as TNF-α, and Ig-E.  Taken together, this study suggested that compd. I (R1 = 4-pyridinyl, R2 = 3,4-dimethoxyphenyl, R3 = CF3) could be an effective PDE4 inhibitor for the potential treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5bazHg2F67rVg90H21EOLACvtfcHk0ljKd416ZmoU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOhsLk%253D&md5=a722f1878d9e863c2b3d513aa1c335b4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.069%26sid%3Dliteratum%253Aachs%26aulast%3DPurushothaman%26aufirst%3DB.%26aulast%3DArumugam%26aufirst%3DP.%26aulast%3DKulsi%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520catecholopyrimidine%2520based%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D673%26epage%3D690%26doi%3D10.1016%2Fj.ejmech.2017.12.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tralau-Stewart, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nials, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoigne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, A. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, R. G.</span></span> <span> </span><span class="NLM_article-title">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.173690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.110.173690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21205923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=145-154&author=C.+J.+Tralau-Stewartauthor=R.+A.+Williamsonauthor=A.+T.+Nialsauthor=M.+Gascoigneauthor=J.+Dawsonauthor=G.+J.+Hartauthor=A.+D.+R.+Angellauthor=Y.+E.+Solankeauthor=F.+S.+Lucasauthor=J.+Wisemanauthor=P.+Wardauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=GSK256066%2C+an+exceptionally+high-affinity+and+selective+inhibitor+of+phosphodiesterase+4+suitable+for+administration+by+inhalation%3A+in+vitro%2C+kinetic%2C+and+in+vivo+characterization&doi=10.1124%2Fjpet.110.173690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span></div><div class="casAuthors">Tralau-Stewart, Cathy J.; Williamson, Richard A.; Nials, Anthony T.; Gascoigne, Michele; Dawson, John; Hart, Graham J.; Angell, Anthony D. R.; Solanke, Yemisi E.; Lucas, Fiona S.; Wiseman, Joanne; Ward, Peter; Ranshaw, Lisa E.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oral phosphodiesterase 4 (PDE4) inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases.  However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea.  Delivering the inhibitor by the inhaled route may improve therapeutic index, and the authors describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy] phenylamino}-3-quinolinecarboxamide (GSK256066), an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration.  GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC50 3.2 pM; steady-state IC50 <0.5 pM), which is more potent than any previously documented compd., for example, roflumilast (IC50 390 pM), tofimilast (IC50 1.6 nM), and cilomilast (IC50 74 nM).  Consistent with this, GSK256066 inhibited tumor necrosis factor α prodn. by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with 0.01 nM IC50 (compared with IC50 values of 5, 22, and 389 nM for roflumilast, tofimilast, and cilomilast, resp.) and by LPS-stimulated whole blood with 126 pM IC50.  GSK256066 was highly selective for PDE4 (>380,000-fold vs. PDE1, PDE2, PDE3, PDE5, and PDE6 and >2500-fold against PDE7), inhibited PDE4 isoforms A-D with equal affinity, and had a substantial high-affinity rolipram binding site ratio (>17).  When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED50 values of 1.1 μg/kg (aq. suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aq. suspension of the corticosteroid fluticasone propionate (ED50 9.3 μg/kg).  Thus, GSK256066 was demonstrated to have exceptional potency in vitro and in vivo and is being clin. investigated as a treatment for chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRV6i1BfsW87Vg90H21EOLACvtfcHk0ljKd416ZmoU-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D&md5=1a4747eadf3541433b9abc043782a0ca</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173690%26sid%3Dliteratum%253Aachs%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DGascoigne%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DG.%2BJ.%26aulast%3DAngell%26aufirst%3DA.%2BD.%2BR.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DWiseman%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DGSK256066%252C%2520an%2520exceptionally%2520high-affinity%2520and%2520selective%2520inhibitor%2520of%2520phosphodiesterase%25204%2520suitable%2520for%2520administration%2520by%2520inhalation%253A%2520in%2520vitro%252C%2520kinetic%252C%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D145%26epage%3D154%26doi%3D10.1124%2Fjpet.110.173690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petavy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, B. J.</span></span> <span> </span><span class="NLM_article-title">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1186%2F1465-9921-11-26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20193079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=26&author=D.+Singhauthor=F.+Petavyauthor=A.+J.+Macdonaldauthor=A.+L.+Lazaarauthor=B.+J.+O%E2%80%99Connor&title=The+inhaled+phosphodiesterase+4+inhibitor+GSK256066+reduces+allergen+challenge+responses+in+asthma&doi=10.1186%2F1465-9921-11-26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma</span></div><div class="casAuthors">Singh Dave; Petavy Frank; Macdonald Alex J; Lazaar Aili L; O'Connor Brian J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects.  We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.  METHODS:  In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge.  Methacholine reactivity was measured 24 h post-allergen.  Plasma pharmacokinetics were measured.  The primary endpoint was the effect on LAR.  RESULTS:  GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.  GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.  There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen.  GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.  CONCLUSIONS:  GSK256066 demonstrated a protective effect on the EAR and LAR.  This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6sWKb5nMe2ROk4JA3soTqfW6udTcc2eYM-4IiOeKcRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ptVyjsw%253D%253D&md5=88d976c3aa2d963dc83c5fa8e32e4f62</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-26%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DPetavy%26aufirst%3DF.%26aulast%3DMacdonald%26aufirst%3DA.%2BJ.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520reduces%2520allergen%2520challenge%2520responses%2520in%2520asthma%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D26%26doi%3D10.1186%2F1465-9921-11-26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henriksson, K.</span>; <span class="NLM_string-name">Lisius, A.</span>; <span class="NLM_string-name">Sjo, P.</span>; <span class="NLM_string-name">Storm, P.</span></span> <span> </span><span class="NLM_article-title">Novel 5,6-Dihydropyrazolo[3,4-E][L,4]Diazepin-4 (IH)-One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease</span>. Patent <span class="NLM_patent">WO2007040435</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Henriksson&author=A.+Lisius&author=P.+Sjo&author=P.+Storm&title=Novel+5%2C6-Dihydropyrazolo%5B3%2C4-E%5D%5BL%2C4%5DDiazepin-4+%28IH%29-One+Derivatives+for+the+Treatment+of+Asthma+and+Chronic+Obstructive+Pulmonary+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenriksson%26aufirst%3DK.%26atitle%3DNovel%25205%252C6-Dihydropyrazolo%255B3%252C4-E%255D%255BL%252C4%255DDiazepin-4%2520%2528IH%2529-One%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Asthma%2520and%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V. P.</span>; <span class="NLM_string-name">Balachandran, A.-N. I. I. S.</span>; <span class="NLM_string-name">Gupta, N.</span>; <span class="NLM_string-name">Kukreja, G.</span>; <span class="NLM_string-name">Khera, M. K.</span>; <span class="NLM_string-name">Baregama, L. K.</span>; <span class="NLM_string-name">Mandadapu, R.</span>; <span class="NLM_string-name">Ray, A.</span>; <span class="NLM_string-name">Dastidar, S. G.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2005051931</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=V.+P.+Palle&author=A.-N.+I.+I.+S.+Balachandran&author=N.+Gupta&author=G.+Kukreja&author=M.+K.+Khera&author=L.+K.+Baregama&author=R.+Mandadapu&author=A.+Ray&author=S.+G.+Dastidar&title=Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPalle%26aufirst%3DV.%2BP.%26atitle%3DPhosphodiesterase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ting, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">House, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celly, C. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of oral and inhaled PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5528</span>– <span class="NLM_lpage">5532</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24018187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5528-5532&author=P.+C.+Tingauthor=J.+F.+Leeauthor=R.+Kuangauthor=J.+Caoauthor=D.+Guauthor=Y.+Huangauthor=Z.+Liuauthor=R.+G.+Aslanianauthor=K.-I.+Fengauthor=D.+Preluskyauthor=J.+Lamcaauthor=A.+Houseauthor=J.+E.+Phillipsauthor=P.+Wangauthor=P.+Wuauthor=D.+Lundellauthor=R.+W.+Chapmanauthor=C.+S.+Celly&title=Discovery+of+oral+and+inhaled+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral and inhaled PDE4 inhibitors</span></div><div class="casAuthors">Ting, Pauline C.; Lee, Joe F.; Kuang, Rongze; Cao, Jianhua; Gu, Danlin; Huang, Ying; Liu, Zhidan; Aslanian, Robert G.; Feng, Kung-I.; Prelusky, Daniel; Lamca, James; House, Aileen; Phillips, Jonathan E.; Wang, Peng; Wu, Ping; Lundell, Daniel; Chapman, Richard W.; Celly, Chander S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5528-5532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compd. 16) and inhaled (compd. 34) PDE4 inhibitors.  Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWC60jYiR9G7Vg90H21EOLACvtfcHk0ljZ7YfC8LChxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ&md5=5b76d198abe24df922d239e48d8813be</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26aulast%3DFeng%26aufirst%3DK.-I.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DLamca%26aufirst%3DJ.%26aulast%3DHouse%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26atitle%3DDiscovery%2520of%2520oral%2520and%2520inhaled%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5528%26epage%3D5532%26doi%3D10.1016%2Fj.bmcl.2013.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shue, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blythin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerdt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celly, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of oxazole-based PDE4 inhibitors with picomolar potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.01.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22401864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFGisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2594-2597&author=R.+Kuangauthor=H.-J.+Shueauthor=L.+Xiaoauthor=D.+J.+Blythinauthor=N.-Y.+Shihauthor=X.+Chenauthor=D.+Guauthor=J.+Schwerdtauthor=L.+Linauthor=P.+C.+Tingauthor=J.+Caoauthor=R.+Aslanianauthor=J.+J.+Piwinskiauthor=D.+Preluskyauthor=P.+Wuauthor=J.+Zhangauthor=X.+Zhangauthor=C.+S.+Cellyauthor=M.+Billahauthor=P.+Wang&title=Discovery+of+oxazole-based+PDE4+inhibitors+with+picomolar+potency&doi=10.1016%2Fj.bmcl.2012.01.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oxazole-based PDE4 inhibitors with picomolar potency</span></div><div class="casAuthors">Kuang, Rongze; Shue, Ho-Jane; Xiao, Li; Blythin, David J.; Shih, Neng-Yang; Chen, Xiao; Gu, Danlin; Schwerdt, John; Lin, Ling; Ting, Pauline C.; Cao, Jianhua; Aslanian, Robert; Piwinski, John J.; Prelusky, Daniel; Wu, Ping; Zhang, Ji; Zhang, Xiang; Celly, Chander S.; Billah, Motasim; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2594-2597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Optimization of oxazole-based PDE4 inhibitors has led to the discovery of a series of quinolyl oxazoles, with 4-benzylcarboxamide and 5-α-aminoethyl groups which exhibit picomolar potency against PDE4.  Selectivity profiles and in vivo biol. activity are also reported.  Compd. 2n (I) was the most potent inhibitor with highest relative selectivity for PDE4/PDE10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBuiSTho0GLVg90H21EOLACvtfcHk0ljZ7YfC8LChxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFGisrk%253D&md5=b4a00096ad528a400b7661eb6cc4fe98</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.115%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DShue%26aufirst%3DH.-J.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DBlythin%26aufirst%3DD.%2BJ.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DSchwerdt%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DAslanian%26aufirst%3DR.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520oxazole-based%2520PDE4%2520inhibitors%2520with%2520picomolar%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2594%26epage%3D2597%26doi%3D10.1016%2Fj.bmcl.2012.01.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid, an improved PDE4 inhibitor for the Treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6747</span>– <span class="NLM_lpage">6752</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6747-6752&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=A.+Trifilieff&title=Discovery+and+optimization+of+4-%288-%283-Fluorophenyl%29-1%2C7-naphthyridin-6-yl%29transcyclohexanecarboxylic+acid%2C+an+improved+PDE4+inhibitor+for+the+Treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Facs.jmedchem.5b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6747-6752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors describe the optimization of a series of PDE4 inhibitors, with special focus on soly. and pharmacokinetics, to clin. compd. 2, 4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid.  Although compd. 2 produces emesis in humans when given as a single dose, its exemplary pharmacokinetic properties enabled a novel dosing regime comprising multiple escalating doses and the resultant achievement of high plasma drug levels without assocd. nausea or emesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmzZuZpBNSLVg90H21EOLACvtfcHk0lgpJQrjMmtrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOju7zI&md5=ddc41343095c67022590f0dc12c41bb2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00902%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25204-%25288-%25283-Fluorophenyl%2529-1%252C7-naphthyridin-6-yl%2529transcyclohexanecarboxylic%2520acid%252C%2520an%2520improved%2520PDE4%2520inhibitor%2520for%2520the%2520Treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6747%26epage%3D6752%26doi%3D10.1021%2Facs.jmedchem.5b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tranter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberthuer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J. D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffnell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7472</span>– <span class="NLM_lpage">7479</span>, <span class="refDoi"> DOI: 10.1021/jm300459a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300459a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7472-7479&author=N.+J.+Pressauthor=R.+J.+Taylorauthor=J.+D.+Fullertonauthor=P.+Tranterauthor=C.+McCarthyauthor=T.+H.+Kellerauthor=N.+Arnoldauthor=D.+Beerauthor=L.+Brownauthor=R.+Cheungauthor=J.+Christieauthor=A.+Denholmauthor=S.+Haberthuerauthor=J.+D.+I.+Hattoauthor=M.+Keenanauthor=M.+K.+Mercerauthor=H.+Oakmanauthor=H.+Sahriauthor=A.+R.+Tuffnellauthor=M.+Tweedauthor=J.+W.+Tylerauthor=T.+Wagnerauthor=J.+R.+Fozardauthor=A.+Trifilieff&title=Solubility-driven+optimization+of+phosphodiesterase-4+inhibitors+leading+to+a+clinical+candidate&doi=10.1021%2Fjm300459a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate</span></div><div class="casAuthors">Press, Neil J.; Taylor, Roger J.; Fullerton, Joseph D.; Tranter, Pamela; McCarthy, Clive; Keller, Thomas H.; Arnold, Nicola; Beer, David; Brown, Lyndon; Cheung, Robert; Christie, Julie; Denholm, Alastair; Haberthuer, Sandra; Hatto, Julia D. I.; Keenan, Mark; Mercer, Mark K.; Oakman, Helen; Sahri, Helene; Tuffnell, Andrew R.; Tweed, Morris; Tyler, John W.; Wagner, Trixie; Fozard, John R.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7472-7479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven optimization of a series of 1,7-naphthyridine phosphodiesterase-4 inhibitors is described.  Directed structural changes resulted in increased aq. soly., enabling superior pharmacokinetic properties with retention of PDE4 inhibition.  A range of potent and orally bioavailable compds. with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized.  Compd. 2d (I) was taken forward as a clin. candidate for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL0BzBNQVqnrVg90H21EOLACvtfcHk0lgpJQrjMmtrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurnO&md5=deee9ca074de0b531a130d9a6ce530b2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm300459a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300459a%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DFullerton%26aufirst%3DJ.%2BD.%26aulast%3DTranter%26aufirst%3DP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DArnold%26aufirst%3DN.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DL.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DDenholm%26aufirst%3DA.%26aulast%3DHaberthuer%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%2BD.%2BI.%26aulast%3DKeenan%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DM.%2BK.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DSahri%26aufirst%3DH.%26aulast%3DTuffnell%26aufirst%3DA.%2BR.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DTyler%26aufirst%3DJ.%2BW.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DSolubility-driven%2520optimization%2520of%2520phosphodiesterase-4%2520inhibitors%2520leading%2520to%2520a%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7472%26epage%3D7479%26doi%3D10.1021%2Fjm300459a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido 2,3-d pyrimidin-2(1H)-one), with little emetogenic activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">260</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10991987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=255-260&author=M.+Aokiauthor=M.+Kobayashiauthor=J.+Ishikawaauthor=Y.+Saitaauthor=Y.+Teraiauthor=K.+Takayamaauthor=K.+Miyataauthor=T.+Yamada&title=A+novel+phosphodiesterase+type+4+inhibitor%2C+YM976+%284-%283-chlorophenyl%29-1%2C7-diethylpyrido+2%2C3-d+pyrimidin-2%281H%29-one%29%2C+with+little+emetogenic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-o ne), with little emetogenic activity</span></div><div class="casAuthors">Aoki, Motonori; Kobayashi, Miki; Ishikawa, Jun; Saita, Yuji; Terai, Yoshiya; Takayama, Kazuhisa; Miyata, Keiji; Yamada, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We synthesized a novel phosphodiesterase type 4 (PDE4) inhibitor, YM976, that is structurally different from the other PDE4 inhibitors like rolipram.  In the present study, the pharmacol. profile of YM976 was investigated.  YM976 exhibited a strong and competitive inhibition against PDE4 purified from human peripheral leukocytes with an IC50 of 2.2 nM.  IC50 values of rolipram and RP73401 were 820 and 0.43 nM, resp.  Test compds. had no effects on the other PDE isoenzymes, PDE1, -2, -3, and -5.  YM976 potentiated prostaglandin E2-induced cAMP accumulation in a human mononuclear cell line, U937, and inhibited tumor necrosis factor-α prodn. from human peripheral blood mononuclear cells stimulated by lipopolysaccharide.  Anti-inflammatory activities of PDE4 inhibitors were compared in rat carrageenan-induced pleurisy models.  YM976, rolipram, and RP73401 inhibited the cell infiltration into the pleural cavity with oral ED30 values of 9.1, 10, and 7.4 mg/kg, resp.  YM976 produced no emesis up to 10 mg/kg, whereas rolipram and RP73401 induced emesis at oral doses of 3 mg/kg.  To evidence the dissocn. of anti-inflammatory activity from emesis, the anti-inflammatory effect of YM976 was examd. in ferrets.  YM976 dose dependently reduced carrageenan-induced leukocyte infiltration at the doses of 1, 3, and 10 mg/kg, p.o.  On the other hand, rolipram failed to show obvious inhibition at doses that do not induce emesis.  In conclusion, YM976 is a novel and orally active PDE4 inhibitor and possesses a good sepn. of emetogenicity from anti-inflammatory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptPaeDyZVsA7Vg90H21EOLACvtfcHk0liVcEzGLEq1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygu7g%253D&md5=d9d5c4ec41d8f93a20152346831ac554</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DJ.%26aulast%3DSaita%26aufirst%3DY.%26aulast%3DTerai%26aufirst%3DY.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520phosphodiesterase%2520type%25204%2520inhibitor%252C%2520YM976%2520%25284-%25283-chlorophenyl%2529-1%252C7-diethylpyrido%25202%252C3-d%2520pyrimidin-2%25281H%2529-one%2529%252C%2520with%2520little%2520emetogenic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D255%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuss, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoefgen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundfeldt, C.</span></span> <span> </span><span class="NLM_article-title">ELB353, a new selective PDE4-inhibitor with a high safety margin and anti-inflammatory effects in rat and ferret lungs</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">S135</span>– <span class="NLM_lpage">S136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=S135-S136&author=H.+Kussauthor=J.+Hoppmannauthor=U.+Egerlandauthor=N.+Hoefgenauthor=T.+Kronbachauthor=C.+Rundfeldt&title=ELB353%2C+a+new+selective+PDE4-inhibitor+with+a+high+safety+margin+and+anti-inflammatory+effects+in+rat+and+ferret+lungs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuss%26aufirst%3DH.%26aulast%3DHoppmann%26aufirst%3DJ.%26aulast%3DEgerland%26aufirst%3DU.%26aulast%3DHoefgen%26aufirst%3DN.%26aulast%3DKronbach%26aufirst%3DT.%26aulast%3DRundfeldt%26aufirst%3DC.%26atitle%3DELB353%252C%2520a%2520new%2520selective%2520PDE4-inhibitor%2520with%2520a%2520high%2520safety%2520margin%2520and%2520anti-inflammatory%2520effects%2520in%2520rat%2520and%2520ferret%2520lungs%26jtitle%3DInflammation%2520Res.%26date%3D2005%26volume%3D54%26spage%3DS135%26epage%3DS136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundfeldt, C.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.059097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.103.059097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=14610230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlSqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2004&pages=555-563&author=R.+Draheimauthor=U.+Egerlandauthor=C.+Rundfeldt&title=Anti-inflammatory+potential+of+the+selective+phosphodiesterase+4+inhibitor+N-%283%2C5-dichloro-pyrid-4-yl%29-%5B1-%284-fluorobenzyl%29-5-hydroxy-indole-3-yl%5D-glyoxylic+acid+amide+%28AWD+12-281%29%2C+in+human+cell+preparations&doi=10.1124%2Fjpet.103.059097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations</span></div><div class="casAuthors">Draheim, Regina; Egerland, Ute; Rundfeldt, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">555-563</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AWD 12-281 is a potent (IC50 = 9.7 nM) and highly selective inhibitor of the phosphodiesterase 4 (PDE4) isoenzyme with low affinity to the high-affinity rolipram-binding site.  The compd. was optimized for topical treatment of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.  The aim of the present study was to assess the effect of AWD 12-281 in human inflammatory cells.  Peripheral blood mononuclear cells (PBMCs), dild. whole blood, and human nasal polyp cells derived from surgically resected nasal polyps from patients with polyposis comprise sources of target tissue cells that can be used to predict anti-inflammatory effects in patients.  AWD 12-281 was capable of suppressing the prodn. of cytokines in stimulated PBMCs: interleukin-2 (IL-2, phytohemagglutinin stimulation), IL-5 (Con A stimulation), IL-5 and IL-4 (anti-CD3/anti-CD28 co-stimulation), and lipopolysaccharide-stimulated release of tumor necrosis factor α (TNFα).  The corresponding values for half-max. inhibition, EC50, for AWD 12-281 were within a narrow range (46-121 nM).  Comparing the effect of AWD 12-281 with roflumilast, cilomilast (SB 207499), rolipram (RPR-73401), and 1-(3-nitrophenyl)-3-(4-pyridylmethyl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (RS-25344-000), it could be shown that the PDE4 inhibitory activity was closely correlated with inhibitory potential as measured by the above-described assays.  AWD 12-281 was also shown to suppress TNFα release in dispersed nasal polyps (EC50 = 111 nM) and in dild. whole blood (EC50 = 934 nM).  The reduced activity in human blood may be related to high plasma protein binding.  Currently, phase II clin. studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2wROcGWIzO7Vg90H21EOLACvtfcHk0liVcEzGLEq1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlSqtbk%253D&md5=7f3a582d8f5bfe7312ff20d1d3734aef</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.059097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.059097%26sid%3Dliteratum%253Aachs%26aulast%3DDraheim%26aufirst%3DR.%26aulast%3DEgerland%26aufirst%3DU.%26aulast%3DRundfeldt%26aufirst%3DC.%26atitle%3DAnti-inflammatory%2520potential%2520of%2520the%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520N-%25283%252C5-dichloro-pyrid-4-yl%2529-%255B1-%25284-fluorobenzyl%2529-5-hydroxy-indole-3-yl%255D-glyoxylic%2520acid%2520amide%2520%2528AWD%252012-281%2529%252C%2520in%2520human%2520cell%2520preparations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D308%26spage%3D555%26epage%3D563%26doi%3D10.1124%2Fjpet.103.059097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poondra, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nallamelli, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meda, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muttabathula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voleti, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsa, K. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1109</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23294698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1104-1109&author=R.+R.+Poondraauthor=R.+V.+Nallamelliauthor=C.+L.+Medaauthor=B.+N.+Srinivasauthor=A.+Groverauthor=J.+Muttabathulaauthor=S.+R.+Voletiauthor=B.+Sridharauthor=M.+Palauthor=K.+V.+Parsa&title=Discovery+of+novel+1%2C4-dihydropyridine-based+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2012.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors</span></div><div class="casAuthors">Poondra, Rajamohan R.; Nallamelli, Ratnam V.; Meda, Chandana Lakshmi Teja; Srinivas, B. N. V.; Grover, Anushka; Muttabathula, Jyotsna; Voleti, Sreedhara R.; Sridhar, Balasubramanian; Pal, Manojit; Parsa, Kishore V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1104-1109</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Substituted 1,4-dihydropyridines were discovered as a novel and potent series of phosphodiesterase 4 (PDE4) inhibitors.  Structure-activity relationships within this series have been carried out and studies revealed that the dihydropyridine core, with indole moiety and 3,4-dimethoxybenzyl group, is a potent analog for PDE4 inhibition.  These novel series of compds. were prepd. via a 3-component reaction in a single pot.  In vitro biol. activity, modeling studies and crystallog. data are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvy7A1FZqiobVg90H21EOLACvtfcHk0liVcEzGLEq1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFCgsA%253D%253D&md5=939181e95fa7e399ce491ee3f54a2f91</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DPoondra%26aufirst%3DR.%2BR.%26aulast%3DNallamelli%26aufirst%3DR.%2BV.%26aulast%3DMeda%26aufirst%3DC.%2BL.%26aulast%3DSrinivas%26aufirst%3DB.%2BN.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DMuttabathula%26aufirst%3DJ.%26aulast%3DVoleti%26aufirst%3DS.%2BR.%26aulast%3DSridhar%26aufirst%3DB.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DParsa%26aufirst%3DK.%2BV.%26atitle%3DDiscovery%2520of%2520novel%25201%252C4-dihydropyridine-based%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1104%26epage%3D1109%26doi%3D10.1016%2Fj.bmcl.2012.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poffe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicentini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P. B.</span></span> <span> </span><span class="NLM_article-title">GSK356278, a potent, selective, brain-penetrant Phosphodiesterase 4 Inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.214155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.114.214155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24784567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGkurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=153-163&author=A.+R.+Rutterauthor=A.+Poffeauthor=P.+Cavalliniauthor=T.+G.+Davisauthor=J.+Schneckauthor=M.+Negriauthor=E.+Vicentiniauthor=D.+Montanariauthor=R.+Arbanauthor=F.+A.+Grayauthor=C.+H.+Daviesauthor=P.+B.+Wren&title=GSK356278%2C+a+potent%2C+selective%2C+brain-penetrant+Phosphodiesterase+4+Inhibitor+that+demonstrates+anxiolytic+and+cognition-enhancing+effects+without+inducing+side+effects+in+preclinical+species&doi=10.1124%2Fjpet.114.214155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species</span></div><div class="casAuthors">Rutter, A. Richard; Poffe, Alessandro; Cavallini, Palmina; Davis, T. Gregg; Schneck, Jessica; Negri, Michele; Vicentini, Elena; Montanari, Dino; Arban, Roberto; Gray, Frank A.; Davies, Ceri H.; Wren, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-163, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Small mol. phosphodiesterase (PDE) 4 inhibitors have long been known to show therapeutic benefit in various preclin. models of psychiatric and neurol. diseases because of their ability to elevate cAMP in various cell types of the central nervous system.  Despite the registration of the first PDE4 inhibitor, roflumilast, for the treatment of chronic obstructive pulmonary disease, the therapeutic potential of PDE4 inhibitors in neurol. diseases has never been fulfilled in the clinic due to severe dose-limiting side effects such as nausea and vomiting.  In this study, we describe the detailed pharmacol. characterization of GSK356278 [5-(5-((2,4-dimethylthiazol-5-yl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine], a potent, selective, and brain-penetrant PDE4 inhibitor that shows a superior therapeutic index to both rolipram and roflumilast in various preclin. species and has potential for further development in the clinic for the treatment of psychiatric and neurol. diseases.  GSK356278 inhibited PDE4B enzyme activity with a pIC50 of 8.8 and bound to the high-affinity rolipram binding site with a pIC50 of 8.6.  In preclin. models, the therapeutic index as defined in a rodent lung inflammation model vs. rat pica feeding was >150 compared with 0.5 and 6.4 for rolipram and roflumilast, resp.  In a model of anxiety in common marmosets, the therapeutic index for GSK356278 was >10 vs. <1 for rolipram.  We also demonstrate that GSK356278 enhances performance in a model of executive function in cynomolgus macaques with no adverse effects, a therapeutic profile that supports further evaluation of GSK356278 in a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo53EDHLd83CrVg90H21EOLACvtfcHk0lhaQmPD6Q8L9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGkurbF&md5=82d72053beda7d67b1d1085470634bf1</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.214155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.214155%26sid%3Dliteratum%253Aachs%26aulast%3DRutter%26aufirst%3DA.%2BR.%26aulast%3DPoffe%26aufirst%3DA.%26aulast%3DCavallini%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DT.%2BG.%26aulast%3DSchneck%26aufirst%3DJ.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DVicentini%26aufirst%3DE.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DWren%26aufirst%3DP.%2BB.%26atitle%3DGSK356278%252C%2520a%2520potent%252C%2520selective%252C%2520brain-penetrant%2520Phosphodiesterase%25204%2520Inhibitor%2520that%2520demonstrates%2520anxiolytic%2520and%2520cognition-enhancing%2520effects%2520without%2520inducing%2520side%2520effects%2520in%2520preclinical%2520species%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D153%26epage%3D163%26doi%3D10.1124%2Fjpet.114.214155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, T. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranshaw, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4237</span>– <span class="NLM_lpage">4241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2008.05.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=18539455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4237-4241&author=J.+N.+Hamblinauthor=T.+D.+R.+Angellauthor=S.+P.+Ballantineauthor=C.+M.+Cookauthor=A.+W.+J.+Cooperauthor=J.+Dawsonauthor=C.+J.+Delvesauthor=P.+S.+Jonesauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=C.+J.+Mitchellauthor=M.+Y.+Neuauthor=L.+E.+Ranshawauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+a+novel+structural+class+of+potent+and+selective+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2008.05.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors</span></div><div class="casAuthors">Hamblin, J. Nicole; Angell, Tony D. R.; Ballantine, Stuart P.; Cook, Caroline M.; Cooper, Anthony W. J.; Dawson, John; Delves, Christopher J.; Jones, Paul S.; Lindvall, Mika; Lucas, Fiona S.; Mitchell, Charlotte J.; Neu, Margarete Y.; Ranshaw, Lisa E.; Solanke, Yemisi E.; Somers, Don O.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4237-4241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Optimization of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4).  Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogs bound to the PDE4 active site.  Pyrazolopyridine 20a (I) was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-α prodn. from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj75z9PAk27Vg90H21EOLACvtfcHk0lhaQmPD6Q8L9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCjt7Y%253D&md5=3b425c80dc0258bab9f2c68297260903</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DAngell%26aufirst%3DT.%2BD.%2BR.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DNeu%26aufirst%3DM.%2BY.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520a%2520novel%2520structural%2520class%2520of%2520potent%2520and%2520selective%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4237%26epage%3D4241%26doi%3D10.1016%2Fj.bmcl.2008.05.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantine, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanke, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, J. O.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2010.07.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=20732811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5803-5806&author=C.+J.+Mitchellauthor=S.+P.+Ballantineauthor=D.+M.+Coeauthor=C.+M.+Cookauthor=C.+J.+Delvesauthor=M.+D.+Dowleauthor=C.+D.+Edlinauthor=J.+N.+Hamblinauthor=S.+Holmanauthor=M.+R.+Johnsonauthor=P.+S.+Jonesauthor=S.+E.+Keelingauthor=M.+Kranzauthor=M.+Lindvallauthor=F.+S.+Lucasauthor=M.+Neuauthor=Y.+E.+Solankeauthor=D.+O.+Somersauthor=N.+A.+Trivediauthor=J.+O.+Wiseman&title=Pyrazolopyridines+as+potent+PDE4B+inhibitors%3A+5-heterocycle+SAR&doi=10.1016%2Fj.bmcl.2010.07.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR</span></div><div class="casAuthors">Mitchell, Charlotte J.; Ballantine, Stuart P.; Coe, Diane M.; Cook, Caroline M.; Delves, Christopher J.; Dowle, Mike D.; Edlin, Chris D.; Hamblin, J. Nicole; Holman, Stuart; Johnson, Martin R.; Jones, Paul S.; Keeling, Sue E.; Kranz, Michael; Lindvall, Mika; Lucas, Fiona S.; Neu, Margarete; Solanke, Yemisi E.; Somers, Don O.; Trivedi, Naimisha A.; Wiseman, Joanne O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5803-5806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective phosphodiesterase 4B inhibitors, [Hamblin, J. N.; Angell, T.; Ballentine, S., et al. Bioorg. Med. Chem. Lett. 2008, 18, 4237] the SAR of the 5-position was investigated further.  A range of substituted heterocycles showed good potencies against PDE4.  Optimization using X-ray crystallog. and computational modeling led to the discovery of 16, with sub-nM inhibition of LPS-induced TNF-α prodn. from isolated human peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWR2Q-5iCeCrVg90H21EOLACvtfcHk0lg3efAHOlJxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7%252FN&md5=89c5cd9bc4e3ec6b0be820192a5967be</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.136%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DBallantine%26aufirst%3DS.%2BP.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DCook%26aufirst%3DC.%2BM.%26aulast%3DDelves%26aufirst%3DC.%2BJ.%26aulast%3DDowle%26aufirst%3DM.%2BD.%26aulast%3DEdlin%26aufirst%3DC.%2BD.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DHolman%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DTrivedi%26aufirst%3DN.%2BA.%26aulast%3DWiseman%26aufirst%3DJ.%2BO.%26atitle%3DPyrazolopyridines%2520as%2520potent%2520PDE4B%2520inhibitors%253A%25205-heterocycle%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5803%26epage%3D5806%26doi%3D10.1016%2Fj.bmcl.2010.07.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grepin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo 1,5-a pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le%0ARouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Grepinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo+1%2C5-a+pyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0lg3efAHOlJxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGrepin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%25201%252C5-a%2520pyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1254/jphs.13103FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1254%2Fjphs.13103FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24152964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVygsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=219-226&author=O.+Suzukiauthor=K.+Mizukamiauthor=M.+Etoriauthor=Y.+Sogawaauthor=N.+Takagiauthor=H.+Tsuchidaauthor=K.+Morimotoauthor=T.+Gotoauthor=T.+Yoshinoauthor=T.+Mikkaichiauthor=K.+Hiraharaauthor=S.+Nakamuraauthor=H.+Maeda&title=Evaluation+of+the+therapeutic+index+of+a+novel+phosphodiesterase+4B-selective+inhibitor+over+phosphodiesterase+4D+in+mice&doi=10.1254%2Fjphs.13103FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice</span></div><div class="casAuthors">Suzuki, Osamu; Mizukami, Kiyoshi; Etori, Maki; Sogawa, Yoshitaka; Takagi, Nana; Tsuchida, Hiroshi; Morimoto, Kiyoshi; Goto, Taiji; Yoshino, Toshiharu; Mikkaichi, Tsuyoshi; Hirahara, Kazuki; Nakamura, Satoshi; Maeda, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-226</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of pulmonary inflammatory diseases, but their clin. use was dose-limited by mainly gastric adverse effects.  Recent studies suggested PDE4B-selective inhibitors over PDE4D are supposed to display a wider therapeutic index than subtype non-selective PDE4 inhibitors such as roflumilast.  Compd. A was identified as an orally active PDE4B-selective inhibitor over PDE4D both in humans (80-fold selective) and mice (29-fold selective).  In this study, the therapeutic effects of compd. A and roflumilast were evaluated on lipopolysaccaride (LPS) injection-induced plasma TNF-α elevation and on LPS inhalation-induced pulmonary neutrophilia in mice.  The inhibitory effect on gastric emptying in mice was evaluated as a gastric adverse effect.  The therapeutic index for TNF-α prodn. (TITNF = ID50 in gastric emptying / ID50 in LPS injection-induced plasma TNF-α elevation) of compd. A was larger than roflumilast (9.0 and 0.2, resp.), whereas the therapeutic index for pulmonary neutrophilia (TINeu = ID50 in gastric emptying / ID50 in LPS inhalation-induced pulmonary neutrophilia) of compd. A was comparable to roflumilast (1.0 and 0.5, resp.).  In conclusion, the TINeu of compd. A was not superior compared to that of roflumilast in spite of its high selectivity for PDE4B over PDE4D in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIz67biC5W6rVg90H21EOLACvtfcHk0lg3efAHOlJxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVygsL7K&md5=4a17a3fa9360fc4c99fc3cec80384ab8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1254%2Fjphs.13103FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.13103FP%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DTsuchida%26aufirst%3DH.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DH.%26atitle%3DEvaluation%2520of%2520the%2520therapeutic%2520index%2520of%2520a%2520novel%2520phosphodiesterase%25204B-selective%2520inhibitor%2520over%2520phosphodiesterase%25204D%2520in%2520mice%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D123%26spage%3D219%26epage%3D226%26doi%3D10.1254%2Fjphs.13103FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano 3,2-d pyrimidine derivatives as highly selective PDE4B inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.12.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24412069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=893-899&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Murataauthor=M.+Tomiiauthor=T.+Yamazakiauthor=K.-i.+Yoshidaauthor=T.+Yoshinoauthor=O.+Suzukiauthor=Y.+Sogawaauthor=K.+Mizukamiauthor=N.+Takagiauthor=T.+Yoshitomiauthor=M.+Etoriauthor=H.+Tsuchidaauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=H.+Takahashiauthor=S.+Sasaki&title=Identification+of+the+5%2C5-dioxo-7%2C8-dihydro-6H-thiopyrano+3%2C2-d+pyrimidine+derivatives+as+highly+selective+PDE4B+inhibitors&doi=10.1016%2Fj.bmcl.2013.12.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Murata, Takeshi; Tomii, Masato; Yamazaki, Takanori; Yoshida, Ken-ichi; Yoshino, Toshiharu; Suzuki, Osamu; Sogawa, Yoshitaka; Mizukami, Kiyoshi; Takagi, Nana; Yoshitomi, Tomomi; Etori, Maki; Tsuchida, Hiroshi; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Takahashi, Hisashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">893-899</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A PDE4B subtype selective inhibitor is expected to have a wider therapeutic window than non-selective PDE4 inhibitors.  In this Letter, two series of 7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivs. and 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivs. were evaluated for their PDE4B subtype selectivity using human PDE4B2 and PDE4D2 full length enzymes.  To improve their PDE4B selectivity over PDE4D, we optimized the substituents on the pyrimidine ring and the side chain Ph ring, resulting in several derivs. with more than 100-fold selectivity for PDE4B.  Consequently, we identified 2-(3-chloro-4-methoxy-phenyl)-5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine deriv. 54 (I) as a highly selective PDE4B inhibitor, which had potent hPDE4B inhibitory activity with an IC50 value of 3.0 nM and 433-fold PDE4B selectivity over PDE4D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUe43J-5CbirVg90H21EOLACvtfcHk0lg-JZGXGUgDOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVenuw%253D%253D&md5=bb81ebe02a372089dca1eaf0db738b95</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.076%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DMurata%26aufirst%3DT.%26aulast%3DTomii%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DK.-i.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DYoshitomi%26aufirst%3DT.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTsuchida%26aufirst%3DH.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520the%25205%252C5-dioxo-7%252C8-dihydro-6H-thiopyrano%25203%252C2-d%2520pyrimidine%2520derivatives%2520as%2520highly%2520selective%2520PDE4B%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D893%26epage%3D899%26doi%3D10.1016%2Fj.bmcl.2013.12.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkaichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7037</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmc.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24094436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7025-7037&author=T.+Gotoauthor=A.+Shiinaauthor=T.+Yoshinoauthor=K.+Mizukamiauthor=K.+Hiraharaauthor=O.+Suzukiauthor=Y.+Sogawaauthor=T.+Takahashiauthor=T.+Mikkaichiauthor=N.+Nakaoauthor=M.+Takahashiauthor=M.+Hasegawaauthor=S.+Sasaki&title=Synthesis+and+biological+evaluation+of+5-carbamoyl-2-phenylpyrimidine+derivatives+as+novel+and+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmc.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors</span></div><div class="casAuthors">Goto, Taiji; Shiina, Akiko; Yoshino, Toshiharu; Mizukami, Kiyoshi; Hirahara, Kazuki; Suzuki, Osamu; Sogawa, Yoshitaka; Takahashi, Tomoko; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Hasegawa, Masashi; Sasaki, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7025-7037</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-Carbamoyl-2-phenylpyrimidine deriv. has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM).  Modification of the carboxylic acid moiety of the deriv. gave N-neopentylacetamide deriv., which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, i.p.).  Furthermore, based on the x-ray crystallog. of N-neopentylacetamide deriv. bound to the human PDE4B catalytic domain, the authors designed 7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one deriv. I, which has a fused bicyclic lactam scaffold.  Compd. I exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) prodn. in mouse splenocytes (IC50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo66taMP2rurVg90H21EOLACvtfcHk0lg-JZGXGUgDOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGnsL%252FN&md5=53de746f90ef183a3c89b36895c3fe2b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DShiina%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DK.%26aulast%3DHirahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DO.%26aulast%3DSogawa%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DMikkaichi%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25205-carbamoyl-2-phenylpyrimidine%2520derivatives%2520as%2520novel%2520and%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7025%26epage%3D7037%26doi%3D10.1016%2Fj.bmc.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of triazines as selective PDE4B versus PDE4D inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4031</span>– <span class="NLM_lpage">4034</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2014.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24998378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4031-4034&author=T.+J.+Hagenauthor=X.+Moauthor=A.+B.+Burginauthor=D.+Foxauthor=Z.+Zhangauthor=M.+E.+Gurney&title=Discovery+of+triazines+as+selective+PDE4B+versus+PDE4D+inhibitors&doi=10.1016%2Fj.bmcl.2014.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazines as selective PDE4B versus PDE4D inhibitors</span></div><div class="casAuthors">Hagen, Timothy J.; Mo, Xuesheng; Burgin, Alex B.; Fox, David, III; Zhang, Zheng; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4031-4034</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we report a series of triazine derivs. that are potent inhibitors of PDE4B.  We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B vs. PDE4D.  A high resoln. co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive 'closed' conformation.  The results show that the compds. interact with both catalytic domain and CR3 residues.  This provides the first structure-based approach to engineer PDE4B-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbx57-V-gPw7Vg90H21EOLACvtfcHk0lg-JZGXGUgDOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgtbbF&md5=17be02bb4e2fe4a89b8a07c311d4d140</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DHagen%26aufirst%3DT.%2BJ.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520triazines%2520as%2520selective%2520PDE4B%2520versus%2520PDE4D%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4031%26epage%3D4034%26doi%3D10.1016%2Fj.bmcl.2014.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, V. A. S. S.</span>; <span class="NLM_string-name">Tadiparthi, R.</span>; <span class="NLM_string-name">Sharma, G. V. R.</span>; <span class="NLM_string-name">Sappanimuthu, T.</span>; <span class="NLM_string-name">Bhakiaraj, D. P.</span>; <span class="NLM_string-name">Kachhadia, V.</span>; <span class="NLM_string-name">Narasimhan, K.</span>; <span class="NLM_string-name">Thara, S. N.</span>; <span class="NLM_string-name">Rajagopal, S.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Parameswaran, V.</span>; <span class="NLM_string-name">Janarthanam, V.</span>; <span class="NLM_string-name">Narayanam, M.</span>; <span class="NLM_string-name">Gadde, S.</span>; <span class="NLM_string-name">Ramachandran, U.</span>; <span class="NLM_string-name">Balasubramanian, G.</span>; <span class="NLM_string-name">Surendran, N.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Vishwakarma, L. S.</span>; <span class="NLM_string-name">Saxena, S.</span>; <span class="NLM_string-name">Reddy, G. O.</span></span> <span> </span><span class="NLM_article-title">Novel Heterocycles</span>. Patent <span class="NLM_patent">WO2009095773</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=V.+A.+S.+S.+Srinivas&author=R.+Tadiparthi&author=G.+V.+R.+Sharma&author=T.+Sappanimuthu&author=D.+P.+Bhakiaraj&author=V.+Kachhadia&author=K.+Narasimhan&author=S.+N.+Thara&author=S.+Rajagopal&author=S.+Narayanan&author=V.+Parameswaran&author=V.+Janarthanam&author=M.+Narayanam&author=S.+Gadde&author=U.+Ramachandran&author=G.+Balasubramanian&author=N.+Surendran&author=S.+Narayanan&author=L.+S.+Vishwakarma&author=S.+Saxena&author=G.+O.+Reddy&title=Novel+Heterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivas%26aufirst%3DV.%2BA.%2BS.%2BS.%26atitle%3DNovel%2520Heterocycles%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S. C. A.</span>; <span class="NLM_string-name">Dolusic, E.</span>; <span class="NLM_string-name">Gao, L.-j.</span>; <span class="NLM_string-name">Herdewijn, P. A. M. M.</span>; <span class="NLM_string-name">Pfleiderer, W. E.</span></span> <span> </span><span class="NLM_article-title">Pyrido(3,2-d)Pyrimidines and Pharmaceutical Compositions Useful for Medical Treatment</span>. Patent <span class="NLM_patent">US20090264415</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+C.+A.+De+Jonghe&author=E.+Dolusic&author=L.-j.+Gao&author=P.+A.+M.+M.+Herdewijn&author=W.+E.+Pfleiderer&title=Pyrido%283%2C2-d%29Pyrimidines+and+Pharmaceutical+Compositions+Useful+for+Medical+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJonghe%26aufirst%3DS.%2BC.%2BA.%26atitle%3DPyrido%25283%252C2-d%2529Pyrimidines%2520and%2520Pharmaceutical%2520Compositions%2520Useful%2520for%2520Medical%2520Treatment%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menge, W. M. P. B.</span>; <span class="NLM_string-name">Sterk, G. J.</span>; <span class="NLM_string-name">Hatzelmann, A.</span>; <span class="NLM_string-name">Barsig, J.</span>; <span class="NLM_string-name">Marx, D.</span>; <span class="NLM_string-name">Kley, H.</span>; <span class="NLM_string-name">Christiaans, J. A. M.</span>; <span class="NLM_string-name">Kley, H. P.</span></span> <span> </span><span class="NLM_article-title">New 2-(Piperidin-4-yl)-4,5-Dihydro-2H-Pyridazin-3-one Derivatives Useful for Treatment of e.g. Airway Disorders, Rheumatoid Arthritis, Osteoarthritis, Multiple Sclerosis and Graft Versus Host Reaction</span>. Patent <span class="NLM_patent">WO2005075456</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=W.+M.+P.+B.+Menge&author=G.+J.+Sterk&author=A.+Hatzelmann&author=J.+Barsig&author=D.+Marx&author=H.+Kley&author=J.+A.+M.+Christiaans&author=H.+P.+Kley&title=New+2-%28Piperidin-4-yl%29-4%2C5-Dihydro-2H-Pyridazin-3-one+Derivatives+Useful+for+Treatment+of+e.g.+Airway+Disorders%2C+Rheumatoid+Arthritis%2C+Osteoarthritis%2C+Multiple+Sclerosis+and+Graft+Versus+Host+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenge%26aufirst%3DW.%2BM.%2BP.%2BB.%26atitle%3DNew%25202-%2528Piperidin-4-yl%2529-4%252C5-Dihydro-2H-Pyridazin-3-one%2520Derivatives%2520Useful%2520for%2520Treatment%2520of%2520e.g.%2520Airway%2520Disorders%252C%2520Rheumatoid%2520Arthritis%252C%2520Osteoarthritis%252C%2520Multiple%2520Sclerosis%2520and%2520Graft%2520Versus%2520Host%2520Reaction%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavalda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl Pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Graciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavaldaauthor=B.+Hernandezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pagesauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andresauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+Pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0ligbR6UUbroxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGracia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavalda%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndres%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520Pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gracia Ferrer, J.</span>; <span class="NLM_string-name">Buil Albero, M. A.</span>; <span class="NLM_string-name">Moreno Mollo, I. M.</span>; <span class="NLM_string-name">Pages Santacana, L. M.</span>; <span class="NLM_string-name">Roberts, R. S.</span>; <span class="NLM_string-name">Sevilla Gome, S.</span>; <span class="NLM_string-name">Taltavull Moll, J.</span></span> <span> </span><span class="NLM_article-title">(3-Oxo)Pyridazin-4-ylurea Derivatives as PDE4 Inhibitors</span>. Patent <span class="NLM_patent">WO2010069504</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Gracia+Ferrer&author=M.+A.+Buil+Albero&author=I.+M.+Moreno+Mollo&author=L.+M.+Pages+Santacana&author=R.+S.+Roberts&author=S.+Sevilla+Gome&author=J.+Taltavull+Moll&title=%283-Oxo%29Pyridazin-4-ylurea+Derivatives+as+PDE4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGracia%2BFerrer%26aufirst%3DJ.%26atitle%3D%25283-Oxo%2529Pyridazin-4-ylurea%2520Derivatives%2520as%2520PDE4%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinsley, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzoneri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, G. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of substituted pyridazinone-1-acetylhydrazones as novel phosphodiesterase 4 inhibitors</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/ardp.201500363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1002%2Fardp.201500363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26686665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCqs77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2016&pages=104-111&author=H.+M.+Abdel-Rahmanauthor=M.+Abdel-Azizauthor=H.+N.+Tinsleyauthor=B.+D.+Garyauthor=J.+C.+Canzoneriauthor=G.+A.+Piazza&title=Design+and+synthesis+of+substituted+pyridazinone-1-acetylhydrazones+as+novel+phosphodiesterase+4+inhibitors&doi=10.1002%2Fardp.201500363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors</span></div><div class="casAuthors">Abdel-Rahman, Hamdy M.; Abdel-Aziz, Mohamed; Tinsley, Heather N.; Gary, Bernard D.; Canzoneri, Joshua C.; Piazza, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">104-111</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of novel pyridazin-6-one/acetylhydrazone hybrids I [R1 = H, Me; R2 = 4-MeOC6H4, 2,3-(MeO)2C6H3, 3,4,5-(MeO)3C6H2, 5-F-2-HOC6H3; R3 = 4-FC6H4, 4-MeOC6H4] was rationally designed to inhibit phosphodiesterase 4 (PDE4B).  The prepd. compds. were evaluated for their in vitro ability to inhibit the PDE4B enzyme; several of these compds. showed moderate activity compared to the ref. drug, rolipram.  Compds. I (R1 = H; R2 = R3 = 4-MeOC6H4) and I [R1 = Me; R2 = 5-F-2-HOC6H3, 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] emerged as the most potent inhibitors in this series.  Compd. I [R1 = Me; R2 = 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] showed an IC50 value of 13 μM against PDE4B.  Docking of the compds. I (R1 = H; R2 = R3 = 4-MeOC6H4) and I [R1 = Me; R2 = 5-F-2-HOC6H3, 3,4,5-(MeO)3C6H2; R3 = 4-MeOC6H4] into the active site of PDE4B illustrated their possible binding mode and provided insights for further optimization of this drug scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmswEg2IDFarVg90H21EOLACvtfcHk0ligbR6UUbroxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCqs77J&md5=b4ed77a5fa2116a5e0c5b82fadc594f8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fardp.201500363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201500363%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DH.%2BM.%26aulast%3DAbdel-Aziz%26aufirst%3DM.%26aulast%3DTinsley%26aufirst%3DH.%2BN.%26aulast%3DGary%26aufirst%3DB.%2BD.%26aulast%3DCanzoneri%26aufirst%3DJ.%2BC.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520substituted%2520pyridazinone-1-acetylhydrazones%2520as%2520novel%2520phosphodiesterase%25204%2520inhibitors%26jtitle%3DArch.%2520Pharm.%26date%3D2016%26volume%3D349%26spage%3D104%26epage%3D111%26doi%3D10.1002%2Fardp.201500363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, L. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcphee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darroch, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, S. J.</span></span> <span> </span><span class="NLM_article-title">The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>538</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejphar.2006.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16674936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVynsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2006&pages=39-42&author=L.+C.+D.+Gibsonauthor=S.+F.+Hastingsauthor=I.+Mcpheeauthor=R.+A.+Claytonauthor=C.+E.+Darrochauthor=A.+Mackenzieauthor=F.+L.+Mackenzieauthor=M.+Nagasawaauthor=P.+A.+Stevensauthor=S.+J.+Mackenzie&title=The+inhibitory+profile+of+Ibudilast+against+the+human+phosphodiesterase+enzyme+family&doi=10.1016%2Fj.ejphar.2006.02.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family</span></div><div class="casAuthors">Gibson, Lucien C. D.; Hastings, Stuart F.; McPhee, Ian; Clayton, Robert A.; Darroch, Claire E.; Mackenzie, Alison; MacKenzie, Fiona L.; Nagasawa, Michiaki; Stevens, Patricia A.; MacKenzie, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">39-42</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ibudilast is widely used in Japan to treat ischemic stroke and bronchial asthma.  Its mode of action is through the inhibition of cyclic nucleotide phosphodiesterases (PDEs).  Growing evidence suggests this compd. has utility in a range of neurol. conditions linked to its ability to elevate cellular cyclic nucleotide concns., however limited data exists on Ibudilast's action on individual PDE families.  We therefore used an extensive panel of human PDE enzymes to define the PDE inhibitory profile of this compd.  Ibudilast preferentially inhibits PDE3A, PDE4, PDE10 and PDE11 with lesser inhibition of a no. of other families.  The significance of these findings is discussed in relation to Ibudilast's obsd. effects on certain disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJ3nKv79XRbVg90H21EOLACvtfcHk0lj8wBT_rTvs3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVynsr8%253D&md5=d1e0e22fb1bdc6807d3aa9f249d7aa16</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DL.%2BC.%2BD.%26aulast%3DHastings%26aufirst%3DS.%2BF.%26aulast%3DMcphee%26aufirst%3DI.%26aulast%3DClayton%26aufirst%3DR.%2BA.%26aulast%3DDarroch%26aufirst%3DC.%2BE.%26aulast%3DMackenzie%26aufirst%3DA.%26aulast%3DMackenzie%26aufirst%3DF.%2BL.%26aulast%3DNagasawa%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DP.%2BA.%26aulast%3DMackenzie%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520inhibitory%2520profile%2520of%2520Ibudilast%2520against%2520the%2520human%2520phosphodiesterase%2520enzyme%2520family%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D538%26spage%3D39%26epage%3D42%26doi%3D10.1016%2Fj.ejphar.2006.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. C.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 and its inhibitors in inflammatory diseases</span>. <i>Biomed. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.4103/2319-4170.106152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.4103%2F2319-4170.106152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=197-210&author=S.+L.+Jinauthor=S.+L.+Dingauthor=S.+C.+Lin&title=Phosphodiesterase+4+and+its+inhibitors+in+inflammatory+diseases&doi=10.4103%2F2319-4170.106152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.4103%2F2319-4170.106152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2319-4170.106152%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DDing%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.%2BC.%26atitle%3DPhosphodiesterase%25204%2520and%2520its%2520inhibitors%2520in%2520inflammatory%2520diseases%26jtitle%3DBiomed.%2520J.%26date%3D2012%26volume%3D35%26spage%3D197%26epage%3D210%26doi%3D10.4103%2F2319-4170.106152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yageta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo 1,5-a pyridines with anti-inflammatory activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5311</span>– <span class="NLM_lpage">5316</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.07.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23988356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlKqsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5311-5316&author=A.+Kojimaauthor=S.+Takitaauthor=T.+Sumiyaauthor=K.+Ochiaiauthor=K.+Iwaseauthor=T.+Kishiauthor=A.+Ohinataauthor=Y.+Yagetaauthor=T.+Yasueauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+6%3A+design%2C+synthesis%2C+and+structure-activity+relationships+of+PDE4-inhibitory+pyrazolo+1%2C5-a+pyridines+with+anti-inflammatory+activity&doi=10.1016%2Fj.bmcl.2013.07.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity</span></div><div class="casAuthors">Kojima, Akihiko; Takita, Satoshi; Sumiya, Tatsunobu; Ochiai, Koji; Iwase, Kazuhiko; Kishi, Tetsuya; Ohinata, Akira; Yageta, Yuichi; Yasue, Tokutaro; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5311-5316</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors previously identified KCA-1490 [(-)-6-(7-methoxy-2-trifluoromethyl-pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone], a dual PDE3/4 inhibitor.  In the present study, the authors found highly potent selective PDE4 inhibitors, e.g. I [R = 4-pyridinylmethyl, (2,6-dichloropyridin-4-ylmethyl)carbonyl, 2,6-dichloropyridin-4-ylaminocarbonyl, etc.] derived from the structure of KCA-1490.  Among them, N-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carboxamide I [R = 2,6-dichloropyridin-4-ylaminocarbonyl] had good anti-inflammatory effects in an animal model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcAMD7IN10hrVg90H21EOLACvtfcHk0lj8wBT_rTvs3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlKqsr7F&md5=878f5842483e65b15fd2e4355b0bbe10</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.069%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DSumiya%26aufirst%3DT.%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DOhinata%26aufirst%3DA.%26aulast%3DYageta%26aufirst%3DY.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25206%253A%2520design%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%2520of%2520PDE4-inhibitory%2520pyrazolo%25201%252C5-a%2520pyridines%2520with%2520anti-inflammatory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5311%26epage%3D5316%26doi%3D10.1016%2Fj.bmcl.2013.07.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span>; <span class="NLM_string-name">Sumiya, T.</span>; <span class="NLM_string-name">Takita, S.</span>; <span class="NLM_string-name">Kojima, A.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Biaryl Derivative, and PDE4 Inhibitor Comprising Same as Active Ingredient</span>. Patent <span class="NLM_patent">WO2010035745</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Kohno&author=T.+Sumiya&author=S.+Takita&author=A.+Kojima&title=Heterocyclic+Biaryl+Derivative%2C+and+PDE4+Inhibitor+Comprising+Same+as+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DHeterocyclic%2520Biaryl%2520Derivative%252C%2520and%2520PDE4%2520Inhibitor%2520Comprising%2520Same%2520as%2520Active%2520Ingredient%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hishinuma, I.</span></span> <span> </span><span class="NLM_article-title">Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.205542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.113.205542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23674603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=105-112&author=N.+Ishiiauthor=M.+Shiratoauthor=H.+Wakitaauthor=K.+Miyazakiauthor=Y.+Takaseauthor=O.+Asanoauthor=K.+Kusanoauthor=E.+Yamamotoauthor=C.+Inoueauthor=I.+Hishinuma&title=Antipruritic+effect+of+the+topical+phosphodiesterase+4+inhibitor+E6005+ameliorates+skin+lesions+in+a+mouse+atopic+dermatitis+model&doi=10.1124%2Fjpet.113.205542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model</span></div><div class="casAuthors">Ishii, Naoto; Shirato, Manabu; Wakita, Hisashi; Miyazaki, Kazuki; Takase, Yasutaka; Asano, Osamu; Kusano, Kazutomi; Yamamoto, Eiichi; Inoue, Chiharu; Hishinuma, Ieharu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) 4 inhibition is a well-known anti-inflammatory mechanism, but the development of PDE4 inhibitors has been hampered by side effects such as nausea and emesis.  Local delivery of a PDE4 inhibitor to the site of inflammation may overcome these issues.  The purpose of this study was to assess the therapeutic potential of E6005 (Me 4-[({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}amino)carbonyl]benzoate), a novel PDE4 inhibitor developed as a topical agent for atopic dermatitis (AD).  E6005 potently and selectively inhibited human PDE4 activity with an IC50 of 2.8 nM and suppressed the prodn. of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM.  In mice models, the topical application of E6005 produced an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion mols.  On the basis of these obsd. effects, topical E6005 ameliorated the appearance of atopic dermatitis-like skin lesions in two types of AD models, hapten- and mite-elicited models, exhibiting inhibitory effects comparable to that of tacrolimus.  The use of 14C-labeled E6005 showed rapid clearance from the blood and low distribution to the brain, contributing to the low emetic potential of this compd.  These results suggest that E6005 may be a promising novel therapeutic agent with antipruritic activity for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLEhu4MKf8TrVg90H21EOLACvtfcHk0ljbnizwi_R92w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajtrvN&md5=cc100191e813b648080f868823a7fc3a</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.205542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.205542%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DShirato%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DH.%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DO.%26aulast%3DKusano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DE.%26aulast%3DInoue%26aufirst%3DC.%26aulast%3DHishinuma%26aufirst%3DI.%26atitle%3DAntipruritic%2520effect%2520of%2520the%2520topical%2520phosphodiesterase%25204%2520inhibitor%2520E6005%2520ameliorates%2520skin%2520lesions%2520in%2520a%2520mouse%2520atopic%2520dermatitis%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D105%26epage%3D112%26doi%3D10.1124%2Fjpet.113.205542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuraishi, Y.</span></span> <span> </span><span class="NLM_article-title">Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1111/exd.12377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fexd.12377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24645735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=359-361&author=T.+Andohauthor=T.+Yoshidaauthor=Y.+Kuraishi&title=Topical+E6005%2C+a+novel+phosphodiesterase+4+inhibitor%2C+attenuates+spontaneous+itch-related+responses+in+mice+with+chronic+atopy-like+dermatitis&doi=10.1111%2Fexd.12377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis</span></div><div class="casAuthors">Andoh, Tsugunobu; Yoshida, Tetsuro; Kuraishi, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-361</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Atopic dermatitis is a chronic inflammatory cutaneous disease with difficult-to-treat pruritus.  Although phosphodiesterase (PDE) 4 inhibitors have an anti-inflammatory effect on inflammatory skin diseases, such as atopic dermatitis, their acute antipruritic activities remain unclear.  Therefore, in this study, we examd. whether E6005, a novel PDE4 inhibitor, has antipruritic activity in dermatitis, using a mouse model of atopic dermatitis (NC/Nga mice).  A single topical application of E6005 inhibited spontaneous hind-paw scratching, an itch-assocd. response and spontaneous activity of the cutaneous nerve in mice with chronic dermatitis.  The cutaneous concn. of cAMP was significantly decreased in mice with chronic dermatitis, and this decrease was reversed by topical E6005 application.  These results suggest that E6005 increases the cutaneous concn. of cAMP to relieve dermatitis-assocd. itching.  Thus, E6005 may be a useful therapy for pruritic dermatitis such as atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH3-W6ItaX-rVg90H21EOLACvtfcHk0ljbnizwi_R92w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlSktrc%253D&md5=813d6286294025e0f5ee081268bff00b</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fexd.12377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12377%26sid%3Dliteratum%253Aachs%26aulast%3DAndoh%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKuraishi%26aufirst%3DY.%26atitle%3DTopical%2520E6005%252C%2520a%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%2520attenuates%2520spontaneous%2520itch-related%2520responses%2520in%2520mice%2520with%2520chronic%2520atopy-like%2520dermatitis%26jtitle%3DExp.%2520Dermatol.%26date%3D2014%26volume%3D23%26spage%3D359%26epage%3D361%26doi%3D10.1111%2Fexd.12377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span>Clinical
trials for oglemilast. <a href="https://www.clinicaltrials.gov/ct2/results?cond=&amp;term=Oglemilast&amp;cntry=&amp;state=&amp;city=&amp;dist=" class="extLink">https://www.clinicaltrials.gov/ct2/results?cond=&term=Oglemilast&cntry=&state=&city=&dist=</a> (accessed Aug 2, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+oglemilast.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DOglemilast%26cntry%3D%26state%3D%26city%3D%26dist%3D+%28accessed+Aug+2%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egerland, U.</span></span> <span> </span><span class="NLM_article-title">Discovery of triazines as potent, selective and orally active PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4308</span>– <span class="NLM_lpage">4314</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.05.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=23806553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSht73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4308-4314&author=R.+Gewaldauthor=C.+Grunwaldauthor=U.+Egerland&title=Discovery+of+triazines+as+potent%2C+selective+and+orally+active+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.05.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazines as potent, selective and orally active PDE4 inhibitors</span></div><div class="casAuthors">Gewald, Rainer; Grunwald, Christian; Egerland, Ute</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4308-4314</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivs. as novel PDE4 inhibitors.  The SAR development and optimization process with the emphasis on ligand efficiency and physicochem. properties led to the discovery of compd. 44 as a potent, selective and orally active PDE4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNEQIHJ0PfFrVg90H21EOLACvtfcHk0ljbnizwi_R92w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSht73M&md5=1bfc86c4cbf79c7fa893b5a556f175ad</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.099%26sid%3Dliteratum%253Aachs%26aulast%3DGewald%26aufirst%3DR.%26aulast%3DGrunwald%26aufirst%3DC.%26aulast%3DEgerland%26aufirst%3DU.%26atitle%3DDiscovery%2520of%2520triazines%2520as%2520potent%252C%2520selective%2520and%2520orally%2520active%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4308%26epage%3D4314%26doi%3D10.1016%2Fj.bmcl.2013.05.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R. V.</span>; <span class="NLM_string-name">Humphries, T.</span>; <span class="NLM_string-name">Hunt, S. F.</span>; <span class="NLM_string-name">Sanganee, H. J.</span></span> <span> </span><span class="NLM_article-title">Chemical Compounds 635: Pyrudopyrimidinediones as PDE4 Inhibitors</span>. Patent <span class="NLM_patent">WO2008084236</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+V.+Bonnert&author=T.+Humphries&author=S.+F.+Hunt&author=H.+J.+Sanganee&title=Chemical+Compounds+635%3A+Pyrudopyrimidinediones+as+PDE4+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26atitle%3DChemical%2520Compounds%2520635%253A%2520Pyrudopyrimidinediones%2520as%2520PDE4%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartopp, P.</span>; <span class="NLM_string-name">Johnson, T.</span>; <span class="NLM_string-name">Sanganee, H. J.</span></span> <span> </span><span class="NLM_article-title">Combination Comprising 6-fluoro-N-((1S,4S)-4-(6-fluoro-2,4-dioxo-1-(4’-(piperazin-1-ylmethyl)biphenyl-3-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)cyclohexyl) imidazo[1,2-a]pyridine-2-carboxamide or A Salt</span>. Patent <span class="NLM_patent">WO2010004319</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=P.+Hartopp&author=T.+Johnson&author=H.+J.+Sanganee&title=Combination+Comprising+6-fluoro-N-%28%281S%2C4S%29-4-%286-fluoro-2%2C4-dioxo-1-%284%E2%80%99-%28piperazin-1-ylmethyl%29biphenyl-3-yl%29-1%2C2-dihydropyrido%5B2%2C3-d%5Dpyrimidin-3%284H%29-yl%29cyclohexyl%29+imidazo%5B1%2C2-a%5Dpyridine-2-carboxamide+or+A+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartopp%26aufirst%3DP.%26atitle%3DCombination%2520Comprising%25206-fluoro-N-%2528%25281S%252C4S%2529-4-%25286-fluoro-2%252C4-dioxo-1-%25284%25E2%2580%2599-%2528piperazin-1-ylmethyl%2529biphenyl-3-yl%2529-1%252C2-dihydropyrido%255B2%252C3-d%255Dpyrimidin-3%25284H%2529-yl%2529cyclohexyl%2529%2520imidazo%255B1%252C2-a%255Dpyridine-2-carboxamide%2520or%2520A%2520Salt%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span>; <span class="NLM_string-name">Cox, R. J.</span>; <span class="NLM_string-name">De Savi, C.</span>; <span class="NLM_string-name">Meghani, P.</span>; <span class="NLM_string-name">Sanganee, H. J.</span>; <span class="NLM_string-name">Warner, D. J.</span></span> <span> </span><span class="NLM_article-title">Phenoxypyridinylamide Derivatives and their Use in the Treatment of PDE4 Mediated Disease States</span>. Patent <span class="NLM_patent">WO2009144494</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=G.+Andrews&author=R.+J.+Cox&author=C.+De+Savi&author=P.+Meghani&author=H.+J.+Sanganee&author=D.+J.+Warner&title=Phenoxypyridinylamide+Derivatives+and+their+Use+in+the+Treatment+of+PDE4+Mediated+Disease+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26atitle%3DPhenoxypyridinylamide%2520Derivatives%2520and%2520their%2520Use%2520in%2520the%2520Treatment%2520of%2520PDE4%2520Mediated%2520Disease%2520States%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, G.</span></span> <span> </span><span class="NLM_article-title">Natural products as modulators of the cyclic-AMP pathway: evaluation and synthesis of lead compounds</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6372</span>– <span class="NLM_lpage">6390</span>, <span class="refDoi"> DOI: 10.1039/C8OB01388H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1039%2FC8OB01388H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=30140804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyjsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=6372-6390&author=S.+Senguptaauthor=G.+Mehta&title=Natural+products+as+modulators+of+the+cyclic-AMP+pathway%3A+evaluation+and+synthesis+of+lead+compounds&doi=10.1039%2FC8OB01388H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products as modulators of the cyclic-AMP pathway: evaluation and synthesis of lead compounds</span></div><div class="casAuthors">Sengupta, Saumitra; Mehta, Goverdhan</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6372-6390</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that the normal cellular response in mammalian cells is critically regulated by the cyclic-AMP (cAMP) pathway through the appropriate balance of adenylyl cyclase (AC) and phosphodiesterase-4 (PDE4) activities.  Dysfunctions in the cAMP pathway have major implications in various diseases like CNS disorders, inflammation and cardiac syndromes and, hence, the modulation of cAMP signalling through appropriate intervention of AC/PDE4 activities has emerged as a promising new drug discovery strategy of current interest.  In this context, synthetic small mols. have had limited success so far and therefore parallel efforts on natural product leads have been actively pursued.  The early promise of using the diterpene forskolin and its semi-synthetic analogs as AC activators has given way to new leads in the last decade from novel natural products like the marine sesterterpenoids alotaketals and ansellones and the 9,9'-diarylfluorenone cored selaginpulvilins, etc. and their synthesis has drawn much attention.  This review captures these contemporary developments, particularly total synthesis campaigns and structure-guided analog design in the context of AC and PDE-4 modulating attributes and the scope for future possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpru9p4_Eg1J7Vg90H21EOLACvtfcHk0lgjWl7hqXXQRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyjsbzP&md5=73bec60647d7da0cbde7c598beac5d69</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1039%2FC8OB01388H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8OB01388H%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DG.%26atitle%3DNatural%2520products%2520as%2520modulators%2520of%2520the%2520cyclic-AMP%2520pathway%253A%2520evaluation%2520and%2520synthesis%2520of%2520lead%2520compounds%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2018%26volume%3D16%26spage%3D6372%26epage%3D6390%26doi%3D10.1039%2FC8OB01388H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, G.</span></span> <span> </span><span class="NLM_article-title">Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">642</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=7664866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2MXmslSnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1995&pages=637-642&author=K.+F.+Rabeauthor=H.+Magnussenauthor=G.+Dent&title=Theophylline+and+selective+PDE+inhibitors+as+bronchodilators+and+smooth+muscle+relaxants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Theophylline and selective phosphodiesterase inhibitors as bronchodilators and smooth muscle relaxants</span></div><div class="casAuthors">Rabe, K. F.; Magnussen, H.; Dent, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">637-42</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with 43 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Zf_Zg8qXYrVg90H21EOLACvtfcHk0lgjWl7hqXXQRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmslSnsbc%253D&md5=399fa9044f1583a60ba104c84bf52cc2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DDent%26aufirst%3DG.%26atitle%3DTheophylline%2520and%2520selective%2520PDE%2520inhibitors%2520as%2520bronchodilators%2520and%2520smooth%2520muscle%2520relaxants%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1995%26volume%3D8%26spage%3D637%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boswell-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Are phosphodiesterase 4 inhibitors just more theophylline?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1243</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2006.02.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jaci.2006.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=16750981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVaqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2006&pages=1237-1243&author=V.+Boswell-Smithauthor=M.+Cazzolaauthor=C.+P.+Page&title=Are+phosphodiesterase+4+inhibitors+just+more+theophylline%3F&doi=10.1016%2Fj.jaci.2006.02.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Are phosphodiesterase 4 inhibitors just more theophylline?</span></div><div class="casAuthors">Boswell-Smith, Victoria; Cazzola, Mario; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1243</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Theophylline has been relegated to a second- or even third-line therapy in the treatment of asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids and β2-agonists, although recent findings have suggested that theophylline possesses anti-inflammatory and immunomodulatory effects in addn. to its well-recognized effects as a bronchodilator.  In part, theophylline has fallen out of favor because of its adverse side-effect profile, and this has led to the search for more effective and safer drugs based on the knowledge that theophylline is orally active and that it is a nonselective phosphodiesterase (PDE) inhibitor.  This has led to the development of selective PDE4 inhibitors, originally designed for depression, for the treatment of both COPD and asthma.  Such drugs have shown clin. efficacy in the treatment of respiratory disease while having a considerably safer side-effect profile in comparison with theophylline, particularly because there are no reported drug interactions with PDE4 inhibitors, a feature that complicates the use of theophylline.  In addn., it is also becoming increasingly apparent that theophylline is not working solely through PDE inhibition, as formerly assumed, and that this drug has other relevant pharmacol. activities that are likely to contribute to its efficacy, such as adenosine receptor antagonism and induction of histone deacetylase.  Thus, the introduction of PDE4 inhibitors represents an entirely new class of drugs for the treatment of respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjribRm-vNzrVg90H21EOLACvtfcHk0lgjWl7hqXXQRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVaqt7g%253D&md5=517737e2ad1d9e932c3eaf225e489da2</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2006.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2006.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell-Smith%26aufirst%3DV.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DAre%2520phosphodiesterase%25204%2520inhibitors%2520just%2520more%2520theophylline%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2006%26volume%3D117%26spage%3D1237%26epage%3D1243%26doi%3D10.1016%2Fj.jaci.2006.02.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of flavonoids as anti-inflammatory agents: a review</span>. <i>Inflammation Allergy: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.2174/187152809788681029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.2174%2F187152809788681029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=19601883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=229-235&author=P.+Ratheeauthor=H.+Chaudharyauthor=S.+Ratheeauthor=D.+Ratheeauthor=V.+Kumarauthor=K.+Kohli&title=Mechanism+of+action+of+flavonoids+as+anti-inflammatory+agents%3A+a+review&doi=10.2174%2F187152809788681029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of flavonoids as anti-inflammatory agents: a review</span></div><div class="casAuthors">Rathee, Permender; Chaudhary, Hema; Rathee, Sushila; Rathee, Dharmender; Kumar, Vikash; Kohli, Kanchan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation & Allergy: Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-235</span>CODEN:
                <span class="NLM_cas:coden">IADTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1871-5281</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Flavonoids are polyphenolic compds. that occur ubiquitously in plants having a variety of biol. effects both in vitro and in vivo.  They have been found to have antimicrobial, antiviral, anti-ulcerogenic, cytotoxic, antineoplastic, mutagenic, antioxidant, antihepatotoxic, antihypertensive, hypolipidemic, antiplatelet and anti-inflammatory activities.  Flavonoids also have biochem. effects, which inhibit a no. of enzymes such as aldose reductase, xanthine oxidase, phosphodiesterase, Ca+2-ATPase, lipoxygenase, cycloxygenase, etc.  They also have a regulatory role on different hormones like estrogens, androgens and thyroid hormone.  They have been found to have anti-inflammatory activity in both proliferative and exudative phases of inflammation.  Several mechanisms of action have been proposed to explain anti-inflammatory action of flavonoids.  The aim of the present review is to give an overview of the mechanism of action of potential anti-inflammatory flavonoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7p7VbR65-TrVg90H21EOLACvtfcHk0lgiT98KtrDjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCju7k%253D&md5=507ef0309658f72713da2ae47c03e7ba</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2174%2F187152809788681029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152809788681029%26sid%3Dliteratum%253Aachs%26aulast%3DRathee%26aufirst%3DP.%26aulast%3DChaudhary%26aufirst%3DH.%26aulast%3DRathee%26aufirst%3DS.%26aulast%3DRathee%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKohli%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520action%2520of%2520flavonoids%2520as%2520anti-inflammatory%2520agents%253A%2520a%2520review%26jtitle%3DInflammation%2520Allergy%253A%2520Drug%2520Targets%26date%3D2009%26volume%3D8%26spage%3D229%26epage%3D235%26doi%3D10.2174%2F187152809788681029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bcp.2004.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=15476679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot12ntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2087-2094&author=W.+C.+Koauthor=C.+M.+Shihauthor=Y.+H.+Laiauthor=J.+H.+Chenauthor=H.+L.+Huang&title=Inhibitory+effects+of+flavonoids+on+phosphodiesterase+isozymes+from+guinea+pig+and+their+structure-activity+relationships&doi=10.1016%2Fj.bcp.2004.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships</span></div><div class="casAuthors">Ko, Wun-Chang; Shih, Chwen-Ming; Lai, Ya-Hsin; Chen, Jun-Hao; Huang, Hui-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2087-2094</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of flavonoids with regard to their inhibitory effects on phosphodiesterase (PDE) isoenzymes are little known.  The activities of PDE1-5 were measured by a two-step procedure using cAMP with [3H]-cAMP or cGMP with [3H]-cGMP as substrates.  In the present results, PDE1, 5, 2, and 4 isoenzymes were partially purified from guinea pig lungs in that order, and PDE3 was from the heart.  The IC50 values of PDE1-5 were greater than those reported previously for the ref. drugs, vinpocetin, EHNA, milrinone, Ro 20-1724, and zaprinast, by 5-, 5-, 7-, 5-, and 3-fold, resp.  As shown in Table 2, luteolin revealed non-selective inhibition of PDE1-5 with IC50 values in a range of 10-20 μM, as did genistein except with a low potency on PDE5.  Daidzein, an inactive analog of genistein in tyrosine kinase inhibition, showed selective inhibition of PDE3 with an IC50 value of around 30 μM, as did eriodictyol with an IC50 value of around 50 μM.  Hesperetin and prunetin exhibited more-selective inhibition of PDE4 with IC50 values of around 30 and 60 μM, resp.  Luteolin-7-glucoside exhibited dual inhibition of PDE2/PDE4 with an IC50 value of around 40 μM.  Diosmetin more-selectively inhibited PDE2 (IC50 of 4.8 μM) than PDE1, PDE4, or PDE5.  However, biochanin A more-selectively inhibited PDE4 (IC50 of 8.5 μM) than PDE1 or PDE2.  Apigenin inhibited PDE1-3 with IC50 values of around 10-25 μM.  Myricetin inhibited PDE1-4 with IC50 values of around 10-40 μM.  The same was true for quercetin, but we rather consider that it more-selectively inhibited PDE3 and PDE4 (IC50 <10 μM).  In conclusion, it is possible to synthesize useful drugs through elucidating the structure-activity relationships of flavonoids with respect to inhibition of PDE isoenzymes at concns. used in this in vitro study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyjKoy2FKJ7Vg90H21EOLACvtfcHk0lgiT98KtrDjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot12ntL0%253D&md5=fc0c7a9e7b73a3ef4cbc9d0a0079a96f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BC.%26aulast%3DShih%26aufirst%3DC.%2BM.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26atitle%3DInhibitory%2520effects%2520of%2520flavonoids%2520on%2520phosphodiesterase%2520isozymes%2520from%2520guinea%2520pig%2520and%2520their%2520structure-activity%2520relationships%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2087%26epage%3D2094%26doi%3D10.1016%2Fj.bcp.2004.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirtskhalava, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigand, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weivoda, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogrodnik, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachfeld, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onken, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verzosa, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhi, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrasseur, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garovic, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedernhofer, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchkonia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, J. L.</span></span> <span> </span><span class="NLM_article-title">Senolytics improve physical function and increase lifespan in old age</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0092-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1038%2Fs41591-018-0092-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29988130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWjs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1246-1256&author=M.+Xuauthor=T.+Pirtskhalavaauthor=J.+N.+Farrauthor=B.+M.+Weigandauthor=A.+K.+Palmerauthor=M.+M.+Weivodaauthor=C.+L.+Inmanauthor=M.+B.+Ogrodnikauthor=C.+M.+Hachfeldauthor=D.+G.+Fraserauthor=J.+L.+Onkenauthor=K.+O.+Johnsonauthor=G.+C.+Verzosaauthor=L.+G.+P.+Langhiauthor=M.+Weiglauthor=N.+Giorgadzeauthor=N.+K.+LeBrasseurauthor=J.+D.+Millerauthor=D.+Jurkauthor=R.+J.+Singhauthor=D.+B.+Allisonauthor=K.+Ejimaauthor=G.+B.+Hubbardauthor=Y.+Ikenoauthor=H.+Cubroauthor=V.+D.+Garovicauthor=X.+Houauthor=S.+J.+Werohaauthor=P.+D.+Robbinsauthor=L.+J.+Niedernhoferauthor=S.+Khoslaauthor=T.+Tchkoniaauthor=J.+L.+Kirkland&title=Senolytics+improve+physical+function+and+increase+lifespan+in+old+age&doi=10.1038%2Fs41591-018-0092-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Senolytics improve physical function and increase lifespan in old age</span></div><div class="casAuthors">Xu, Ming; Pirtskhalava, Tamar; Farr, Joshua N.; Weigand, Bettina M.; Palmer, Allyson K.; Weivoda, Megan M.; Inman, Christina L.; Ogrodnik, Mikolaj B.; Hachfeld, Christine M.; Fraser, Daniel G.; Onken, Jennifer L.; Johnson, Kurt O.; Verzosa, Grace C.; Langhi, Larissa G. P.; Weigl, Moritz; Giorgadze, Nino; LeBrasseur, Nathan K.; Miller, Jordan D.; Jurk, Diana; Singh, Ravinder J.; Allison, David B.; Ejima, Keisuke; Hubbard, Gene B.; Ikeno, Yuji; Cubro, Hajrunisa; Garovic, Vesna D.; Hou, Xiaonan; Weroha, S. John; Robbins, Paul D.; Niedernhofer, Laura J.; Khosla, Sundeep; Tchkonia, Tamara; Kirkland, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1246-1256</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Phys. function declines in old age, portending disability, increased health expenditures, and mortality.  Cellular senescence, leading to tissue dysfunction, may contribute to these consequences of aging, but whether senescence can directly drive age-related pathol. and be therapeutically targeted is still unclear.  Here we demonstrate that transplanting relatively small nos. of senescent cells into young mice is sufficient to cause persistent phys. dysfunction, as well as to spread cellular senescence to host tissues.  Transplanting even fewer senescent cells had the same effect in older recipients and was accompanied by reduced survival, indicating the potency of senescent cells in shortening health- and lifespan.  The senolytic cocktail, dasatinib plus quercetin, which causes selective elimination of senescent cells, decreased the no. of naturally occurring senescent cells and their secretion of frailty-related proinflammatory cytokines in explants of human adipose tissue.  Moreover, intermittent oral administration of senolytics to both senescent cell-transplanted young mice and naturally aged mice alleviated phys. dysfunction and increased post-treatment survival by 36% while reducing mortality hazard to 65%.  Our study provides proof-of-concept evidence that senescent cells can cause phys. dysfunction and decreased survival even in young mice, while senolytics can enhance remaining health- and lifespan in old mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdvfVKJxYgrVg90H21EOLACvtfcHk0lgiT98KtrDjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWjs7nE&md5=9f9a509553254b5f6a839d6927801ff3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0092-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0092-9%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPirtskhalava%26aufirst%3DT.%26aulast%3DFarr%26aufirst%3DJ.%2BN.%26aulast%3DWeigand%26aufirst%3DB.%2BM.%26aulast%3DPalmer%26aufirst%3DA.%2BK.%26aulast%3DWeivoda%26aufirst%3DM.%2BM.%26aulast%3DInman%26aufirst%3DC.%2BL.%26aulast%3DOgrodnik%26aufirst%3DM.%2BB.%26aulast%3DHachfeld%26aufirst%3DC.%2BM.%26aulast%3DFraser%26aufirst%3DD.%2BG.%26aulast%3DOnken%26aufirst%3DJ.%2BL.%26aulast%3DJohnson%26aufirst%3DK.%2BO.%26aulast%3DVerzosa%26aufirst%3DG.%2BC.%26aulast%3DLanghi%26aufirst%3DL.%2BG.%2BP.%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DGiorgadze%26aufirst%3DN.%26aulast%3DLeBrasseur%26aufirst%3DN.%2BK.%26aulast%3DMiller%26aufirst%3DJ.%2BD.%26aulast%3DJurk%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DAllison%26aufirst%3DD.%2BB.%26aulast%3DEjima%26aufirst%3DK.%26aulast%3DHubbard%26aufirst%3DG.%2BB.%26aulast%3DIkeno%26aufirst%3DY.%26aulast%3DCubro%26aufirst%3DH.%26aulast%3DGarovic%26aufirst%3DV.%2BD.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DRobbins%26aufirst%3DP.%2BD.%26aulast%3DNiedernhofer%26aufirst%3DL.%2BJ.%26aulast%3DKhosla%26aufirst%3DS.%26aulast%3DTchkonia%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DJ.%2BL.%26atitle%3DSenolytics%2520improve%2520physical%2520function%2520and%2520increase%2520lifespan%2520in%2520old%2520age%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1246%26epage%3D1256%26doi%3D10.1038%2Fs41591-018-0092-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A.</span>; <span class="NLM_string-name">Gericke, N.</span>; <span class="NLM_string-name">Viljoen, A.</span></span> <span> </span><span class="NLM_article-title">Use of Pharmaceutical Compositions Containing Mesembrenone</span>. Patent <span class="NLM_patent">WO2010106494</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Harvey&author=N.+Gericke&author=A.+Viljoen&title=Use+of+Pharmaceutical+Compositions+Containing+Mesembrenone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%26atitle%3DUse%2520of%2520Pharmaceutical%2520Compositions%2520Containing%2520Mesembrenone%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljoen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, N. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of the south African medicinal and functional food plant <i>Sceletium tortuosum</i> and its principal alkaloids</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.jep.2011.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.jep.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=21798331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOksbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=1124-1129&author=A.+L.+Harveyauthor=L.+C.+Youngauthor=A.+M.+Viljoenauthor=N.+P.+Gericke&title=Pharmacological+actions+of+the+south+African+medicinal+and+functional+food+plant+Sceletium+tortuosum+and+its+principal+alkaloids&doi=10.1016%2Fj.jep.2011.07.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids</span></div><div class="casAuthors">Harvey, Alan L.; Young, Louise C.; Viljoen, Alvaro M.; Gericke, Nigel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The South African plant Sceletium tortuosum has been known for centuries for a variety of traditional uses, and, more recently, as a possible source of anti-anxiety or anti-depressant effects.  A standardised ext. Zembrin was used to test for pharmacol. activities that might be relevant to the ethnopharmacol. uses, and three of the main alkaloids were also tested.  A standardised ethanolic ext. was prepd. from dried plant material, along with the purified alkaloids mesembrine, mesembrenone and mesembrenol.  These were tested on a panel of receptors, enzymes and other drug targets, and for cytotoxic effects on mammalian cells.  The ext. was a potent blocker in 5-HT transporter binding assays (IC50 4.3 μg/mL) and had powerful inhibitory effects on phosphodiesterase 4 (PDE4) (IC50 8.5 μg/mL), but not other phosphodiesterases.  There were no cytotoxic effects.  Mesembrine was the most active alkaloid against the 5-HT transporter (Ki 1.4 nM), while mesembrenone was active against the 5-HT transporter and PDE4 (IC50's < 1 μM).  The activity of the Sceletium tortuosum ext. on the 5-HT transporter and PDE4 may explain the clin. effects of prepns. made from this plant.  The activities relate to the presence of alkaloids, particularly mesembrine and mesembrenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc9_BiKIeVCLVg90H21EOLACvtfcHk0liaiOtD6uM-9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOksbnL&md5=142b80eafa58077de45622f21e3518bc</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%2BL.%26aulast%3DYoung%26aufirst%3DL.%2BC.%26aulast%3DViljoen%26aufirst%3DA.%2BM.%26aulast%3DGericke%26aufirst%3DN.%2BP.%26atitle%3DPharmacological%2520actions%2520of%2520the%2520south%2520African%2520medicinal%2520and%2520functional%2520food%2520plant%2520Sceletium%2520tortuosum%2520and%2520its%2520principal%2520alkaloids%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2011%26volume%3D137%26spage%3D1124%26epage%3D1129%26doi%3D10.1016%2Fj.jep.2011.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and modelling studies of natural ingredients from <i>Gaultheria yunnanensis</i> (FRANCH.) against phosphodiesterase-4</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2015.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26978121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFeqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=134-140&author=Y.+H.+Caiauthor=Y.+Guoauthor=Z.+Liauthor=D.+Wuauthor=X.+Liauthor=H.+Zhangauthor=J.+Yangauthor=H.+Luauthor=Z.+Sunauthor=H.-B.+Luoauthor=S.+Yinauthor=Y.+Wu&title=Discovery+and+modelling+studies+of+natural+ingredients+from+Gaultheria+yunnanensis+%28FRANCH.%29+against+phosphodiesterase-4&doi=10.1016%2Fj.ejmech.2015.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4</span></div><div class="casAuthors">Cai, Ying-Hong; Guo, Yanqiong; Li, Zhe; Wu, Deyang; Li, Xiruo; Zhang, Heng; Yang, Junjie; Lu, Heng; Sun, Zhaowei; Luo, Hai-Bin; Yin, Sheng; Wu, Yinuo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-140</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) is an anti-inflammatory target for treatment of asthma and chronic obstructive pulmonary disease (COPD).  Here, the authors report the isolation and characterization of 13 compds. by bioassay-guided fractionation of the Et acetate extn. of Gaultheria yunnanensis (FRANCH.), one of which pentacyclic triterpene I has never been reported.  Four of them inhibit PDE4 with the IC50 values < 20 μM and I is the most potent ingredient with an IC50 of 245 nM and moderate selectivity over other PDE families.  Mol. dynamics simulations suggest that I forms a hydrogen bond with Asn362, in addn. to the hydrogen bond with Gln369 and π-π interactions with Phe372, which are commonly obsd. in the binding of most PDE4 inhibitors.  The calcd. binding free energies for the interactions of PDE4-I and PDE4-II are -19.4 and -18.8 kcal/mol, in consistence with the bioassay that I and II have IC50 of 245 nM and 542 nM, resp.  The modeling results of these active compds. may aid the rational design of novel PDE4 inhibitors as anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLBW4itpbzLVg90H21EOLACvtfcHk0liaiOtD6uM-9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFeqs7w%253D&md5=8d77d41002edb04508e44e12504a7624</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DY.%2BH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DH.-B.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520modelling%2520studies%2520of%2520natural%2520ingredients%2520from%2520Gaultheria%2520yunnanensis%2520%2528FRANCH.%2529%2520against%2520phosphodiesterase-4%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D114%26spage%3D134%26epage%3D140%26doi%3D10.1016%2Fj.ejmech.2015.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span> <span> </span><span class="NLM_article-title">Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3261</span>– <span class="NLM_lpage">3264</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22483586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1ahurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3261-3264&author=S.+K.+Chenauthor=P.+Zhaoauthor=Y.+X.+Shaoauthor=Z.+Liauthor=C.+Zhangauthor=P.+Liuauthor=X.+Heauthor=H.-B.+Luoauthor=X.+Hu&title=Moracin+M+from+Morus+alba+L.+is+a+natural+phosphodiesterase-4+inhibitor&doi=10.1016%2Fj.bmcl.2012.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor</span></div><div class="casAuthors">Chen, Shang-Ke; Zhao, Peng; Shao, Yong-Xian; Li, Zhe; Zhang, Cuixian; Liu, Peiqing; He, Xixin; Luo, Hai-Bin; Hu, Xiaopeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3261-3264</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) has been identified to be a promising target for treatment of asthma.  Moracin M extd. from Chinese herbal drug 'Sang-Bai-Pi' (Morus alba L.) was studied for the inhibitory affinity towards PDE4.  It inhibited PDE4D2, PDE4B2, PDE5A1, and PDE9A2 with the IC50 values of 2.9, 4.5, >40, and >100 μM, resp.  Our mol. docking and 8 ns mol. dynamics (MD) simulations demonstrated that moracin M forms three hydrogen bonds with Gln369, Asn321, and Asp318 in the active site and stacks against Phe372.  In addn., comparative kinetics anal. of its analog moracin C was carried out to qual. validate their inhibitory potency as predicted by the binding free energy calcns. after MD simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlhLEN0Zrmc7Vg90H21EOLACvtfcHk0lj0Ct-OWErGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1ahurc%253D&md5=af16683e16f894e760cf27724eea0360</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BK.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DShao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.-B.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DMoracin%2520M%2520from%2520Morus%2520alba%2520L.%2520is%2520a%2520natural%2520phosphodiesterase-4%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3261%26epage%3D3264%26doi%3D10.1016%2Fj.bmcl.2012.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span> <span> </span><span class="NLM_article-title">Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2017.12.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29291443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=758-766&author=Y.+Q.+Guoauthor=G.+H.+Tangauthor=L.+L.+Louauthor=W.+Liauthor=B.+Zhangauthor=B.+Liuauthor=S.+Yin&title=Prenylated+flavonoids+as+potent+phosphodiesterase-4+inhibitors+from+Morus+alba%3A+Isolation%2C+modification%2C+and+structure-activity+relationship+study&doi=10.1016%2Fj.ejmech.2017.12.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study</span></div><div class="casAuthors">Guo, Yan-Qiong; Tang, Gui-Hua; Lou, Lan-Lan; Li, Wei; Zhang, Bei; Liu, Bo; Yin, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">758-766</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A bioassay-guided phytochem. study of a traditional Chinese medicine, M. alba root bark, led to the isolation of 18 prenylflavonoids (1-18), of which (±)-cyclomorusin (1/2), a pair of enantiomers, and 14-methoxy-dihydromorusin (3) are new compds.  Subsequent structural modification of the selected components by methylation, esterification, hydrogenation, and oxidative cyclization led to 14 more derivs. (19-32).  The small library was screened for its inhibition against phosphodiesterase-4 (PDE4), which is a drug target for the treatment of asthma and chronic obstructive pulmonary disease (COPD).  Among them, 9 compds. (1-5, 8, 10, 16, and 17) exhibited remarkable activities with IC50 values ranging from 0.0054 to 0.40 μM, being more active than the pos. control, rolipram (IC50 = 0.62 μM).  (+)-Cyclomorusin (1), the most active natural PDE4 inhibitor reported so far, also showed a high selectivity across other PDE members with a selective fold of >55.  The SAR study revealed that the presence of prenyl groups at C-3 and/or C-8, 2H-pyran ring D, and phenolic OH groups were important for the activity, which was further supported by the recognition mechanism study of the inhibitors with PDE4 by using mol. modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGUEMMg82erVg90H21EOLACvtfcHk0lj0Ct-OWErGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWgtA%253D%253D&md5=af2011096b1eb003cc73e9607e5f82e5</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.057%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BQ.%26aulast%3DTang%26aufirst%3DG.%2BH.%26aulast%3DLou%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DS.%26atitle%3DPrenylated%2520flavonoids%2520as%2520potent%2520phosphodiesterase-4%2520inhibitors%2520from%2520Morus%2520alba%253A%2520Isolation%252C%2520modification%252C%2520and%2520structure-activity%2520relationship%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D758%26epage%3D766%26doi%3D10.1016%2Fj.ejmech.2017.12.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.-B.</span></span> <span> </span><span class="NLM_article-title">The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from <i>Selaginella pulvinata</i></span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bcp.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=28159622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFeitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=51-59&author=Y.+Huangauthor=X.+Liuauthor=D.+Wuauthor=G.+Tangauthor=Z.+Laiauthor=X.+Zhengauthor=S.+Yinauthor=H.-B.+Luo&title=The+discovery%2C+complex+crystal+structure%2C+and+recognition+mechanism+of+a+novel+natural+PDE4+inhibitor+from+Selaginella+pulvinata&doi=10.1016%2Fj.bcp.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata</span></div><div class="casAuthors">Huang, Yiyou; Liu, Xin; Wu, Deyan; Tang, Guihua; Lai, Zengwei; Zheng, Xuehua; Yin, Sheng; Luo, Hai-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase-4 (PDE4) is an important drug target for treatment of inflammation-related diseases.  Till now, natural PDE4 inhibitors are rare and their co-crystal structures with PDE4 are hardly available.  In the present study, selaginpulvilins K (I) and L, two novel fluorene derivs., were isolated from a traditional Chinese medicine Selaginella pulvinata and exhibited remarkable inhibition against phosphodiesterase-4D (PDE4D) at IC50 11 nM and 90 nM, resp.  Compd. I also showed a good selectivity across PDE families with the selective fold ranging from 30 to 909.  To understand the recognition mechanism of selaginpulvilins towards PDE4, the crystal structure of PDE4D bound with I was successfully detd. by the X-ray diffraction method and presented an unusual binding mode in which the stretched skeleton of the inhibitor bound shallowly to the active site but had interactions with multi sub-pockets, such as Q, HC, M, and S, esp. strong interaction with the metal region.  Assisted with mol. modeling, the structure-activity relationship and the selectivity of selaginpulvilins were also well explored, which would facilitate the future rational inhibitor design or structural optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmSGuWv9caMLVg90H21EOLACvtfcHk0lj0Ct-OWErGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFeitL4%253D&md5=799a1437e87de5926a1dba69e91faf71</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DH.-B.%26atitle%3DThe%2520discovery%252C%2520complex%2520crystal%2520structure%252C%2520and%2520recognition%2520mechanism%2520of%2520a%2520novel%2520natural%2520PDE4%2520inhibitor%2520from%2520Selaginella%2520pulvinata%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D130%26spage%3D51%26epage%3D59%26doi%3D10.1016%2Fj.bcp.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Nanodomain regulation of cardiac cyclic nucleotide signaling by phosphodiesterases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010716-104756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev-pharmtox-010716-104756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27732797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=455-479&author=K.+Kokkonenauthor=D.+A.+Kass&title=Nanodomain+regulation+of+cardiac+cyclic+nucleotide+signaling+by+phosphodiesterases&doi=10.1146%2Fannurev-pharmtox-010716-104756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases</span></div><div class="casAuthors">Kokkonen, Kristen; Kass, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-479</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3',5'-monophosphate (cAMP or cGMP).  These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides.  Seven PDE family members are physiol. relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP.  New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors.  In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHS7lTakIRrVg90H21EOLACvtfcHk0lhJFSaFywFuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN&md5=0bbfd7fecacc24ec40b76e7406495313</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104756%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonen%26aufirst%3DK.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DNanodomain%2520regulation%2520of%2520cardiac%2520cyclic%2520nucleotide%2520signaling%2520by%2520phosphodiesterases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D455%26epage%3D479%26doi%3D10.1146%2Fannurev-pharmtox-010716-104756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting beta(2)-adrenoceptor agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.210997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1124%2Fjpet.113.210997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24513870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=85-93&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=Z.-H.+Cuiauthor=M.+Kimauthor=L.+Patelauthor=W.+R.+Bakerauthor=G.+B.+Phillipsauthor=C.+D.+Wrightauthor=M.+Salmon&title=The+in+vitro+pharmacology+of+GS-5759%2C+a+novel+bifunctional+phosphodiesterase+4+inhibitor+and+long+acting+beta%282%29-adrenoceptor+agonist&doi=10.1124%2Fjpet.113.210997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Cui, Zhi-Hua; Kim, Musong; Patel, Leena; Baker, William R.; Phillips, Gary B.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhaled long-acting β2-adrenoceptor agonists (LABA) that act as bronchodilators and the oral anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast are both approved therapies for chronic obstructive pulmonary disease (COPD).  Here we describe the activity of a novel, inhaled, bifunctional, small mol. (R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GS-5759), which has specific β2 agonist and PDE4 inhibitory activity.  GS-5759 demonstrated potent and full agonist activity at β2 adrenoceptors (EC50 = 8 ± 4 nM) and is a potent inhibitor of the PDE4 enzyme (IC50 = 5 ± 3 nM).  In cell assays, GS-5759 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) prodn. in human peripheral mononuclear cells (PBMC) with an IC50 = 0.3 nM [confidence interval (CI) 0.1-0.6] and in human neutrophils formyl-methionyl-leucyl-phenylalanine (fMLP)-induced super oxide anion prodn. with an IC50 = 3 nM (CI 0.8-8).  The addn. of the β2 antagonist ICI 118551 shifted the IC50 in these cell assays to 4 and 38 nM, resp., demonstrating the contribution of both β2 agonist and PDE4 inhibitory activity to GS-5759.  GS-5759 was also a potent inhibitor of profibrotic and proinflammatory mediator release from human lung fibroblasts.  GS-5759 relaxed guinea pig airway smooth muscle strips precontracted with carbachol in a concn.-dependent manner with an EC50 = 0.5 μM (CI 0.2-2) and had slow dissocn. kinetics with an Off T1/2 > 720 min at an EC80 concn. of 3 μM.  GS-5759 is a novel bifunctional mol. with both potent β2 agonist and PDE4 inhibitor activity that could provide inhaled bronchodilator and anti-inflammatory therapy for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_BKbLa3cVLVg90H21EOLACvtfcHk0lhJFSaFywFuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D&md5=b0017107ab4935141406708f98a8eec3</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210997%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DCui%26aufirst%3DZ.-H.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26aulast%3DPhillips%26aufirst%3DG.%2BB.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520in%2520vitro%2520pharmacology%2520of%2520GS-5759%252C%2520a%2520novel%2520bifunctional%2520phosphodiesterase%25204%2520inhibitor%2520and%2520long%2520acting%2520beta%25282%2529-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D85%26epage%3D93%26doi%3D10.1124%2Fjpet.113.210997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. S.</span></span> <span> </span><span class="NLM_article-title">Dual beta(2)-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22297114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1523-1526&author=W.+J.+Shanauthor=L.+Huangauthor=Q.+Zhouauthor=H.+L.+Jiangauthor=Z.+H.+Luoauthor=K.+F.+Laiauthor=X.+S.+Li&title=Dual+beta%282%29-adrenoceptor+agonists-PDE4+inhibitors+for+the+treatment+of+asthma+and+COPD&doi=10.1016%2Fj.bmcl.2012.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD</span></div><div class="casAuthors">Shan, Wen-Jun; Huang, Ling; Zhou, Qi; Jiang, Huai-Lei; Luo, Zong-Hua; Lai, Ke-fang; Li, Xing-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1523-1526</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized a novel class of dual pharmacol. bronchodilators targeting both β2-adrenoceptor and PDE4 by applying a multivalent approach.  The most potent dual pharmacol. mol., compd. 29, possessed good inhibitory activity on PDE4B2 (IC50 = 0.278 μM, which was more potent than phthalazinone, IC50 = 0.520 μM) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC50 = 9.3).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxvQC2OsmiBbVg90H21EOLACvtfcHk0lhJFSaFywFuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCks7c%253D&md5=bb62adf5681621c26bf29aa8dce93e21</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DW.%2BJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DLuo%26aufirst%3DZ.%2BH.%26aulast%3DLai%26aufirst%3DK.%2BF.%26aulast%3DLi%26aufirst%3DX.%2BS.%26atitle%3DDual%2520beta%25282%2529-adrenoceptor%2520agonists-PDE4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1523%26epage%3D1526%26doi%3D10.1016%2Fj.bmcl.2012.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of dual pharmacology beta(2)-adrenoceptor agonists and PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2013.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24300734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWrsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=249-253&author=L.+Huangauthor=W.+Shanauthor=Q.+Zhouauthor=J.+Xieauthor=K.+Laiauthor=X.+Li&title=Design%2C+synthesis+and+evaluation+of+dual+pharmacology+beta%282%29-adrenoceptor+agonists+and+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors</span></div><div class="casAuthors">Huang, Ling; Shan, Wenjun; Zhou, Qi; Xie, Jiaxing; Lai, Kefang; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-253</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of formoterol-phthalazinone hybrids were synthesized and evaluated as dual pharmacol. β2-adrenoceptor agonists and PDE4 inhibitors.  Most of the hybrids displayed high β2-adrenoceptor agonist and moderate PDE4 inhibitory activities.  The most potent compd., I, exhibited agonist (EC50 = 1.05 nM, pEC50 = 9.0) and potent PDE4B2 inhibitory activities (IC50 = 0.092 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcYmhg2Ao4NbVg90H21EOLACvtfcHk0lgTfoRkNYo6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWrsbnL&md5=f57566d3c422ba339f0dd7d4113c5e92</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520dual%2520pharmacology%2520beta%25282%2529-adrenoceptor%2520agonists%2520and%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D249%26epage%3D253%26doi%3D10.1016%2Fj.bmcl.2013.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cashman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of phosphodiesterase-4 and serotonin reuptake</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1021/jm8010993</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010993" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ars7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1530-1539&author=J.+R.+Cashmanauthor=T.+Voelkerauthor=H.+T.+Zhangauthor=J.+M.+O%E2%80%99Donnell&title=Dual+inhibitors+of+phosphodiesterase-4+and+serotonin+reuptake&doi=10.1021%2Fjm8010993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Phosphodiesterase-4 and Serotonin Reuptake</span></div><div class="casAuthors">Cashman, John R.; Voelker, Troy; Zhang, Han-Ting; O'Donnell, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1530-1539</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of multitarget compds. was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4 inhibitor.  The new dual PDE4 inhibitor/SSRI showed antidepressant-like activity in the forced swim test in mice.  The SSRIs 2-{5-[3-(5-fluoro-2-methoxyphenyl)ethyl]tetrahydrofuran-2-yl}ethylamine and 2-{5-[3-(5-fluoro-2-methoxyphenyl)propyl]tetrahydrofuran-2-yl}ethylamine were both individually linked to the PDE4 inhibitor 4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one, via a five-carbon chain.  The dual PDE4 inhibitor/SSRI 2-{5-[3-(5-fluoro-2-methoxyphenylethyltetrahydrofuran-2-yl}ethylamino)pentyl]-4,5,8,8a-tetrahydro-2H-phthalazin-1-one (I) showed potent and selective serotonin reuptake inhibition (IC50 value of 127 nM).  The dual PDE4 inhibitor/SSRI I also inhibited PDE4D3 with a Ki value of 2.0 nM.  The dual PDE4 inhibitor/SSRI was significantly more effective than the individual SSRI alone or fluoxetine in the forced swim test at std. doses.  On a molar basis, the antidepressant-like effect of the dual PDE4 inhibitor/SSRI I showed a 129-fold increase in in vivo efficacy compared to fluoxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqll1QZUolKq7Vg90H21EOLACvtfcHk0lgTfoRkNYo6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ars7w%253D&md5=2a0fcfa45c51500a029f231f7df4e48e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm8010993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010993%26sid%3Dliteratum%253Aachs%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DVoelker%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520inhibitors%2520of%2520phosphodiesterase-4%2520and%2520serotonin%2520reuptake%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1530%26epage%3D1539%26doi%3D10.1021%2Fjm8010993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J.F.</span>; <span class="NLM_string-name">Wan, Z.</span>; <span class="NLM_string-name">Yan, H.</span></span> <span> </span><span class="NLM_article-title">Dual Pharmacophores-PDE4-Muscarinic Antagonistics</span>. Patent <span class="NLM_patent">WO2009100170</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.F.+Callahan&author=Z.+Wan&author=H.+Yan&title=Dual+Pharmacophores-PDE4-Muscarinic+Antagonistics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DJ.F.%26atitle%3DDual%2520Pharmacophores-PDE4-Muscarinic%2520Antagonistics%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elisabetta, A.</span>; <span class="NLM_string-name">Gabriele, A.</span>; <span class="NLM_string-name">Carmelida, C.</span>; <span class="NLM_string-name">Baker-Glenn, C.</span></span> <span> </span><span class="NLM_article-title">Carbamate Derivatives which are both Phosphodiesterase 4 (PDE4) Enzyme Inhibitors and Muscarinic M3 Receptor Antagonists</span>. Patent <span class="NLM_patent">WO2015185650</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Elisabetta&author=A.+Gabriele&author=C.+Carmelida&author=C.+Baker-Glenn&title=Carbamate+Derivatives+which+are+both+Phosphodiesterase+4+%28PDE4%29+Enzyme+Inhibitors+and+Muscarinic+M3+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DElisabetta%26aufirst%3DA.%26atitle%3DCarbamate%2520Derivatives%2520which%2520are%2520both%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Enzyme%2520Inhibitors%2520and%2520Muscarinic%2520M3%2520Receptor%2520Antagonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blocher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopireddy, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnych, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Orally available soluble epoxide hydrolase/phosphodiesterase 4 dual inhibitor treats inflammatory pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3541</span>– <span class="NLM_lpage">3550</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01804</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01804" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3541-3550&author=R.+Blocherauthor=K.+M.+Wagnerauthor=R.+R.+Gopireddyauthor=T.+R.+Harrisauthor=H.+Wuauthor=B.+Barnychauthor=S.+H.+Hwangauthor=Y.+K.+Xiangauthor=E.+Proschakauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Orally+available+soluble+epoxide+hydrolase%2Fphosphodiesterase+4+dual+inhibitor+treats+inflammatory+pain&doi=10.1021%2Facs.jmedchem.7b01804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain</span></div><div class="casAuthors">Blocher, Rene; Wagner, Karen M.; Gopireddy, Raghavender R.; Harris, Todd R.; Wu, Hao; Barnych, Bogdan; Hwang, Sung Hee; Xiang, Yang K.; Proschak, Ewgenij; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3541-3550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by previously discovered enhanced analgesic efficacy between sol. epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors.  The best of these displayed good efficacy in in vitro assays.  Further pharmacokinetic studies of a subset of four selected compds. led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA).  In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h.  Addnl., MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorY4r0p-vHgbVg90H21EOLACvtfcHk0lgTfoRkNYo6Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCnsb4%253D&md5=3a1321852da65c85999de6e5bf993a9b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01804%26sid%3Dliteratum%253Aachs%26aulast%3DBlocher%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DGopireddy%26aufirst%3DR.%2BR.%26aulast%3DHarris%26aufirst%3DT.%2BR.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DBarnych%26aufirst%3DB.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DXiang%26aufirst%3DY.%2BK.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOrally%2520available%2520soluble%2520epoxide%2520hydrolase%252Fphosphodiesterase%25204%2520dual%2520inhibitor%2520treats%2520inflammatory%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3541%26epage%3D3550%26doi%3D10.1021%2Facs.jmedchem.7b01804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, Y.</span>; <span class="NLM_string-name">Ochiai, K.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Kojima, A.</span></span> <span> </span><span class="NLM_article-title">2-Alkyl-6-(pyrazolopyridin-4-yl)pyridazinone Derivative and PDE Inhibitor Using them as Active Ingredient</span>. Patent <span class="NLM_patent">JP2010013354</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Kono&author=K.+Ochiai&author=T.+Takita&author=A.+Kojima&title=2-Alkyl-6-%28pyrazolopyridin-4-yl%29pyridazinone+Derivative+and+PDE+Inhibitor+Using+them+as+Active+Ingredient"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DY.%26atitle%3D2-Alkyl-6-%2528pyrazolopyridin-4-yl%2529pyridazinone%2520Derivative%2520and%2520PDE%2520Inhibitor%2520Using%2520them%2520as%2520Active%2520Ingredient%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiraku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allcock, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 3: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmc.2012.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22336247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1644-1658&author=K.+Ochiaiauthor=S.+Takitaauthor=T.+Eirakuauthor=A.+Kojimaauthor=K.+Iwaseauthor=T.+Kishiauthor=K.+Fukuchiauthor=T.+Yasueauthor=D.+R.+Adamsauthor=R.+W.+Allcockauthor=Z.+Jiangauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+3%3A+design%2C+synthesis+and+structure-activity+relationships+of+dual+PDE3%2F4-inhibitory+fused+bicyclic+heteroaromatic-dihydropyridazinones+with+anti-inflammatory+and+bronchodilatory+activity&doi=10.1016%2Fj.bmc.2012.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity</span></div><div class="casAuthors">Ochiai, Koji; Takita, Satoshi; Eiraku, Tomohiko; Kojima, Akihiko; Iwase, Kazuhiko; Kishi, Tetsuya; Fukuchi, Kazunori; Yasue, Tokutaro; Adams, David R.; Allcock, Robert W.; Jiang, Zhong; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1644-1658</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity.  A survey of potential bicyclic heteroarom. replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin-5-yl analogs as dual PDE3/4-inhibitory compds. that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx4LlKRHG4R7Vg90H21EOLACvtfcHk0lhgf6wZvENBMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12gsrc%253D&md5=d4ef993ba2bd87efd2b87f76cf98d8c9</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DEiraku%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DFukuchi%26aufirst%3DK.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DAllcock%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25203%253A%2520design%252C%2520synthesis%2520and%2520structure-activity%2520relationships%2520of%2520dual%2520PDE3%252F4-inhibitory%2520fused%2520bicyclic%2520heteroaromatic-dihydropyridazinones%2520with%2520anti-inflammatory%2520and%2520bronchodilatory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1644%26epage%3D1658%26doi%3D10.1016%2Fj.bmc.2012.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiraku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohinata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yageta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, Y.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5833</span>– <span class="NLM_lpage">5838</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2012.07.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22884989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5833-5838&author=K.+Ochiaiauthor=S.+Takitaauthor=A.+Kojimaauthor=T.+Eirakuauthor=N.+Andoauthor=K.+Iwaseauthor=T.+Kishiauthor=A.+Ohinataauthor=Y.+Yagetaauthor=T.+Yasueauthor=D.+R.+Adamsauthor=Y.+Kohno&title=Phosphodiesterase+inhibitors.+Part+4%3A+design%2C+synthesis+and+structure-activity+relationships+of+dual+PDE3%2F4-inhibitory+fused+bicyclic+heteroaromatic-4%2C4-dimethylpyrazolones&doi=10.1016%2Fj.bmcl.2012.07.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors. Part 4: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones</span></div><div class="casAuthors">Ochiai, Koji; Takita, Satoshi; Kojima, Akihiko; Eiraku, Tomohiko; Ando, Naoki; Iwase, Kazuhiko; Kishi, Tetsuya; Ohinata, Akira; Yageta, Yuichi; Yasue, Tokutaro; Adams, David R.; Kohno, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5833-5838</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity.  Here we show that a 4,4-dimethylpyrazolone subunit serves as an effective surrogate for the 5-methyl-4,5-dihydropyridazin-3(2H)-one ring of KCA-1490 while lacking a stereogenic center.  The 2- and 7-substituents in the pyrazolo[1,5-a]pyridine subunit markedly influence the PDE-inhibitory profile and can be adjusted to afford either potent PDE4-selective inhibitors or dual PDE3/4 inhibitors.  A survey of bicyclic heteroarom. replacements for the pyrazolo[1,5-a]pyridine allowed further refinement of the inhibitory profile and identified 3-(8-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)-4,4-dimethyl-1H-pyrazol-5(4H)-one as an orally active, achiral KCA-1490 analog with well-balanced dual PDE3/4-inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KLCxyhkIvbVg90H21EOLACvtfcHk0lhgf6wZvENBMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzL&md5=956a10c4d4f8f192f2bbf3282947b9ac</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.088%26sid%3Dliteratum%253Aachs%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DTakita%26aufirst%3DS.%26aulast%3DKojima%26aufirst%3DA.%26aulast%3DEiraku%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DN.%26aulast%3DIwase%26aufirst%3DK.%26aulast%3DKishi%26aufirst%3DT.%26aulast%3DOhinata%26aufirst%3DA.%26aulast%3DYageta%26aufirst%3DY.%26aulast%3DYasue%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DKohno%26aufirst%3DY.%26atitle%3DPhosphodiesterase%2520inhibitors.%2520Part%25204%253A%2520design%252C%2520synthesis%2520and%2520structure-activity%2520relationships%2520of%2520dual%2520PDE3%252F4-inhibitory%2520fused%2520bicyclic%2520heteroaromatic-4%252C4-dimethylpyrazolones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5833%26epage%3D5838%26doi%3D10.1016%2Fj.bmcl.2012.07.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbott-Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fbcpt.12209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=24517491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=365-376&author=K.+H.+Abbott-Bannerauthor=C.+P.+Page&title=Dual+PDE3%2F4+and+PDE4+inhibitors%3A+novel+treatments+for+COPD+and+other+inflammatory+airway+diseases&doi=10.1111%2Fbcpt.12209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases</span></div><div class="casAuthors">Abbott-Banner, Katharine H.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential therapeutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bronchodilator/anti-inflammatory (PDE3/4) effects.  Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled.  Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization.  The majority of the compds. that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes.  Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with subtype specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy vs. inhibition of either PDE3 or PDE4 alone, given the potential pos. interactions with regard to anti-inflammatory and bronchodilator effects that have been obsd. pre-clin. with dual inhibition of PDE3 and PDE4 compared with inhibition of either isoenzyme alone.  This MiniReview will summarize recent clin. data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj1ILnRPA11rVg90H21EOLACvtfcHk0liJCHr1FH0xGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D&md5=d29edfe27d2514633d532bdd47d938d4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott-Banner%26aufirst%3DK.%2BH.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DDual%2520PDE3%252F4%2520and%2520PDE4%2520inhibitors%253A%2520novel%2520treatments%2520for%2520COPD%2520and%2520other%2520inflammatory%2520airway%2520diseases%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D365%26epage%3D376%26doi%3D10.1111%2Fbcpt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelcman, B.</span>; <span class="NLM_string-name">Krog-Jensen, C.</span>; <span class="NLM_string-name">No, K.</span>; <span class="NLM_string-name">Sanin, A.</span></span> <span> </span><span class="NLM_article-title">Pyrimidinones for Use as Medicaments</span>. Patent <span class="NLM_patent">WO2011114103</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Pelcman&author=C.+Krog-Jensen&author=K.+No&author=A.+Sanin&title=Pyrimidinones+for+Use+as+Medicaments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPelcman%26aufirst%3DB.%26atitle%3DPyrimidinones%2520for%2520Use%2520as%2520Medicaments%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelcman, B.</span>; <span class="NLM_string-name">Yee, J.</span>; <span class="NLM_string-name">Gee, K.</span>; <span class="NLM_string-name">Mackenzie, L. F.</span>; <span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Han, K.</span></span> <span> </span><span class="NLM_article-title">Isochromenones Useful in the Treatment of Inflammation</span>. Patent <span class="NLM_patent">WO2010076564</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=B.+Pelcman&author=J.+Yee&author=K.+Gee&author=L.+F.+Mackenzie&author=Y.+Zhou&author=K.+Han&title=Isochromenones+Useful+in+the+Treatment+of+Inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPelcman%26aufirst%3DB.%26atitle%3DIsochromenones%2520Useful%2520in%2520the%2520Treatment%2520of%2520Inflammation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span>; <span class="NLM_string-name">Gupta, N.</span>; <span class="NLM_string-name">Chandrakant, K. G.</span>; <span class="NLM_string-name">Jain, T.</span>; <span class="NLM_string-name">Voleti, S. R.</span>; <span class="NLM_string-name">Ray, A.</span>; <span class="NLM_string-name">Dastidar, S. G.</span>; <span class="NLM_string-name">Vijaykrishnan, L.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors</span>. Patent <span class="NLM_patent">WO2010046791</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Rudra&author=N.+Gupta&author=K.+G.+Chandrakant&author=T.+Jain&author=S.+R.+Voleti&author=A.+Ray&author=S.+G.+Dastidar&author=L.+Vijaykrishnan&title=Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRudra%26aufirst%3DS.%26atitle%3DPhosphodiesterase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C. S.</span>; <span class="NLM_string-name">Ivey, F. D.</span>; <span class="NLM_string-name">Wyman Petri, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclic AMP Phosphodiesterases</span>. Patent <span class="NLM_patent">US20100227853</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+S.+Hoffman&author=F.+D.+Ivey&author=A.+Wyman+Petri&title=Inhibitors+of+Cyclic+AMP+Phosphodiesterases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520Cyclic%2520AMP%2520Phosphodiesterases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chlon-Rzepa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swierczek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pociecha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawalska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaczkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span> <span> </span><span class="NLM_article-title">Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.ejmech.2018.01.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=29407965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=381-394&author=G.+Chlon-Rzepaauthor=A.+Jankowskaauthor=M.+Slusarczykauthor=A.+Swierczekauthor=K.+Pociechaauthor=E.+Wyskaauthor=A.+Buckiauthor=A.+Gawalskaauthor=M.+Kolaczkowskiauthor=M.+Pawlowski&title=Novel+butanehydrazide+derivatives+of+purine-2%2C6-dione+as+dual+PDE4%2F7+inhibitors+with+potential+anti-inflammatory+activity%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.01.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Chlon-Rzepa, Grazyna; Jankowska, Agnieszka; Slusarczyk, Marietta; Swierczek, Artur; Pociecha, Krzysztof; Wyska, Elzbieta; Bucki, Adam; Gawalska, Alicja; Kolaczkowski, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381-394</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel butanehydrazide derivs. of purine-2,6-dione I [R = H, EtO, PhCH2NH, (furan-2-ylmethyl)amino, etc.; R1 = 2-HOC6H4, 2,4-(HO)2C6H3, 2,3,4-(HO)3C6H2, 2-HO-4-MeOC6H3] designed using a ligand-based approach were synthesized and their in vitro activity against both PDE4B and PDE7A isoenzymes was assessed.  The 7,8-disubstituted purine-2,6-dione derivs. I [R = PhCH2NH, PhCH2CH2NH, (furan-2-ylmethyl)amino, (pyridin-2-ylmethyl)amino; R1 = 2,3,4-(HO)3C6H2] appeared to be the most potent PDE4/7 inhibitors with IC50 values in the range of that of the ref. rolipram and BRL-50481, resp.  Moreover, docking studies explained the importance of N-(2,3,4-trihydroxybenzylidene)butanehydrazide substituent in position 7 of purine-2,6-dione core for dual PDE4/7 inhibitory properties.  The inhibition of both the cAMP-specific PDE isoenzymes resulted in a strong anti-TNF-α effect.  Compds. I [R = PhCH2NH, PhCH2CH2NH, (furan-2-ylmethyl)amino; R1 = 2,3,4-(HO)3C6H2] in the in vivo study in rats with LPS-induced endotoxemia decreased the max. concn. of this proinflammatory cytokine by 53, 84 and 88%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrENI95nbu1DLVg90H21EOLACvtfcHk0liJCHr1FH0xGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrtLk%253D&md5=088cb6d842d7dbf0ce5ca44c4623631c</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.068%26sid%3Dliteratum%253Aachs%26aulast%3DChlon-Rzepa%26aufirst%3DG.%26aulast%3DJankowska%26aufirst%3DA.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSwierczek%26aufirst%3DA.%26aulast%3DPociecha%26aufirst%3DK.%26aulast%3DWyska%26aufirst%3DE.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DGawalska%26aufirst%3DA.%26aulast%3DKolaczkowski%26aufirst%3DM.%26aulast%3DPawlowski%26aufirst%3DM.%26atitle%3DNovel%2520butanehydrazide%2520derivatives%2520of%2520purine-2%252C6-dione%2520as%2520dual%2520PDE4%252F7%2520inhibitors%2520with%2520potential%2520anti-inflammatory%2520activity%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D381%26epage%3D394%26doi%3D10.1016%2Fj.ejmech.2018.01.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaeta, F. C. A.</span>; <span class="NLM_string-name">Johnson, K. W.</span>; <span class="NLM_string-name">Gross, M. I.</span>; <span class="NLM_string-name">Ledeboer, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Pyrazolo[1,5-a]pyridine Compounds Having Multi-Target Activity</span>. Patent <span class="NLM_patent">WO2010144416</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=F.+C.+A.+Gaeta&author=K.+W.+Johnson&author=M.+I.+Gross&author=A.+Ledeboer&title=Substituted+Pyrazolo%5B1%2C5-a%5Dpyridine+Compounds+Having+Multi-Target+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaeta%26aufirst%3DF.%2BC.%2BA.%26atitle%3DSubstituted%2520Pyrazolo%255B1%252C5-a%255Dpyridine%2520Compounds%2520Having%2520Multi-Target%2520Activity%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, R.</span>; <span class="NLM_string-name">Blythin, D.</span>; <span class="NLM_string-name">Shih, N. Y.</span>; <span class="NLM_string-name">Shue, H. J.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Gu, D.</span>; <span class="NLM_string-name">Huang, Y.</span>; <span class="NLM_string-name">Schwerdt, J. H.</span>; <span class="NLM_string-name">Ting, P. C.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors</span>. Patent <span class="NLM_patent">WO2005116009</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Kuang&author=D.+Blythin&author=N.+Y.+Shih&author=H.+J.+Shue&author=X.+Chen&author=J.+Cao&author=D.+Gu&author=Y.+Huang&author=J.+H.+Schwerdt&author=P.+C.+Ting&title=Substituted+2-quinolyl-oxazoles+useful+as+PDE4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DR.%26atitle%3DSubstituted%25202-quinolyl-oxazoles%2520useful%2520as%2520PDE4%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamiot-Clerc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derimay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grepin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.bmcl.2015.11.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26681511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=454-459&author=J.+Le+Rouxauthor=C.+Lericheauthor=P.+Chamiot-Clercauthor=J.+Feutrillauthor=F.+Halleyauthor=D.+Papinauthor=N.+Derimayauthor=C.+Muglerauthor=C.+Grepinauthor=L.+Schio&title=Preparation+and+optimization+of+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+new+potent+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors</span></div><div class="casAuthors">Le Roux, Jacques; Leriche, Caroline; Chamiot-Clerc, Philippe; Feutrill, John; Halley, Frank; Papin, David; Derimay, Nathalie; Mugler, Christelle; Grepin, Claudine; Schio, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-459</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of pyrazolo[1,5-a]pyrimidines exemplified by compd. I, has been identified with moderate activity (IC50 = 165 nM), following GSK256066 rescaffolding.  Compd. I optimization at positions 2, 3, 6 and 7 gave compd. II with high in vitro activity (IC50 = 0.7 nM).  Modeling studies based on the PDB structure 3GWT with compd. III showed the expected overlay with the carboxamide, the aryl moiety and the sulfone.  Cyclization of the primary amide to the 5 position of the pyrazolo[1,5-a]pyrimidines scaffold afforded compds. IV [R = 3-MeO, 3,5-Cl] with 200-fold enhancement in activity and cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmgso9aPgRr7Vg90H21EOLACvtfcHk0lhRtUq4_DVhBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2msbrJ&md5=962985b2b1ff0cb57e104018b75d23fa</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.093%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRoux%26aufirst%3DJ.%26aulast%3DLeriche%26aufirst%3DC.%26aulast%3DChamiot-Clerc%26aufirst%3DP.%26aulast%3DFeutrill%26aufirst%3DJ.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DPapin%26aufirst%3DD.%26aulast%3DDerimay%26aufirst%3DN.%26aulast%3DMugler%26aufirst%3DC.%26aulast%3DGrepin%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DPreparation%2520and%2520optimization%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520new%2520potent%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D454%26epage%3D459%26doi%3D10.1016%2Fj.bmcl.2015.11.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cieslinski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=7791113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK2MXmsVCgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1995&pages=1396-1402&author=M.+S.+Barnetteauthor=M.+Grousauthor=L.+B.+Cieslinskiauthor=M.+Burmanauthor=S.+B.+Christensenauthor=T.+J.+Torphy&title=Inhibitors+of+phosphodiesterase+IV+%28PDE+IV%29+increase+acid+secretion+in+rabbit+isolated+gastric+glands%3A+correlation+between+function+and+interaction+with+a+high-affinity+rolipram+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site</span></div><div class="casAuthors">Barnette, Mary S.; Grous, Marilyn; Cieslinski, Lenora B.; Burman, Miriam; Christensen, Siegfried B.; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1396-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In this report, we describe the ability of selective inhibitors of phosphodiesterase (PDE) isoenzymes to increase aminopyrine accumulation in rabbit isolated gastric glands.  Aminopyrine accumulation in the presence of histamine was increased by the nonselective PDE inhibitor isobutylmethylxanthine (EC50 = 4.8 μM) and by two selective PDE IV inhibitors, rolipram and Ro 20-1724 (EC50 = 0.013 and 0.07 μM, resp.) but not by selective PDE III inhibitors (siguazodan and SK&F 94120) or by a selective PDE V inhibitor (zaprinast).  These results suggest that PDE IV is an important regulator of acid secretion in response to histamine.  One of the more fascinating properties of PDE IV is the expression of a high-affinity binding site for [3H]-rolipram in addn. to cAMP catalytic activity.  Although agents that inhibit PDE IV catalytic activity also appear to bind to the high-affinity rolipram-binding site, the rank-order potencies of compds. for these two effects are poorly correlated.  Also, certain pharmacol. actions of PDE IV inhibitors appear to be related to an interaction with this binding site.  In this study, we obsd. that the ability of PDE IV inhibitors to enhance acid secretion was not assocd. with their ability to inhibit PDE IV catalytic activity but did show a strong correlation with their ability to compete for [3H]-rolipram binding.  Furthermore, we were able to detect [3H]-rolipram binding sites in gastric glands that had characteristics similar to those of the [3H]-rolipram binding sites in rat brain microsomes and human recombinant PDE IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGYysc0iW3hbVg90H21EOLACvtfcHk0lhRtUq4_DVhBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsVCgu7o%253D&md5=cc7c72c84e09753b8d46d8df2bb60b36</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26aulast%3DGrous%26aufirst%3DM.%26aulast%3DCieslinski%26aufirst%3DL.%2BB.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DS.%2BB.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DInhibitors%2520of%2520phosphodiesterase%2520IV%2520%2528PDE%2520IV%2529%2520increase%2520acid%2520secretion%2520in%2520rabbit%2520isolated%2520gastric%2520glands%253A%2520correlation%2520between%2520function%2520and%2520interaction%2520with%2520a%2520high-affinity%2520rolipram%2520binding%2520site%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D273%26spage%3D1396%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmiechen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachtel, H.</span></span> <span> </span><span class="NLM_article-title">Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1007/BF02245738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1007%2FBF02245738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=2392503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVGhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1990&pages=17-20&author=R.+Schmiechenauthor=H.+H.+Schneiderauthor=H.+Wachtel&title=Close+correlation+between+behavioural+response+and+binding+in+vivo+for+inhibitors+of+the+rolipram-sensitive+phosphodiesterase&doi=10.1007%2FBF02245738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase</span></div><div class="casAuthors">Schmiechen, Ralph; Schneider, Herbert H.; Wachtel, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-20</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The antidepressant rolipram interacts in vitro with a binding site in brain tissue labeled by [3H]rolipram.  A [3H]rolipram binding assay was employed in vivo to compare the affinity of rolipram-related compds. and ref. phosphodiesterase (PDE) inhibitors with their potency in behavioral measures for potential antidepressant property.  In mice and rats, the potency of a no. of compds. to antagonize reserpine-induced hypothermia (mice) and to induce head twitches (rats) was detd., as well as their potency to displace [3H]rolipram from forebrain binding sites in vivo.  The treatment schedules for the two series of expts. were identical.  Correlations between pharmacol. effects and displacement of [3H]rolipram binding in vivo were obsd. in both species.  Since the ref. PDE inhibitors closely fit into the binding-pharmacol. activity relationship, the PDE inhibitory properties of the substances involved are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvgKEhvFtsrVg90H21EOLACvtfcHk0lhRtUq4_DVhBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVGhtL0%253D&md5=c8596b92dab447707f96919309ea24e4</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2FBF02245738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02245738%26sid%3Dliteratum%253Aachs%26aulast%3DSchmiechen%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DH.%2BH.%26aulast%3DWachtel%26aufirst%3DH.%26atitle%3DClose%2520correlation%2520between%2520behavioural%2520response%2520and%2520binding%2520in%2520vivo%2520for%2520inhibitors%2520of%2520the%2520rolipram-sensitive%2520phosphodiesterase%26jtitle%3DPsychopharmacology%26date%3D1990%26volume%3D102%26spage%3D17%26epage%3D20%26doi%3D10.1007%2FBF02245738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=8863835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=891-899&author=S.+Jacobitzauthor=M.+M.+McLaughlinauthor=G.+P.+Liviauthor=M.+Burmanauthor=T.+J.+Torphy&title=Mapping+the+functional+domains+of+human+recombinant+phosphodiesterase+4A%3A+structural+requirements+for+catalytic+activity+and+rolipram+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding</span></div><div class="casAuthors">Jacobitz, Susanne; McLaughlin, Megan M.; Livi, George P.; Burman, Miriam; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To identify functional domains of the 886-amino acid human recombinant cAMP-specific phosphodiesterase (PDE) subtype A (rhPDE4A), we engineered the expression of seven mutant proteins contg. both NH2- and COOH-terminal truncations.  The level of rhPDE4A protein expression in yeast was monitored by immunoblotting using enzyme-specific antisera.  Biochem. profiles of the mutant proteins were compared with those of the full-length protein or a fully active truncated form of the enzyme (rhPDE4A Met265-886), lacking the first 264 amino acids.  The smallest catalytically active fragment generated was Met332-722, which at 45 kDa is less than half the mass of the full-length enzyme (∼110 kDa) but spans the most highly conserved region of the PDE superfamily.  Two prototypical PDE4 inhibitors, rolipram and RP 73401, inhibited cAMP-hydrolyzing activity of all truncated forms of the enzyme, with IC50 values of 70-2000 nM and 0.2-0.6 nM, resp.  [3H](R)-Rolipram bound to two sites on Met265-886, a high affinity site (Kd1 = 0.7 ± 0.3 nM) and a low affinity site (Kd2 = 34 ± 10 nM).  Interestingly, [3H](R)-rolipram failed to bind to Met332-886 with high affinity, indicating that high affinity binding is not required for inhibition of enzyme activity.  Low affinity rolipram-binding was still present in Met332-886 (Kd = 101 ± 7 nM).  In contrast to [3H](R)-rolipram, [3H]RP 73401 bound to a single class of high affinity sites on Met265-886 (Kd = 0.4 ± 0.1 nM).  Further truncation of the enzyme to Met332-886 had no effect on [3H]RP 73401 binding (Kd = 0.2 ± 0.03 nM).  We conclude that the catalytic center of rhPDE4A lies between amino acids 332 and 722.  Furthermore, amino acids 265-332 may form a high affinity binding site for rolipram that is outside the catalytic domain.  As a more likely alternative, these amino acids may not form a distinct binding site but instead may be required for the recombinant enzyme to assume a conformation that binds rolipram at the catalytic domain with a high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQO9hB-XY4nrVg90H21EOLACvtfcHk0lj2SQN85o_xQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D&md5=17e514f10560b1472aedbac336b58882</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobitz%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DMapping%2520the%2520functional%2520domains%2520of%2520human%2520recombinant%2520phosphodiesterase%25204A%253A%2520structural%2520requirements%2520for%2520catalytic%2520activity%2520and%2520rolipram%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauda, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, E. C.</span></span> <span> </span><span class="NLM_article-title">Revisiting cAMP signaling in the carotid body</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">406</span>, <span class="refDoi"> DOI: 10.3389/fphys.2014.00406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphys.2014.00406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25389406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC2M3nsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=406&author=A.+R.+Nunesauthor=A.+P.+Holmesauthor=S.+V.+Condeauthor=E.+B.+Gaudaauthor=E.+C.+Monteiro&title=Revisiting+cAMP+signaling+in+the+carotid+body&doi=10.3389%2Ffphys.2014.00406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting cAMP signaling in the carotid body</span></div><div class="casAuthors">Nunes Ana R; Conde Silvia V; Monteiro Emilia C; Holmes Andrew P; Gauda Estelle B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">406</span>
        ISSN:<span class="NLM_cas:issn">1664-042X</span>.
    </div><div class="casAbstract">Chronic carotid body (CB) activation is now recognized as being essential in the development of hypertension and promoting insulin resistance; thus, it is imperative to characterize the chemotransduction mechanisms of this organ in order to modulate its activity and improve patient outcomes.  For several years, and although controversial, cyclic adenosine monophosphate (cAMP) was considered an important player in initiating the activation of the CB.  However, its relevance was partially displaced in the 90s by the emerging role of the mitochondria and molecules such as AMP-activated protein kinase and O2-sensitive K(+) channels.  Neurotransmitters/neuromodulators binding to metabotropic receptors are essential to chemotransmission in the CB, and cAMP is central to this process. cAMP also contributes to raise intracellular Ca(2+) levels, and is intimately related to the cellular energetic status (AMP/ATP ratio).  Furthermore, cAMP signaling is a target of multiple current pharmacological agents used in clinical practice.  This review (1) provides an outline on the classical view of the cAMP-signaling pathway in the CB that originally supported its role in the O2/CO2 sensing mechanism, (2) presents recent evidence on CB cAMP neuromodulation and (3) discusses how CB activity is affected by current clinical therapies that modify cAMP-signaling, namely dopaminergic drugs, caffeine (modulation of A2A/A2B receptors) and roflumilast (PDE4 inhibitors). cAMP is key to any process that involves metabotropic receptors and the intracellular pathways involved in CB disease states are likely to involve this classical second messenger.  Research examining the potential modification of cAMP levels and/or interactions with molecules associated with CB hyperactivity is currently in its beginning and this review will open doors for future explorations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK20E-hdrxgDEwO064Z95rfW6udTcc2eZq9FGgYUpvibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3nsVKksQ%253D%253D&md5=9b044d38fa02de39d985d73d152adf92</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2014.00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2014.00406%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DA.%2BR.%26aulast%3DHolmes%26aufirst%3DA.%2BP.%26aulast%3DConde%26aufirst%3DS.%2BV.%26aulast%3DGauda%26aufirst%3DE.%2BB.%26aulast%3DMonteiro%26aufirst%3DE.%2BC.%26atitle%3DRevisiting%2520cAMP%2520signaling%2520in%2520the%2520carotid%2520body%26jtitle%3DFront.%2520Physiol.%26date%3D2014%26volume%3D5%26spage%3D406%26doi%3D10.3389%2Ffphys.2014.00406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prysyazhna, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, P.</span></span> <span> </span><span class="NLM_article-title">Redox regulation of cGMP-dependent protein kinase Ialpha in the cardiovascular system</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26236235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=139&author=O.+Prysyazhnaauthor=P.+Eaton&title=Redox+regulation+of+cGMP-dependent+protein+kinase+Ialpha+in+the+cardiovascular+system&doi=10.3389%2Ffphar.2015.00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Redox regulation of cGMP-dependent protein kinase Iα in the cardiovascular system</span></div><div class="casAuthors">Prysyazhna, Oleksandra; Eaton, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139/1-139/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Elevated levels of oxidants in biol. systems have been historically referred to as "oxidative stress," a choice of words that perhaps conveys an imbalanced view of reactive oxygen species in cells and tissues.  The term stress suggests a harmful role, whereas a contemporary view is that oxidants are also crucial for the maintenance of homeostasis or adaptive signaling that can actually limit injury.  This regulatory role for oxidants is achieved in part by them inducing oxidative post-translational modifications of proteins which may alter their function or interactions.  Such mechanisms allow changes in cell oxidant levels to be coupled to regulated alterations in enzymic function (i.e., signal transduction), which enables "redox signaling." In this review we focus on the role of cGMP-dependent protein kinase (PKG) Iα disulfide dimerization, an oxidative modification that is induced by oxidants that directly activates the enzyme, discussing how this impacts on the cardiovascular system.  Addnl., how this oxidative activation of PKG may coordinate with or differ from classical activation of this kinase by cGMP is also considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG5unr18UpcbVg90H21EOLACvtfcHk0lj2SQN85o_xQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals77E&md5=fabe432b3ae84c251bd8395323a40f6c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00139%26sid%3Dliteratum%253Aachs%26aulast%3DPrysyazhna%26aufirst%3DO.%26aulast%3DEaton%26aufirst%3DP.%26atitle%3DRedox%2520regulation%2520of%2520cGMP-dependent%2520protein%2520kinase%2520Ialpha%2520in%2520the%2520cardiovascular%2520system%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D139%26doi%3D10.3389%2Ffphar.2015.00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inserte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Dorado, D.</span></span> <span> </span><span class="NLM_article-title">The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1996</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1111/bph.12959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1111%2Fbph.12959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=25297462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslems7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1996-2009&author=J.+Inserteauthor=D.+Garcia-Dorado&title=The+cGMP%2FPKG+pathway+as+a+common+mediator+of+cardioprotection%3A+translatability+and+mechanism&doi=10.1111%2Fbph.12959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism</span></div><div class="casAuthors">Inserte, Javier; Garcia-Dorado, David</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1996-2009</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Cardiomyocyte cell death occurring during myocardial reperfusion (reperfusion injury) contributes to final infarct size after transient coronary occlusion.  Different interrelated mechanisms of reperfusion injury have been identified, including alterations in cytosolic Ca2+ handling, sarcoplasmic reticulum-mediated Ca2+ oscillations and hypercontracture, proteolysis secondary to calpain activation and mitochondrial permeability transition.  All these mechanisms occur during the initial minutes of reperfusion and are inhibited by intracellular acidosis.  The cGMP/PKG pathway modulates the rate of recovery of intracellular pH, but has also direct effect on Ca2+ oscillations and mitochondrial permeability transition.  The cGMP/PKG pathway is depressed in cardiomyocytes by ischemia/reperfusion and preserved by ischemic postconditioning, which importantly contributes to postconditioning protection.  The present article reviews the mechanisms and consequences of the effect of ischemic postconditioning on the cGMP/PKG pathway, the different pharmacol. strategies aimed to stimulate it during myocardial reperfusion and the evidence, limitations and promise of translation of these strategies to the clin. practice.  Overall, the preclin. and clin. evidence suggests that modulation of the cGMP/PKG pathway may be a therapeutic target in the context of myocardial infarction.  Linked Articles : This article is part of a themed section on Conditioning the Heart - Pathways to Translation.  To view the other articles in this section visit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_vbPKbLCAJ7Vg90H21EOLACvtfcHk0lj2SQN85o_xQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslems7o%253D&md5=e4f6edfa8bbeabafbf7f731e70543cee</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1111%2Fbph.12959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12959%26sid%3Dliteratum%253Aachs%26aulast%3DInserte%26aufirst%3DJ.%26aulast%3DGarcia-Dorado%26aufirst%3DD.%26atitle%3DThe%2520cGMP%252FPKG%2520pathway%2520as%2520a%2520common%2520mediator%2520of%2520cardioprotection%253A%2520translatability%2520and%2520mechanism%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1996%26epage%3D2009%26doi%3D10.1111%2Fbph.12959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span> <span> </span><span class="NLM_article-title">Imaging alterations of cardiomyocyte cAMP microdomains in disease</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">172</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26379548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=172&author=A.+Froeseauthor=V.+O.+Nikolaev&title=Imaging+alterations+of+cardiomyocyte+cAMP+microdomains+in+disease&doi=10.3389%2Ffphar.2015.00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging alterations of cardiomyocyte cAMP microdomains in disease</span></div><div class="casAuthors">Froese, Alexander; Nikolaev, Viacheslav O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172/1-172/5</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">3',5'-Cyclic adenosine monophosphate (cAMP) is an important second messenger which regulates heart function by acting in distinct subcellular microdomains.  Recent years have provided deeper mechanistic insights into compartmentalized cAMP signaling and its link to cardiac disease.  In this mini review, we summarize newest developments in this field achieved by cutting-edge biochem. and biophys. techniques.  We further compile the data from different studies into a bigger picture of so far uncovered alterations in cardiomyocyte cAMP microdomains which occur in compensated cardiac hypertrophy and chronic heart failure.  Finally, future research directions and translational perspectives are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYBE_4d12BAbVg90H21EOLACvtfcHk0lg6Fgz0NO-TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wjt7vN&md5=d92490a473560c77209d792615fec6cc</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00172%26sid%3Dliteratum%253Aachs%26aulast%3DFroese%26aufirst%3DA.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26atitle%3DImaging%2520alterations%2520of%2520cardiomyocyte%2520cAMP%2520microdomains%2520in%2520disease%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D172%26doi%3D10.3389%2Ffphar.2015.00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Nanodomain regulation of cardiac cyclic nucleotide signaling by phosphodiesterases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010716-104756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1146%2Fannurev-pharmtox-010716-104756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=27732797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=455-479&author=K.+Kokkonenauthor=D.+A.+Kass&title=Nanodomain+regulation+of+cardiac+cyclic+nucleotide+signaling+by+phosphodiesterases&doi=10.1146%2Fannurev-pharmtox-010716-104756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases</span></div><div class="casAuthors">Kokkonen, Kristen; Kass, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-479</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3',5'-monophosphate (cAMP or cGMP).  These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides.  Seven PDE family members are physiol. relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP.  New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors.  In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptHS7lTakIRrVg90H21EOLACvtfcHk0lg6Fgz0NO-TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ykt7rN&md5=0bbfd7fecacc24ec40b76e7406495313</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104756%26sid%3Dliteratum%253Aachs%26aulast%3DKokkonen%26aufirst%3DK.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DNanodomain%2520regulation%2520of%2520cardiac%2520cyclic%2520nucleotide%2520signaling%2520by%2520phosphodiesterases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D455%26epage%3D479%26doi%3D10.1146%2Fannurev-pharmtox-010716-104756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boularan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, C.</span></span> <span> </span><span class="NLM_article-title">Cardiac cAMP: production, hydrolysis, modulation and detection</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">203</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3389%2Ffphar.2015.00203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=26483685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A280%3ADC%252BC28zjs1Kguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=203&author=C.+Boularanauthor=C.+Gales&title=Cardiac+cAMP%3A+production%2C+hydrolysis%2C+modulation+and+detection&doi=10.3389%2Ffphar.2015.00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac cAMP: production, hydrolysis, modulation and detection</span></div><div class="casAuthors">Boularan Cedric; Gales Celine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Cyclic adenosine 3',5'-monophosphate (cAMP) modulates a broad range of biological processes including the regulation of cardiac myocyte contractile function where it constitutes the main second messenger for β-adrenergic receptors' signaling to fulfill positive chronotropic, inotropic and lusitropic effects.  A growing number of studies pinpoint the role of spatial organization of the cAMP signaling as an essential mechanism to regulate cAMP outcomes in cardiac physiology.  Here, we will briefly discuss the complexity of cAMP synthesis and degradation in the cardiac context, describe the way to detect it and review the main pharmacological arsenal to modulate its availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLm-3l1g5G-9bHMBt0mMIXfW6udTcc2eZenaX0bUbaZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjs1Kguw%253D%253D&md5=a528a924581daefb03da81c8b10d47b8</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00203%26sid%3Dliteratum%253Aachs%26aulast%3DBoularan%26aufirst%3DC.%26aulast%3DGales%26aufirst%3DC.%26atitle%3DCardiac%2520cAMP%253A%2520production%252C%2520hydrolysis%252C%2520modulation%2520and%2520detection%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D203%26doi%3D10.3389%2Ffphar.2015.00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurumaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki-Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takehara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisada, T.</span></span> <span> </span><span class="NLM_article-title">Roles of cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1346</span>, <span class="refDoi"> DOI: 10.3390/ijms20061346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.3390%2Fijms20061346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1346&author=Y.+Kogaauthor=H.+Tsurumakiauthor=H.+Aoki-Saitoauthor=M.+Satoauthor=M.+Yatomiauthor=K.+Takeharaauthor=T.+Hisada&title=Roles+of+cyclic+AMP+response+element+binding+activation+in+the+ERK1%2F2+and+p38+MAPK+signalling+pathway+in+central+nervous+system%2C+cardiovascular+system%2C+osteoclast+differentiation+and+mucin+and+cytokine+production&doi=10.3390%2Fijms20061346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production</span></div><div class="casAuthors">Koga, Yasuhiko; Tsurumaki, Hiroaki; Aoki-Saito, Haruka; Sato, Makiko; Yatomi, Masakiyo; Takehara, Kazutaka; Hisada, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1346</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There are many downstream targets of mitogen-activated protein kinase (MAPK) signalling that are involved in neuronal development, cellular differentiation, cell migration, cancer, cardiovascular dysfunction and inflammation via their functions in promoting apoptosis and cell motility and regulating various cytokines.  It has been reported that cAMP response element-binding protein (CREB) is phosphorylated and activated by cAMP signalling and calcium/calmodulin kinase.  Recent evidence also points to CREB phosphorylation by the MAPK signalling pathway.  However, the specific roles of CREB phosphorylation in MAPK signalling have not yet been reviewed in detail.  Here, we describe the recent advances in the study of this MAPK-CREB signalling axis in human diseases.  Overall, the crosstalk between extracellular signal-related kinase (ERK) 1/2 and p38 MAPK signalling has been shown to regulate various physiol. functions, including central nervous system, cardiac fibrosis, alc. cardiac fibrosis, osteoclast differentiation, mucin prodn. in the airway, vascular smooth muscle cell migration, steroidogenesis and asthmatic inflammation.  In this review, we focus on ERK1/2 and/or p38 MAPK-dependent CREB activation assocd. with various diseases to provide insights for basic and clin. researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Kdas4OAHmrVg90H21EOLACvtfcHk0lizH2OJ7rW7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWgurg%253D&md5=38d299804b0054cbf46ca8db20abcff0</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3390%2Fijms20061346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061346%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DY.%26aulast%3DTsurumaki%26aufirst%3DH.%26aulast%3DAoki-Saito%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DYatomi%26aufirst%3DM.%26aulast%3DTakehara%26aufirst%3DK.%26aulast%3DHisada%26aufirst%3DT.%26atitle%3DRoles%2520of%2520cyclic%2520AMP%2520response%2520element%2520binding%2520activation%2520in%2520the%2520ERK1%252F2%2520and%2520p38%2520MAPK%2520signalling%2520pathway%2520in%2520central%2520nervous%2520system%252C%2520cardiovascular%2520system%252C%2520osteoclast%2520differentiation%2520and%2520mucin%2520and%2520cytokine%2520production%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1346%26doi%3D10.3390%2Fijms20061346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span> <span> </span><span class="NLM_article-title">Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=10.1016%2Fj.cell.2012.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=22304913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFakurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=421-433&author=S.+J.+Parkauthor=F.+Ahmadauthor=A.+Philpauthor=K.+Baarauthor=T.+Williamsauthor=H.+Luoauthor=H.+Keauthor=H.+Rehmannauthor=R.+Taussigauthor=A.+L.+Brownauthor=M.+K.+Kimauthor=M.+A.+Beavenauthor=A.+B.+Burginauthor=V.+Manganielloauthor=J.+H.+Chung&title=Resveratrol+ameliorates+aging-related+metabolic+phenotypes+by+inhibiting+cAMP+phosphodiesterases&doi=10.1016%2Fj.cell.2012.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases</span></div><div class="casAuthors">Park, Sung-Jun; Ahmad, Faiyaz; Philp, Andrew; Baar, Keith; Williams, Tishan; Luo, Haibin; Ke, Hengming; Rehmann, Holger; Taussig, Ronald; Brown, Alexandra L.; Kim, Myung K.; Beaven, Michael A.; Burgin, Alex B.; Manganiello, Vincent; Chung, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-433</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Resveratrol, a polyphenol in red wine, has been reported as a calorie restriction mimetic with potential antiaging and antidiabetogenic properties.  It is widely consumed as a nutritional supplement, but its mechanism of action remains a mystery.  Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels.  The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca2+ levels and activates the CamKKβ-AMPK pathway via phospholipase C and the ryanodine receptor Ca2+-release channel.  As a consequence, resveratrol increases NAD+ and the activity of Sirt1.  Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, phys. stamina, and glucose tolerance in mice.  Therefore, administration of PDE4 inhibitors may also protect against and ameliorate the symptoms of metabolic diseases assocd. with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8zHottwfaS7Vg90H21EOLACvtfcHk0lizH2OJ7rW7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFakurc%253D&md5=6e8e92e1140c0c63c0fc92314e0f0c5c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DPhilp%26aufirst%3DA.%26aulast%3DBaar%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DRehmann%26aufirst%3DH.%26aulast%3DTaussig%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DA.%2BL.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DManganiello%26aufirst%3DV.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26atitle%3DResveratrol%2520ameliorates%2520aging-related%2520metabolic%2520phenotypes%2520by%2520inhibiting%2520cAMP%2520phosphodiesterases%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D421%26epage%3D433%26doi%3D10.1016%2Fj.cell.2012.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G45" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G45','PDB','3G45'); return false;">PDB: 3G45</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G58" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G58','PDB','3G58'); return false;">PDB: 3G58</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMY','PDB','1XMY'); return false;">PDB: 1XMY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU','PDB','1XMU'); return false;">PDB: 1XMU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XM4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XM4','PDB','1XM4'); return false;">PDB: 1XM4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GWT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GWT','PDB','3GWT'); return false;">PDB: 3GWT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3D3P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3D3P','PDB','3D3P'); return false;">PDB: 3D3P</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOR','PDB','1XOR'); return false;">PDB: 1XOR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KP6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KP6','PDB','4KP6'); return false;">PDB: 4KP6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WQA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WQA','PDB','5WQA'); return false;">PDB: 5WQA</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02170&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02170" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02170" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                12MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b26219303c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
